Conferences

Coverage from professional conferences related to lung cancer.

Interview with Paul A. Bunn, Jr., MD Dr. Bunn: There are six new drugs which have been approved or are about to be approved for treating lung cancer and they're probably all six of them better than drugs which we've had in the past, and I think they will improve survival for patients with lung cancer. I guess the second point is that the patients who have "earlier-stage" ,
Exclusive Interview with John Glick, MD Dr. Bunn: There are six new drugs which have been approved or are about to be approved for treating lung cancer and they're probably all six of them better than drugs which we've had in the past, and I think they will improve survival for patients with lung cancer. I guess the second point is that the patients who have "earlier-stage" ,
The Internet for Oncologists: Hunting for Genes on the World Wide Web Panelists CHAIR: Mark Boguski, MD PhD National Center for Biotechnology Information Susan Hubbard, RN National Cancer Institute, International Cancer Information Center L. Michael Glode, MD University of Colorado Sciences Center Photo: Susan Hubbard, RN SUMMARY Growth of the Internet has exploded in the past several years and
New Combinations in Lung Cancer Panelists CHAIR: Paul A. Bunn, Jr., MD University of Colorado Cancer Center Robert Ginsberg, MD Memorial Sloan-Kettering Cancer Center William T. Sause, MD LDS Hospital Photo (l to r): Paul A. Bunn, Jr., MD.; Robert Ginsberg, MD; William T. Sause, MD SUMMARY The primary focus of this session was to compare and contrast the
Importance of Outcomes Research The American Society of Clinical Oncology (ASCO) held an interactive discussion of "outcomes research" -- one of the most timely issues in cancer treatment. This roundtable occurred between an expert panel and oncology specialists at the Annual Meeting. "In an environment where cancer care accounts for 10% of all medical costs and nearly
Presidential Symposium on Genetic Testing Would you want to know if you are at an approximately 90% risk of developing breast and/or ovarian cancer at some point in your life, perhaps even before the age of 40? The availabiility of the DNA test for BRCA1 mutations has raised questions and issues that go beyond clinical diagnosis, and involve legal, ethical, and emotional aspects.
Phase I Study Results for Thrombopoietin, A New Cytokine Saroj Vadhan-Raj, M.D., associate professor and director, Regulation of Hematopoiesis, Bioimmunotherapy Department, M.D. Anderson Cancer Center (Houston, Texas), presented interim results of two Phase I studies of single-dose recombinant human thrombopoietin (rhTPO) therapy given to patients receiving chemotherapy. Patients who undergo intensive
Optimal Timing of Breast Cancer Surgery Within Menstrual Cycle Mark Norman Levine, M.D., Ontario Cancer Foundation, Hamilton University and professor of medicine, McMaster University, National Cancer Institute of Canada Clinical Trials Group (Kingston, Ontario, Canada), presented a study which examined the relationship between the timing of breast cancer surgery during the menstrual cycle and the risk of
Phase I Study Results for Pegylated Megakaryocyte Growth And Development Factor, A New Platelet Growth Factor Results of the first trial of pegylated megakaryocyte growth and development factor (PEG_rHuMGDF), a novel platelet growth factor, in human beings were presented at the ASCO Annual Meeting by Michael Fanucchi, M.D., associate professor of medicine, Winship Cancer Center, Emory University (Atlanta, GA). Decreased platelet production, which can be
National Cancer Insitute Director's Address Note: Dr. Richard Klausner, Director of the National Cancer Institute since August 1995, was today inducted into the membership of ASCO by Dr. John Glick, outgoing president of ASCO. He addressed a packed Exhibit Hall in Philadelphia's Convention Center; parts of his speech follow. (Portions of the speech will be placed online in RealAudio
New Discoveries in Treating Women's Cancer Reported at ASCO Meeting Philadelphia, PA, May 20, 1996 -- Exciting new discoveries in the treatment of ovarian and breast cancer were reported today at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Ovarian Cancer is the second most common gynecological cancer, and half of all cases occur in women over the age of 65. An estimated 14,500
Randomized Trial Of 2 Vs. 5 Years Of Adjuvant Tamoxifen In Postmenopausal Women With Early-Stage Breast Cancer Lars E. Rutqvist, M.D., Ph.D., director, Oncology Center, Karolinska Hospital (Stockholm, Sweden), presented the results of a study which aimed to determine the optimal duration of tamoxifen treatment for early-stage breast cancer patients. Adjuvant treatment with tamoxifen in some patients with early-stage breast cancer has conclusively been
Interferon Plus Chemotherapy Is Better Than Chemotherapy Alone In Renal Cell Cancer Seppo Pyrhönen, M.D., senior physician, chief, Outpatient Chemotherapy Unit, Helsinki University Central Hospital (Helsinki, Finland), presented the results of a multicenter trial which compared the effects of combination therapy with chemotherapy and interferon alfa-2a cersus chemotherapy alone on the overall survival of patients with
Interferon Plus Interleukin-2 Is The Optimal Treatment To Induce Responses In Metastatic Renal Cell Cancer Sylvie Négrier, M.D., associate professor, Department of Medical Oncology, Centre Leon Berard (Lyon, France), presented the results of another study demonstrating the effects of interferon, as well as another cytokine, interleukin-2, in advanced renal cell carcinoma (RCC). According to Dr. Négrier, despite the large number of
Long-Term Survival Following Immunization with BEC2 Plus BCG after Initial Therapy for Small Cell Lung Cancer Sylvie Négrier, M.D., associate professor, Department of Medical Oncology, Centre Leon Berard (Lyon, France), presented the results of another study demonstrating the effects of interferon, as well as another cytokine, interleukin-2, in advanced renal cell carcinoma (RCC). According to Dr. Négrier, despite the large number of
James O. Armitage, M.D., Assumes ASCO Presidency Philadelphia, PA, May 20, 1996 -- James O. Armitage, M.D., professor and chairman, Department of Internal Medicine, University of Nebraska Medical Center, today assumed the presidency of the American Society of Clinical Oncology (ASCO) during the Society's Annual Meeting. An internationally-recognized oncologist, Dr. Armitage's research
American Society of Clinical Oncology Announces Research Awards Henry T. Lynch, M.D., professor and chairman, Department of Preventive medicine and Public Heath, and Director, Creighton Cancer Center, Creighton University (Omaha, NE), presented a study of 14 families with hereditary breast-ovarian cancer (HBOC), comprising 2,549 direct line blood relatives. All the families were under evaluation for at least
John H. Glick, MD Gives Presidential Address Philadelphia, PA , May 20, 1996 John H. Glick, MD, President of ASCO (1995-1996) and Director, University of Pennsylvania Cancer Center, gave his Presidential Address today at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Following are excerpts from his presentation: "It is a time of transition, growth,
Research Presented Helps to Define Best Use and Timing of Bone Marrow Transplantation Philadelphia, PA, May 18, 1996-- Exciting new research that better defines the role and timing of bone marrow transplantation was presented at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Bone marrow transplantation is commonly used in cancer of the blood and lymphatic systems, and is being increasingly used in
Combined Modality Therapy Shows Improvements in Survival for Certain Cancer Patients Philadelphia, PA, May 20, 1996 -- Important new data regarding the use of combined modality therapy were reported today at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Combined modality therapy refers to the use of more than on technique for fighting cancer. These modalities include chemotherapy surgery,
Advances in Supportive Care Offer New Opportunities for Oncology Patients and Clinicians Philadelphia, PA, May 20, 1996 -- Research presented at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO) provided insight into new solutions for maximizing the quality of cancer care. The cost of cancer care is rising at a rate that cannot be sustained. The costs of treatment have risen from $35 billion to more than
Phase I/II Trial Results Of 131-I-Anti-B1 (Anti-CD20) Non-Myeloablative Radioimmunotherapy For Refractory B-Cell Lymphoma Researchers at the University of Michigan Medical Center (Ann Arbor, MI) presented results of a Phase I/II clinical trial of a new form of treatment for non-Hodgkin's lymphoma. There are approximately 51,000 new cases of non-Hodgkin's lymphoma in the U.S. each year. Chemotherapy and radiotherapy have been the mainstays of lymphoma
A Clinical Trial Of Antigen-Pulsed Dendritic Cells (DC) In The Treatment Of Patients With B-Cell Lymphoma Researchers at Stanford University Medical Center presented preliminary results of a study on a new vaccine treatment for B-cell lymphoma. Chemotherapy and/or radiation can cause remission in most patients with B-cell lymphoma. However, despite responsiveness to treatment, patients ultimately relapse and most cannot be cured with standard
Clinical Benefits versus Quality of Life of Patients Receiving Interferon Bernard Cole, Ph.D., assistant professor of community health (Research), Center for Statistical Science, Brown University (Providence, RI), presented an analysis of the quality of life of melanoma patients receiving interferon alfa-2b therapy following surgery. In a study of 280 patients conducted by the Eastern Cooperative Oncology Group
Interferon Therapy Delays Disease Recurrence and Prolongs Survival in Patients with Resected Melanoma Jean-Jacques Grob, MD, professor dermatology, University of Marseille, Hopital Sante-Marguerite (Marseille, France), presented a study of interferon alfa-2a as adjuvant therapy in patients with resected (surgically removed) early stage melanoma. Melanoma is a cancer which arises in the pigment cells of the skin, mucuous membranes, eyes and
Superiority of Chemo-Radiotherapy Vs. Radiotherapy In Patients with Esophageal Cancer Arnold Herskovic, M.D., medical director, Radiation Oncology Department, Oakwood Hospital and Medical Center (Dearborn, MI), presented the results o a study which compared the overall survival of esophageal cancer patients treated with radiotherapy (RT) alone versus treatment with chemo-radiotherapy (CT-RT). The study was conducted by the
What PSA Nadir Level Should Be Achieved After Irradiation For Prostate Cancer? Arnold Herskovic, M.D., medical director, Radiation Oncology Department, Oakwood Hospital and Medical Center (Dearborn, MI), presented the results o a study which compared the overall survival of esophageal cancer patients treated with radiotherapy (RT) alone versus treatment with chemo-radiotherapy (CT-RT). The study was conducted by the
Immediate Hormonal Therapy Improves Survival In Patients With Locally Advanced Prostate Cancer Michel Bolla, M.D., professor of radiation oncology, University Joseph Fourier Grenoble (Grenoble, France) presented a study which aimed to increase the survival of patients suffering from locally advanced prostate cancers by combining radiation with adjuvant hormone therapy administered from the start of treatment. Prostate cancer is the
Patterns of Care for Women with Ovarian Cancer in the United States Michel Bolla, M.D., professor of radiation oncology, University Joseph Fourier Grenoble (Grenoble, France) presented a study which aimed to increase the survival of patients suffering from locally advanced prostate cancers by combining radiation with adjuvant hormone therapy administered from the start of treatment. Prostate cancer is the
Reduction of Skeletal Morbidity and Prevention of Bone Metastases with Oral Clodronate in Women with Recurrent Breast Cancer in the Absence of Skeletal Metastases A.H.G. Paterson, MD, head, Division of Medical Oncology, Department of Medicine, University of Calgary (Alberta, Canada), presented the results of a study which examined the effect of clodronate on the incidence of skeletal metastases and skeletal morbidity in women with recurrent breast cancer. Bone is a frequent site for recurrent breast
Monoclonal Antibody that Binds to Breast Cancer Cells Helps Stop Cancer Spread and Shrink Tumors This study analyzed Herceptin, a monoclonal antibody directed against the "HER2/Neu" surface protein on breast cancer cells and interfere with the cells' biological processes, which eventually causes cell death. The researchers recently completed a multinational, controlled, randomized phase III trial involoving 469 patients. The trial tested
Single Treatment of Engineered Antibody Demonstrates 100 Percent Response Rate in Follicular Lymphoma Monoclonal antibodies are small proteins directed against ³marker proteins,² known as antigens, present on the surface of tumor cells. This antibody, known as Anti-B1 Antibody, is directed against CD-20 antigens present on follicular lymphoma cancer cells. Radioactive iodine (I-131) attached to the monoclonal antibody provides directed killing
Raloxifene Reduces Incidence of Breast Cancer by 58-66% and May Reduce Risk of Endometrial Cancer in Postmenopausal Women Raloxifene is a novel selective estrogen receptor modulator that has estrogenic effects on bone and lipids, but estrogen antagonist effects on the breast and uterus. A new study indicates that Raloxifene, widely used for the treatment of osteoporosis, can substantially reduce the risk of breast cancer in postmenopausal women who are at normal
Canadian Study is First to Show Screening Reduces Prostate Cancer Deaths An eight-year large-scale randomized study, begun in 1988, was designed to evaluate the survival benefit of prostate cancer screening. The study randomly divided 46,193 men aged 45 to 80 into those who would be screened and those who would not. Those screened received a PSA (prostate-specific antigen) test and digital rectal examination at the
Vitamin A Derivative Effective in Treating Neuroblastoma Neuroblastoma, a malignant solid tumor which arises from the peripheral nervous system, is one of the most aggressive of childhood cancers. Five hundred new neuroblastoma cases are diagnosed each year in the U.S. 539 high-risk neuroblastoma patients (85% stage IV) were treated in this study, the first randomized study to show that
Increased Frequency of Radiation Therapy Treatment for Small-Cell Lung Cancer Improves Survival Rates Lung cancer is the leading cancer killer, with more than 160,000 deaths annually. Radiation therapy is a standard treatment approach for people with lung cancer, and can be used alone or in combination with surgery or chemotherapy. In this study of radiation treatment schedules for patients with small-cell lung cancer, after five years of
Higher Doses of Paclitaxel Fail to Improve Survival Rates in Women with Metastatic Breast Cancer Each year approximately 45,000 women in the U.S. are diagnosed with metastatic breast cancer. New research demonstrates that higher doses of Paclitaxel (Taxol) are not necessarily more effective in patients with advanced breast cancers, and that patients can be spared the increased toxicities associated with high doses. This study of 475
Taxol Use Results in Significant Survival Benefit When used in Adjuvant Setting for Node-Positive Breast Cancer Patients For the first time, researchers have found that Paclitaxel (Taxol), the widely-used chemotherapy agent originally developed from compounds found in the bark of the yew tree, increases a woman's chance of survival when used in combination with other chemotherapy drugs after surgery. Previously, no randomized trial had found an adjuvant
New Agent Tested to Attack Blood Vessels that Feed Tumors Tumor growth beyond the size of a pinpoint is dependent on the formation of new blood vessels, a process called angiogenesis. "Anti-angiogenesis" agents are being explored as a way to inhibit new blood vessel formation, and thus starve tumors of the blood supply they need to grow and spread. The agent was engineered to identify and attack the
Poor Understanding of Guidelines Results in Low National Use of Breast-Conserving Therapy According to a report of the American College of Surgeons and the American College of Radiology, thousands of women every year could be spared mastectomies if national guidelines developed six years ago were properly followed. According to these guidelines, developed by the National Cancer Institute, approximately 75% of women diagnosed with
Cancer Vaccine Triggers Immune System to Recognize Melanoma Unlike vaccines that are used to prevent infectious disease, cancer vaccines attempt to stimulate the body's own immune system to recognize cancer cells as foreign and destroy them. These researchers examined tyrosinase, a normal protein present in melanin (which gives moles their color), and in melanoma cells. Patients were treated with
Herpes Gene May Help Attack Prostate Cancer A certain herpes gene may help fight prostate cancer, according to the first study to demonstrate that gene therapy is safe and active against prostate cancer. This phase I trial examined 18 patients who had local recurrence of prostate cancer following initial treatment with radiation. The herpes gene (thymidine kinase) activates a normally
Study Finds that Elderly are Severely Underrepresented in Clinical Trials Half of all new cancer cases occur inpeople older than 65, yet a growing body of evidence shows that elderly patients are chronically underrepresented in clinical trials. Moreover, it has been presumed that older patients cannot handle the aggressive chemotherapy used on younger patients, given that concurrent illnesses are common. But because
Vinorelbine Plus Supportive Care Increases Survival and Quality of Life for Elderly Lung Cancer Patients Lung cancer is expected to claim the lives of more than 160,000 Americans this year -- many over the age of 65. Survival rates are improving, especially when the cancer is detected early. Treatment is often difficult, however, and is often palliative, directed only toward relieving symptoms as the disease progresses, rather than actively
New Drug Expands Limited Treatment Arsenal for for Colorectal Cancer Colorectal cancer is one of the most common malignancies, with over 131,000 new cases diagnosed in the U.S. each year. 5FU has been used as the primary treatment for colon cancer for decades, with few effective new drugs to complement this therapy. Patients who do not respond to the standard chemotherapy treatment for metastatic colorectal
CAF Slightly Improves Survival for High-Risk Localized Breast Cancer Patients Adjuvant chemotherapy — chemotherapy administered to prevent the recurrence of cancer after surgery — has been an important contributor to improved survival rates for many breast cancer patients. This study compared the newer chemotherapy regimen CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) to the standard CMF
Tamoxifen Reduces Breast Cancer Incidence by 45% in Women at High Risk of Developing the Disease Tamoxifen has been used for the past twenty years to treat breast cancer and prevent its recurrence. Knowledge of its benefit in preventing breast cancer remained unknown, however. Today researchers from the National Surgical Breast and Bowel Project (NSABP) presented the results of a trial examining the breast cancer prevention benefits of
Chemical Derived from Naturally-Occurring Mold May Slow Growth of Metastatic Kidney Cancer by Inhibiting Growth of Tumor Blood Supply Anti-angiogenesis agents are showing promise in inhibiting tumor growth by attacking the tumor's blood supply. In this Phase II study of 33 patients, researchers used an anti-angiogenesis agent called TNP-470, a synthetic form of a chemical secreted by the aspergillus fumigatus mold, to slow the growth of metastatic kidney cancer, which claims
New Antisense Agent Stops Production of Cancer-Causing Protein Antisense therapy is a novel cancer treatment approach that works at the genetic level to interrupt the process by which cancerous cells produce certain proteins. An antisense compound consists of a single strand of DNA designed in the laboratory to complement the single strand of messenger RNA (mRNA) produced by the cancer cell. These two
Six-Month Chemotherapy Regimen for Colon Cancer Replaces Conventional 12-Month Regimen Adjuvant chemotherapy -- drugs used to prevent the recurrence of cancer after surgery -- is an important weapon in the treatment of the disease. Until now, the combination most often used included fluorouracil (FU) and levamisole (LEV) for a full year after surgery . This major 5-year study of 3,759 patients -- the largest trial to evaluate
Standard Chemotherapy Shows Increased Toxicity for Elderly with Node-Positive Breast Cancer While another study presented yesterday demonstrates that older breast cancer patients with early stage breast cancer can tolerate standard adjuvant chemotherapy, this study finds that elderly patients whose breast cancer has spread to the lymph nodes do not appear to be able to tolerate standard chemotherapy as well as younger patients when
Older Breast Cancer Patients can Tolerate Adjuvant Therapy with Doxorubicin and Cyclophosphamide Traditionally, older women with breast cancer are given less aggressive chemotherapy than younger women, primarily because of concern about increased toxicity. This study demonstrates that older women receiving adjuvant chemotherapy do not experience clinically significant increases in toxicity. In this study, 44 women aged 35 to 79 with
Primary Breast Cancers are Reduced by Raloxifene In a second analysis of the study presented yesterday, researchers found that the risk of developing breast cancer was reduced by 58% in women taking Raloxifene, compared to women receiving a placebo. This dramatic reduction was observed in postmenopausal women being treated for osteoporosis who had no history of breast cancer. The researchers
Energy and intensity modulated electron beams for treatment of breast cancer Presenter: Charles Ma Affiliation: Stanford University School of Medicine Summary:Breast cancer has traditionaly been treated with photon beams. The purpose of this study was to investigate the feasibility of using energy and intensity modulated electron beams for breast cancer treatment. The use of Electron Intensity Modulated Radiation
Prelimimary results of a randomized dose-escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer Presenter: Alan Pollack Affiliation: MD Anderson Cancer Center Summary:- The purpose of this study was to compare the impact of 70 Gy versus 78 Gy on relapsing/rising PSA and biopsy positivity. Methods: 298 patients were enrolled in a single institution randomized clinical trial comparing 70 Gy vs. 78 Gy in the treatment of prostate cancer.
Randomized Phase III Trial of Radiation +/- Amifostine in Patients with Advanced Stage Lung Cancer Presenter: Antonadou D Affiliation: Hellenic Group Clinical-Radiation Oncology, Greece Summary:Pneumonitis and esophagitis are two of the most problematic adverse effects associated with thoracic irradiation. Severe symptoms can cause patient distress and may necessitate treatment delays or possibly premature termination. This, in turn, could
Randomized Prospective Comparison of Adjuvant Mediastinal Radiation (RT) with or without Concurrent Chemotherapy with Cisplatin and Etoposide (PE) for Patients with Completely Resected T1-3N1-2M0 Non-Small Cell Lung Cancer (NSCLC): US Presenter: Keller SM et al Affiliation: Beth Israel Medical Center Summary:Multiple retrospective reviews as well as the prospective study from the Lung Cancer Study Group have demonstrated a local control advantage to adjuvant radiation therapy for NSCLC. However, the overwhelming pattern of failure remains distant. This trial was initiated
Improved Conformality and Reduced Toxicity with High-Dose Intensity Modulated Radiation Therapy (IMRT) for Patients with Prostate Cancer Presenter: Michael J. Zelefsky, M.D. Affiliation: Memorial Sloan Kettering Cancer Center Summary: There has been recent evidence to suggest that with increased radiation dose comes increased efficacy in the treatment of prostate cancer. However, the ability to deliver dose is most often limited by the tolerance of normal tissues proximal to
A Radiation Therapy Oncology Group (RTOG) Phase III Randomized Study to Compare Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinomas: Preliminary Results of RTOG Presenter: Karen K. Fu, MD Affiliation: RTOG and University of California San Francisco Summary:Various fractionation schemes have been advocated for the treatment of head and neck cancer based on single institution experiences. This multi-institutional Phase III trial was performed to evaluate disease free survival, overall survival, local
Long Term Results of Immediate Adjuvant Hormonal Therapy with Goserelin in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy (Phase III EORTC Study) Presenter: Bolla M et al Affiliation: EORTC Radiotherapy Cooperative Group Summary:Traditionally, patients with locally advanced, high risk adenocarcinoma of the prostate have been treated with radiation therapy. However, local control and survival have been somewhat disappointing. This study was initiated to investigate whether concurrent
3-D Intensity Modulated Radiotherapy (IMRT) in the Treatment of Nasopharyngeal Carcinoma: The UCSF Experience Presenter: Khalil Sultanem, MD Affiliation: University of California (San Francisco) Summary:Due to the proximity of critical normal tissues, carcinoma of the nasopharynx requires technically complex radiation treatment planning. The nasopharynx is an ideal location to evaluate IMRT for both tumor control and toxicity. This study was
Accuracy of the Extent of Axillary Nodal Positivity Related to Primary Tumor Size, Number of Involved Nodes and Number of Nodes Examined Presenter: Rajesh V Iyer, MD Affiliation: Fox Chase Cancer Center Background:As radiation therapy's utility becomes more established in the breast conservation and post-mastectomy setting, the issue of axillary lymph node status remains in the forefront in directing treatment recommendations. Specifically, patients with four or more positive
Internal Mammary Node Coverage - An Investigation of Presently-Accepted Techniques Presenter: Douglas Arthur, MD Affiliation: Virginia Commonwealth University/Medical College of Virginia Background:The Internal mammary nodes (IMNs) are found lateral to the internal mammary vessels from the 1st rib to the 4th intercostal space. Radiation therapy (RT) to this area can be administered using various techniques. The purpose of
Internal Mammary Node Irradiation Does Not Decrease Distant Metastases or Improve Survival in Stages I and II Breast Cancer Presenter: Barbara Fowble, MD Affiliation: Fox Chase Cancer Center Background:Internal mammary node (IMN) irradiation has remained a controversial subject. Though historical data demonstrate that high-risk patients (axillary lymph node positive) have a significant rate of pathological IMN involvement, it continues to be debatable whether
Impact of Hemoglobin (Hgb) Level and Use of Recombinant Human Erythropoieten (r-HuEPO) on Response to Neoadjuvant Chemoradiation Therapy, Tumor Control, and Survival in Patients With Oral or Oropharyngeal Squamous Cell Carcinoma (SCCA) Presenter: Christoph M. Glaser, MD Affiliation: General Hospital Vienna, Austria Summary:Anemia is a frequent finding in patients with head and neck cancer and has been found to be a poor prognostic factor. This study was performed to evaluate the impact of r-HuEPO on patients with a low Hgb level. Methods: All 187 patients in this
Extracapsular Axillary Nodal Extension (ECE) in Breast Cancer: Patterns of Recurrence, Arm Edema, and Survival after Mastectomy with and Without Irradiation Presenter: Robert Kuske, MD Affiliation: Ochsner Clinic/Tulane University School of Medicine, New Orleans, LA Background:The prognostic implications of extracapsular extension (ECE) in breast cancer with axillary lymph node (ALN) disease is debatable. It has not been conclusively demonstrated that having ECE in positive ALNs is an indication
Radiation Therapy With Concurrent Weekly Carboplatin and Paclitaxol in Advanced Stage Unresectable Squamous Cell Carcinoma of the Head and Neck Presenter: Michael L. Haas, MD Affiliation: University of Maryland Summary:Advanced squamous cell carcinoma of the head and neck region generally has a poor outcome with radiation therapy alone. This study was designed to evaluate concurrent chemoradiation therapy for the treatment of unresectable head and neck cancer. Methods: From
Intensity modulated stereotactic radiosurgery using a micro-multileaf compared with gamma knife and linac arc radiosurgery Presenter: Wu QJ Affiliation: Case Western Reserve University Summary:Stereotactic radiosurgery is delivered with the use of gamma knife or linac based photon beams. Both of these modalities can provide an acceptable dose distribution. However, they are time consuming. The development of micro-multileaf collimators (mMLC) and intensity
Final Report of a Phase III Randomized Trial of Amifostine as a Radioprotectant in Head and Neck Cancer Presenter: Brizel DM et al Affiliation: Duke University Medical Center Summary:Xerostomia (dry mouth) is a difficult and often permanent complication of head and neck radiotherapy. Life long consequences include difficulty with eating, speaking, and dental complications. This phase III randomized trial of radiation therapy with or without
PET Scanning in Radical Radiation Therapy Candidates with Non-Small Cell Lung Cancer: High Impact on Staging and Management and Delineation of a Subgroup with Poor Survival Presenter: Mac Manus MP Affiliation: Peter MacCallum Cancer Institute Summary:The standard work-up for a patient with non-small cell lung cancer (NSCLC) includes surgical staging as well as imaging by CT, bone scan, and possibly MRI. Even in the most experienced hands, however, these modalities do not always accurately reflect the true extent
Can We Predict Radiation (RT)-Induced Changes in Pulmonary Function Tests (PFTs) Based on the Lung Dose-Volume Histogram? Presenter: Ming Fan, M.D. Affiliation: Duke University Medical Center Summary: Radiation induced pulmonary changes can cause serious, even life-threatening problems in patients whose lung function is already compromised by tumor burden and smoking. There are many studies which qualitatively document pulmonary toxicity relative to dosing
Circulating Humoral Factors and Lymphocyte Subsets as Markers for Radiation Pulmonary Injury Presenter: Yuhchyau Chen, M.D. Affiliation: University of Rochester Summary:Radiation induced pulmonary changes can cause serious, even life-threatening problems in patients whose lung function my already be compromised by tumor burden and/or smoking. Humoral factors and immune cells have been previously associated with the presence of
Preliminary Results of Gamma-I Trial, Multi-institution Double Blind Prospective Randomized Study Evaluating the Efficacy of IR-192 to Reduce Coronary In-stent Restenosis Presenter: Prabhakar Tripuraneni, M.D. Affiliation: Scripps Clinic Summary: One of the major disadvantages of coronary angioplasty is the high rate of re-stenosis in the months following the procedure. Single arm endovascular brachytherapy trials have yielded encouraging results suggesting decreased re-stenosis with minimal toxicity after
Panel Discusses the Rapidly Evolving Standards of Care for Cervix Cancer In February 1999, the National Cancer Institute issued a clinical alert stating that concurrent cisplatin-based chemotherapy plus radiation therapy appears to be a superior treatment to radiation alone for women with cervix cancer. This statement was based on the results of five phase III trials that demonstrated a significant survival
Chemoprevention for Head and Neck Cancer "Can chemopreventive therapy restore molecular defects in target tissues?" That was the key question posed by Dr. Wang Ki Hong, Chair of Thoracic Oncology at the University of Texas M.D. Anderson Cancer Center, in his keynote address to a packed hall this morning. Speaking on "The Genetic and Molecular Basis for Prevention: Head and Neck
Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx Presenter: Aebersold, DM Affiliation: Department of radiation oncology, Inselspital Berne, Switzerland Summary: Angiogenesis is thought to play a role in radiosensitivity. The differences in radiosensitivity are thought to be related to the influence of oxygenation, vasculotoxicity of radiation, and angiogenic factors that inhibit radiation
Impact of Risk Factors and Total Time for Combined Surgery and Radiotherapy on the Outcome of Patients with Advanced Head and Neck Cancer Presenter: Ang, KK Affiliation: MD Anderson Cancer Center Background:We know from the literature that certain patients are at higher risk for postoperative recurrence based on previously described adverse prognostic features. This prospective study was performed to determine: The validity of these previously defined risk groups and Whether the
Postoperative Irradiation for Stage T4 Colon Cancer Presenter: Christopher Willett, MD Affiliation: Massachusetts General Hospital, Boston, MA and Roswell Park Cancer Institute, Buffalo, NY Background:Postoperative systemic therapy is the standard of care for intermediate to advanced colon cancer. Radiation therapy (RT) has been utilized far less due to the technical considerations such as not
Preliminary Analysis of Radiotherapy Data from CALGB 9082: Variability of Treatment Fields for Local/Regional Breast Cancer and the Impact of High Dose Chemotherapy on the Ability to Deliver Radiation Therapy Presenter: Lawrence B. Marks, M.D. Affiliation: Duke University/CALGB/SWOG Summary:Positive contributions of radiotherapy (RT) and chemotherapy in patients with high-risk breast cancer are well documented, but the sequencing of these modalities and dosage of chemotherapy in such patients remains controversial. This offering examines the effect
Timescale of Evolution of Late Radiation Injury after Postoperative Radiotherapy of Breast Cancer Patients Presenter: Silvia Johansson Affiliation: Umea University Hospital, Sweden Summary:Most of the modern randomized trials in breast cancer document toxicity associated with treatment, but none document these toxicities over the scale of decades. These data are important because many women are diagnosed with breast cancer at a relatively young age,
Anemia is associated with decreased local control of surically treated squamous cell carcinoma of the glottic larynx Presenter: Guttenberger R Affiliation: University of Freiberg, Freiberg, Germany Summary:-There is a known correlation between anemia and local control in head and neck cancer. -This study was performed to demonstrate a difference in treatment outcome in patients with a low pretreatment hemoglobin who recieved surgery alone. -From
Image Localization For Frameless Stereotactic Radiotherapy Presenter: Sanford L. Meeks, MD Affiliation: University of Iowa Summary:Confirmation of accurate patient positioning is paramount in treatment of tumors utilizing stereotactic radiotherapy. Typically, invasive head rings are used for the treatment of many patients with CNS disease. The University of Florida has utilized infrared emitting
Second Malignancies after Treatment of Early Stage Breast Cancer with Lumpectomy and Radiation or Mastectomy without Radiation Presenter: E. Obedian Affiliation: Yale University School of Medicine Summary:Multiple studies have demonstrated the clinical efficacy of breast conserving therapy (BCT) for early stage breast cancer. Despite decades of experience, however, there are limited data regarding the safety of this treatment, specificially the risk of second
Local-Regional Control in in Breast Cancer Patients with a Presumed Genetic Predisposition Presenter: LM Freedman Affiliation: University of Texas M.D. Anderson Cancer Center Summary:Breast cancers associated with a genetic predisposition (e.g., BRCA-1 & BRCA-2 mutations) may behave more aggressively than sporadically occurring tumors. In particular, they tend to present at higher grades, lack hormone receptors, and have mutations
Squamous Cell Carcinoma of the Base of Tongue Treated with External Beam Radiation Therapy: A Preferred Alternative to Surgery Presenter: Mendenhall WM et al Affiliation: University of Florida College of Medicine Summary:Surgery has traditionally been the mainstay of treatment for squamous cell carcinoma of the base of tongue. However, the morbidity with this surgery is significant. This retrospective study was performed to compare outcomes with definitive
Long Term Results of the Concomitant Boost Fractionation Schedule for Treatment of Oropharyngeal Carcinoma Presenter: Morrison WH Affiliation: M.D. Anderson Cancer Center Summary:A potential deterrent to obtaining local control with radiation therapy for head and neck cancer is the problem of accelerated repopulation of cancer cells. This becomes more problematic after several weeks of treatment. The rationale for this study of a concomitant boost
Robert Brook, M.D., an Expert on Medical Quality Assurance, Suggests Strategies for "Making Radiation Therapy Error-Free" In this morning's keynote address, Robert Brook, M.D., an expert on quality of care issues, encouraged radiation oncologists to apply lessons learned from a range of medical specialties to ensure that all patients receive appropriate treatment. During a hard-hitting talk that called physicians to task for not being sufficiently concerned about
Giulio D'Angio, M.D. Received Gold Medal Award November 2nd from the American Society for Therapeutic Radiation Oncology Dr. Giulio D'Angio, Professor of Radiation Oncology at the University of Pennsylvania and a specialist in children's cancers, received a Gold Medal Award from the American Society for Therapeutic Radiation Oncology at its annual conference in San Antonio, Texas. For nearly a half-century, Dr. D'Angio has been a central contributor to advancements
Gold Medal Award Presentations Kick Off Day 4 at ASTRO Conference Giulio J. D'Angio, M.D., and J. Martin Brown, Ph.D., were presented with ASTRO's highest honor, the Gold Medal Award, at a ceremony this morning. Dr. D'Angio is Professor of Radiation Oncology at the University of Pennsylvania Medical Center, and Dr. Brown is Professor and Director, Division of Radiation Biology, and Director of the Program
Improving Radiation Efficacy: The Advent of New Sensitizers Panelists:Gillies McKenna, MD, PhDTheodore S. Lawrence, MD, PhDJames A. Bonner, MD In this session, some of the newest and most exciting anticancer agents being used as radiation sensitizers were discussed. The panelists each reviewed their work with farnesyl transferase inhibitors, nucleoside analogs, and anti-EGFR antibodies. The
Proton Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base Presenter: Eugene B. Hug Affiliation: Loma Linda University Medical Center Background:The treatment of tumors of the skull base poses technical difficulties for conventional photon therapy due to the presence of critical adjacent normal structures. Proton therapy provides a physical beam that conforms to the target without exit dose beyond the
Chemoradiation With or Without Surgery for Stage IIIA Non-Small Cell Lung Cancer (NSCLC): A Comparison of Survival and Patterns of Failure Presenter: Mitchell Machtay, MD Affiliation: University of Pennsylvania Background:One of the most controversial topics in the management of NSCLC is the treatment of stage IIIA disease. Chemotherapy is generally accepted as an indicated treament in patients with good performance status. The management of local disease using surgery versus
Complications and Patient Satisfaction Following Breast Implant Reconstruction with and without Radiotherapy Presenter: Edith Krueger Affiliation: University of Michigan and William Beaumont Hospital Background:Women undergoing breast implant reconstruction after mastectomy may also require radiation therapy, but data regarding complications and patient satisfaction are limited. The Michigan Breast Reconstruction Outcome Study (MBROS) was designed to
Radiation Exposure to Women Radiation Oncologists During Pregnancy: Results of a North American Survey Presenter: Rachel Rabinovitch Affiliation: University of Colorado Health Sciences Center Background:Although safeguards exist to limit radiation exposure during pregnancy, female radiation oncologists remain at risk of occupational exposure. The incidence, cause, and outcomes of this are not well defined. Materials and Methods: 293 of 865
Intensity Modulated Radiation Therapy (IMRT) May Reduce Small Bowel, Rectum, and Bladder Complications in Patients with Cervical Cancer Treated to the Pelvis and Paraaortic Area Presenter: Lorraine Portelance Affiliation: Mallinckrodt Institute of Radiology, St Louis, MO Background:Combined modality therapy (chemotherapy plus radiation therapy) has made a major impact on treatment of cervix cancer from bulky Stage I disease up to Stage IV. With the improvement of local control and survival with the use of combined
Patterns of Failure and Impact of Adjuvant Therapy Following Pancreaticoduodenectomy for Ampullary Carcinoma Presenter: Jason H. Lee, MD Affiliation: University of Pennsylvania Background:The prognosis for ampullary carcinoma is somewhat more favorable than pancreatic cancer and other biliary carcinomas. However, aproximately 50% of patients experience a relapse of their disease. The role of adjuvant therapy after radical resection remains unclear.
Health Futurist Dr. Leland Kaiser Urges Radiation Oncologists to Chart The Future of Cancer Care "We don't predict the future . . . we create it." This was the central theme of Dr. Leland Kaiser's keynote address this morning on "Cancer Care in the 21st Century." Describing himself as a "health futurist," Dr. Kaiser, who is both a consultant and a professor of business at the University of Colorado at Denver, urged his audience to
Small French Study Shows Longer Time to Relapse for High-Dose Chemotherapy in Metastatic Breast Cancer Begun in 1992, this study of 61 women with metastatic breast cancer responsive to chemotherapy, who were randomized to receive either high-dose chemotherapy supported by stem cell transplant, or standard doses of chemotherapy. The chemotherapy regimen used in the high-dose arm was cyclophosphamide, mitoxantrone and Melphalan (CMA), while
New Chemotherapy Combination Causes Brain Tumors to Regress Researchers have found that a chemotherapy regimen, including procarbazine, CCNU and Vincristine (PVC), given before radiation therapy to patients with low-grade oligodendroglioma or oligoastrocytoma brain tumors, causes tumors to regress in 28 percent of patients. Jan Buckner, MD, medical oncologist at Mayo Clinic and colleagues entered 31
ASCO Surveys Demonstrate Problems with Clinical Trials System The three most comprehensive surveys to date of the cancer clinical trials system, commissioned by the American Society of Clinical Oncology, reveal a high level of oncologist participation in clinical research, despite severe underfunding and a lack of research resources. Patient paticipation, however, remains dismal. These separate
Margin Width the Key to Control of Ductal Carcinoma In Situ of the Breast Atlanta, May 15, 1999 -- Patients with one of the most common and curable forms of breast cancer may be undergoing radiation therapy unnecessarily, according to study findings revealed at the 1999 American Society of Clinical Oncology (ASCO) meeting by Melvin J. Silverstein, MD, medical directory of the Harold E. and Henrietta C. Lee Breast
Hepatic Infusion Increases Survival and Reduces Liver Metastases from Colorectal Cancer when Combined with Chemotherapy Approximately 138,000 new cases of colorectal cancer are diagnosed in the US every year. Eventually, 60% of these patients will develop liver metastasis but only a small percentage of these patients respond to systemic chemotherapy, a common treatment. Now, researches at Memorial Sloan-Kettering Cancer Center have found that a novel
Tiny Radioactive Spheres Increase Survival and Reduce Liver Metastases When Combined with Chemotherapy Tiny radioactive spheres can reduce the size of liver metastases in patients and significantly increase survival, according to results of this phase III trial that tested the effect of adding a single dose of the spheres to chemotherapy delivered into the hepatic artery, which feeds the liver. The study enrolled 71 patients whose colorectal
Pre-cancerous Prostate Lesions Indicate Increased Risk of Cancer Prostate lesions known as PIN (prostatic intraepithelial neoplasia) have generally been suspected to be precancerous by the prostate research community. However, little is known about the long-term significance of these lesions. Now a research team at the Boston VA Hospital and the Boston University School of Medicine has shown that the presence
Novel Immunotherapy Targets Her2-Positive Prostate Cancer A novel immunotherapy that directly links immune cells to Her2-positive prostate cancer cells shows the first documented responses to immunotherapy in prostate cancer. As in breast cancer, some prostate cancer cells produce excessive amounts of the Her2 protein that tells cells to divide, making the cancer particularly aggressive and unresponsive
Replacing P53 Gene in Prostate Cancer Helps Shrink Tumors A team of investigators from the M.D. Anderson Cancer Center, led by Dr. Christopher Logothetis, has demonstrated evidence that replacement of the p53 gene may shrink prostate cancers. The function of the p53 gene, which induces damaged cells to activate "programmed cell death," is lost as cancer progresses and spreads. Therefore, replacing
Male Bone Density Decreases at a Steady Rate During Hormone-Suppressing Prostate Cancer Treatment The same bone loss seen in women who aren't producing estrogen is now being seen soon after men suppress testosterone and androgen production during prostate cancer therapy. These male hormones are known to stimulate the early growth of prostate cancer, so at the first signs of a rising PSA level -- a test that measures a protein produced by
Carboplatin/Paclitaxel Preferable to Cisplatin/Paclitaxel in Optimal Stage III Epithelial Ovarian Cancer Robert Ozols, M.D. from the Fox Chase Cancer Center presented data from the Gynecologic Oncology Group (GOG) Protocol #158 a randomized Phase III clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimally surgically cytoreduced epithelial ovarian cancer. This important study is the largest reported randomized trial in
Cyclophosphamide/Cisplatin Possibly Preferable Preferable to 32P in Treament of Early High-Risk Ovarian Cancer Robert Young, M.D. from the Fox Chase Cancer Center presented the data from Gynecologic Oncology Group (GOG) Protocol #95 a randomized clinical trial of adjuvant treatment of early (Stage IA-IIA high-risk) ovarian cancer patients. The regimen of GOG #95: Regimen 1: 15 mc intraperitoneal 32P given once (n= 98) Regimen 2: Cyclophosphamide 1
Sequential Couplets of Cisplatin/Topotecan and Cisplatin/Paclitaxel as First-Line Therapy in Advanced Epithelial Ovarian Cancer Dr. P. Hoskins presented a Phase II trial of sequential couplets of cisplatin (DDP) and topotecan (TOP) and cisplatin and paclitaxel (T) as first-line therapy for advanced epithelial ovarian cancer on behalf of the National Cancer Institute of Canada. The dosage used were as follows: DDP/TOP cycles: DDP 50 mg/m2 and TOP 0.75 mg/m2 DDP/T
Smokers at Highest Risk of Developing Secondary Head and Neck Tumors Smokers are not only the most likely people to develop lung cancer, but also cancer of the head and neck. This study by the M.D. Anderson Cancer Center shows that they are also at highest risk of developing a secondary head and neck cancer -- which is defined as cancer of a different origin than a patient's primary tumor. That is the interim
Federal Funding of Pap Smears Saves Lives After an intense lobbying effort, the federal government agreed in 1990 to fund Pap smear tests for elderly recipients of Medicare. Now, researchers conclude that the tests have remarkably reduced the rate of invasive cervical cancer for at-risk women. Dr. Fredrick Montz, of Johns Hopkins Hospital and Medical Institution, and other researchers
New Diabetes Drug Helps Cancer Cells Differentiate, Making them More Like Normal Cells Researchers in Boston have used a new diabetes drug to push cancer cells to mature, shifting them from rapidly dividing and dangerous undifferentiated cells to slower growing and less aggressive cells. The study is the first to demonstrate that such so-called "differentiation therapy" can be effective in patients with certain solid tumors. The
Patients Self-Administer Protein in Nose Drops to Treat Kaposi's Sarcoma An anti-angiogenesis and immune-stimulating protein, delivered via nose drops, has resulted in a complete or major response in more than one-third of patients with late-stage Kaposi's Sarcoma (KS), an AIDS-related skin and body cancer which originates from the cells that line the blood vessels, in a trial led by Dr. Parkash Gill of the
Melanoma Patients Could be Spared Radical Surgery by Sentinel Node Mapping A technique called "sentinel node mapping" can accurately diagnose the minority of patients whose melanoma has spread, while saving the majority from radical lymph node dissection surgery, according to results of a five-year, multi-center study. In sentinel node mapping, injections of radioisotope makers and blue dye are used to pinpoint the
Prophylactic Mastectomy Satisfactory to Majority of Patients A recent study has found that the majority of women at increased risk for breast cancer who elected prophylactic mastectomy as a preventive measure were satisfied with the procedure. Marlene Frost, RN, PhD, and colleagues found that of women who were mailed questionnaires following the procedure, 38 percent were satsifed and 31 percent were
Study of High-Dose Chemotherapy in Metastatic Breast Cancer Finds No Survival Benefit Analysis of data as of March 31, 1999, from the largest randomized trial of high-dose chemotherapy with stem cell transplant in the treatment of responding metastatic breast cancer has shown no significant difference in overall survival or lethal toxicity when compared to conventional dose maintenance chemotherapy. The study was led by Edward
Combination Chemotherapy Regimen Yields Impressive Results in Late-Stage Prostate Cancer Atlanta, GA, May 17, 1999 -- The chemotherapeutic taxane agent docetaxel, combined with the nitrogen mustard estramustine phosphate and low dose hydrocortisone, appears to be a promising treatment for men with an advanced form of prostate cancer, according to the results of a phase II trial conducted by the Cancer and Leukemia Group B (CALGB)
Stem Cells May be Engineered to Resist Toxic Effects of Chemotherapy A research team led by the National Cancer Institute has taken the first steps toward making bone marrow stem cells resistant to the toxic effects of chemotherapy. Such an advance could potentially allow patients to undergo multiple rounds of high dose chemotherapy without having to remove their marrow, the source of "stem" cells that produce
PET Scans More Effective than Standard Technique at Accurately Staging Lung Cancer Classic "TNM" staging in lung cancer (an assessment of primary Tumor, regional lymph Node involvement, distant Metastasis) has only been partially effective at accurately predicting patient survival. Now, researchers at the University Hospital Gasthuisberg, Belgium, have examined the use of PET imaging to provide a more accurate, and
Preliminary Results of High-Dose Chemotherapy in Primary Breast Cancer Show Equivalency to Intermediate-Dose Treatment; 3 Years of Additional Follow-up Required 783 women with primary breast cancer that has spread to 10 or more lymph nodes under the arm were randomized to receive either high-dose chemotherapy (cyclophosphamide, cisplatin and BCNU) with bone marrow and peripheral blood stem cell support, or intermediate-dose chemotherapy using the same drugs at doses that could be safely administered
Scandinavian Study Finds No Overall Survival Benefit to High-Dose Chemotherapy in Primary Breast Cancer A randomized Scandinavian study of 525 women with high-risk breast cancer, conducted over a four year period betwen 1994-1998 at a constant inclusion rate, indicates that there is no overall benefit to high-dose chemotherapy with bone marrow stem cell support versus those who received "tailored" chemotherapy doses tailored according to blood
South African Study Finds Survival Benefit to High-Dose Chemotherapy in Primary Breast Cancer UPDATE: The data from this study have since been called into question. For more information concerning this, please consult: OncoLink NCI/PDQ: Misconduct Suspected in South African Breast Cancer Study. A South African study of 154 women with high-risk breast cancer involving 10 or more lymph nodes shows increased survival rates and lower
Soy Remedy Not Effective for Hot Flashes with Breast Cancer Researchers have found that a soy phytoestrogen preparation was ineffective for diminishing hot flashes in breast cancer survivors. This is despite soy phytoestrogen being touted by some to be helpful for diminishing hot flashes. Charles Loprinzi, MD, and colleagues developed a double-blind, placebo-controlled clinical trial in which breast
First Independent Assessment of Breast Cancer Risk Reduction Drugs Supports a Role for Tamoxifen Therapy Atlanta, GA -- The first independent assessment of tamoxifen and raloxifene, conducted by a special American Society of Clinical Oncology (ASCO) Working Group, confirms that, based on an examination of all available literature since 1990, tamoxifen may be offered to reduce the risk of developing breast cancer for some women, but that it is
First Kidney Cancer Blood Test Could Prevent Removal of Kidneys Researchers at New York Presbyterian Hospital have devised the first kidney cancer blood test that may spare some patients removal of their kidneys. Although not yet accurate enough to be used as a screening tool for the general population, the test did detect 60 percent of cancers in a test group of kidney cancer patients. It did not detect any
New Approach Reduces Side Effects of High-Dose Chemotherapy Atlanta, May 18, 1999 — Research conducted at City of Hope Cancer Center in Los Angeles suggests that the most serious and costly side effects of high-dose chemotherapy — including long-term hospitalization and severe inflammation of the mouth — can be reduced by a new approach to adjusting dosage of the chemotherapy agent Taxol
Tamoxifen Also Effective in Stopping Abnormal Breast Cells from Becoming Cancerous Last year a major study of 13,000 women demonstrated that tamoxifen can significantly reduce the risk of developing breast cancer in some women. In October 1998, the federal Food and Drug Administration (FDA) approved the drug for use in women at increase risk of developing the disease. Now, after further analysis of the data, researchers have
ASTRO President David Hussey, MD, Outlines Coming Changes in Certification for Radiation Oncologists Patients have become much more educated over the past few years, thanks in large part to the unprecedented availability of medical information on the Internet. They also are demanding greater assurance that their physicians are competent. This public movement has been fueled by reports like the one issued by the Institute of Medicine last year,
Preliminary Report of RTOG 9508: A Phase III Trial Comparing Whole Brain Irradiation Alone Versus Whole Brain Irradiation Plus Stereotactic Radiosurgery for Patients with Two or Three Unresected Brain Metastases Presenter: P. W. Sperduto Affiliation: Radiation Therapy Oncology Group Summary: Brain metastases develop in approximately 25% of all cancer patients. Management with stereotactic radiotherapy for patients with 3 or less solitary lesions remains an area of controversy. This preliminary analysis is of a group of patients treated with whole
Intergroup 0116 (SWOG 9008)- phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Evaluation of efficacy and radiotherapy treatment planning Presenter: S. Smalley Affiliation: Intergroup/SWOG Background: The management of patients with locally advanced gastric adenocarcinoma (ACA) remains a major challenge for oncologists. Complete surgical resection has been the standard care for this group of patients. However, the long-term outcome has been dismal. In
Randomized Treatment of Brain Metastasis with Gamma Knife Radiosurgery, Whole Brain Radiotherapy or Both Presenter: P. B. Chougule Affiliation Rhode Island Hospital/Brown University, Providence, RI Summary: Brain metastases develop in approximately 25% of all cancer patients. Management with whole brain RT may palliated these patients, but survival remains dismal. This report is of a group of patients randomized to either whole brain RT
RTOG Protocol 92-02: A phase II trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate Presenter: Gerald E. Hanks Affiliation: RTOG Background: Controversy exists on the integration of hormonal therapy for the treatment of locally advanced prostate cancer. This trial was designed to determine if long term androgen ablation is superior to short term ablation. Materials and Methods: 1554 patients with
Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both Presenter: P.B. Chougule Affiliation: Rhode Island Hospital, Brown University Summary: Whole brain radiation therapy (WBRT) has been the standard care for the majority of patients with brain metastasis. However, the outcome of these patients has been dismal due to both local and systemic failure. Stereotactic radiosurgery
Very accelerated versus conventional radiotherapy in HNSCC: Results of the GORTEC 94-02 randomized trial Presenter: J. Bourhis, et al. Affiliation: Institut Gustave Roussy, Villejuif, France Summary: Squamous cell carcinomas of the head & neck are considered to be fairly rapid growing tumors. Advanced tumors are frequently unresectable and treated with radiotherapy. Theoretically, better tumor control might be
A Phase II Randomized Trial of Synchronous Radiotherapy With Temozolomide in Brain Metastases Presenter: E. Paraskevaidis Affiliation: Metaxas Cancer Hospital, Pireus, Greece Summary: The majority of patients with brain metastases has a dismal survival of approximately 4 months. Various strategies have been investigated, including whole brain radiation therapy (WBRT), craniotomy, stereotactic radiosurgery boost,
Impact of a boost dose of 16 Gy on the local control and cosmesis in patients with early breast cancer: The EORTC boost versus no boost trial Presenter: H. Bartelink Affiliation: The Netherlands Cancer Institute Summary: Breast conservation therapy (BCT) is a standard of care in the management of patients with early stage breast cancers. BCT results have consistently shown survival equivalence to mastectomy. However, the question remains whether boost is
Neuropsychological effects of fractionated, stereotactic radiation therapy (FSRT) in patients with meningiomas Presenter: G. Welzel Affiliation: University of Heidelberg Summary: Meningiomas are benign, slow growing tumors with a good survival rate after radiotherapy. Neurotoxicity after irradiation of the central nervous system is widely discussed and of special interest in patients with meningiomas. The purpose of this study was
Sequential Vs. Concurrent Chemotherapy and Radiation Therapy for Inoperable Non-Small Cell Lung Cancer (NSCLC) Analysis of Failures in a Phase III Study (RTOG 9410) Presenter: R. Komaki, MD Affiliation: University of Texas MD Anderson Cancer Center Summary: Since the randomized trial reported by Dillman et al., the standard of care for the treatment of unresectable or inoperable non small cell lung cancer in patients with a good performance status has been sequential chemotherapy
Panel Presentation Examines the Use of Unconventional Medical Therapies by Cancer Patients Some recent scientific studies, combined with anecdotal evidence from doctors and nurses, suggest that many cancer patients are using so-called "unconventional medical therapies" while they are undergoing radiation, chemotherapy, or other conventional cancer treatments. The most commonly used unconventional therapies range from vitamins and
Health Policy Expert Marc Roberts, PhD, Urges Physicians to Be on the Front Lines of Change in the Health Care System Inevitable changes in how services are paid for in our current health care system require physicians to take the initiative to get involved, said Marc Roberts, Harvard University Professor of Political Economy and Health Policy, during this morning's keynote address on the second day of the ASTRO meeting. During an hour-long talk peppered
Preliminary Results from a Phase II Trial of Conformal Radiation Therapy for Localized Pediatric Brain Tumors Presenter: TE Merchant, MD Affiliation: St. Jude Children's Research Hospital, Memphis, TN Background: Use of Conformal Radiation Therapy (CRT) for treatment of pediatric brain tumors has the potential for reducing toxicity and improving the therapeutic ratio.Ê The results of such treatment, and the relationships between dose,
Results From the IRS IV Randomized Trial of Hyperfractionated Radiation in Children with Rhabdomyosarcoma Presenter: S. S. Donaldson, MD Affiliation: The Intergroup Rhabdomyosarcoma Study Background: Hyperfractionated radiation therapy (HFRT) has the theoretical potential for improving efficacy without producing more late effects of children with rhabdomyosarcoma (RMS). This analysis of the IRS experience in treating rhabdomyosarcomas
Proton radiation therapy in the management of prediatric base of skull tumors Presenter: E. B. Hug Affiliation: Loma Linda University Background: Treatment of pediatric skull base tumors is limited by the dose of radiation that can be delivered because of critical normal tissues in this region.Ê Becuase of the unique physical characteristics of proton beams, a much higher dose of radiation can be delivered
The Impact of Hormonal Therapy on Outcome in Moderate to High Risk Prostate Cancer Treated with Permanent Radioactive Seed Implantation Presenter: L. N. Lee Affiliation: Mount Sinai School of Medicine, New York, NY Background: Prostate radioactive seed implantation is an effective treatment option for clinically organ- confined prostate carcinoma. Hormonal therapy (HT) has been used in addition to local therapy in selected group of patients in an attempt to improve
Submandibular Salivary Gland Transfer Prevents XRT Xerostomia Presenter: N Jha Affiliation: Cross Cancer Institute Edmonton, AB Canada, Universsity of Alberta Background: Xerostomia is a significant problem for many patients after XRT to the head and neck. This study looks at a novel surgical procedure to prevent radiation induced xerostomia. The submandibular salivary gland is transferred to
Effects of Pamidronate Use on the Palliative Radiotherapy of Bone Metastases Presenter: M.N. Yavux Affiliation: Karadeniz University, Trabzone, Turkey Background: Between 15-70% of all cancer patients are found to have bone metastases over the course of their lifetime. These lesions are frequently painful, cause a decrease in mobility, and negatively impact on the quality of life. While radiation therapy can
A Randomized Trial Comparing the Efficacy of Single Radiation Fraction with Fractionated Radiation Therapy in the Palliation of Skeletal Metastases Presenter: P. Kirkbride Affiliation: Princess Margaret Hospital, Toronto, Canada Background: Controversy exists about whether painful bone metastases can be palliated equally well by short hypofractionated radiation therapy regimens as by more prolonged radiation therapy (RT). This randomized study was primarily designed to compare the
Advantage of protons compared to IMRT in the treatment of medulloblastoma Presenter: W. H. St. Clair Affiliation: Massachusetts General Hospital Background: There is continued interest in finding ways to reduce the radiation related toxicity associated with the treatment of medulloblastoma. Both proton radiotherapy and intensity modulated radiation therapy (IMRT) have been shown to
Senator Kennedy (D-MA) Tells Radiation Oncologists He Will Continue to Support Physicians' and Patients' Best Interests He Also Urges Their Involvement in Debates Over the Pain Relief Promotion Act Speaking this morning before a nearly full ballroom of ASTRO attendees, Massachusetts senator Edward M. Kennedy asserted that he will continue to be a pro-patient, pro-physician, and pro-research voice in our nation's Congress. Kennedy first expressed pride in the important role that Massachusetts academic centers, biotechnology companies, and
Creating Human Cancer Cells out of Normal Cells to Better Understand the Disease Process: Biologist Robert Weinberg Describes His Lab's Successes A human cancer cell is the product of a series of genetic mutations that transform a normal cell into a progressively abnormal cell. Currently, it is impossible for researchers to retrace the complex series of steps that were actually involved in any given cancer cell's transformation-there are simply too many unknowns. So instead, cancer
The impact of an aggressive local control policy and of adjuvant chemotherapy in primary presentation extremity adult soft-tissue sarcoma in sequential cohorts over 20 years at the Princess Margaret Hospital Presenter: B. O'Sullivan Affiliation: Princess Margaret Hospital Background: Some controversy remains over the optimal management of adult patients with extremity soft tissue sarcomas. This study was performed to determine the impact of different treatment policies over a 20 year period. Materials and Methods: 592 patients
The Role of Sentinel Node Lymphoscintigraphy in Identifying Patterns of Internal Mammary Node Drainage in Breast Cancer Presenter: M. C. Smitt Affiliation: Stanford University, Stanford, CA Background: Postmastectomy radiation therapy has recently been shown in randomized studies to improve overall survival for patients with node-positive breast cancer. It remains controversial whether or not to treat internal mammary node (IMN). Both Danish and
Black and White Patients Fare Equally Well When Treated with Post-lumpectomy Radiotherapy Presenter: S. H. Burri Affiliation: Emory University School of Medicine, Atlanta, GA Background: African-American women have a lower survival rate than white women following a diagnosis of invasive breast cancer. Limited information is available regarding the impact of race on results of breast conservation therapy (BCT). In this
RSR 13 Plus Cranial Radiation Therapy Improves Survival in Patients With Brain Metastases Compared to RTOG Recursive Partitioning Analysis Brain Metastases Database Presenter: E. Shaw Affiliation: Wake Forest University School of Medicine Background: RSR 13 is a potential enhancer of ionizing radiation by decreasing hemoglobin-O2 binding affinity and increasing tumor oxygenation. This is a Phase II open label study design to assess the efficacy/safety of RSR 13 plus external beam radiation
Conformal Proton Beam Therapy of Prostate cancer — Report of Long-term PSA Based Outcomes in Over Twelve Hundred Patients Presenter: C. J. Rossi Affiliation: Loma Linda University Background: Conformal proton beam therapy for prostate cancer has been performed for almost a decade at Loma Linda University Medical Center. This presentation is an update of the outcomes based on PSA. Materials and Methods: 1257 patients with localized prostate
Quality of Life After Definitive Treatment for Prostate Cancer. Differences Based on Treatment Modality Presenter: J. W. Davis Affiliation: Eastern Virginia Medical School, Norfolk, VA Background: This is a retrospective study comparing the general health and disease-specific quality of life (HRQOL) in patients with localized prostate cancer treated with brachytherapy (PD103), external beam radiation therapy (XRT), and radical
Update of Toxicity Following 3D Radiation Therapy for Prostate Cancer on RTOG 9406 Presenter: J.M. Michalski Affiliation: Radiation Therapy Oncology Group Background: Randomized data have been reported that show improvements in biochemical outcomes for high risk prostate cancer patients treated with 3D conformal dose escalation. However, the therapeutic window has yet to be defined regarding the perceived
Is Breast Cancer in the Elderly An Indolent Disease? Presenter: R. Singh Affiliation: The University of Chicago Hospital, Chicago, IL Background: Among elderly women with early-stage breast cancer, age has a strong influence on treatment patterns, and many elderly women are not offered the full range of options. This is partly due to a long-held perception that breast cancer in elderly women
Fatigue During Radiation Therapy of Patients with Breast Cancer Presenter: H. Geinitz Affiliation: Technical University Munich, Muenchen, Germany Background: The purpose of this study was to evaluate the course and the possible causes of fatigue during postoperative radiation therapy (RT) of patients with breast cancer. Materials and Methods: 41 patients with postoperative RT after breast
Final Keynote Address Highlights the Uncertainties Surrounding Prostate Cancer Screening and Treatment In this "PSA era" — that is, a time when PSA (prostate-specific antigen) blood tests are detecting prostate cancer at a much earlier stage than in the past — there is a great deal of uncertainty about what the best treatments are and whether finding and treating the cancer early makes a difference in survival. Dr. Michael Barry, the
Phase III Comparison of Sequential vs Concurrent Chemoradiation for Patients (Pts) with Unresected Stage III Non-Small Cell Lung Cancer (NSCLC): Initial Report of Radiation Therapy Oncology Group (RTOG) 9410. Presenter: Walter Curran Affiliation: Bodine Ctr for Cancer Treatment Background: Radiation therapy with or without chemotherapy is standard therapy for locally advanced unresectable non-small cell lung cancer (NSCLC) The use of sequential cisplatin-based chemotherapy followed by thoracic radiation therapy has been shown to be
Alternating Chemo-Radiotherapy Versus Partly Accelerated Radiotherapy in Advanced Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Randomized Trial Presenter: M. Benasso Affiliation: Inst Nazionale per la Ricera sul Cancro and affiliated centers, Genoa, Italy Background: It has previously been shown that alternating chemo-radiotherapy (ALT) has improved outcome compared with conventional RT in advanced-stage Squamous cell carcinoma of the head and neck. This study compared the
Clinical Trial Costs Are Similar To and May be Less Than Standard Care and Inpatient (INPT) Charges at an Academic Medical Center (AMC) are Similar to Major, Minor and Non-Teaching Hospitals Presenter: J. Quirk Affiliation: Memorial Sloan-Kettering Cancer Center Background: Payers limit access to medical centers where clinical trials are performed. Insurance companies and Medicare have not facilitated treatment in clinical trials due to presumed huge costs. Materials and Methods: Retrospective review of 152 medicare eligible
Effective First Line Therapy of Ovarian Cancer with Cisplatin and Prolonged Topotecan Infusion - A NYGOG/ECOG Study Presenter: J. Speyer Affiliation: Mt. Sinai Sch of Med, NYU Sch of Med, Albert Einstein Sch of Med Background: Becuase of the known activity of cisplatin and topotecan as second line treatment of ovarian cancer and the favorable results with a Phase II 21-day prolonged infusion of topotecan the authors combined these agents in a first line
Preliminary Results of Intergroup INT 0123 Randomized Trial of Combined Modality Therapy (CMT) for Esophagel Cancer: Standard vs. High Dose Radiation Therapy Presenter: B.D. Minsky Affiliation: RTOG, ECOG, NCCTG, others Background: Although definitive chemoradiation for esophageal cancer is a relatively good treatment option for patients with non-metastatic disease, survival rates remain disappointing. This intergroup trial tests the dose escalation hypothesis in this population receiving
A Phase III Randomized Trial Comparing Concurrent Chemotherapy-Radiotherapy with Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma Presenter: A.T. Chan Affiliation: Chinese University Hospital of Hong Kong, and others. Background: Nasopharyngeal carcinoma (NPC) has been shown to be highly responsive to chemoradiation. The intergroup trial 0099 (Al-Sarraf, et al) showed a significant difference in progression free survival and overall survival of 5-FU/cisplatin and
A Phase II Study (GOG 153) of Recurrent and Advanced Endometrial Carcinoma Treated with Alternating Courses of Megestrol Acetate and Tamoxifen Citrate Presenter: James V. Fiorica Affiliation: H. Lee Moffitt Cancer Center, others Background: Progestins are commonly used in the treatment of endometrial cancer, but downregOLation of progesterone receptors may shorten response duration. Tamoxifen binding may recruit receptors and thus increase response duration. This phase II trial tests
A clinical trial comparing concurrent Cisplatin and radiation therapy versus radiation alone for locally advanced Squamous Cell Carcinoma of the cervix carried out by the National Cancer Institute of Canada Clinical Trials Group Presenter: Gavin Stuart Affiliation: NCI Canada, University of Alberta, Edmonton, Canada, others Background: In 1999, multiple abstracts of phase III trials comparing chemoradiation with radiation alone in localized cervix cancer were presented at ASCO. All of these trials showed that multiagent platinum-containing chemotherapy was
A Multi-Center Study of the Costs of Enrolling Cancer Patients on Phase II Clinical Trials Presenter: T.J. Stinson Affiliation: Northwestern University Background: It has long been assumed by health insurance companies that clinical trial costs are much larger than those incurred in standard practice. For this reason, both medicare and private insurers have not reimbursed charges for patients in clinical trials. Only 3-8% of
A Phase III Comparison of Standard Radiation Therapy (RT) Versus RT Plus Concurrent Cisplatin (CDDP) Versus Split-Course RT Plus ConcurrentCDDPP and 5-Flourouracil (5-FU) in Patients with Unresectable Squamous Cell Head and Neck Cancer (SCHNC): An Intergroup Study Presenter: DJ Adelstein Affiliation: ECOG & SWOG Background: Unresectable squamous cell carcinoma of the head and neck region conotates a very poor prognosis overall. Recent Phase II trials have suggested the addition of concurrent chemotherapy to radiation therapy may improve survival. This study was performed to compare standard
Does pretreatment PSA add to predicting long-term survival from prostate cancer? Presenter: M. Roach III Affiliation: Univ of California San Francisco, Univ of Michigan Background: Numerous prognostic indicators, such as Gleason score and tumor stage are known to be significant in assessing risk of recurrence of or death from prostate cancer. Although prostate specific antigen (PSA) is useful in predicting
3 Versus 6 Cycles of CMF in Breast Cancer Patients with 1 to 9 Positive Nodes: Results of the German Adjuvant Breast Cancer Group (GABG) III Trial Presenter: H. Maass Affiliation: GABC Background: For breast cancer, one of the standard adjuvant chemotherapy regimens is CMF for 6 cycles. Although there is clear data that prolonging CMF for more than 6 cycles is not beneficial, there are limited data evaluating the efficacy of fever cycle of CMF. This study was performed to better
Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC] Versus Cisplatin (P) Plus Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results. Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC] Versus Cisplatin (P) Plus Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results (Abstract 1502) Presenter: Jean Louis Misset Affiliation: Htpital Paul Brousse, Villejuif, France; Ctr Oscar Lambret, Lille, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Curie, Paris, France; Ctr Hospitalier, Bourg en Bresse, France; Clin St Pierre, Perpignan, France; Ctr Val d'Aurelle, Montpellier, France; Policlinico Umberto, Rome, Italy; Ctr Paul
Induction Chemotherapy for High Grade Extremity Soft Tissue Sarcomas: Histologic Response and Correlation of Tumor Necrosis to Long Term Disease Free and Overall Patient Survival Presenter: R.M. Henshaw Affiliation: Washington Cancer Institute at Washington Hospital Center Background: The role of chemotherapy in soft tissue sarcoma remains controversial. Multiple randomized trials have shown no benefit in the addition of chemotherapy to surgery and radiation therapy (RT). High grade sarcomas have a greater
Comparative Cost-Effectiveness of Paclitaxel-Cisplatin (TP) vs Cyclophosphamide-Cisplatin (CP) in Women with Advanced Epithelial Ovarian Cancer: Results from a Randomized Trial Presenter: Hugh Walker Affiliation: Queens Univ. and Tom Baker Cancer Ctr, Canada Background: This sub-analysis of 160 patients in the intergroup trial (EORTC-GCCG, NOCOVA, NCIC-CTG, SGCSG) compares the cost effectiveness of paclitaxel (Taxol) - cisplatin (TP) vs. cyclophosfamide-cisplatin in the treatment of epithelial ovarian cancer.
The Role of Radiotherpay and Tamoxifen in the Management of Node Negative Invasive Breast Cancer </= 1.0 cm Treated with Lumpectomy: Preliminary Results of NSABP Protocol B-21 Presenter: N. Wolmark Affiliation: NSABP Background: Although definitive radiation therapy after lumpectomy has been standard of care for breast conservation for breast cancer, there has been some debate if radiation therapy is needed for small tumors (< 1.0cm) when the patient is treated with Tamoxifen. This study was performed to
Postoperative Combined Radiation and Chemotherapy Improves Disease-Free Survival (DFS) and Overall Survival (OS) in Resected Adenocarcinoma of the Stomach and G.E. Junction. Results of Intergroup Study INT-0116 (SWOG 9008) Presenter: John S. Macdonald Affiliation: SWOG; ECOG; RTOG; CALGB; NCCTG Background: It is estimated that there will be 22,000 new cases and 13,500 deaths from gastric cancer in the US this year. The cure rate for gastric carcinoma treated with surgery alone ranges between 10% - 30% for node positive patients and 40% - 60% for
Cytoreduction Nephrectomy in Metastatic Renal Cancer: The Results of Southwest Oncology Group Trial 8949 Presenter: Robert Charles Flanigan Affiliation: Southwest Oncology Group Background: Metastatic renal cancer has a poor prognisis and is classically highly resistant to chemotherapy. A number of case series have reported a benefit to neprhectomy in patients with metastatic renal cancer. This prospective randomized trial was
A Randomized Trial Comparing Two Fractionation Schedules for Breast Irradiation Postlumpectomy in Node-Negative Breast Cancer Presenter: Timothy J. Whelan Affiliation: Hamilton Regional Cancer Ctr, Hamilton, ON, Canada; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; McMaster Univ, Hamilton, ON, Canada; Kingston Regional Cancer Ctr, Kingston, ON, Canada; Ottawa Regional Cancer Ctr, Ottawa, Background: Many women with early stage
A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) Presenter: Joan H. Schulter Affiliation: ECOG Background: Since the initial randomized trials in the early 1990's which showed improved median and overall survival by adding chemotherapy to radiation therapy (RT) in NSCLC patients, several newer agents have been introduced. Some of these agents are used off protocol based on
A Multicenter Randomized Phase III Study Comparing Paclitaxel-Cisplatin-Etoposide (TEP) Versus Cisplatin-Etoposide (EP) as Front - Line Treatment in Patients with Small Cell Lung Cancer (SCLC) Presenter: Dimitrios Mavroudis Affiliation: The Greek Lung Cancer Cooperative Group Background: The combination of etoposide (E) and cisplatin (P) is standard first line treatment for small cell lung cancer (SLSC). A complete response (CR) rate of 30-40% is seen in limited stage (LS) and 10-20% in extensive stage (ES). Paclitaxel
Topotecan (T) vs. Observation (OB) Following Cisplatin (P) Plus Etoposide (E) in Extensive Stage Small Cell Lung Cancer (ES SCLC) (E7593): A Phase III Trial of the Eastern Cooperative Oncology Group (ECOG) Presenter: D. H. Johnson Affiliation: Vanderbilt University Background: Topotecan, a topoisomerase I inhibitor, has a 40% response rate as a first line agent in SCLC and moderate activity in chemoresistant SCLC. This Phase III trial was designed to determine Topotecan?s efficacy in combination with standard chemotherapy.
Comparison of health-related quality of life (HRQOL) after brachytherapy, radical prostatectomy, or external beam radiation for localized prostate cancer Presenter: M.G. Sanda Affiliation: University of Michigan Background: Many oncologists believe that in selected patients, the differences between disease free survival and overall survival for radical prostatectomy (RP), external beam radiation therapy (ERT), and brachytherapy (BT) are negligable. Given the rough equivalence of
A Phase III Trial of the Use of Long Term Androgen Suppression Following Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate. Presenter: Gerald E. Hanks Affiliation: Fox Chase Cancer Center Background: Radiation therapy is a long-standing treatment option for prostate cancer Previous studies by the RTOG and the EORTC have demonstrated improved disease-specific survival using the combination of adjuvant hormone therapy and radiation therapy The duration of
Venlafaxine Alleviates Hot Flashes: An NCCTG Trial Presenter: Charles L Loprinzi Affiliation: North Central Cancer Treatment Group, Rochester, MN Background: Hot flashes can be a significant problem for many cancer patients. Unconventional treatments such as vitamin E and soy have been shown to be only marginally better than a placebo in controlling such symptoms. Estrogen and
Impact of Tumor Control on Survival in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Treated with Concurrent Thoracic Radiotherapy (TRT) and Chemotherapy (CT). Presenter: K. Furuse Affiliation: Health Insurance Union Osaka Cent Hosp, Osaka Background: Radiation therapy and chemotherapy is standard therapy in good performance status patients with locally advanced unresectable non-small cell lung cancer (NSCLC) A previously reported study by Furuse et al (J Clin Oncol 1999;17:2692)
Continued Response Following Treatment with IMC-C225, an EGFr MoAb, Combined with RT in Advanced Head and Neck Malignancies. Presenter: James A. Bonner Affiliation: University of Alabama, ImClone Background: Radiation therapy with or without chemotherapy is standard therapy for locally advanced head and neck squamous cell cancer Because of the relatively poor outcome with nonoperative therapy, newer systemic agents are being investigated which may
Comparative Cost-Effectiveness of Paclitaxel-Cisplatin (TP) vs Cyclophosphamide-Cisplatin (CP) in Women with Advanced Epithelial Ovarian Cancer: Results from a Randomized Trial. Presenter: Hugh Walker Affiliation: Queens Univ, Kingston, NC, Canada Background: Postoperative paclitaxel and cisplatin (TP) chemotherapy improves survival compared with cyclophosphamide and cisplatin (CP) in patients with advanced ovarian cancer The combination of TP is considerably more expensive than CP, and may raise
A Randomized Phase II Trial Comparing RhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) Plus Carboplatinum/Paclitaxel (CP) to CP Alone in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Presenter: Russel DeVore, MD Affiliation: Vanderbilt University Background: For advanced and metastatic non-small cell lung cancer, current therapies are limited. These therapies at best may offer patients survival benefits on the order of approximately 4 months, and can still have side effects which may be serious. Newer therapies are in
Forum on Clinical Trials and Public Perception Focuses on the Role of the Media "No disease has been cured as many times as cancer has." -Ellen Stovall, National Coalition for Cancer Survivorship (NCCS), quoting Rick Weiss of The Washington Post The media plays a pivotal role in shaping public perceptions of cancer clinical trials, since this is where most people get their information about health and medicine.
ASCO Broadcasts Unique Interactive Forum Live On Monday morning, ASCO tested new ground by broadcasting its first-ever satellite-fed live session on patient-physician communication to more than 425 hospitals and medical centers nationwide. The session itself, which was attended by a few hundred oncologists and other health care professionals, had a decidedly different feel than most of the
ASCO Broadcasts Unique Interactive Forum Live This morning, ASCO tested new ground by broadcasting its first-ever satellite-fed live session on patient-physician communication to more than 425 hospitals and medical centers nationwide. The session itself, which was attended by several hundred oncologists and other health care professionals, had a decidedly different feel than most of the
Keeping cancer guidelines current: results of a comprehensive prospective literature monitoring strategy Presenter: M.C. Brouwers/G. P.Browman Affiliation: McMaster University, Hamilton Regional Cancer Centre, Hamilton, Canada Background: A Clinical Practice Guideline (CPG) is an evidence-based statement that assists patients and health care providers make appropriate decisions about cancer care. CPGs are developed and updated through the
An EORTC Randomized Phase III Trial of Three Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer (NSCLC) Presenter: J. P. Van Meerbeeck Affiliation: EORTC Background: Combination chemotherapy improves survival in advanced NSCLC based on numerous reports. Cisplatin based chemotherapy has remained the standard regimen used in most studies. This study was designed to compare 3 different chemotherapy regimens, 2 containing cisplatin and one
Results of a Spanish Lung Cancer Group Phase III Trial Presenter: V. Alberola Affiliation: Spanish Lung Cancer Group Background: The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung cancer. This study was designed to evaluate this regimen against two other chemotherapy regimens,
Health outcomes following primary Androgen therapy in a population-based cohort Presenter: K. B. Knopf Affiliation: National Cancer Institute, Bethesda, MD Background: There are scant data on how quality of life is affected among men with prostate cancer who have no symptoms related to the tumor but are receiving adjuvant hormonal therapies. Evidence from such patients on the effects of various androgen suppression
Myelodysplastic (MDS) Syndrome and Leukemia After Autotransplantation for Lymphoma: a Multicenter Case-Control Study Presenter: D. J. Rizzo Affiliation: NCI, Bethesda, MD Background: Increased survival has been seen in pateints with Hodgkin?s disease and Non-Hodgkin?s lymphoma who underwent autotransplantation, with a 40-50% long-term disease-free-survival rate. However, previous reports indicate that pts receiving autotransplants for lymphoma have an
Amifostine (AF) Cytoprotetion (CP) of Escalating Doses of Melphalan (MEL) and Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Final Results of a Phase I & II study Presenter: G. L. Phillips Affiliation: University of Maryland / Greenebaum Cancer Center Background: Alkylating agents show a steep dose response curve. Regimen related toxicity (RRT) is dose- limiting with AHSCT Growth factors and stem cell transplantation permits dose escalation to non- hematologic organ limit. Melphalan dose at 220 mg/
Efficacy of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Reducing Mucositis in Patients with Hematologic Malignancies Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation (auto-PBPCT) After Radiation-Based Conditioning ? Resu Presenter: R. T. Spielberger Affiliation: City of Hope National Medical Center, Duarte, CA Background: TBI/VP16/Cyclophosphamide is the established conditioning regimen for auto-PBPCT and it causes approximaetly 80% of severe oral mucositis. Currently, no standard therapy is available to prevent or reduce severe oral mucositis rHuKGF
A Prospective Randomized Trial of Prophylactic Platelet Transfusion and Bleeding Incidence in Hematopoietic Stem Cell Transplant (HSCT) Recipients: 10, 000 μL vs. 20,000 μL Threshold Presenter: M.S. Zumberg Affiliation: University of Florida College of Medicine Background: Threshold of Prophylactic Platelet Transfusion (PPT) for HSCT has yet to be determined One retrospective review in bone marrow transplant patients showed no difference in the incidence of major bleeding episodes in pts that received PPT at 10,000 μL
A single Dose of Pegylated Filgrastim (SD/01) is as effective as Daily Filgrastim for Hematologic Support of Chemotherapy in Breast Cancer Patients: Results of a Randomized,k Double-Blind, Phase 3 Trial Presenter: F.A. Holmes Affiliation: US Oncology, Houston, TX Background: Neutropenia is a frequent result of cytotoxic chemotherapy and increases patient risk for serious infection and treatment failure due to dose-reduction or delay. Pegylated Filgrastim (long acting, once per cycle) single dose SD/01 has been shown previously to
Satisfaction and anxiety are improved with the use of an easy-to-read informed consent document: a randomized multi-group study Presenter: P. C. Raich Affiliation: AMC Cancer Research Center, Denver, CO Background: Informed consent is a process in which the patient is given all the information needed to decide whether to participate in a clincal trial. The signing of the informed consent document by both the patient and the investigator is the written verification of
Informed consent to cancer clinical trials Presenter: S. Joffe Affiliation: Dana-Farber Cancer Institute, Boston, MA Background: For valid informed consent to be obtained, the prospective subject must have an understanding of the medical and research issues involved to make an informed and enlightened decision. Assuring an understanding of the research procedure requires thorough and
Cisplatin/Gemcytobine (CG) vs Cisplatin/Gemcytobine/Vinorelbine (CGV) vs Sequential Doublets of Gemcytobine/Vinorelbine Followed by Ifosfamide/Vinorelbine (GV/IV) in Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase III Trial Presenter: V. Alberola Affiliation: Spanish Lung Cancer Group Background: The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung cancer. This study was designed to evaluate this regimen against two other chemotherapy regimens,
A Randomized, Double-blind, Phase III Study Evaluating Fixed Dose, Once-Per-Cycle Pegylated Filgrastim (SD/01) vs Daily Filgrastim to Support Chemotherapy for Breast Cancer Presenter: M. Green Affiliation: Multicenter Trial Background: It has been shown prolonged neutropenia associated with chemotherapy administration can be significantly decreased by daily Filgrastim. Pegylated Filgrastim is a sustained duration form administered once per chemotherapy cycle. This study was performed to compare the
Providing Audiotapes of Primary Adjuvant Treatment Consultations to Women with Breast Cancer: a Multi-Site Randomized Controlled Trial Presenter: T. Hack Affiliation: University of Manitoba, Winnipeg, MB, Canada; British Columbia Cancer Agency, Vancouver; BC, Canada; Tom Baker Cancer Centre, Calgary, AB, Canada; Cross Cancer Institute, Edmonton, AB, Canada Background: Patient education is an important part of a patient therapeutic plan. Empirical evidence supports the use of
Non-Adherence with Adjuvant Tamoxifen Therapy in Women with Early Stage Breast Cancer Presenter: A. H. Partridge, P. S. Wang, E. P. Winer, J. L. Avorn Affiliation: Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA Background: Tamoxifen has been shown to help prevent breast cancer recurrence and death in women with early breast cancer. Yet, non-compliance for a number of reasons appears to be an
The Effect of Hospital Volume and Socioeconomic Status on Colostomy Rates for Rectal Cancer Presenter: D. C. Hodgson Affiliation: Background: Loss of sphincter function due to rectal cancer is associated with significant impairment in the quality of a patient?s life. This study evaluated the impact of surgical case-volume or patient demographics on the risk of undergoing permanent colostomy for rectal cancer. Materials and
The Quality of Non-Cancer Care Delivered to Elderly Breast Cancer Survivors Presenter: C.C. Earle, H. f Burstein, F. P. Winer, J. C. Weeks Affiliation: Dana-Farber Cancer institute, Boston, MA Background: There are currently more than 2 million breast cancer survivors in the US; as screening and treatment improve we expect that this number will increase. Elderly survivors of breast cancer, like their non-breast cancer
How Much Chemotherapy Are Cancer Patients Receiving at the End of Life? Presenter: E.J. Emanuel Affiliation: National Institutes of Health Background: End of life issues are an important part of oncology care. This study was performed to determine the proportion of cancer patients getting chemotherapy at the end-of-life, their characteristics, and how chemotherapy relates to receiving hospice. Materials and
Opening Address: NCI Director Dr. Richard Klausner Welcomes ASCO Members Saturday morning, National Cancer Institute Director Richard Klausner, MD, welcomed attendees to the ASCO annual meeting by also welcoming them into what he sees as a new era for oncology: the so-called "post-genomic era." With the completion of the draft sequence of the human genome three months ago, said Klausner, we passed a
ASCO/European Society for Medical Oncology Joint Session Addresses the Clinical and Ethical Implications of the Human Genome Project A panel of American and European presenters came together Saturday afternoon in a special joint session to share perspectives on how the sequencing of the Human Genome will likely affect the clinical practice of oncology is practiced in the clinic. All four speakers agreed that this development holds forth great promise for a better
Role of body-surface area in Cisplatin pharmacokinetics Presenter: F. de Jongh Affiliation: Rotterdam Cancer Institute, Rotterdam, Netherlands Background: Dosages of anticancer drugs are usually calculated on the basis of a uniform standard, the body surface area (BSA). Although many physiological functions are proportionate to BSA, overall drug clearance is only partially related to this
A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Of Novel Erythropoiesis Stimulating Protein (NESP) In Patients Undergoing Platinum Treatment For Lung Cancer Presenter: Robert Pirker Affiliation: NESP 980297 Study Group Background: Studies indicate that the carbohydrate content of erythropoietin influences serum half-life. The novel erythropoiesis stimulating protein darbepoetin alfa (NESP) is a glycoprotein with 2 more N linked carbohydrate side chains than Recombinant human erythropoietin
Predicting Risk Of Neutropenic Complications: A Point-Of-Care Assessment Tool Presenter: Lloyd Lininger Affiliation: SUNY Albany, Albany, NY Background: Neutropenia induced by chemotherapy (CT) is associated with increased morbidity and decreased quality-of-life. Dose reductions and delays due to severe neutropenia may also compromise long- term survival. Prophylactic use of G-CSF has been shown to be effective in
Phase III Trial of BCNU Plus Cisplatin (CDDP) Versus BCNU Alone, and Standard Radiation Therapy (SRT) Versus Accelerated Radiation Therapy (ART) in Glioblastoma (GBM) Patients: NCCTG/SWOG Results Presenter: J.C. Buckner Affiliation: Mayo Clinic, Rochester, MN Background: The adjuvant treatment for GBM is radiation therapy plus or minus BCNU. With this therapy, the median survival is about 10 months and the 5- year overall survival is about 1%. With such poor outcomes, new therapeutic approaches are needed. This study was designed
A Multicenter, Randomized, Double Blind, Placebo (PB) Controlled Trial of Marimastat (MT) In Patients with Glioblastoma Multiforme (GBM) or Gliosarcoma (GS) Following Completion of Conventional, First-Line Treatment Presenter: S. Phuphanich Affiliation: The Marimastat Glioblastoma Study Group Background: The standard adjuvant therapy for GBM is radiation therapy with or without BCNU. The outcomes of therapy for GBM or GS are poor. There is clearly a need for novel treatment approaches. This study looks a Marimastat administration as an attempt to
Clinical pharmacology of paclitaxel in relation of patient age: CALGB 9762 Presenter: S.M. Lichtman Affiliation: CALGB, Chicago, IL Background: The taxanes are one of the most important new classes of anticancer agents to emerge in the last decade. Paclitaxel, one of the two taxanes, has been widely used in patients with various malignancies, especially in the elderly population. However, its pharmacokinetics
Role of body-surface area in Cisplatin pharmacokinetics Presenter: F. de Jongh Affiliation: Rotterdam Cancer Institute, Rotterdam, Netherlands Background: Dosages of anticancer drugs are usually calculated on the basis of a uniform standard, the body surface area (BSA). Although many physiological functions are proportionate to BSA, overall drug clearance is only partially related to this
A Phase I study of oxaliplatin in cancer patients with impaired renal function Presenter: M.A. Graham Affiliation: University of Texas Health Science Center, San Antonio Background: Oxaliplatin is a new platinum derivative with activity in several solid tumors, especially in some cisplatin/carboplatin-refractory neoplasms. Oxaliplatin clinical toxicity is also distinct from other platinum drugs: it has minimal renal
Phase I evaluation of an epothilone B analog (BMS-247550): clinical findings and molecular correlates Presenter: S. Mani Affiliation: NYU Medical Center, NY Background: The epothilones are naturally occurring antimitotic drugs that share with the taxanes a similar mechanism of action without apparent structural similarity. Some early pre-clinical data demonstrated activity against taxane- sensitive and -resistant tumors, Materials and
A phase I and Pharmacologic trial of weekly epothilone B in patients with advanced malignancies Presenter: E.H.Rubin Affiliation: The Cancer Institute of New Jersey, New Brunswick, NJ Background: The epothilones are equipotent and exhibit kinetics similar to taxol in inducing tubulin polymerization into microtubules in vitro and in producing enhanced microtubule stability and bundling in cultured cells. Epothilones also cause cell cycle
Primary Chemotherapy (PCT) For Patients With Operable Oral Cavity Cancer: Results Of A Randomized Study Presenter: Lisa Licitra Affiliation: Istituto Nazionale Tumori, Milan, Italy Background: This study was designed to investigate the impact of neoadjuvant chemotherapy on primary surgery in operable oral cavity cancer. Materials and Methods: Randomized trial of 195 patients with operable squamous cell carcinoma of the oral cavity
Preliminary results of RTOG 9703 - a phase II randomized trial of concurrent radiation (RT) and chemotherapy for advanced Squamous Cell Carcinomas (SCC) of the head and neck Presenter: A.S. Garden Affiliation: U.T.M.D. Anderson Cancer Center, Houston, TX Background: Concurrent chemoradiation may improve Survival for advanced Head and Neck cancer. 2. Numerous studies have evaluated different treatment approaches with different fractionation, chemotherapeutic agents, and timing of drug administration. Materials
Accelerated chemoradiation to 70.6 gy is more effective than accelerated radiation to 77.6 gy alone — two year's results of a German multicenter randomized trial (ARO 95-6) Presenter: Volker Gustav Budach Affiliation: Charite University Clinics, Berlin, Germany Background: This study attempts to answer whether accelerated chemoradiation is more effective than accelerated radiation therapy alone? Materials and Methods: Multicenter study of 384 pts, between March 1995 and May 1999, with locally advanced head
Maximizing Local Control And Organ Preservation In Advanced Squamous Cell Head And Neck Cancer (SCHNC) With Hyperfractionated Radiation (HRT) And Concurrent Chemotherapy Presenter: David J. Adelstein Affiliation: Cleveland Clinic Foundation, Cleveland, OH. Background: 5Fu and cDDP are the best studied and most effective drugs for head and neck cancer. Both agents are radiosensitizers. Altered fractionation regimen is more effective than conventional therapy. Materials and Methods: 44 patients (pts) with
Phase III Study Comparing Cisplatin (C) & 5-Flurouracil (F) Versus Cisplatin & Paclitaxel (T) In Metastatic/Recurrent Head & Neck Cancer (MHNC) Presenter: B Murphy Affiliation: Vanderbilt-Ingram Cancer Center Background: CF is the standard combination regimen for MHNC. With expected response rate of 30%, medium survival (MS) 6 mos, 1 yr overal survival (OS) of 20%. An ECOG trial found paclitaxel is an active agent for the treatment of squamous cell carcinoma of the head and neck.
Efficacy And Safety Of The Anti-Epidermal Growth Factor Antibody (EGFR) IMC-C225, In Combination With Cisplatin In Patients With Recurrent Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Refractory To Cisplatin Containing Chemotherapy Presenter: Waun Ki Hong/Roy S. Herbst Affiliation: Anderson Cancer Center Background: Patients with recurrent SCCHN who fail to respond to platinum-based therapy rarely respond to second-line treatment This study was performed to evaluate IMC-C225 in patients that have failed standard chemotherapy. Materials and Methods: Patients (pts) with
A Phase III Study Of Concomitant Oral Pilocarpine To Reduce Hypo-Salivation And Mucositis Assocated With Curative Radiation Therapy (RT) In Head And Neck (H&N) Cancer Patients. RTOG 9709 Presenter: Charles W. Scarantino/Charles B. Scott Affiliation: Multi-institutional Background: Radiotherapy plays a major role in the management of H&N cancer. The major treatment side effects are mucositis and xerostomia (dry mouth), which can affect tolerance and result in treatment interuptions. For patients recieving > 50Gy of radiation,
Nutrition and Cancer: An Update What definite positive associations have researchers found between certain nutrients or dietary components and the development of cancer? Very few, according to three researchers who attempted to summarize the state of nutritional research at ASCO this afternoon. Arthur Schatzkin, MD, of the National Cancer Institute, Maria Elana
The Shape of Things to Come: Sunday Afternoon Special Session Focuses on the Biology of Cancer During a panel presentation that ASCO members "are likely to be talking about ten years from now," to use the words of ASCO president- elect Dr. Larry Norton, four leading researchers in the molecular biology of cancer looked back, looked ahead, and also talked about some of the current exciting developments in the field. Harold Varmus,
Evaluation Of The Safety And Efficacy Of An Oral Molecularly-Targeted Therapy, STI-571, In Patients (PTS) With Unresectable Or Metastatic Gastrointestinal Stromal Tumors (GISTS) Expressing C-KIT (CD117) Presenter: Charles D. Blanke Affiliation: Oregon Health Sciences University, Portland, OR Background: GISTs are cancers which arise from intestinal cells in the abdomen and are characterized by expression of the proto-oncogene c-kit. c-KIT mutation is seen in 56-80% of GISTs GISTs are unresponsive to standard chemotherapy with median
Second Primary Neoplasms (SPNS) Of The Central Nervous System (CNS) In Survivors Of Childhood Cancer - A Report From The Childhood Cancer Survivor Study (CCSS) Presenter: J. Neglia Affiliation: Childhood Caner Survivor Study, University of Minnesota, Minneapolis, MN Background: Second neoplasms of the CNS are well- recognized events among survivors of childhood cancer, often following leukemia or primary CNS tumors. The CCSS is a multi-institutional retrospective cohort study created as a
Recombinant Human Keratinocyte Growth Factor (RHUKGF) Prevents Chemotherapy-Induced Mucositis In Patients With Advanced Colorectal Cancer: A Randomized Phase II Trial Presenter: Stephen John Clarke Affiliation: Royal Prince Alfred Hospital, Camperdown, Australia Background: Oral mucositis in cancer patients receiving chemotherapy can lead to dose reduction and/or treatment breaks, both of which could have a negative impact on treatment outcomes. The use of 5-fluorouracil (5-FU) and folinic acid for the
Fluoxetine Versus Placebo In Advanced Cancer Outpatients: A Placebo-Controlled, Double-Masked Trial Of The Hoosier Oncology Group Presenter: Michael Jordan Fisch Affiliation: UT/MD Anderson Cancer Center, Houston, TX Background: Depressive symptoms are prevalent in advanced cancer patients, and no standard of care exists regarding assessment and management of this clinical problem. Studies have demonstrated that Serotonin reuptake inhibitors such as fluoxetine are
Effect Of An SSRI Antidepressant On Fatigue And Depression In Seven Hundred Thirty-Eight Cancer Patients Treated With Chemotherapy: A URCC CCOP Study Presenter: Gary R. Morrow Affiliation: University of Rochester Cancer Center, Rochester, NY Background: Fatigue can significantly interfere with a cancer patient's ability to fulfill daily responsibilities and enjoy everyday life. It commonly co-exists with depression in patients undergoing chemotherapy, suggesting that administration of an
Clinicians' Assessment Of Quality Of Life (QOL) In Outpatients With Advanced Cancer: How Accurate Is Our Prediction? A Hoosier Oncology Group Study Presenter: Michael L. Titzer Affiliation: Indiana University Cancer Center and the Walther Cancer Institute, Indianapolis, IN Background: Cancer and its related symptoms, such as depression and fatigue, can have substantial impact on a cancer patient's quality of life (QOL). Studies indicate that QOL can be and important prognostic factor. QOL
STI 571, An Active Drug In Metastatic Gastro Intestinal Stromal Tumors (GIST), An EORTC Phase I Study Presenter: Allan T. Van Oosterom Affiliation: EORTC Soft Tissue and Bone Sarcoma Group, Brussels, Belgium Background: The overall survival for patients with GISTs is poor with an estimated 10 to 20 month median survival in patients with metastatic disease. GISTs are characterized by expression of the c- kit proto-oncogene product (KIT) in
SWOG 8710 (INT-0080): Randomized Phase III Trial of Neoadjuvant MVAC+Cystectomy Versus Cystectomy Alone in Patients With Locally Advanced Bladder Cancer Presenter: R.B. Natale Affiliation: SWOG Background: Radical cystectomy has been the gold standard for the treatment of locally advanced bladder cancer. However, 50-60% develop recurrent or metastatic disease after cystectomy. It has been hypothesized that neoadjuvant therapy for advanced bladder cancer will 1)immediately treat
Phase III Trial To Preserve The Larynx: Induction Chemotherapy And Radiotherapy Versus Concomitant Chemoradiotherapy Versus Radiotherapy Alone, Intergroup Trial R91-11 Presenter: Arlene A. Forastiere Affiliation: Intergroup Background: Induction chemotherapy (IC) followed by radiation has been the standard of treatment for advanced laryngeal carcinoma. In the landmark study of the VA laryngeal trail. (NEJM 324:1685, 1995), induction chemotherapy using cis-platinum (cDDP) and 5-Fu followed by radiation
A randomized Comparison of Radiofrequency Thermal Ablation and Percutaneous Ethanol Injection for the Treatment of Small Hepatocellular Carcinoma Presenter: H. P. Allgaier/M. Olschewski Affiliation: University of Pisa, Pisa, Italy Background: Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide. Approximately 80% of patients are inoperable at the time of diagnosis. The treatment of choice for hepatocellular carcinoma remains surgical resection or liver
PELF is More Active than FAMTX in Metastatic Gastric Carcinoma (MGC) Presenter: G. Cocconi Affiliation: Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy Background: Most patients with gastric cancer in the United States are found at the time of diagnosis to have advanced disease. The prognosis of these patients is extremely poor. Various treatment regimens have been explored. Materials
Surgical Resection with or without pre-operative chemotherapy in oesophageal cancer: an updated analysis of a randomized controlled trial conducted by the UK Medical Research Council Upper GI Tract Cancer Group Presenter: P. Clark Affiliation: MRC Clinical Trials Unit, London, UK Background: The poor survival of patients with clinically localized squamous cell or adenocarcinoma of the esophagus suggests that occult dissemination of disease is present in most patients at diagnosis. This provides a rationale for adding a systemic therapy to local
A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative oncology Group (ECOG) trial Presenter: J. Berlin Affiliation: ECOG, USA Background: The vast majority of patients with pancreatic cancer are diagnosed with locally advanced unrespectable or advanced disease for which there is no curative therapy. Many chemotherapeutic agents have been evaluated in patients with pancreatic cancer. Gemcitabine (gem) and 5-FU are the
Gemcitabine-Oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a Gercor Multicenter phase II study Presenter: C. Louvet Affiliation: Hospital St-Antoine, Paris France Background: Gemcitabine has been shown to be an active agent in the treatment of pancreatic cancer. Some preclinical data showed that the combination of gemcitabine with oxaliplatin (GEMOX) exerts potent antiproliferative effects in human cancer cell lines, including
International Symposium Takes a Global Look at Treatment for Advanced Breast Cancer What's the single biggest risk factor for dying of breast cancer, both in the U.S. and worldwide? Poverty, according to a series of presentations given by international researchers at ASCO this morning. Oncologists from the United States, Brazil, India, Australia, South Africa, and Germany came together to take their audience on a
Radiation Therapy Oncology Group (RTOG) 95-14; a phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in high risk (HR), high grade, soft tissue sarcomas (STS) of the extremities and body wall: a preliminary report Presenter: W.G.Kraybill Affiliation: RTOG Background: Radiation therapy plays a central role in the management of many soft tissue sarcomas and allows for a substantial reduction in the extent of surgical resection. The addition of chemotherapy to preoperative irradiation has been investigated Materials and Methods: A total of 45
Response to neoadjuvant thermochemotherapy as significant prognosticator for long-term survival of patients with retroperitoneal or visceral high-risk soft-tissue sarcoma Presenter: C.M.Wendtner Affiliation: Ludwig-Maximilian-University Background: The clinical application of hyperthermia with increase of tissue temperatures (range 40-44 degrees C) has been integrated in multimodal anti- cancer strategies. The combination of hyperthermia and chemotherapy or radiochemotherapy has been tested within clinical
Therapy-related Myelodysplasia (T-MDS/T-AML) Following Treatment Of Children With Osteosarcoma Presenter: Smita Bhatia Affiliation: City of Hope Comprehensive Cancer Center, Duarte, CA Background: T-MDS/T-AML is known to be associated with anti-neoplastic treatment. With alkylating agents, T-MDS/T-AML is associated with deletion of chromosome 5 and/or 7, with a long latency (4-7 yrs) and MDS. With Topoisomerase II, abnormality of
Second Malignant Neoplasms (SMN) In Children Treated For Rhabdomyosarcoma: A Report From The Intergroup Rhabdomyosarcoma Studies (IRS) I-IV Presenter: Sheri L. Spunt Affiliation: Children's Oncology Group Soft Tissue Sarcoma Committee, Arcadia, CA Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of the childhood (5%). Multimodality therapy can provide cure in > 70% of pts. Treatment related late squalae become important as long term survival increases.
Clinical Significance Of Axillary Micrometastases In Breast Cancer: How Small Is Too Small? Presenter: Nora M Hansen Affiliation: John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA Background: Lymph node metastases are the most significant prognostic indicator for patients with breast cancer. a. 15-20% LN ? pts die within 5 yrs b. 20-30% LN ? pts recurs > 10 yrs Historically hematoxylin and eosin (H&E)
Preliminary Results Of A Randomized Study Of Tamoxifen +/- Breast Radiation In T1/2 N0 Disease In Women Over 50 Years Of Age Presenter: Anthony Fyles Affiliation: Princess Margaret Hospital, Toronto, ON, Canada Background: Breast radiation (RT) shows definitive reduction in local relapses, however, with moderal toxicity and without a survival benefit. In Tamoxifen (TAM) treated pts, majority have no relpase without RT. With RT, TAM further decreased rate of
Comparison Of Lumpectomy Plus Tamoxifen With And Without Radiotherapy (RT) In Women 70 Years Of Age Or Older Who Have Clinical Stage I, Estrogen Receptor Positive (ER+) Breast Carcinoma Presenter: Kevin S. Hughes Affiliation: Massachusetts General Hospital Background: No survival impact of RT from previous studies. Tumor in this group of pts grow slowly, therefore, less time at risk. This study is designed to assess, in this population, whether RT, when added to tamoxifen: 1) decreases locoregional recurrence, 2)
Overall Survival After Cyclophosphamide, Adriamycin, 5-FU, And Tamoxifen (CAFT) Is Superior To T Alone In Postmenopausal, Receptor (+), Node (+) Breast Cancer: New Findings From Phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100) Presenter: Kathy Albain Affiliation: Loyola Univ. Med. Center, Maywood, IL Background: The treatment of older women with breast cancer presents many unique treatment issues. One such issue is the use of anthracyclines to treat older patients who are receptor positive and node positive. The objectives of INT-0100 were to determine 1) if
Effect Of Raloxifene After Tamoxifen On Breast And Endometrial Cancer Growth Presenter: Ruth M. O'Regan Affiliation: Northwestern University, Chicago, IL Background: After the completion of 5 years of tamoxifen therapy, breast cancer patients are still at risk for osteoporosis and breast cancer recurrence. Raloxifene (RAL) is a selective estrogen receptor modulator, approved for the prevention of osteoporosis in
Bone Mineral Density In Premenopausal Patients In A Randomized Trial Of Adjuvant Endocrine Therapy (ZIPP-TRIAL) Presenter: Asgerdur Sverrisdóttir Affiliation: University Hospital, Stockholm, Sweden Background: There is evidence that ovarian ablation can improve survival in pre-menopausal patients with early-stage breast cancer. However, there is concern that a premature menopause may be associated with long-term adverse side effects, such as a
Incidence And Prognostic Impact Of Amenorrhea During Adjuvant Therapy In High Risk Premenopausal Breast Cancer Patients: Analysis Of A National Cancer Institute Of Canada Clinical Trials Group (NCIC CTG) Phase III Study Presenter: W. Parulekar Affiliation: Kingston, ON, Canada Background: One of the consequences of adjuvant therapy for breast cancer is drug-induced amenorrhea. The incidence and prognostic impact of drug induced amenorrhea (DIA) during adjuvant therapy with anthracycline containing regimens compared to standard CMF chemotherapy is poorly
Preventing Chemotherapy-associated Amenorrhea (CRA) With Leuprolide In Young Women With Early-stage Breast Cancer Presenter: Kevin R. Fox Affiliation: University of Pennsylvania Cancer Center, Philadelphia, PA Background: Premature amenorrhea is often associated with adjuvant chemotherapy treatment for breast cancer. The rate of amenorrhea varies to 10 to 100% in studies depending on the age of patients and the type of chemotherapy used. Whether or
American Cancer Society Award Winner Sidney Winawer, MD, Discusses the Progress and Promise of Colorectal Cancer Screening "The best screening test is the screening test that gets done." That was the central point repeatedly made by Sidney Winawer, MD, Chief of Gastroenterology at Memorial Sloan Kettering Cancer Center, as he sketched out a twenty-five year history of developments in colorectal cancer screening on the final morning of ASCO 2001. Winawer's
Integrative Approaches to Health and Healing: Empowering Mind, Body and Spirit featuring Joan Borysenko, PhD Date: November 10, 2001 Location: Philadelphia, Pennsylvania, USA Symposium Web Page: www.lindacreed.org, www.joanborysenko.comand www.drsavard.com Sponsors: Linda Creed Breast Cancer Foundation and the Center for Integrative Medicine at Thomas Jefferson University Hospital Objectives: To discover and integrate alternative
Perspectives in Breast Cancer Date: November 10, 2001 Location: Philadelphia, Pennsylvania, USA Symposium Web Page: www.lindacreed.org, www.joanborysenko.comand www.drsavard.com Sponsors: Linda Creed Breast Cancer Foundation and the Center for Integrative Medicine at Thomas Jefferson University Hospital Objectives: To discover and integrate alternative
Advances in Pediatric Hematology/Oncology Date: November 14-16, 2001 Location: Clearwater Beach, Florida, USA Symposium Web Page: www.moffitt.usf.edu/faptp Sponsors: Florida Association of Pediatric Tumor Programs Who Should Attend: Health care professionals working in pediatric hematology and oncology Objectives: Learn the latest treatments and trends in childhood
Leukemia and Myelodysplasia: Advances in Biology, Diagnosis and Management Date: November 14-16, 2001 Location: Clearwater Beach, Florida, USA Symposium Web Page: www.moffitt.usf.edu/faptp Sponsors: Florida Association of Pediatric Tumor Programs Who Should Attend: Health care professionals working in pediatric hematology and oncology Objectives: Learn the latest treatments and trends in childhood
Perpectives in Bladder Cancer Date: November 14-16, 2001 Location: Clearwater Beach, Florida, USA Symposium Web Page: www.moffitt.usf.edu/faptp Sponsors: Florida Association of Pediatric Tumor Programs Who Should Attend: Health care professionals working in pediatric hematology and oncology Objectives: Learn the latest treatments and trends in childhood
DOSGEL '01 - 2nd International Conference on Radiotherapy Gel Dosimetry Date: November 18-21, 2001 Location: Queensland University of Technology, Brisbane, Australia Symposium Web Page: www.dosgel.qut.edu.au Sponsors: IOMP, ACPSEM, AAPM, COMP, IPEM Who Should Attend: Individuals currently undertaking gel dosimetry Objectives: Bring together individuals with an interest in three-dimensional
Integrating JCAHO Pain Standards in Special Populations Date: November 2, 2001 Location: Woodbridge, New Jersey, USA Symposium Web Page: www.medsch.ucla.edu/som/medicine/cewm/education.asp Sponsors: New Jersey Pain Initiative, American Cancer Society, Eastern Division, Inc., New Jersey Commission on Cancer Research Who Should Attend: Health Professionals Topics: Summarize
Improving Quality of Life: Integrative Approaches to Pain & Cancer Date: November 2, 2001 Location: Woodbridge, New Jersey, USA Symposium Web Page: www.medsch.ucla.edu/som/medicine/cewm/education.asp Sponsors: New Jersey Pain Initiative, American Cancer Society, Eastern Division, Inc., New Jersey Commission on Cancer Research Who Should Attend: Health Professionals Topics: Summarize
Endocrine prevention and treatment of breast and gynaecological cancer Date: November 2, 2001 Location: Woodbridge, New Jersey, USA Symposium Web Page: www.medsch.ucla.edu/som/medicine/cewm/education.asp Sponsors: New Jersey Pain Initiative, American Cancer Society, Eastern Division, Inc., New Jersey Commission on Cancer Research Who Should Attend: Health Professionals Topics: Summarize
It's Time To Focus On Lung Cancer Date: November 4, 2001 Location: Philadelphia, Pennsylvania, USA Symposium Web Page: www.twcp.org Sponsors: The Wellness Community, Bristol-Myers Squibb, CancerCare, Oncology Nursing Society, The Chest Foundation
The 2nd International Conference on Systems Biology Date: November 4-7, 2001 Location: Caltech, Pasadena, California, USA Symposium Web Page: www.icsb2001.org Sponsors: Caltech and Japan Science and Technology Corporation Topics: Systems biology is the application of experimental, theoretical and modeling techniques to the study of biological organisms at all scales, from the
43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology Date: November 4-8, 2001 Location: San Francisco, California, USA Symposium Web Page: www.astro.org Sponsors: ASTRO Who Should Attend: Radiation Oncology professionals Topics: Various topics regarding Radiation Oncology Registration Info: Registration information available on our website as of April 2001.
Chemotherapy Foundation Symposium XIX: Innovative Cancer Therapy For Tomorrow Date: November 7-10, 2001 Location: Marriott Marquis, New York, New York, USA Symposium Web Page: www.mssmtv.org Sponsors: Page & William Black Post-Graduate School and Chemotherapy Foundation Who Should Attend: Oncologists, immunologists, radiologists, hematologists, physicians with secondary in oncology, nurses, pharmacists,
Marrow Transplantation in Children: Current Results and Controversies - Meeting #6 Date: November 8 - 10, 2001 Location: St. Augustine, Florida, USA Venue: World Golf Village Renaissance Resort Symposium Web Page: www.pedsref.org Sponsor: The Alfred I. duPont Hospital for Children of The Nemours Foundation Who should attend: Pediatric marrow transplanters, pediatric hematologists/oncologists,
Non-Small Cell Lung Cancer Update Date: November 12, 2001 at 3pm EST Location: WebMD Online Event Symposium Web Page: To be provided. Sponsors: Alliance for Lung Cancer Advocacy, Support, and Education Who should attend: Lung Cancer Patients, Families, Caregivers Topics: Current therapies, healthy lifestyle tips, and the many forms of support available for
Coping More Effectively: Living with Lymphedema Date: November, 2001 Location: Philadelphia, Pennsylvania, USA Sponsors: Cancer Rehabilitation Program, H.U.P. Who should attend: Patients with lymphedema and their families Objectives: Patients to learn coping strategies Topics: Coping with lymphedema is callenging. Come hear a discussion of coping strategies for you and your
The Psychologist and the supportive home care in terminal cancer patient: The diagnostic process Date: November 24, 2001 Location: Milan, Italy Symposium Web Page: www.vidas.it Sponsors: VIDAS Topics: Palliative Care Agenda: Nursing of terminal patient. A therapeutic chance? Questions about addressing the patient to the psychologist. Home as setting: the importance to keep it under observation. The
The Group Room: Special Remote broadcast on lung cancer, live from Philadelphia! The Group Room-the nationally syndicated radio call-in talk show about cancer-will feature a multidisciplinary panel of cancer experts discussing the latest advances in lung cancer research, screening and treatment from CHEST 2001--the American College of Chest Physicians' (ACCP) 67th annual scientific meeting, November 4th 4-6 pm ET (1-3 pm
24th Annual San Antonio Breast Cancer Symposium Date: December 10-13, 2001 Location: San Antonio, Texas, USA Symposium Web Page: www.sabcs.org Sponsors: Cancer Therapy & Research Center, and UTHSCSA Who Should Attend: Academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other
Fifth European Course of Reconstruction in Head and Neck Oncology Location: San Antonio, Texas, USA Date: December 10-13, 2001 Symposium Web Page: www.sabcs.org Sponsors: Cancer Therapy & Research Center, and UTHSCSA Who Should Attend: Academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other appropriate
The Second European Conference: Perspectives in Lung Cancer Date: December 6-8, 2001 Location: Barcelona, Spain Symposium Web Page: www.imedex.com/oncology.htm
Advances in Pituitary Disease: Metabolic, Neuroendocrine and Psychosocial Issues Date: December 6-8, 2001 Location: Barcelona, Spain Symposium Web Page: www.imedex.com/oncology.htm
First International Congress on Salivary Gland Diseases Date: January 27, 2002 - January 30, 2002 Location: Geneva, Switzerland Symposium Web Page: www.symporg.ch/conferences/2002/sgd/ Sponsor: University of Geneva Who Should Attend: Otolaryngologists, Dentists, Maxillofacial surgeons, Oncologists Objectives: Review of new developments in diagnosis and treatment of salivary
Cancer, Culture and Literacy Conference Date: January 8-12, 2002 Location: Tampa, Florida, USA Symposium Web Page: www.moffitt.usf.edu/promotions/cclinstitute/ Sponsors: H. Lee Moffitt Cancer Center & Research Institute Who Should Attend: Recent Doctorates or mid career investigators (PhD, DrPH, MD, DNS, SCD or equivalent) Topics: The Cancer, Culture and Literacy
54th Annual Midwinter Radiation Oncology Conference Date: January 18-20, 2002 Location: Anaheim, California, USA Symposium Web Page: www.larad.org/meetings/index.htm Sponsors: Southern California Radiation Oncology Society Who should attend: Radiation Oncologists, Physicists, Radiation Therapists, Oncology Specialists, and Physicians with an interest in cancer treatment
NBTF/ALCASE Brain Metastases Patient Teleconference Date: January 16, 2002 Location: Teleconference; 10:am Pacific Time, 1:00 pm Eastern Time Symposium Web Page: www.braintumor.org Sponsors: NBTF/ ALCASE Who Should Attend: Patients and Caregivers Topics: Symptom management for patients with brain metastases. Agenda: Mark Gilbert, M.D., Anderson Cancer Center, Houston,
Cellular & Molecular Biology of Cancer Date: February 25 - March 1, 2002 Location: Wolfson Conference Centre, Imperial College, Hammersmith Hospital Campus, Du Cane Road, London, England Symposium Web Page: www.med.ic.ac.uk/divisions/cc/wolfson.asp Objectives: This is the 7th year of an intensive 5-day course presented by international distinguished experts.The format
7th Annual NCCN Conference: Practice Guidelines and Outcomes Data in Oncology Date: February 28 - March 3, 2002 Location: Hollywood, Florida, USA Symposium Web Page: www.nccn.org Sponsors: National Comprehensive Cancer Network Topics: Breast cancer Chronic myelogenous leukemia Hodgkin's disease Early detection of prostate cancer Anemia Endometrial/cervical cancer NCCN Oncology Outcomes Database
2nd International Conference on Oncology "Oncology in Africa" Date: Februrary 7-10 2002 Location: Tripoli, Libya Sponsors: African Institute of Oncology, Sabratha, Libya Objectives: Focus on Oncology in Africa. Who should attend: Oncologists, Research Scientists, Physicians, Surgeons and Oncology nurses Topics: INFECTION AND CANCER Nasopharyngeal carcinoma Kaposi's sarcoma
The 3rd Genolier-Geneva-MSKCC Cancer Conference: Upper Gastrointestinal Cancers Date: February 7-8, 2002 Location: Geneva, Switzerland Symposium Web Page: www.imedex.com/Imedex%20website/images/Flash/GI02.htm Sponsors: Genolier Hospital, Switzerland; Memorial Sloan-Kettering Cancer Center, New York Who Should Attend: Medical Oncologists, Gastroenterologists, GI Surgeons and Radiation Therapists Topics:
Focus on Breast Cancer Date: February 9, 2002 Location: The Wellness Community fo Philadelphia, Ridgeland mansion, Chamounix drive, West Fairmount Park, Philadelphia, Pennsylvania, USA Symposium Web Page: www.twcp.org Sponsors: The Wellness Community of Philadelphia Who Should Attend: Women with breast cancer and their support people Objective:
American Cancer Society CareCast Date: February 26, 2002 Location: Washington, DC, USA Symposium Web Page: www.aicr.org Sponsors: American Cancer Society & Cancer Survivors Network Topics: On February 26, from 7:00PM to 8:00PM EST, the Cancer Survivors Network will host a live web cast, focusing on cancer-related issues in the workplace. This forum was created
International Conference on Emerging Trends in Cancer Research Date: March 14-16, 2002 Location: University, New Delhi, India Symposium Web Page: in.geocities.com/jnucancerconf Sponsors: JNU Who Should Attend: Cancer researchers, Clinicians, Students Objectives: Share and discuss current trends in cellular and molecular concept of causation, prevention and cure of cancer Topics:
Fourth Annual Palm Beach Cancer Symposium: Moving Beyond the Ordinary Date: March 22-23, 2002 Location: Delray Beach, Florida, USA Symposium Web Page: www.cbcbiomed.com Sponsors: Boca Raton Community Hospital CME Committee Who Should Attend: Medical Oncologists, Radiation Oncologists, Surgical Oncologists, Gynecologic Oncologists, Pulmonologists, Gastroenterologists, Urologists, Primary Care
Gastrointestinal Cancers: Critical Advances in Risk Assessment, Screening and Management Date: March 23, 2002 Location: City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, California, USA Symposium Web Page: www.cityofhope.org/ccgp/ Sponsors: Primary care physicians, surgical oncolgoists, gastroenterologists, pathologists, nurses, genetic counselors Who Should Attend: Medical Oncologists, Radiation
Skill Building in Psychosocial Oncology and Pallliative Care Date: March 6-8, 2002 Location: Tampa, Florida, USA Symposium Web Page: www.moffitt.usf.edu Sponsors: Moffitt Cancer Center Who Should Attend: Social workers, Psychologists Topics: psychosocial aspects of cancer challenging psychosocial issues in the oncology setting an introduction to pain and symptom management
Colon Cancer: Genetics to Prevention Date: March 7-10, 2002 Location: Loews Philadelphia Hotel, Philadelphia, Pennsylvania, USA Symposium Web Page: www.aacr.org/4310x.asp Sponsors: American Association for Cancer Research Who Should Attend: Basic Scientists, Clinicians and Trainees Conference Objectives: Education for the Multiple Myeloma patient on the latest
Trauma to Triumph: Coping with the Cancer Experience Featuring Edward Leigh, MA This program features the Trauma-to-Triumph story of Edward Leigh, a motivational speaker and colorectal cancer survivor who has appeared on The Today Show. "His amazing story will inspire and encourage you to get tested for colon cancer." Katie Couric, co-anchor The Today Show Join us for an
CCA's 2nd Annual Colorectal Cancer Conference Date: March 1-3, 2002 Location: Marriot Downtown Courtyard, Philadelphia, Pennsylvania, USA Symposium Web Page: www.CCAlliance.org Sponsors: Colon Cancer Alliance Who Should Attend: This event, intended for colorectal cancer survivors, caregivers, friends, family, health care professionals, members of the crc community and
13th Annual Cancer Control Conference: Supportive care throughout the cancer continuum Date: March 6, 2002 Location: The Modern Maturity Center, Inc. Dover, Delaware, USA Symposium Web Page: www.christianacare.org Sponsors: Christiana Care Health System and Delaware Diamond Chapter Oncology Nursing Society Who Should Attend: NursesSocial workersPastoral care providersStudents from these disciplines Conference
Philadelphia Flyers' Wives Gear up for 26th Annual Fundraising Carnival on March 3rd The Philadelphia Flyers organization is no stranger to the emotional and psychological impact of cancer. More than 25 years ago, player Barry Ashbee was diagnosed with leukemia and forced to retire. He died in 1977. Just this past year, the wife of Bill Barber, Flyers head coach, lost her battle with lung cancer. Three years ago, long time
Philadelphia Flyers' Wives Fight For Lives Carnival Coverage A sold-out crowd of 9,000 fans filled the First Union Center in Philadelphia for the 26th annual Flyers' Wives Fight For Lives Carnival. This year's carnival was dedicated to the memory of Jenny Barber, wife of Flyers' head coach, Bill Barber, who died of lung cancer last year. The flyers' family also remembered the life of Stephanie
Philadelphia Flyers' Wives Fight For Lives Carnival: Bill Barber On a day when The First Union Center is filled with a circus-like atmosphere one cannot help but to notice that there is sadness in Bill Barber's smile. Given the recent death of his wife secondary to complications of lung cancer, a person wonders what is racing through the mind of the Flyers head coach. "It's difficult , but the carnival is for
Third Annual Scientific Meeting of the American Society of Breast Surgeons Date: April 24 -28, 2002 Location: Boston, Massachusetts, USA Symposium Web Page: www.breastsurgeons.org Sponsors: The American Society of Breast Surgeons
3rd North American Symposium on Skeletal Complications of Malignancy Date: April 25-27, 2002 Location: Natcher Conference Center-National Institutes of Health Sponsors: Paget Foundation, Penn State College of Medicine, National Cancer Institute URL of Homepage: www.paget.org Who should attend: Oncologists, Hematologists, Urologists, and anyone interested in the bone metastases issue of cancer Topics: Skeletal
2nd Annual Colorectal Cancer Survivors Conference Date: April 19-22, 2002 Location: Newport Beach, California, USA Symposium Web Page: www.colorectal-cancer.net Sponsors: Colorectal Cancer Network Who Should Attend: Colon and rectal cancer survivors, caregivers and advocates Topics: Meet and hear notable colon and rectal cancer experts, survivors, and advocacy leaders
Novel Therapeutic Approaches in Treating Multiple Myeloma Date: April 3, 2002 Location: Cleveland, Ohio, USA Symposium Web Page: www.multiplemyeloma.org Sponsors: Cleveland Clinic and Multiple Myeloma Research Foundation Who Should Attend: Patients and their families Conference Objectives: Education for the Multiple Myeloma patient on the latest available treatment of Multiple
Focus on Gynecologic Cancers: 3rd Annual Conference Date: Friday, April 26, 2002 Location: Adams Mark Hotel, City Line and Monument Road, Philadelphia, Pennsylvania, USA Sponsors: The University of Pennsylvania Cancer Center Who Should Attend: Women Whose Lives have Been Touched by Gynecologic Cancer Conference Objectives: Learn about the latest advances in diagnosis, surgical
It's Time to FOCUS ON Ovarian and Gynecologic Cancers Conference Dates: April 6, 2002 Conference Location: Philadelphia, Pennsylvania, USA Sponsoring Group: The Wellness Community of Philadelphia Conference Web Page URL: www.twcp.org Topics Covered: Disscussion of Treatment Options followed by questions and answers Questions and Answers about Symptom Management during and after
4th International Magnetic Microsphere Conference Date: May 9-11, 2002 Location: Tallahassee, Florida, USA Symposium Web Page: www.magneticmicrosphere.com Sponsors: Who Should Attend: Molecular biologists, Biophysicists,Radiobiologists, Radiation Physicists, Radiation Oncologists Topics: Preparation and Modification of Biodegradable Magnetic Particles, Characterization of
Florida Prostate Cancer Symposium 2002 Date: May 3-4, 2002 Location: Tradewinds Sirata Beach Resort, St. Pete Beach, Florida, USA Symposium Web Page: www.cment.med.usf.edu Sponsors: University of South Florida College of Medicine, Florida Prostate Cancer Network, Maia Associates, Inc. Who Should Attend: Physicians and nurses treating prostate cancer in the
Nutrition After Cancer: A Conference on the Role of Diet and Cancer Survivorship Conference Dates: May 8, 2002 Conference Location: Chicago, Illinois, USA Sponsoring Group: American Institute for Cancer Research Conference Web Page URL: www.aicr.org Topics Covered: Specific topics include soy, flaxseed, vegetables, exercise and obesity. Conference Objectives: This one-day conference has three important
The Group Room^® Cancer Talk Radio Show to Present Two Broadcasts at ASCO Meeting: Live Remote Show, Sunday, May 19 and OncoLink Webcast, Saturday, May 18 LOS ANGELES, May 15, 2002 This year, The Group Room, the nationally syndicated weekly radio call-in cancer talk show, will present two broadcasts from the 38th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida's Orange County Convention Center. On Saturday, May 18, The Group Room and OncoLink will collaborate
Emerging Concepts in the Treatment of Prostate Cancer Conference Dates: May 24, 2002 Conference Location: The Rosen Centre Hotel Sponsoring Group: PIM & Intramed Conference Web Page URL: www.intramedgroup.com/huggins Topics Covered: Emerging Concepts in the Treatment of Prostate Cancer 2nd Annual Charles Huggins Symposium A CME Symposium held just prior to the AUA?s 97th Annual Meeting
14th International Symposium on Supportive Care in Cancer - MASCC/ISOO Date: June 23 - 26, 2002 Location: Boston, Massachusetts, USA Sponsors: MASCC/ISOO Web Site: www.imedex.com
World Conference on Breast Cancer Date: June 4-8, 2002 Location: Victoria Conference Centre, Victoria, BC, Canada Sponsors: WCBC Web Site: www.brcancerconf.kos.net Who Should Attend: Survivors, health care professionals, scientists, physicians, advocates, environmental professionals, educators, journalists, government representatives Objectives: Educate
Endosonography - 5th annual course (Victoria, BC, Canada ) Date: June 4-8, 2002 Location: Victoria Conference Centre, Victoria, BC, Canada Sponsors: WCBC Web Site: www.brcancerconf.kos.net Who Should Attend: Survivors, health care professionals, scientists, physicians, advocates, environmental professionals, educators, journalists, government representatives Objectives: Educate
Endosonography - 5th annual course (Amsterdam, The Netherlands) Date: June 6 & 7, 2002 Location: June 6 & 7, 2002, Amsterdam, The Netherlands Objectives: This course has become an established postgraduate training program, not only for those starting in EUS, but also for the more experienced endosonographist who wishes to optimize his or her skills. Sponsor: European Postgraduate Gastorsurgical
3rd International BCIRG Conference Breast Cancer: Current Evidence and Translational Research Opportunities for Improving Patient Outcomes Date: January 18-20, 2002 Location: Anaheim, California, USA Symposium Web Page: www.larad.org/meetings/index.htm Sponsors: Southern California Radiation Oncology Society Who should attend: Radiation Oncologists, Physicists, Radiation Therapists, Oncology Specialists, and Physicians with an interest in cancer treatment
Third International Laryngeal Cancer Conference: The Management of Laryngeal Carcinoma in the New Millennium This conference is supported by an educational grant from eMedicine.com. Date: June 14-15, 2002 Location: University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Call for
13th Ljudevit Jurak International Symposium on Comparative Pathology Conference Dates: June 7-8, 2002 Conference Location: Multimedial Centar, Sisters of Charity University Hospital, Vinogradska 29, Zagreb, Croatia Sponsoring Group: Olympus, DACO, Shendon Conference Web Page URL: www.kbsm.hr/Jurak/symposium.htm Topics Covered: pathology, human, animal, comparative, experimental, iatrogenic,
ASCO Review 2002 Conference Dates: June 1, 2002 Conference Location: Grand Hyatt New York Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: A concise overview of ASCO 2002. Leading clinical specialists will analyze and interpret the most important data presented in the areas of lung cancer, breast
Novel therapeutic Approaches in the treatment of Multiple Myeloma Conference Dates: Friday, June 21, 2002 Conference Location: Fairchild Auditorium, Stanford Hospital and Clinics, 291 Campus Drive West, Stanford, California, USA Sponsoring Group: Multiple Myeloma Research Foundation Who Should Attend: Professionals: hematologists, oncologists, internists, oncology nurses. Patients and families Topics
The Group Room^® Cancer Talk Radio Show to Broadcast Special Taped Program on International High-Dose Chemotherapy Conference in Canada LOS ANGELES--July 1, 2002--The Group Room--the nationally syndicated weekly radio call-in cancer talk show--will broadcast a special taped program from the "Second International Conference on High-Dose Chemotherapy: Innovation and Evolution," Sunday, July 7 from 4-6 pm ET (1-3 pm PT). The conference, held this past spring in Banff, Alberta,
The Era of Hope Meeting for the Department of Defense (DOD) Breast Cancer Research Program (BCRP) Date: September 25-28, 2002 Location: Orange County Convention Center, Orlando, Florida, USA Symposium Web Page: http://cdmrp.army.mil/bcrp/ Sponsors: US Department of Defense Congressionally Directed Medical Research Program Objectives: To gain greater insight into breast cancer through the scientific exchange between
World Assembly on Tobacco Counters Health (WATCH) - 2002 Date: September 29 - October 4, 2002 Location: New Delhi, India Symposium Web Page: www.watch-2000.org Sponsors: UICC, WHO, ESMO Who should attend: Who should attend: Physicians, Health Care advocates, Nurses, etc. Topics: All tobacco related health issues including national and international efforts to curb tobacco
Leukemia 2002 - towards the cure Date: September 19-22, 2002 Location: Miami, Florida, USA Symposium Web Page: www.goal-med.org Who Should Attend: Academics, clinicians & health care industry Conference Objectives: Largest international meeting for clinicians and research scientists who specialize in the treatment of patients with leukemia. Topics:
Cancer As a Turning Point, From Surviving to Thriving^tm Date: September 14-15, 2002 Location: Chabot College, Hayward, California, USA Symposium Web Page: www.HealingJourneys.org Sponsors: Healing Journeys, Chabot College, A.C.S., Komen Foundation Who Should Attend: Any one whose life has been touched by cancer. Survivors, health professionals, family and care-givers. Topics: A
Changing Concepts in Breast Cancer 2002 Conference Dates: Friday, September 13, 2002 Conference Location: The Rittenhouse Hotel , 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: University of Pennsylvania Cancer Center Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Topics
Novel therapeutic approaches in the treatment of Multiple Myeloma Conference Dates: September 24, 2002 Conference Location: University of Pennsylvania, Philadelphia, Pennsylvania, USA Sponsoring Group: University of Pennsylvania and the Multiple Myeloma Research Foundation Topics Covered: thalidomide transplantation prognostic indicators bisphosphonates novel therapies Conference
IBC's 2nd Protein Kinases Conference Dates: September 9-10, 2002 Conference Location: Seaport Hotel, Boston, Massachusetts, USA Sponsoring Group: IBC Life Sciences Conference Web Page URL: www.LifeSciencesInfo.com/kinases/?source=2722-5 Topics Covered: Defining Kinase Selectivity as a Predictor in Clinical Development New Lead Discovery for Kinase
The 6th World Conference on Melanoma Conference Dates: September 2 - 9, 2005 Conference Location: Vancouver Convention & Exhibition Centre Sponsoring Group: WHO Melanoma Programme Conference Web Page URL: www.worldmelanoma.com Topics Covered: melanoma: surgery, clinical diagnosis, pathology, epidemiology, basic research, dermoscopy, sentinel node biopsy, genetic, vaccine
Interventional Oncology: From Benchtop to Bedside Conference Dates: September 18 & 19, 2002 Conference Location: Tyson's Corner, Virginia, USA Sponsoring Group: Cardiovascular and Interventional Radiology Research and Education Foundation (CIRREF) Conference Web Page URL: www.cirref.org Topics Covered: The Cardiovascular and Interventional Radiology Research and Education Foundation
The 3rd Annual Perspectives in Colorectal Cancer Conference Dates: September 19 - 20, 2002 Conference Location: Chicago, Illinois, USA Sponsoring Group: Imedex Conference Web Page URL: http://www.imedex.com/Imedex%20website/images/Flash/USColo02.htm Topics Covered: Biology, Prevention, Testing and Screening, Operable Colorectal Cancer, Management of Hepatic Metastases, Innovative
The 2nd Princess Margaret Hospital Conference on New Developments in Cancer Management Conference Dates: September 19 - 21, 2002 Conference Location: Toronto, Ontario Canada Sponsoring Group: Princess Margaret Hospital and Imedex, Inc. Conference Web Page URL: http://www.imedex.com/Imedex%20website/images/Flash/pmh02.htm Topics Covered: Lung Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer,
The 7th International Conference on Geriatric Oncology - Cancer in the Elderly. The 3rd Meeting of SIOG Conference Dates: September 27 - 28, 2002 Conference Location: Boston, Massachusetts, USA Sponsoring Group: SIOG - International Society of Geriatric Oncology Conference Web Page URL: www.imedex.com/Imedex%20website/images/Flash/siog02.htm Topics Covered: Progress in the Past year in Surgical Oncology, Biology of Aging, Radiation
7th National Brain Tumor Conference Conference Dates: September 20-21, 2002 Conference Location: San Francisco Bay Area, Denver, Phoenix Sponsoring Group: National Brain Tumor Foundation Conference Web Page URL: http://www.braintumor.org/pservices/wnnewsletter.asp Topics Covered: Symptom management, new treatments, understanding diagnostics, long term issues, research
Beyond Tomorrow: New Horizons in Targeted Breast Cancer Therapies Town Meeting Conference Dates: September 19, 2002 Conference Location: People can attend in Houston in person, over the phone or on the Internet Sponsoring Group: This program is produced by the HealthTalk? Breast Cancer Education Network in partnership with The University of Texas M. D. Anderson Cancer Center in association with the University of
Molecular Targets for Cancer Therapay & Prevention: Second Biennial Meeting Date: October 11-15, 2002 Location: St. Petersburg Beach, Florida, USA Symposium Web Page: www.moffitt.usf.edu/promotions/molecular/index.htm Sponsors: H. Lee Moffitt Cancer Center & Research Institute Topics: The purpose of this meeting is to foster exchange of the most recent findings and ideas in cancer biology. Special
International Clinical Trials Symposium Date: October 11-15, 2002 Location: St. Petersburg Beach, Florida, USA Symposium Web Page: www.moffitt.usf.edu/promotions/molecular/index.htm Sponsors: H. Lee Moffitt Cancer Center & Research Institute Topics: The purpose of this meeting is to foster exchange of the most recent findings and ideas in cancer biology. Special
Third International Conference on Family Care: Empowerment Through Innovation Date: October 12-14, 2002 Location: Arlington, Virginia, USA Symposium Web Page: www.caregiving.org/content/conference2002.html Sponsors: National Alliance for Caregiving Who Should Attend: Administrators, Clinicians, Service Providers, Policymakers, Educators, Advocates Topics: Care at the end of life, Eldercare, Care for
Second Biennial Symposium on Biology, Diagnosis and Treatment of Lymphomas Conference Dates: Friday, October 4, 2002 Conference Location: Philadelphia Marriott West, 111 Crawford Ave., West Conshohocken, PA Sponsoring Group: University of Pennsylvania Cancer Center Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Topics
Cancer and Aging: A Call to Action Conference Dates: October 4-5, 2002 Conference Location: Princeton, New Jersey, USA Sponsoring Group: Saint Barnabas Health Care System, Meridian HEalth System, NJ Commission on Cancer Research Conference Web Page URL: www.cancerandaging.org Topics Covered: Co-Morbidities Best Treatment Practices Pain Management Economic
Novel Therapeutic Approaches in the Treatment of Multiple Myeloma (Chapel Hill, North Carolina) Conference Dates: October 24-25, 2002 Conference Location: The School of Medicine of The University of North Carolina at Chapel Hill Sponsoring Group: The University of North Carolina at Chapel Hill and The Multiple Myeloma Research Foundation Conference Web Page URL: www.multiplemyeloma.org/events/seminars.html Topics Covered:
A Comprehensive Board Review in Hematology and Medical Oncology Conference Dates: October 4 - 9, 2002 Conference Location: M.D. Anderson Cancer Center, Houston, TX Sponsoring Group: M.D. Anderson Cancer Center and Baylor College of Medicine Conference Web Page URL: www.mdanderson.org/conferences Topics Covered: See website for topics Conference Objectives: Demonstrate proficiency of knowledge in
Novel Therapeutic Approaches in the Treatment of Multiple Myeloma (New York, New York) Conference Dates: October 3, 2002 Conference Location: Marquis Ballroom, Marriott Marquis, 1535 Broadway, NY, NY 10036 Sponsoring Group: The Multiple Myeloma Research Foundation Conference Web Page URL: www.multiplemyeloma.org Topics Covered: bisphosphonates thalidomide novel therapies genetics transplantation current
2002 Cancer Symposium: "Controversies in Cancer Care" Conference Dates: October 1, 2002 Conference Location: Newark, Delaware, USA Sponsoring Group: Medical Society of Delaware and Christiana Care Health System Topics Covered: Lung Cancer Screening: Pros and Cons Controversy Surrounding Screening Mammography Prostate Cancer Treatment: Radical Prostatectomy, Radiation and Watchful
The 7th Annual Perspectives in Thoracic Cancer Conference Dates: October 4 - 5, 2002 Conference Location: New York, New York, USA Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/announcements/uslung02.htm Topics Covered: Imaging and Surgical Staging in NSCLC, Management of Resectable Disease, Management of Metastatic/Recurrent Disease, Malignant Mesothelioma
Lymphoma & Myeloma 2002 Conference Dates: October 3 - 5, 2002 Conference Location: New York, New York, USA Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/announcements/l&m02.htm Topics Covered: Myeloma-Basic Science, Plasma Cell Dyscrasias and Other Lymphoplasmacytic Disorders, Bone Disease, Chemotherapy for Myeloma and for Lymphoma,
8th Annual Perspectives in Breast Cancer Conference Dates: October 17 - 18, 2002 Conference Location: Atlanta, Georgia, USA Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/announcements/breast02.html Topics Covered: Breast Cancer Biology, Screening and Diagnosis, DCIS and Early Breast Cancer, DCIS and Early Breast Cancer, Systemic Therapies, New
4th Annual Palliative Care & Pain Management Conference Conference Dates: October 25-26, 2002 Conference Location: Anaheim, California, USA Sponsoring Group: City of Hope National Medical Center Conference Web Page URL: www.cityofhope.org/cme Topics Covered: Geriatric Cancer, Depression, Side effects of Opiate Therapy, Interventional Pain Management, Headache, Arthritis Pain, Regulatory
PEAK HIKE 2002 - New Jersey Conference Dates: October 19, 2002 Conference Location: Dunnfield Creek Natural Area located in, Worthington State Forest, in northwestern New Jersey Sponsoring Group: The Breast Cancer Fund Conference Web Page URL: www.breastcancerfund.org Topics Covered: Conference Objectives: To raise awareness and funds for breast cancer
Eleventh Annual Life After Breast Cancer Conference Conference Dates: October 21, 2002 Conference Location: Philadelphia, Pennsylvania, USA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: Cancer Detection and Diagnosis Mammography: What's All the Fuss? The Use of Ductal Lavage for Detection and Risk Assessment Understanding Your
Patient & Family Seminar Conference Dates: November 8 & 9, 2002 Conference Location: Seattle Washington Sponsoring Group: International Myeloma Foundation Conference Web Page URL: www.Myeloma.org Topics Covered: This interactive forum is a unique opportunity to learn the latest in the treatment and management of myeloma from a panel of world experts.
Colon Cancer Conference Conference Dates: Friday, November 8, 2002 Conference Location: The Rittenhouse Hotel, 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: University of Pennsylvania Cancer Center Topics Covered: TBA Conference Objectives: TBA ---> Who Should Attend: Surgeons, Medical Oncologists, Radiation Oncologists, Nurses, and other
Clinical Diagnosis and Management of Patients With HNPCC and FAP Conference Dates: Wednesday, November 13, 2002 Conference Location: Teleconference, 12PM until 1PM Sponsoring Group: Myriad Genetics Conference Web Page URL: http://registration.intercall.com/go/myriad Topics Covered: Clinical diagnosis and management of patients with familial adenomatous polyposis and hereditary non-polyposis colon
Controversies in the Management of Gynecologic Malignancies 3 Conference Dates: December 5-6, 2002 Conference Location: Washington, DC Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/announcements/usgynonc02.htm Topics Covered: Epithelial Ovarian Cancer, Cervical Cancer, Vulvar Cancer, Endometrial Cancer Since 1999, this debate-based conference series has won the interest and
The Effects of Radiotherapy on Brain & Behavior Through the Lifespan Conference Dates: December 6 - 8, 2002 Conference Location: Westin Rio Mar Beach Resort, Rio Grande, Puerto Rico Sponsoring Group: The Children's Hospital of Philadelphia Conference Web Page URL: www.chop.edu/cme/radiotherapy/ Registration Information: Registration and conference information is available online at
How to talk with your doctor about cancer clinical trials Selma Schimmel, CEO and founder of Vital Options International, will be joining Dr. Robert Comis, leading national oncologist, President and Chairman, CNCCG, on Wednesday Dec. 4, 2002 12:00 Noon EST, for a clinical trials discussion online. Join the live on-line discussion at either Washington Post Live Online or MSNBC Newsweek Viewpoint. Hosted
Multiple Myeloma Patient & Family Seminar Conference Dates: January 24th & 25th, 2003 Conference Location: Los Angeles, California, USA Sponsoring Group: International Myeloma Foundation Conference Web Page URL: www.Myeloma.org Topics Covered: This interactive forum is a unique opportunity to learn the latest in the treatment & management of myeloma from a panel of world
Renal Cell Cancer Symposium Conference Dates: January 25, 2003 Conference Location: Moffitt Cancer Center, Tampa, FL Sponsoring Group: Moffitt Cancer Center & Chiron Conference Web Page URL: www.moffittcancercenter.com Topics Covered: . Distinguished faculty will present information on surgical aspects, conventional therapy, underlying physiology of targeted
Tandem BMT Meetings Conference Dates: January 30-February 3, 2003 Conference Location: Keystone, Colorado Conference Dates: February 10-14, 2005 Conference Location: Keystone, Colorado Conference Dates: February 13-17, 2004 Conference Location: Orlando, Florida Sponsoring Group: American Society for Blood and Marrow Transplantation (ASBMT), and the
New Targets and Innovative Strategies in Cancer Treatment: A Short Course for Clinicians Conference Dates: February 6-8, 2003 Conference Location: Monte Carlo, Monaco Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: The course has been designed with three specific objectives in mind. The first objective is to explain, and to clarify in an often somewhat simplified
The Fourth Annual Wallace H. Clark, Jr. Lectureship in Cutaneous Oncology and Melanoma Symposium Conference Dates: Thursday, February 6, 2003 Conference Location: Philadelphia, Pennsylvania Sponsoring Group: University of Pennsylvania Abramson Cancer Center and the Department of Dermatology Topics Covered: Melanoma, cutaneous oncology, and general neoplasia Conference Objectives: To provide updates on melanoma prognosis and issues
The 5th National Urologic Oncology Update Conference Dates: February 28 - March 1, 2003 Conference Location: Newport Beach, California Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/announcements/uroonc03.html Topics Covered: Diagnosis and Management of Bladder Cancer, Adrenal Tumors, Renal Cell Carcinoma, Testis Cancer, Prostate Cancer, Urology in the
Second International Conference on Translational Research and Pre-Clinical Strategies in Clinical Radio-Oncology - ICTR-2003 Conference Dates: March 16-19, 2003 Conference Location: Lugano, Switzerland Sponsoring Group: Conference Web Page URL: http://www.osg.ch/it/conferenze/ictr2003.html Topics Covered: The conference will deal with the following topics: Radiobiology and Translational Research Cell cycle and related topics Intra- and
Prostate Cancer Conference Conference Dates: Friday, March 28, 2003 Conference Location: Loews Philadelphia Hotel, 1200 Market Street, Philadelphia, PA Sponsoring Group: University of Pennsylvania Cancer Center Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Topics Covered:
Issues In Women's Healthcare: Genetics, Cancer and the Hormone Controversy Conference Dates: March 15, 2003 Conference Location: City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, California, USA Conference Web Page URL: www.cityofhope.org/ccgp Topics Covered: Primary care physicians, ob/gyn physicians, oncologists, surgeons and other allied health care professionals who participate in this course
Skill Building in Psychosocial Oncology & Palliative Care Conference Dates: March 26-28, 2003 Conference Location: Embassy Suites, Tampa, FL Sponsoring Group: Moffitt Cancer Center Conference Web Page URL: www.moffittcancercenter.com Topics Covered: The purpose of this program is to provide clinical social workers, psychologists, psychiatric nurse practitioners and other health care
Ask The Doctor About Colorectal Cancer Conference Dates: Monday, March 10, 2003/6:30-8:00P.M. Conference Location: The Wellness Community Philadelphia Sponsoring Group: Roche Conference Web Page URL: www.twcp.org Topics Covered: Join Weijing Sun, M.D. from the University of Pennsylvania and learn about new treatment for colorectal cancers. Conference Objectives: education
Current Concepts in the Management of Thyroid and Parathyroid Neoplasms Conference Dates: Friday, April 4, 2003 Conference Location: Loews Philadelphia Hotel, 1200 Market Street, Philadelphia, PA Sponsoring Group: University of Pennsylvania Cancer Center Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Topics Covered:
Lymphedema Management Conference: Skill Building Workshops and Presentations for Certified Lymphedema Therapists Conference Dates: April 24-26, 2003 Conference Location: Philadelphia, Pennsylvania Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania and Klose Norton Training and Consulting Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online.
Lymphoma...the Next Questions Conference Dates: April 24-25, 2003 Conference Location: San Juan, Puerto Rico Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/announcements/lymph_tnq.htm Topics Covered: New Techniques and Treatments, Hodgkin's Disease and Variants, Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma, Aggressive Non-Hodgkin's
Third International "North Adriatic Sea" Symposium on Novel Targets for Cancer Therapy Conference Dates: April 28-29, 2003 Conference Location: Trieste, Italy Sponsoring Group: Conference Web Page URL: www.augustea.net/north_adriatic_sea Topics Covered: This year you will discuss about proteomics, immunology, innovations in cancer treatment, and about what help could arrive from research for clinicians. We are sure that,
Cancer Survivorship and Late Effects of Cancer Treatment Conference Dates: Saturday, April 26, 2003 Conference Location: The Wellness Community Philadelphia Sponsoring Group: The Wellness Community Philadelphia Conference Web Page URL: www.twcp.org Topics Covered: Long term side effects of cancer treatment, sexuality issues, coping with the fear of recurrence, etc. Conference Objectives:
Cancer Survivors Conference Conference Dates: Saturday, April 12, 2003 Conference Location: Holiday Inn, City Line Avenue, Philadelphia, PA Sponsoring Group: American Cancer Society Topics Covered: Medical, emotional and nutritional needs after treatment ends; humor and mindfulness healing; breathing for relaxation; family communications; movement; complementary
Third Annual Colorectal Cancer Conference Conference Dates: April 4-6, 2003 Conference Location: Washington, DC Sponsoring Group: Colon Cancer Alliance Conference Web Page URL: www.ccalliance.org/cca/events/conference2003/index.html Topics Covered: Conference Objectives: To provide attendees with the most up-to date colorectal cancer (crc) information in a supportive and
Spectrum of Pain Conference Dates: May 9-10, 2003 Conference Location: Sheraton Sand Key Resort, Clearwater Beach, Florida Sponsoring Group: Moffitt Cancer Center, University of South Florida, Florida Pain Initiative Conference Web Page URL: www.moffitt.usf.edu/promotions/spectrum/index.htm Topics Covered: Cancer pain management Non-malignant
Spectrum of Pain: Comprehensive Assessment and Multimodal Management Conference Dates: May 9-10, 2003 Conference Location: Sheraton Sand Key Resort, Clearwater Beach, FL Sponsoring Group: Moffitt Cancer center Conference Web Page URL: www.moffittcancercenter.com Topics Covered: This two-day conference focuses on pain assessment, management, and multidisciplinary care of the oncology patient.
First Montreal International Lymphedema Congress Conference Dates: May 28-30, 2003 Conference Location: Montreal, Canada Sponsoring Group: McGill University Department of Oncology & Lymphedema Association of Quebec Conference Web Page URL: www.infolympho.icomm.ca Topics Covered: Lymphedema Fundamentals Lymphedema and Palliative Care Experience of the Dr. Vodder School,
Brain Tumor Action Week Symposium Conference Dates: May 8, 2003 Conference Location: Medical Alumni Hall, Philadelphia, PA Sponsoring Group: Division of Neuro-Oncology Topics Covered: Presentation(s) from Department(s) of Neurosurgery, Neuro-Oncology, Radiation-Oncology, and Rehabilitation from UPHS. Further, panel members will represent Children's Hospital of
The Patient Active Guide to Living with Ovarian Cancer Conference Dates: May 12, 2003, 6:30-8:30PM Conference Location: The Wellness Community Philadelphia Sponsoring Group: GlaxoSmithKline Oncology Conference Web Page URL: www.twcp.org Topics Covered: Dr. Christina S. Chu, a gynecologic oncologist from the University of Pennsylvania Health System will provide information about treatment
IMRT and Emerging Technologies Conference Dates: May 8, 2003 Conference Location: St. Louis, Missouri Sponsoring Group: Varian Medical Systems Conference Web Page URL: http://www.varian.com/dev/onc/imr019_07.html Topics Covered: Workshop: Setting up an IMRT QA Program Implementing IMRT Today IMRT Treatment Planning Head and Neck Target Volume Delineation
MASCC/ISOO 15th International Symposium Supportive Care in Cancer Conference Dates: June 18 - 21, 2003 Conference Location: Hotel Inter-Continental, Berlin, Germany Sponsoring Group: Conference Web Page URL: www.symposium-online.de/mascc Topics Covered: growth factors, mucositis, emesis, pain management, late toxicity, fatigue, psychosocial aspects, Conference Objectives: Who Should Attend:
Musculoskeletal Oncology Review Conference Dates: June 13-15, 2003 Conference Location: Cheeca Lodge & Spa, Islamorada, FL Sponsoring Group: Moffitt Cancer Center Conference Web Page URL: www.moffittcancercenter.com Topics Covered: Clinical radiographic and pathologic correlation and medical and surgical management of musculoskeletal disease will be addressed,
First International Melanoma Research Congress Conference Dates: June 21-24, 2003 Conference Location: Wyndham Franklin Plaza Hotel in Philadelphia Sponsoring Group: Foundation for Melanoma Research Conference Web Page URL: www.foundationformelanomaresearch.org Topics Covered: Immunology, Epidemiology, Biology, Molecular Biology and Tumor Microenvironment. Conference Objectives:
PICC 03 - The 5th International Conference: Perspectives in Colorectal Cancer Conference Dates: June 26-28, 2003 Conference Location: Barcelona, Spain Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.picccongress.com Topics Covered: Molecular Biology & Prevention, Imaging Techniques in Staging and Diagnosis of Colorectal Cancer, The Management of Hepatic Mestases, Chemotherapy of Colorectal Cancer,
Workshop on IMRT Treatment Planning & Dosimetry Conference Dates: June 5-7, 2003 Conference Location: Memorial Sloan Kettering Cancer Center in New York, NY Sponsoring Group: MSKCC and Varian Medical Systems Conference Web Page URL: http://www.varian.com/dev/onc/imr023f.html Topics Covered: Introduction to IMRT Clinical Basis of IMRT IMRT Treatment planning Questions and
ESMO Summer Educational Conference Conference Dates: June 19-22, 2003 Conference Location: Edinburgh International Conference Centre Sponsoring Group: European Society of Medical Oncology Conference Web Page URL: www.esmo.org/SummerConference/ Topics Covered: There are few fields in clinical medicine that are expanding as rapidly as oncology. Don't miss your chance to
10th World Conference on Lung Cancer Conference Dates: August 10-14, 2003 Conference Location: Vancouver, British Columbia, Canada Sponsoring Group: International Association for the Study of Lung Cancer Conference Web Page URL: www.2003worldlungcancer.org Topics Covered: Review of eepidemiology of the global lung cancer problem Update on the monecular biology of lung
6th Annual Changing Concepts in Breast Cancer Conference Dates: September 11-12, 2003 Conference Location: Philadelphia, PA Sponsoring Group: The University of Pennsylvania Abramson Cancer Center and The School of Medicine Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Topics Covered: This
Perspectives in Colorectal Cancer Conference Dates: September 12-13, 2003 Conference Location: Washington, D.C. Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: Conference Objectives: Who Should Attend: oncologists, gastroenterologists, colorectal surgeons, radiation oncologists Conference Agenda:
The 3rd Princess Margaret Hospital Conference on New Developments in Cancer Management Conference Dates: September 11-13, 2003 Conference Location: Toronto, Ontario Canada Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: online: www.imedex.com, tel: 770-751-7332, fax: 770-751-7334 Continuing Education: Yes
Predictive Oncology Conference Dates: September 15-16, 2003 Conference Location: Portsmouth, UK Sponsoring Group: International Society for Chemosensitivity Testing in Oncology Conference Web Page URL: www.predictiveoncology.co.uk Topics Covered: Oncology is currently an empirical discipline in which all patients with a particular type of cancer are
CDC's 2003 Cancer Conference Conference Dates: September 15-18, 2003 Conference Location: Marriott Marquis hotel, Atlanta, GA, USA Sponsoring Group: Centers for Disease Control and Prevention, American Cancer Society, Chronic Disease Directors, National Cancer Institute, North American Association of Central Cancer Registries Conference Web Page URL:
Frankly Speaking about Lymphoma Conference Dates: Saturday, September 20, 2003 Conference Location: The Wellness Community Philadelphia Sponsoring Group: The Wellness Community Philadelphia Conference Web Page URL: www.twcp.org Topics Covered: Special focus on treatment for Non-Hodgkin's Lymphoma with Steven Schuster, M.D. There will also be a panel of survivors who
Ovarian Cancer National Alliance 6th Annual Advocacy Conference Conference Dates: September 17-19, 2003 Conference Location: San Francisco, CA Sponsoring Group: Ovarian Cancer National Alliance Conference Web Page URL: www.ovariancancer.org Topics Covered: Current & emerging therapies, outreach across barriers, palliative support care, nutrition & complementary healing, cutting edge research,
2003 Cancer Symposium - Hormone Replacement Therapy: Benefits and Risks Conference Dates: September 24, 2003 Conference Location: Harry's Savoy Ballroom - Wilmington, Delaware Sponsoring Group: Medical Society of Delaware, in joint sponsorship with Christiana Care Health System Topics Covered: Benefits of Hormone Replacement Therapy Risks Associated with the use of Hormone Replacement Therapy Recent
9th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy (ISPCC) Conference Dates: October 8-11, 2003 Conference Location: New York, NY Sponsoring Group: New York University Conference Web Page URL: www.imedex.com/announcements/platinum03.html Topics Covered: This symposium combines the latest information on both the clinical and mechanistic aspects of the use of platinum-based anticancer agents. The
9th Annual Conference: Perspectives in Breast Cancer Conference Dates: November 13-14, 2003 Conference Location: Monte Carlo, Monaco Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Who Should Attend: oncologists, radiation oncologists Registration Information: www.imedex.com, tel: 770-751-7332, fax:770-751-7334, h.drew@imedex.com
The 1st European Conference: Perspectives in Melanoma Management Conference Dates: October 9-11, 2003 Conference Location: Amsterdam, The Netherlands Sponsoring Group: Imedex. Under the auspices of EORTC Conference Web Page URL: www.imedex.com/announcements/emelanoma03.html Topics Covered: EORTC Melanoma Group Program Scientific Reports, Phase III Trials in Stage IV Melanoma, Vaccine Development in
Melanoma Regional Symposium Conference Dates: October 4, 2003 Conference Location: Stabile Research Building at Moffitt Cancer Center, Tampa, Florida Sponsoring Group: Moffitt Cancer Center Conference Web Page URL: www.moffitt.usf.edu Topics Covered: Melanoma, plastic surgery, immune therapy Conference Objectives: Discuss treatment options. Evaluate the latest
The 6th International Thyroid Cancer Survivors' Conference Conference Dates: October 24-26, 2003 Conference Location: Houston, Texas Sponsoring Group: ThyCa: Thyroid Cancer Survivors' Association, Inc. Conference Web Page URL: www.thyca.org Topics Covered: Endocrinologists, surgeons, nuclear medicine physicians, a pathologist, and a palliative care physician will address issues ranging from
Lymphedema Fall Fashion Show Conference Dates: October 16th, 2003 Conference Location: King of Prussia Mall, Nordstrom 2nd floor at Personal Touch Counter Sponsoring Group: Penn Therapy & Fitness Lymphedema Program, Abramson Cancer Rehabilitation Program Topics Covered: Clothing, shoe and lingerie options for those with lymphedema. Men and women with any type of
Frankly Speaking about Colorectal Cancer Conference Dates: October 25, 2003 Conference Location: The Wellness Community Philadelphia Sponsoring Group: The Wellness Community Philadelphia Conference Web Page URL: www.twcp.org Topics Covered: Dr. Weijing Sun of the University of Pennsylvania will discuss new treatment for colorectal cancers. Liz Goodman, Health Educator, will
Treating Advanced Lymphoma Conference Dates: October 29, 2003 Conference Location: Penn Tower Bridge Level Conference Room Sponsoring Group: Abramson Cancer Center and Leukemia-Lymphoma Society Topics Covered: "Latest Developments in Research and Clinical Applications" "The Use of Radioimmunotherapy" "Living Well and Coping with Lymphoma" Conference Objectives:
The 8th International Conference on Geriatric Oncology - Cancer in the Elderly. The 4th Meeting of SIOG. Conference Dates: November 21-22, 2003 Conference Location: Rome, Italy Sponsoring Group: SIOG, Imedex Conference Web Page URL: www.cancerworld.org Who Should Attend: oncologists, radiation therapists, physicians, nurses, nurse practitioners and other health care professionals in active clinical practice interested and/or involved with
3rd Annual Perspectives in Bladder Cancer Conference Dates: November 14-15, 2003 Conference Location: Padova, Italy Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Who Should Attend: oncologists, urologists Registration Information: www.imedex.com, tel: 770-751-7332, fax: 770-751-7334, h.drew@imedex.com Continuing Education:
3rd European Conference: Perspectives in Breast Cancer Conference Dates: November 7-8, 2003 Conference Location: Nice, France Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: www.imedex.com, tel: 770-751-7332, fax: 770-751-7334, h.drew@imedex.com Continuing Education: No
The 2nd International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes Conference Dates: October 16-18, 2003 Conference Location: New York, NY Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/announcements/silver03.htm Topics Covered: Keynote: Angiogenesis and vascular growth factors in myeloproliferative and myelodysplastic disorders Session 1: Myelodysplasia Medical
8th Annual Conference: Perspectives in Thoracic Oncology Conference Dates: October 17-18, 2003 Conference Location: New York, NY Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Who Should Attend: oncologists, thoracic surgeons Registration Information: www.imedex.com, tel: 770-751-7332, fax: 770-751-7334, h.drew@imedex.com Continuing
4th European Conference: Perspectives in Lung Cancer Conference Dates: November 28-29, 2003 Conference Location: Monte Carlo, Monaco Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Continuing Education: No
Chemotherapy Foundation Symposium XXI: Innovative Cancer Therapy for Tomorrow Conference Dates: November 12-15, 2003 Conference Location: Marriott Marquis Hotel, New York, NY Sponsoring Group: Chemotherapy Foundation Conference Web Page URL: www.mssm.edu/tcf Topics Covered: Novel strategies for control and cure of breast, ovarian, prostate, GI, bladder, hematologic malignancies, melanomas, head and neck, lung and
IMF Patient & Family Seminar Conference Dates: November 7 & 8, 2003 Conference Location: Baylor University - Baylor Sammons Cancer Center, Dallas, TX Sponsoring Group: The International Myeloma Foundation Conference Web Page URL: www.myeloma.org Topics Covered: Myeloma 101 - The Basics Frontline Therapies Standard Therapies Transplantation Novel
Second Annual Clinical Research Conference Conference Dates: November 2-4, 2003 Conference Location: Washington, DC Sponsoring Group: National Patient Safety Foundation Conference Web Page URL: www.researchsafety.org Topics Covered: Plenary Session: Troubling issues discussed during the meeting will include: New and Improved Informed consent Taking Another Look at
Lives Touching Lives - The Consequences of Caring Conference Dates: November 14, 2003 Conference Location: The Gregg Conference Center, The American College Sponsoring Group: The Wellness Community Philadelphia Conference Web Page URL: www.twcp.org Topics Covered: Dan Gottlieb,Ph.D. will speak on "Giving Care and Taking Care: Living on the Precipice of What it Means to Be Human". Four
Your New 'Normal': Taking Charge of the Lingering Side Effects of Treatment Conference Dates: Saturday, November 15, 2003 Conference Location: Pennsylvania Convention Center Sponsoring Group: Living Beyond Breast Cancer Conference Web Page URL: www.lbbc.org Topics Covered: Learn how the brain functions, how breast cancer treatment can impact its work and what practical steps you can take to overcome memory
Feeding the Body and Soul: A Dietitian's Journey Conference Dates: November 21, 2003 Conference Location: Zubrow Auditorium at Pennsylvania Hospital Sponsoring Group: Joan Karnell Cancer Center Conference Web Page URL: www.pahosp.com/cancer Topics Covered: Join us for the inspirational story of Diana Dyer, a three-time cancer survivor, registered dietitian and author of the book "A
Controversies in the Management of Gynecologic Malignancies Conference Dates: December 12-13, 2003 Conference Location: Chicago, IL Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: Cervical cancer, uterine cancer, ovarian cancer, vulvar cancer Who Should Attend: Oncologists, gynecologists Registration Information:
Your Life on High Dose Steroids Conference Dates: Wednesday, December 17, 2003 Conference Location: Penn Tower Hotel, Bridge Level Conference Room Sponsoring Group: Abramson Cancer Center/Leukemia-Lymphoma Society Conference Objectives: Patient Education Who Should Attend: Patients, families, caregivers Conference Agenda: Edward A. Stadtmauer, M.D. Associate
PICC 04 - The 6th International Conference: Perspectives in Colorectal Cancer Conference Dates: June 17-19, 2004 Conference Location: Barcelona, Spain Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.picccongress.com Registration Information: www.picccongress.com, tel: 770-751-7332, fax: 770-751-7334, h.drew@imedex.com Continuing Education: No
The 9th International Conference on Geriatric Oncology: Cancer in the Elderly The 5th Meeting of SIOG Conference Dates: October 15-16, 2004 Conference Location: San Francisco, CA Sponsoring Group: SIOG, Imedex, Inc. Conference Web Page URL: www.cancerworld.org Registration Information: www.imedex.com, tel: 770-751-7332, fax: 770-751-7334, h.drew@imedex.com Continuing Education: Yes
Opening Ribbon Cutting Ceremony at the 43rd Annual ASTRO Meeting imgCt) { thisPic = 0 } if (thisPic Slide Show of this morning's opening of the conference. previous next
Selective Bladder Preservation by Combined Modality Treatment of Invasive Bladder Cancer: 10 Year Outcome Presenter: W. U. Shipley Affiliation: Massachusetts General Hospital BackgroundThe standard of care for muscle invasive bladder cancer is radical cystectomy +/- adjuvant chemotherapy with or without radiation. However, to improve quality of life in these patients, there is much interest in bladder-conserving therapies, using transurethral
RTOG 9706: Initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with cisplatin followed by adjuvant MCV chemotherapy Presenter: M. P. Hagan Affiliation: Medical College of Virginia Background The standard of care for muscle invasive bladder cancer is radical cystectomy +/- adjuvant chemotherapy with or without radiation. However, there is much interest in organ preserving therapy with combined chemotherapy and radiation therapy.Materials and Methods
Biclutamide ("Casodex") 150 mg as Adjuvant to Radiotherapy in Localized or Locally Advanced Prostate Cancer Presenter: C. Tyrrell Affiliation: Plymouth Oncology Centre, Plymouth, United Kingdom BackgroundBiclutamide (Casodex) is often used as adjuvant therapy in patients who have biochemical failure after definitve therapy. This is a study to evaluate the use of biclutamide as an immediate therapy or as adjuvant to therapy of curative intent in
Randomized Study of Single Versus Fractionated Radiotherapy (RT) in the Palliation of Non-Small Cell Lung Cancer; NCIC CTG SC.15 Presenter: A. Bezjak Affiliation: Dept of Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada Background In comparison to definitive radiation therapy, the optimal doses and fraction schedules for palliative treatments are less well defined. Theoretically, administration of larger daily fractions over fewer days offers
Preliminary Results of a Radiation Therapy Oncology Group Trial (RTOG 9311), A Dose Escalation Study Using 3D Conformal Radiation Therapy in Patients with Inoperable Non-small Cell Lung Cancer Presenter: M.V. Graham Affiliation: Radiation Oncology, Phelps County Regional Medical Center, Rolla, MO Background Some investigators and clinicians are now questioning the utility of elective nodal irradiation in the treatment of lung cancer. Theoretically, if the volume of tissue to be irradiated were to exclude clinically uninvolved
Preoperative Chemoradiation using Capecitabine in Locally Advanced Rectal Cancer Presenter: J.S. Kim Affiliation: Department of Therapeutic Radiology, Chungnam National University, Taejon, South Korea BackgroundStudies indicate that preoperative chemoradiation can result in tumor downstaging with increase resectability and sphincter preservation in locally advanced rectal lesions. Capecitabine is a new fluoropyrimidine
Impact of TNM Stage on Survival and Disease Control in Adjuvant Rectal Cancer Pooled Analysis Presenter: L.L. Gunderson Affiliation: Institution: Oncology, Mayo Clinic, Rochester, MN BackgroundThis study attempts to evaluate the TMN staging and the MAC staging as predictors of outcome such as overall survival and patterns of failure for patients with rectal cancer who have undergone adjuvant therapy. The study evaluates patients from 3
Randomized Phase III Study of Amifostine in Patients Treated with Chemoradiation for Inoperable Stage II-III Non-Small Cell Lung Cancer (NSCLC) Presenter: R. Komaki Affiliation: Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX Background The radioprotective property of thiol-containing compounds has been well known for some time. Amifostine(WR-2721) is the most well known of these agents. The proposed mechanism of action is the scavenging of
Epidermal Growth Factor Receptor is a Predictor of Tumor Response in Locally Advanced Rectal Cancer Patients treated with Preoperative Radiotherapy Presenter: J.S. Kim Affiliation: Radiation Oncology, Hospital Vall d'Hebron, Barcelona, Spain Background Epidermal growth factor receptor (EGFR) is a member of the tyrosine kinase receptor family and is expressed in a variety of different cell lines. EGFR overexpression is observed in 50- 70% of colorectal carcinomas and is associated with
Phase II Trial of Preoperative Chemoradiation with a Hyperfractionated RT Boost in Locally Advanced Rectal Cancer Presenter: H. Diratzouian Affiliation: Fox Chase Cancer Center, Philadelphia, PA Background Studies have reported a dose response relationship for preoperative radiation therapy. The Fox Chase group has previously reported the results of a phase I dose escalation trial demonstrating the tolerability of preoperative chemoradiation with a
Survival Benefit for Early Initiation of Hormone Ablation Therapy in Patients who Fail Definitive XRT for Prostate Cancer (ACP) Presenter: T.C. Tenenholz Affiliation: Medical College of Virginia Background There is a dispute over the timing of starting hormones after biochemical failure. This study was initiated to determine when the benefits of hormonal ablation outweighs its potential morbidity. Materials and Methods Retrospective study of 931 patients who
Quantitation of the Early Effects of Radiation and Hormonal Therapy on Hemoglobin Levels in Men Treated for Prostate Cancer Presenter: J. Wilson Affiliation: University of Pennsylvania BackgroundAnemia has been shown to be a prognostic factor in head and neck and cervical cancer. However, unless hemoglobin falls to values Materials and Methods This is a retrospective study of 198 men with stage T1-4N0M0 prostate cancer. Hemoglobin levels were measured before
Is the Therapeutic Index Better with Gemcitabine-Based Chemoradiation Presenter: Christopher Crane Affiliation: M.D. Anderson Cancer Center Type of Session: Scientific Background Locally advanced pancreatic cancer is both radioresistant and chemoresistant. "Traditional" treatment with concurrent 5-FU chemoradiation results in a median survival of 9-12 months In metastatic/advanced disease, gemcitabine
Control of Regional Metastasis after Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma Presenter: D. Chua Affiliation: Queen Mary Hospital, The University of Hong Knog Type of Session: Scientific Background Nasopharyngeal cancer has a high incidence of metastases. The evidence of regional nodal meastases may be the most important prognosticator of distant meastases and survival This study was done to determine if adding
A Phase II Study of External Irradiation and Weekly Paclitaxel for Non-Metastatic, Unresectable Pancreatic Cancer: A Preliminary Report of RTOG Protocol 98-12 Presenter: T. Rich Affiliation: University of Virginia Type of Session: Scientific Background Unresectable/locally advanced pancreatic cancer remains a difficult disease to treat, with median survival of less than 1 year This is a new approach to the management of pancreatic cancer, using paclitaxel (Taxol) and radiation therapy to improve
CANCER AND LEUKEMIA GROUP B (CALGB) 89805: Phase II Chemoradiation Trial using Gemcitabine in Patients with Locoregional Adenocarcinoma of the Pancreas Presenter: A.W. Blackstock Affiliation: CALGB Type of Session: Scientific Background Pancreatic cancer has a high mortality without significant changes in life expectancy over the past several years 50% have distant disease at diagnosis and cure rates remain low even in locally advanced disease. Gemcitabine administered twice-weekly produces
Simultaneous Gemcitabine/Cisplatin and Radiotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma using a Strict GEM/RT Time Schedule. A Phase I/II Study Presenter: T. Brunner Presenter's Affiliation: University Hospitals Erlangen, Erlangen, Germany Type of Session: Scientific Background Patients with locally advanced pancreatic cancer treated with induction chemoradiation (CRT) prior to surgery have a survival advantage as compared to patients treated with resection at diagnosis. Snady et al.
Mature Survival Results with Preoperative Cisplatin, Protracted Infusion 5-FU, and 45 GY Radiotherapy for Esophageal Cancer Presenter: L. Kleinberg Presenter's Affiliation: Johns Hopkins Oncology Center, Baltimore, MD Type of Session: Scientific Background Neoadjuvant chemoradiation for Esophageal cancer is controversial, however, many patients are offered this therapy as a standard of treatment. Randomized trials has shown mixed results The US Intergroup study
Involved-Field Radiotherapy in Patients with Stage III/IV Hodgkin's Lymphoma: First Results of the Randomized EORTC Trial # 20884 Presenter: B.M. Aleman Presenter's Affiliation: EORTC Lymphoma Group, Brussels, Belgium Type of Session: Plenary Background While the role of radiation therapy in the treatment of early stage Hodgkins Disease is well established, its utility in advanced disease is not as clear. Materials and Methods 736 patients were enrolled in a phase-III
Preliminary Results of the GORTEC 96-01 Randomized Trial, Comparing Very Accelerated Radiotherapy Versus Concomitant Radio-Chemotherapy for Locally Inoperable HNSCC Presenter: J. Bourhis Presenter's Affiliation: Institut Gustave Roussy, Villejuif, France Type of Session: Plenary Background There is some clinical evidence that radiation therapy administered over a shorter period of time offers better tumor control by decreasing the ability of cancer cells to repair themselves from radiation-induced damage.
Chemo-Radiotherapy, as Compared to Radiotherapy Alone, Significantly Increases Disease-Free and Overall Survival in Head and Neck Cancer Patients After Surgery: Results of EORTC Phase III Trial 22931 Presenter: J. Bernier Presenter's Affiliation: Radio-Oncology, Ospedale San Giovanni, Bellinzona, Switzerland Type of Session: Plenary Background Standard adjuvant therapy for advanced head and neck cancer in the post-operative setting is radiation alone. This study was designed to determine if there is an advantage of treating patients with
A Phase I/II Trial of Escalating Doses of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Head & Neck Cancer (HNC) Patients Receiving Radiotherapy (RT) with Concurrent Chemotherapy (CCT) Presenter: D.M. Brizel Presenter's Affiliation: Duke University Type of Session: Scientific Background Evidence from recent studies suggest that the combination of chemotherapy and radiation therapy improves outcome in advanced head and neck cancers, compared to single modality therapy. But these aggressive therapies frequently cause increases in
Gemcitabine, Paclitaxel, and Radiation for Locally Advanced Pancreatic Cancer: A Phase I Trial Presenter: T. Dipetrillo Presenter's Affiliation: Brown University Type of Session: Scientific Background Locally advanced pancreatic cancer has Gemcitabine and paclitaxel are both radiation sensitizers The use of paclitaxel has demonstrated efficacy in RTOG 98-12 The feasibility of concurrent weekly paclitaxel and gemcitabine with
B.I.D. Radiotherapy and Chemotherapy With CDDP/5-FU in Unresectable Pharyngeal Carcinoma: 10 Years Experience at the Centre Antoine-Lacassagne. Impact of Tumoral EGFR Level on Response and Survival Presenter: R.J. Bensadoun Presenter's Affiliation: Radiotherapy, Centre A-Lacassagne, NICE, France Type of Session: Scientific Background Combination chemotherapy/radiation therapy regimens are increasingly being employed in the management of advanced head and neck cancers. There is emergening evidence that the proliferation of certain solid
Radiation Alone (RT) Versus RT with Concomitant Chemotherapy (CT) in Stages III and IV Oropharynx Carcinoma. Final Results of the 94-01 GORTEC Randomized Study Presenter: Bourhis, J Presenter's Affiliation: GORTEC, Tours, France Type of Session: Reporting Background This study was designed to test whether the addition of three cycles of chemotherapy during standard radiation therapy would improve disease-free survival in patients with stages III and IV oropharynx carcinoma Preliminary results of this
Sequencing of Chemotherapy and Radiation Therapy for Patients with Early Stage Breast Cancer: Updated Results of a Prospective Randomized Trial Presenter: Bellon, JR Presenter's Affiliation: Harvard Medical School Type of Session: Plenary Background This study was designed to evaluate the optimal sequencing of radiation therapy and chemotherapy in early stage breast cancer patients treated initially with lumpectomy The initial report with 5 yrs of follow-up showed for patients at
Conventionally Fractionated Stereotactic Radiotherapy for Vestibular Schwannoma: Long-Term Outcome and Cranial Nerve Function Presenter: Chan, A Presenter's Affiliation: Massachusetts Gerneral Hospital, Boston, MA Type of Session: Scientific Background Vestibular schwannoma/acoutic neuroma comprises 8% of all primary brain tumors. It?s location ? closely associated with brain stem and cranial nerve, creates great challenge for treatment. Surgical outcome has shown good
Treatment of Acoustic Neuroma: Stereotactic Radiosurgery vs Microsurgery Presenter: Butler, EB Presenter's Affiliation: Baylor College of Medicine Type of Session: Scientific Background Two major treatment options are available for patients with acoustic neuroma, microsurgery and radiosurgery. The objective of this study was to compare these two treatment modalities with respect to tumor growth control, hearing
A Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Preliminary Analysis of RTOG 9413 Presenter: M. Roach III Presenter's Affiliation: Radiation Oncology, UCSF, San Francisco, CA Type of Session: Plenary Background Many unanswered questions await definitive resolution in the treatment of prostate cancer. There has been significant controversy in the field of radiation oncology regarding the optimal field size and ideal integration
Selenium in the Treatment of Radiation-Associated Lymphedemas Presenter: F. Bruns Presenter's Affiliation: Department of Radiotherapy and Radiation Oncology, University Hospital, Muenster, Germany Type of Session: Reporting Background : Lymphedema is a relatively common side effect after surgical and/or radiotherapeutic treatment of lymph node areas. It can also be seen due to tumor compression of the
Eight Year Results in the Treatment of Keloids by HDR Brachytherapy Presenter: B. Guix Presenter's Affiliation: Radiation Oncology, Fundacio IMOR, Barcelona, Spain Type of Session: Scientific Background Keloids form as a result of abnormal growth of scar tissue usually after injury to the skin. The incidence ranges form 3 to 15%. The formation of keloids can result in itching, burning and bleeding. This prospective
Cost-Utility Analysis of RTOG 90-03: Phase III Randomized Study Comparing Altered Fractionation to Standard Fractionation Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma Presenter: A. Konski Presenter's Affiliation: Toledo Radiation Oncology, Hickman Cancer Center, Adrian, MI Type of Session: Scientific Background RTOG 90-03 a four-arm study that evaluated various fractionation schedules for the treatment of locally advanced head and neck cancer. This study attempts to determine the cost-effectiveness using
One Year Follow-up Reveals No Difference in Quality of Life Between High Dose and Conventional Dose Radiation: A Quality of Life Assessment of RTOG 94-05 Presenter: L.A. Kachnic Presenter's Affiliation: Radiation Therapy Oncology Group Type of Session: Scientific Background Nonsurgical standard of care for esophageal cancer is concurrent chemoradiation. A survival advantage has been demonstrated using chemoradiation to a dose of 50.4 Gy over radiation alone. Many believe that dose escalation
COX Inhibitors Markedly enhance Tumor Radiosensitization of Cultured Human Cancer Cells under Acidic Microenvironment Presenter: T.R. Shah Presenter's Affiliation: Henry Ford Hospital Type of Session: Scientific Background Prostaglandins are synthesized by COX enzymes. These prostaglandins have been implicated in carcinogenesis, angiogenesis, invasiveness, and metastatic potential, as well as resistance to treatment. COX inhibitors may stop the production of
PET Response is the Most Powerful Predictor of Survival after Radical Radiotherapy/Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer Presenter: M.P. MacManus Presenter's Affiliation: Peter MacCallum Cancer Institute, East Melbourne, Australia Type of Session: Scientific Background Frequently, clinicians have difficulty interpreting CT scans and MRI's done on patients with cancer, particularly after surgery or radiation therapy. Positron emission tomography (PET) is an imaging
The Impact of Anemia on PSA Outcome following Radiation and Androgen Suppression Therapy in Patients with High-Risk Prostate Cancer Presenter: A.V. DAmico Presenter's Affiliation: Brigham and Women's Hospital, Boston, MA Type of Session: Scientific Background It is well known that in men testosterone has a permissive effect on hemeglobin (Hb)levels in the bone marrow and on erythropoetin levels in the kidney. Androgen suppression therapy (AST), frequently used in the treatment
Preliminary Results of a Randomized Study of Tamoxifen Alone or Tamoxifen and Breast Radiation in Women over 50 Years of Age with T1/2 N0 Disease Presenter: A. Fyles Presenter's Affiliation: Princess Margaret Hospital Type of Session: Scientific Background The standard of care for women with invasive breast cancer who were treated with lumpectomy is adjuvant radiation therapy and tamoxifen in patients with ER (+) tumors with no contraindications. This is a study investigating the
Locoregional Failure of Post-Mastectomy Patients Who Had 1-3 Positive Axillary Lymph Nodes without Adjuvant Radiotherapy Presenter: C. Cheng Presenter's Affiliation: Sun Yat-Sen Cancer Center Type of Session: Scientific Background Post-mastectomy radiation is routinely given for patients with 4 or more positive lymph nodes to reduce locoregional failure. However, optimal adjuvant treatment for those with 1-3 positive lymph nodes is debated. This study was
Molecular Markers of Patient Outcome in Prostate Cancer Treated with Radiotherapy: Ki-67, Bcl-2, Bax, and Bcl-x Presenter: A. Pollack Presenter's Affiliation: UT MD Anderson Cancer Center, Houston, TX Type of Session: Scientific Background Abnormal expression of certain proteins have been found to alter the normal process of dying, or apoptosis, in cells. To date, there is little data correlating the presence of these proteins with outcome after radiation
Patterns of Local Regional Failure in Head and Neck Cancer Treated with IMRT Presenter: Tran, BN Presenter's Affiliation: Mallinckrodt Institute of Radiology, Radiation Oncology Center, Washington University Medical Center, St. Louis, MO Type of Session: Scientific Background Intensity modulated radiation therapy allows sparing of the parotid glands when treating head and neck cancer. However, the effect on local regional
A Prospective Study on Tumor Hypoxia Kinetics to Implement Hypoxic Imaging-Guided IMRT Presenter: Chao, KS Presenter's Affiliation: Radiology, Washington University, St. Louis, St. Louis, MO Type of Session: Scientific Background Unsatisfactory local/regional tumor control for locally advanced cancers with radiation therapy is in part associated with the phenomenon of tumor hypoxia. There is a lack of non-invasive and reproducible
A Phase II Trial of Subcutaneous Amifostine and Radiation Therapy in Patients with Head and Neck Cancer (WR-B060) Presenter: P. Anne Presenter's Affiliation: Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA Type of Session: Scientific Background Amifostine is an organic thiophosphate that protects normal tissues from the cytotoxic effects of radiation therapy (RT) and has been shown, in a Phase III trial of RT ± amifostine in head and
Internet Utilization by Radiation Oncology Patients Presenter: J.M. Metz Presenter's Affiliation: Radiation Oncology, University of Pennsylvania, Philadelphia, PA Type of Session: Scientific Background Millions of people use the Internet daily. It is not unreasonable to postulate that many cancer patients are among these Internet users. This multi-institutional study evaluated the use of the
Positron Emission Tomography after Three-Dimensional Conformal Radiation Presenter: K.E. Rosenzweig Presenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York Type of Session: Scientific Background Frequently, clinicians have difficulty interpreting CT scans and MRI's done on patients with cancer, particularly after surgery or radiation therapy. Positron emission tomography (PET) is an imaging
Treatment, Patient and Tumor Characteristics Impact Quality of Life (QOL) in Patients with Locally Advanced Head and Neck Cancer: Report of the Radiation Therapy Oncology Group (RTOG) Trial 90-03 Presenter: J. Fisher Presenter's Affiliation: Bon Secours Cottage Health Services, Grosse Pointe Farms, MI Type of Session: Scientific Background The RTOG 90-03 was a four-arm trial that enrolled patients with locally advanced head and neck cancer. This study evaluated the factors that could potentially affect the QOL for patients randomized to
Neoadjuvant Chemotherapy and Radiotherapy for Large Extremity Soft Tissue Sarcomas Presenter: T.F. DeLaney Presenter's Affiliation: Massachusetts General Hospital, Boston, MA Type of Session: Scientific Background The management of extremity soft tissue sarcomas has evolved from amputation to limb sparing surgery with radiation therapy. While local control rates are generally quite high, the development of distant metastases
Sexual Function after Permanent Prostate Brachytherapy Presenter: W.M. Butler Presenter's Affiliation: Schiffler Cancer Center, Wheeling Hospital, Wheeling Type of Session: Scientific Background There continues to be uncertainty about the incidence of impotence after radiation therapy for prostate cancer. There is especially a paucity of information on prostate brachytherapy implants. This study
Preliminary Report of Toxicity Following 3D Conformal Radiation Therapy (3DCRT) for Prostate Cancer on 3DOG/RTOG 9406, Level III (79.2 Gy) Presenter: J. Ryu Presenter's Affiliation: Rad Onc, UCD, Sacramento, CA Type of Session: Scientific Background The high rates of local relapse observed in prostate cancer patients with conventional radiation techniques have stimulated research to develop high precision radiation to decrease the risks of local recurrence. The three dimensional
Brain Metastases in Lung Cancer: The Results of Radiosurgery in 238 Consecutive Patients Presenter: B.E. Amendola Presenter's Affiliation: Radiosurgery Department, Miami Neuroscience Center, Coral Gables, FL Type of Session: Scientific Background Lung cancer is the leading cause of cancer death in this country. 50% of all brain metastases have lung primary tumors Stereotactic radiosurgery is udergoing continued evaluation in the
Presentation, Prognostic Factors and Patterns of Failure in Adult Rhabdomyosarcoma Presenter: J.H. Simon Presenter's Affiliation: University of Iowa, Iowa City Type of Session: Scientific Background Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood, with about 400 new cases per year. Five year survival rates are around 70%. Unfortunately, adults with rhabdomyosarcoma have a much poorer prognosis. This
Sildenafil (Viagra) and Erectile Dysfunction following Conformal Radiotherapy for Prostate Cancer: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Presenter: L. Incrocci Presenter's Affiliation: University Hospital Rotterdam-Daniel Type of Session: Scientific Background The incidence of Erectile Dysfunction (ED) following external beam radiation therapy is commonly reported as 35-45%. With the author's form of conformal therapy, the first 1/3 of the penis lies within the radiation field,
Improved Local Control with RSR-13 and Concurrent Radiation Therapy in a Phase II Study for Locally Advanced Inoperable Non-Small Cell Lung Cancer Presenter: H. Choy Presenter's Affiliation: Vanderbilt University Medical Center, Nashville, TN Type of Session: Scientific Background RSR13 is a synthetic allosteric modifier of hemeglobin (Hb). It decreases Hb-oxygen binding affinity by causing a change in the shape of the Hb tetramer molecule. This change results in an increase in tumor
Concurrent Chemoradiation for Locally Advanced NSCLC in the RTOG Experience: Effect of Overall Treatment Time Presenter: M. Machtay Presenter's Affiliation: University of Pennsylvania Type of Session: Scientific Background A survival advantage has been shown in patients with non small cell lung cancer (NSCLC) with concurrent chemoradiation vs sequential chemoradiation or radiation alone. With concurrent chemoradiation comes increased toxicity, and,
Treatment of Prostate Cancer with Radiotherapy: Should the Entire Seminal Vesicles be Included in the CTV Presenter: L.L. Kestin Presenter's Affiliation: William Beaumont Hospital Type of Session: Scientific Background Dose escalation (to upper 70s to >80 Gy) has been shown to be efficacious in the treatment of prostate cancer. With this escalation, patients will likely experience toxicity directly related to volume treated, and the inclusion of
Stereotactic Radiosurgery (SRS) Dose Selection for < 2 cm Brain Metastases: The Influence of Planned Whole Brain Radiation Therapy (WBRT) Presenter: Young, AB Presenter's Affiliation: Neurosurgery, University of Kentucky, Lexington, KY Type of Session: Scientific Background Based on RTOG 9005, 24 Gy as SRS dose for treatment of brain metastases This analysis reviews a single institutional protocol experience utilizing 20 Gy SRS in patients with newly diagnosed and/or recurrent
Results of Whole Brain Radiation Therapy in Breast Cancer Patients with Brain Metastases Presenter: A.S. Mahmoud-ahmed Presenter's Affiliation: Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH Type of Session: Scientific Background Brain metastasis is the most common neurologic complication experienced breast cancer patients. Whole brain irradiation is a known methods of palliation for these lesions. Some previous
Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from INT 0114 Presenter: M O'ConnellPresenter's Affiliation: National Intergroup TrialType of Session: ScientificBackground Although rectal cancer is usually an aggressive cancer, the resection of metastatic disease is thought to be efficacious. Although this thought is eminent among oncologists, there is little prospective data regarding the resection of
Tumor microsatellite instability (MSI) and the benefit of 5-FU based chemotherapy in stage II & stage III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials Presenter: C.M. RibicPresenter's Affiliation: Lunenfeld Research InstituteType of Session: ScientificBackground Adding adjuvant chemoradiation therapy to resected T3-4 and N+ colon cancer increases survival, based on several large randomized studies. However, since these trials were completed, new information on the carcinogenesis of colon cancer
Cancer Patients in US Nursing Homes: Quality of End of Life Care Presenter: V.M.P. JohnsonPresenter's Affiliation: Brown University Medical SchoolType of Session: ScientificBackground As the American population ages, increasing numbers of Americans are receiving their end of life care in nursing homes. Little information has been published regarding care in these nursing homes. Materials and Methods Secondary
Final Report of the Efficacy and Safety of the Anti-Epidermal Growth Factor Antibody, Cetuximab (IMC-C225), in Combination with Cisplatin in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) Refractory to Cisplatin Containing-Chemotherapy Presenter: Merrill S. KiesPresenter's Affiliation: MC Anderson Cancer CenterType of Session: PosterBackground Recurrent squamous cell cancer of the head and neck (SCCHN) is a clinical challenge, especially in the setting of disease that is refractory to platinum-based agents. Less than 5% of these patients will respond to second-line therapy.
Effect Of Nerve Stimulation Therapy On Chemotherapy Induced Emesis (Cie): A Randomized, Placebo Controlled Trial Evaluating The Efficacy Of The Reliefband (Rb) Device Presenter: Imad M TreishPresenter's Affiliation: University of North CarolinaType of Session: ScientificBackground Despite the improvements made in treating chemotherapy-induced nausea and vomiting (CINV), they remain some of patients' most feared effects of cancer treatment. Approximately, 70% to 80% of all patients who receive chemotherapy
Weekly taxol (T) and carboplatin (P) as first-line therapy in advanced ovarian cancer (AOC): a phase II study Presenter: J. SehouliPresenter's Affiliation: North-East Society of Gynaecological Oncology (NOGGO), Berlin, GermanyType of Session: ScientificBackground Ovarian cancer often remains asymptomatic until it progresses to an advanced stage. This causes delay in diagnosis until patients have advanced disease. Therefore, chemotherapy remains an
Parenteral Opioid Rotation in Advanced Cancer Presenter: F.A. MahmoudPresenter's Affiliation: Cleveland Clinic FoundationType of Session: ScientificBackground Opioid side effects sometimes can limit upward titration of dosage to levels adequate for effective pain relief. Opioid rotation, utilizing equianalgesic amounts of medication, has been reported as efficacious in these situations.
Phase III Quality Of Life (QOL) Study: Reduction In Hyposalivation Does Not Improve Qol For Head And Neck (H&N) Cancer Patients Post Radiation Therapy (P-Rt). Rtog 9709 Presenter: Jacquelyn J FisherPresenter's Affiliation: RTOGType of Session: ScientificBackground When radiation therapy treatment fields include the major salivary glands, many patients will experience dryness of the oral mucosa during the first 1 or 2 weeks of treatment. Not only is the quantity of saliva reduced, but its composition and physical
Issues in the Access of Promising New Cancer Agents "Miracle Cure for Cancer," "New Drug Gives Hope to Cancer Patients". Headlines like these make us cringe as health professionals, but are reported in the media on a daily basis, playing on the desperation of many cancer patients. Often times, patients do not hear that a drug or test is still in early development, or the bad outcomes that were
Phase I Study of Docetaxel (D), Cisplatin (P), and Concomitant Boost Radiation for Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCHN) Presenter: B GlissonPresenter's Affiliation: MD Anderson Cancer Center, TexasType of Session: PosterBackground Both concurrent chemoradiation, with conventionally fractionated radiation (RT), and concomitant boost RT have been shown in randomized trials to improve the locoregional control in advanced SCHN. Docetaxel (D) has been shown to have
Use of Low-dose Fractionated Radiation (LDFRT) as a Chemosensitizer of Neoadjuvant Paclitaxel (P) and Carboplatin (CBCDA) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) - Results of a New Treatment Paradigm Presenter: Susanne ArnoldPresenter's Affiliation: Markey Cancer Center, Lexington , KentuckyType of Session: PosterBackground Radiation resistance is a major cause of treatment failure in squamous cell cancer of the head and neck (SCCHN). Low dose fractionated radiation (LDFRT), defined as doses Materials and Methods 38 patients with advanced
Prostate Cancer Radiation Dose Response: Final Planned Analysis Of A Phase III Randomized Trial Presenter: Alan PollackPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground Between 1993 and 1998, a randomized trial at MDACC was conducted to assess the effectiveness of two radiotherapy doses, 70 Gy versus 78 Gy, in preventing biochemical and/or clinical relapse of prostate cancer. Materials and Methods Of 301
Caelyx (Ca) And Carboplatin (Pa) In Patients With Advanced Ovarian Cancer In Late Relapse (> 6 Months) (AOCLR): A GINECO Phase II Trial Presenter: JM FerreroPresenter's Affiliation: GINECO, Paris, FranceType of Session: PosterBackground Previous studies have demonstrated that patients with ovarian cancer who have a time-to-relapse interval > 6 months retain sensitivity to platinum-derivatives Caelyx (Ca, doxil) is a liposomal doxorubicin that has been shown to be as effective as
Weekly Erythropoietin For Patients With Chemotherapy Induced Anemia: A Randomized, Placebo-Controlled Trial In The North Central Cancer Treatment Group Presenter: Peter T SilbersteinPresenter's Affiliation: The North Central Cancer Treatment Group RTOGType of Session: ScientificBackground Anemia occurs in a significant number of patients with cancer, and is associated with symptoms of fatigue, dizziness, headache and decreased health-related quality of life (QoL). Clinical trials have
Prostate Cancer Radiation Dose Response: Final Planned Analysis Of A Phase III Randomized Trial Presenter: Alan PollackPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PAType of Session: PosterBackground Between 1993 and 1998, a randomized trial at MDACC was conducted to assess the effectiveness of two radiotherapy doses, 70 Gy versus 78 Gy, in preventing biochemical and/or clinical relapse of prostate cancer Materials and
Inhibition of Epidermal Growth Factor/HER2 Receptor Signaling Using ZD1839 Presenter: S. MassarwehPresenter's Affiliation: Baylor Breast CenterType of Session: ScientificBackground Resistance of some breast cancers to endocrine therapy remains a problem for clinicians. Research into preventing or reversing endocrine resistance in breast cancer is needed. Some prior studies have shown Her2-positive tumors to be less
Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small cell lung cancer (NSCLC): final results of Czech Lung Cancer Cooperative Group phase III randomized trial Presenter: L. NovakovaPresenter's Affiliation: Czech Lung Cancer Cooperative GroupType of Session: PosterBackground Advanced non-small cell lung cancer has a poor survival. A majority of the patients fail distantly, with metastatic disease. Gemcitabine has been shown to have significant anti-tumor properties against NSCLC, a disease in which
Cetuximab (C225) Plus Irinotecan (CPT-11) Plus Infusional 5FU/Folinic Acid (FA) is Safe and Active in Metastatic Colorectal Cancer (MCRC) that Expresses Epidermal Growth Factor Receptor (EGFR) Presenter: P. SchoffskiPresenter's Affiliation: Hannover Medical School (Hannover, Germany)Type of Session: PosterBackground EGFR is a transmembrane glycoprotein receptor overexpressed in many human solid tumors. EGFR is a mediator of intracellular signals involved in cancer growth/metastatic spread. C225 is one of a few monoclonal antibodies
Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC) Presenter: H. ChoyPresenter's Affiliation: ACRType of Session: ScientificBackground The majority of NSCLC patients present with inoperable disease. Therefore, the definitive treatment is with a combination of chemotherapy (most notably platinum containing regimens) and radiation therapy. It has been shown that chemoradiation is more efficacious
Final Results From A Phase II Trial Of Zd1839 ('Iressa') For Patients With Advanced Non-Small-Cell Lung Cancer (IDEAL 1) Presenter: Masahiro FukuokaPresenter's Affiliation: Kinki University, Osaka, JapanType of Session: PosterBackground Iressa is an oral preparation of a selective inhibitor of the epidermal growth factor receptor tyrosine kinase It interferes with signal transduction pathways implicated in proliferation and survival of cancer cells The IDEAL 1
Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG) Presenter: C. SederholmPresenter's Affiliation: University Hospital, Linkoping, SwedenType of Session: ScientificBackground Chemotherapy is indicated in patients with locally advanced and metastatic lung cancer who have good performance status and minimal weight loss. The use of combined chemotherapeutic regimens (i.e. doublets) have better
Lymphatic Mapping And Sentinel Lymph Node Sampling In Breast Cancer: A Meta-Analysis Presenter: T. KimPresenter's Affiliation: Albany Medical CenterType of Session: ScientificBackground Sentinel lymph node sampling (SLNS) in breast cancer has become a common practice There is a lack of randomized clinical trials comparing SLNS to standard axillary lymph node dissection in the staging of breast cancer. This trial was designed to
The Role Of Sentinel Lymphadenectomy In Thin Cutaneous Melanomas Presenter: Richard J. BleicherPresenter's Affiliation: The John Wayne Cancer Institute, Santa Monica, CAType of Session: ScientificBackground The sentinel lymph node (SLN) biopsy is revolutionizing the surgical management of primary malignant melanoma. Lymphatic mapping and sentinel lymphadenectomy (LM/SL) has become standard to assess regional
Phase III Trail Comparing TAC (docetaxel, dosorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 Study Presenter: J-M NabholtzPresenter's Affiliation: Breast Cancer International Research Group (BCIRG)Type of Session: ScientificBackground Doxorubin and cyclophosphamide, with or without 5-fluorouracil, are standard chemotherapy agents in the adjuvant treatment of node positive breast cancer. Taxanes are a novel class of chemotherapeutic agents with
A Phase II Trial of Celecoxib (CX), Irinotecan (I), 5-Fluorouracil (5FU), and Leucovorin (LCV) in Patients with Unresectable or Metastatic Colorectal Cancer (CRC) Presenter: C.D. BlankePresenter's Affiliation: Oregeon Health Sciences UniversityType of Session: ScientificBackground Previous studies have shown that cyclooxygenase-II (COX-2) is present in the majority of CRCs, with expression associated with worse prognosis. Celecoxib is a selective COX-2 inhibitor which has demonstrable anti-angiogenesis
Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Presenter: L. SaltzPresenter's Affiliation: Memorial Sloan-Kettering Cancer CenterType of Session: ScientificBackground In a previous trial (reported at ASCO last year), IMC-C225, in combination with CPT-11, was demonstrated to have a 22.5% response rate in 120 patients with CRC refractory to CPT-11 treatment. A tumor xenograft model of
Incorporating Angiogenesis Inhibition with Bevacizumab (anti-VEGF) into Frontline Chemotherapy with Irinotecan (CPT-11), Fluorouracil and Leucovorin (FU/LV) for Advanced Colorectal Cancer (advCRC): A Toxicity Analysis of ECOG Study E2200 Presenter: B.J. GiantonioPresenter's Affiliation: University of PennsylvaniaType of Session: ScientificBackground Anti-angiogenesis therapy has received much publicity recently. Such molecularly-targeted therapies hold promise as the next wave of directed therapies against cancer. Early studies of these therapies have held some promise, but more
Cetuximab (IMC-C225) plus Weekly Irinotecan (CPT-11), Fluorouracil (5FU), and Leucovorin (LV) in Colorectal Cancer (CRC) that Expresses the Epidermal Growth Factor Receptor (EGFR) Presenter: Arthur RosenbergPresenter's Affiliation: The Bendheim Cancer Center of Greenwich Hospital, ConnecticutType of Session: PosterBackground Previous studies have shown that increased expression of Epidermal Growth Factor Receptor (EGFR) conveys an unfavorable prognosis in multitude of cancers, including colorectal cancer. Cetuximab
A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus Presenter: B. H. BurmeisterPresenter's Affiliation: Trans Tasmanian Radiation Oncology Group, Australasian Gastrointestinal Trials Group, and Clinical Trials Centre, Sydney, AustraliaType of Session: ScientificBackground Previous randomized studies have suggested a role for pre-operative chemoradiation in the treatment of esophageal cancer, not
Efficacy and Tolerability of Two Dosing Regimens of R115777 (Zarnestra), a Farnesyl Protein Transferase Inhibitor, in Patients with Advanced Breast Cancer Presenter: Stephen R. JohnstonPresenter's Affiliation: Royal Bournemouth Hospital, Bournemouth, UKType of Session: ScientificBackground Farnesylation is a process that activates proteins involved in growth factor dependent signal transduction pathways. Farnesyl transferase inhibitors are a novel class of agents that specifically block this process.
Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- AND Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- And NOGGO-Intergroup Study Presenter: Jens U BlohmerPresenter's Affiliation: Humboldt University, Berlin, GermanyType of Session: PosterBackground The aim of the study was to compare the disease-free survival achieved by an adjuvant sequential chemoradiotherapy regimen with vs. without Erythropoeitin (EPO) for patients with high-risk cervical cancer The second endpoints of
Multicenter Phase II Trial Of Paclitaxel (P), Ifosfamide (I), And Carboplatin (C) In Previously Untreated Extensive Stage Small Cell Lung Cancer (ES?SCLC) Presenter: Marcus A NeubauerPresenter's Affiliation: US Oncology Inc, Houston, TXType of Session: PosterBackground ES-SCLC accounts for 60-70% of the 30-35,000 new cases of SCLC diagnosed each year in the US The median survival for ES-SCLC reported in phase III trials is 9-12 months Overall survival at 2 years is Platinum + etoposide are
Long Term Survival Of Stage II And III Melanoma Patients With Respect To Serial Tyrosinase RT-PCR Testing In Peripheral Blood Presenter: Christiane A VoitPresenter's Affiliation: University of Mainz, Mainz, GermanyType of Session: ScientificBackground Melanoma has a high metastatic potential even in small primary lesions, and an early distinction between localized and regionally/distally advanced disease is of major importance for the patients' treatment and,

Phase III single-blinded study of premexetred + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma Presenter: N.J. VogelzangPresenter's Affiliation: U of ChicagoType of Session: PlenaryBackground Mesothelioma is an aggressive malignancy with no consistent, proven benefit to any traditional treatment: surgery, radiation therapy, or any combination of chemotherapy. Premexetred is an anitfolate, targeting key enzymes in the purine and pyrimidine
PSA Testing Interval Reduction In Screening Intervals: Data From The Prostate, Lung, Colorectal And Ovarian Cancer (PLCO) Screening Trial Presenter: E. D CrawfordPresenter's Affiliation: Univ of Colorado Health Sciences Ctr, Denver, COType of Session: PlenaryBackground Prostate cancer is the most commonly diagnosed malignancy in males and the second leading cause of cancer mortality in males The prostate, lung, colorectal (PLCO) trial is a large, controlled randomized trial
Risk-reducing salpingo-oopherectomy in women with BRCA1 and BRCA2 mutations Presenter: K. OffitPresenter's Affiliation: Memorial Sloan Kettering Cancer CenterType of Session: PlenaryBackground BRCA1 and BRCA2 mutations have been proven to place patients at higher risk for both breast cancer and ovarian cancer. Screening of high-risk women began in the mid 1990s without data to support what should be done in response to a
Single-Agent (SA) Versus Combination Chemotherapy (CC) In Advanced Non-Small Cell Lung Cancer (NSCLC): A CALGB Randomized Trial Of Efficacy, Quality Of Life (QoL), And Cost-Effectiveness Presenter: Rogerio C LilenbaumPresenter's Affiliation: CALGBType of Session: PlenaryBackground The standard of care for patients with locally advanced NSCLC and good performance status (PS) is combination chemotherapy (CC). However, while CC has demonstrated increased tumor response rates, these often have not translated to increased overall
STI-571 (Gleevac/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study Presenter: B.J. DrukerPresenter's Affiliation: IRIS Study Group, Portland, ORType of Session: PlenaryBackground The standard therapy for newly diagnosed chronic myelogenous leukemia (CML) is interferon (IFN). The addition of cytarabine to IFN has been shown to improve response rates and overall survival. For patients who have failed treatment
Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102) Presenter: L. BedennePresenter's Affiliation: Sevice de Hepato-Gastroenterologie-Chu-Le Bocage, Dijon-Cedex, FranceType of Session: ScientificBackground While surgical resection remains part of the standard of care for locally advanced esophageal cancer, non-randomized studies have demonstrated outcomes for radiochemotherapy alone that are
Initial Results Of Preoperative Gemcitabine (GEM)-Based Chemoradiation For Resectable Pancreatic Adenocarcinoma Presenter: Robert A WolffPresenter's Affiliation: UT MD Anderson Cancer Ctr, Houston, TXType of Session: ScientificBackground The recurrence rate in patients with adenocarcinoma of the pancreas following pancreaticoduodenectomy with curative intent is > 80% Preoperative Chemoradiotherapy increases the proportion of patients that undergo
Phase II Study Of STI571 (Gleevec^TM) For Patients With Small Cell Lung Cancer Presenter: Bruce E JohnsonPresenter's Affiliation: Dana-Farber Cancer Inst, Boston, MAType of Session: ScientificBackground STI571 is a small molecule that inhibits the tyrosine kinase activity of the BCR-Abl and Kit receptors The oral preparation of STI571 has been proven safe and very efficacious against CML (BCR-ABL positive) and GIST (Kit
Responding to the IOM?s Challenge to Improve Palliative Care: Nurse/Physician Collaborative Care Model In June of 2000, the Institute of Medicine issued a report addressing barriers to palliative care in the United States. From this report came a mandate for improvements in palliative care. A presentation at the ASCO annual meeting addressed the collaborative response from the American Society of Clinical Oncology (ASCO) and the Oncology Nursing
SWOG 0004 - Pilot Study Of Tirapazamine (TPZ) Plus Cisplatin/Etoposide (PE) And Concurrent Thoracic Radiotherapy (RT) In Limited Small Cell Lung Cancer (LSCLC) Presenter: Quynh-Thu LePresenter's Affiliation: SWOGType of Session: ScientificBackground Tirapazamine (TPZ)is a novel hypoxic cytotoxin that has been proven to increase cell killing in hypoxic cells. TPZ has also demonstrated synergistic increases in the effectiveness of chemotherapy and radiation therapy (RT) in both preclinical and clinical
A Phase II Trial Of Pemetrexed In Malignant Pleural Mesothelioma (MPM) Patients: Clinical Outcome, Role Of Vitamin Station, Respiratory Symptoms Upplemenand Lung Function Presenter: Dong M Shin,Presenter's Affiliation: University of PittsburghType of Session: ScientificBackground Malignant pleural mesothelia (MPM) is generally caused by exposure to asbestos and is commonly accompanied by pleural effusion, sometimes making radiologic images difficult to interpret. As the worldwide incidence of MPM increases, few
Cisplatin And Etoposide Plus Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy (TRT) Followed By Three Cycles Of Irinotecan And Cisplatin For The Treatment Of Limited-Stage Small-Cell Lung Cancer (SCLC); Updated Results: JCOG 9903-DI Presenter: Kiyoshi MoriPresenter's Affiliation: National Cancer Center Hospital, Tokyo, Japan.Type of Session: ScientificBackground Noda K. et al have demonstrated that Irinotecan and cisplatin (IP) significantly improves survival compared with cisplatin and etoposide (EP) in patients with extensive stage SCLC (Pro ASCO, 483a, 2000). The use of
Survival and Long-Term Toxicity Results in the SCOTROC Study: Docetaxel-Carboplatin (DC) vs. Paclitaxel-Carboplatin (PC) in Epithelial Ovarian Cancer (EOC) Presenter: P.A. VaseyPresenter's Affiliation: Scottish Gynaecological Cancer Trials GroupType of Session: ScientificBackground The Scottish Gynaecological Cancer Trials Group undertook a study of DC vs. PC in FIGO stage 1C-4 EOC. Data presented at ASCO last year demonstrated equivalent response rates in both arms. However, it was noted the DC
Chemotherapy +/- whole-brain irradiation (WBI) for primary CNS lymphoma (PCNSL)-first experience with a randomized trial Presenter: A. KorfelPresenter's Affiliation: Klinikum Benjamin Franklin, BerlinType of Session: PosterBackground The prognosis of primary CNS lymphoma (PCNSL) is poor. The trend has been to treat without the use of whole brain radiation, as results with chemotherapy are better, and adding radiation to chemotherapy is thought to add toxicity. This
p21 and p53 as prognostic factors for bladder preservation and survival in patients with bladder cancer treated with neoadjuvant chemotherapy Presenter: Garcia Del MuroPresenter's Affiliation: Institut Catala d'Oncologia-Ciutat Sanitaria de BellvitgeType of Session: ScientificBackground Muscle invasive cancer has traditionally been treated with cystectomy. However, more recently, combined chemoradiation has been used as a bladder sparing regimen in selected patients. This study
Multicenter Phase III Trial to Compare Radical Nephrectomy Plus Adjuvant Autologous Tumor Cell-Lysate Vaccine Versus Radical Nephrectomy Without Adjuvant Treatment for Renal Cell Carcinoma Stages pT2-3bN0-3M0: a 3-year Analysis Presenter: C. DoehnPresenter's Affiliation: University of Luebeck Medical SchoolType of Session: ScientificBackground According to SEER data, 50% of renal cell carcinomas (RCC) are localized in extent. The five-year survival rate for localized tumors is 90%, but drops to 60% if disease is regional in extent and 10% if metastatic. Standard therapy
Updated results of a randomized controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer Presenter: R.R. HallPresenter's Affiliation: MRC Clinical Trials UnitType of Session: ScientificBackground Muscle-invasive bladder cancer continues to have a high rate of failure, with the majority with distant metastases. The use of chemotherapy, both in the adjuvant and neoadjuvant setting has been used to try to increase survival and decrease
Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) porgressing on a same dose and schedule platinum-based regimen Presenter: J. BaselgaPresenter's Affiliation: Institut Goustave-Roussy, Villejuif, FranceType of Session: ScientificBackground Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)who fail first line therapy have a very poor prognosis, with a response rate of Materials and Methods Eligible patients had SCCHN
Preliminary results fo the GORTEC 96-01 randomized trail, comparing very accelerated radiotherapy versus concomitant radio-chemotherapy for locally inoperable HNSCC Presenter: J. BourhisPresenter's Affiliation: Institute Goustave-Roussy, Villejuif, FranceType of Session: ScientificBackground Recent evidence demonstrates improved outcome in squamous cell carcinoma of the head and neck(HNSCC) with altered fractionation radiation (RT) or concurrent chemoradiotherapy (CRT). There have been few direct comparisons
Protective Effect Of Vitamin E (VE ) In Head And Neck Cancer Radiation Induced Mucositis: A Double-Blind Randomized Trial Presenter: Paulo R FerreiraPresenter's Affiliation: Hospital de Clinicas de Porto Alegre, Porto Alegre, BrazilType of Session: ScientificBackground Vitamin E is the most important antioxidant in the human body It scavenges free radicals and prevents lipid membrane peroxidation Vitamin E has been proposed as a potential radioprotectant agent A
Improving the Management of Chemotherapy-Induced Neutropenia: Progress in Developing Once-per-Cycle Cytokine Support Presenter: Jeffrey Crawford, MD Chemotherapy induced neutropenia is one of the primary dose limiting toxicities of cancer treatment, putting patients at risk of infection and frequently leading to treatment interruptions and sub-optimal chemotherapy or radiotherapy dosing. Daily filgrastim is a widely used agent to reduce the clinical impact of
Cytokine-Based Approaches for Reducing the Impact of Chemoradiotherapy-Induced Mucositis and Graft-Versus-Host Disease Presenter: Bruce Blazar, MD Stem cell plasticity refers to the recently discovered ability of bone marrow stem cells (BMSCs) to generate non-hematopoietic cell types, such as epithelial, skeletal muscle, bone, liver, and neural cells. Dr. Orlic and his group have investigated the ability of adult mouse BMSCs to differentiate into myocardial
Clinical Implications of Stem Cell Plasticity: Repair of the Infarcted Heart by Cytokine-Mobilized Bone Marrow Stem Cells Presenter: Donald Orlic, PhD Stem cell plasticity refers to the recently discovered ability of bone marrow stem cells (BMSCs) to generate non-hematopoietic cell types, such as epithelial, skeletal muscle, bone, liver, and neural cells. Dr. Orlic and his group have investigated the ability of adult mouse BMSCs to differentiate into myocardial
Alternative Targets for Immunotherapy: Targeting CD22 With Monoclonal Antibodies for the Treatment of Non-Hodgkin?s Lymphoma Presenter: John P. Leonard, MD Affiliation: Cornell University While mortality rates for patients with prostate cancer or breast cancer are decreasing, death rates for patients with non-Hodgkin?s lymphoma continue to rise. Accordingly, the search for more efficacious agents continues. Indolent lymphomas are generally incurable with
Study of Bone Marrow Involvement in 1161 Consecutive Hodgkin's Lymphoma Patients. Presenter: Alessandro Lewis Affiliation: Piemonte Hodgkin's Disease Registry. Alessandria, Italy Background In Hodgkin's Disease(HD) bone marrow involvement(BMI) has been reported as a unfavorable prognostic factor. Accordingly, bone marrow biopsy(BMB) is frequently used in staging of disease. Increasingly, the utility of this procedure
Candidate Gene Targets of the c-Myb Protooncogene in Human Myloid Leukemia Presenter: Susan E. Shetzline Institution: University of Pennsylvania Background: The c-Myb proto-oncogene encoded transcription factor, Myb is required for normal and malignant hematopoeisis. Ectopic c-Myb expression can transform hematopoetic cells, thus Myb may play a role in leukemogenesis. To identify potential downstream targets
Utility of 18-FDG-PET Scanning in Lymphoma by WHO Classification Presenter: Rebecca L. Elstrom Background: 18-FDG-PET scanning is an important imaging modality in the staging and monitoring of many malignancies, including lymphoma. Some tumors, however, do not have the high glucose uptake needed for 18-FDG uptake, and are therefore not well imaged by PET. In order to assess whether the histologic subtype of a
Low Penetration of Imatinib (STI571) into the CSF Indicates the Need for Standard CSF Prophylaxis in Patients with CML Lymphoid Blast Crisis and Philadelphia Chromosome Positive ALL Presenter: Jose F. Leis Affiliation: Oregon Health & Sciences University Background: Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ ALL) are hematologic malignancies caused by the BCR-ABL gene, a constitutively active tyrosine kinase fusion protein generated by a 9:22 translocation.
Positron Emission Tomography with 18F-FDG in the Evaluation of Post-Treatment Residual Mass in Patients with Malignant Lymphoma. Presenter: Ralph Naumann Affiliation: University Hospital, Dresden, Germany Background: Management of residual mass after lymphoma treatment is a problematic issue for oncologists. It is not easy to determine if such masses represent active malignant disease or scar tissue that requires no further treatment. Positron emission Tomography
Analysis of Predisposing Factors for Hepatic Veno-Occlusive Disease after Treatment with Gemtuzumab Ozogamicin (Mylotargr, CMA-676). Presenter: Edward Stadtmauer University of Pennsylvania Cancer Center Background: Hepatic veno-occlusive disease (VOD) occurs frequently after hematopoietic stem cell transplantation (HSCT) but is rarely seen with other forms of therapy. Gemtuzumab Ozogamicin is a monoclonal anti-CD33 antibody that is used in the treatment of Acute
Novel Erythropoeisis Stimulating Protein (Aranesp) Enhances Pegylated Soluble Tumor Necrosis Factor Receptor Type 1 (PEG sTNF-R1) Alleviation of Anemia of Chronic Disease (ACD) in a Rodent Model of Systemic Inflammation. Presenter: Greg Stoney Affiliation: Amgen Inc. Introduction Anemia of Chronic Disease is commonly associated with several chronic inflammatory disease states. ACD has a multifactorial pathogenesis mediated by multiple inflammatory cytokines. Aranesp is a novel erythropoetin analogue with a sustained duration of action, known to
Inter-Institutional Second Opinion Pathologic Review of Lymphoproliferative Disorders After WHO Classification. Presenter: Jonathon Silberstein Affiliation: Memorial Sloan-Kettering Cancer Center Background: The World Health Organization (WHO) classification of lymphoproliferative disorders is the most recent classification scheme available. It incorporates recent advances in diagnosis and biology, including immunohistochemistry and genetic analysis.
STI-571 in the Treatment of Children with Philadelphia (Ph+) Chromosome-Positive Leukemia: Results from a Children's Oncology Group (COG) Phase I Study. Presenter: Martin A. Champagne Background: STI-571 is a novel chemotherapeutic agent that selectively inhibits the abnormal tyrosine kinase that results from the translocation of the c-abl gene on chromosome 9 to one of two breakpoint regions on chromosome 22 (t 9;22). This translocation, known as the Philadelphia Chromosome, results
The Pharmacokinetics of Darbopoetin Alpha Administered Subcutaneously in Patients with Non-Myeloid Malignancies Receiving Multicycle Chemotherapy Presenter: A. C. Heatherington Presenter's Affiliation: Amgen, Inc. Type of Session: Poster Background Darbopoetin Alpha (NESP, Aranesp) is a novel synthetic variant of rHuEPO possesing 2 additional consensus N-linked carbohydrate groups. Darbopoetin alpha has been shown to have a 2-3 fold increased half life compared to rHuEPO in patients
Development and Validation of the FACT-Neutropenia Presenter: Elizabeth A. Calhoun Presenter's Affiliation: Northwestern University Background The Functional Assessment of Cancer Therapy (FACT)is a series of validated scales designed to measure quality of life (QOL). It consists of a general measure (FACT-G) and specific subscales related to the effects of the disease, its symptoms, and
The Epidemiology and Economics of Neutropenia in Hospitalized Adult Cancer Patients: Data From the University HealthSystem Consortium Presenter: Gary H. Lyman Presenter's Affiliation: Albany Medical College Type of Session: Poster Background Neutropenia is a common toxicity of conventional chemotherapy accounting for a large percentage of inpatient hospital expenditures, particularly when neutropenia related fever results. Febrile neutropenia patients generally require
Dose Response of Darbepoetin Alfa Is Similar in Anemic Patients with Solid Tumors or Lymphoproliferative Malignancies. Presenter: Michael Hedenus Presenter's Affiliation: Sundsvall, Sweden Type of Session: Poster Background One of the most problematic side-effects of chemotherapy is anemia, or a decreased red blood cell count. Not only can anemia cause shortness of breath and fatigue, but it can also cause delays in cancer treatment. There is a substance,
Darbepoetin Alfa Administered Every 1 or 2 Weeks Alleviates Anemia in Patients With Solid Tumors Presenter: John Glaspy Presenter's Affiliation: UCLAType of Session: Poster Background One of the most problematic side-effects of chemotherapy is anemia, or a decreased red blood cell count. Not only can anemia cause shortness of breath and fatigue, but it can also cause delays in cancer treatment. There is a substance, erythropoieten,
Molecular and Chromosomal Characterization of Resistance in CML Patients after STI-571 (Glivec) Therapy Presenter: Andreas Hochhaus Presenter's Affiliation: Universitat Heidelberg Type of Session: Plenary Background STI-571 is a promising new treatment modality for CML which functions by potent and selective inhibition of the BCR-ABL oncogene. However, STI-571 resistance has been documented in a proportion of patients undergoing STI-571
Combining an Allogeneic Graft-Vs-Myeloma Effect with High-Dose Autologous Stem Cell Rescue in the Treatment of Multiple Myeloma Presenter: David G. Maloney Presenter's Affiliation: Fred Hutchinson Cancer Research Center, Seatle, WA Type of Session: Plenary Background Myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for Multiple Myeloma has been associated with high transplant-related mortality (TRM), limiting its clinical usefulness despite its
HRI is necessary for Regulation of Globin Translation and Survival of Erythroid Precursors in Iron-Deficiency Presenter: An-Ping Han Presenter's Affiliation: MIT Type of Session: Plenary Background The balanced production of heme and globin chains during erythroid cell development results in the production of 250 million hemoglobin molecules per red blood cell. The production of globin chains is exquisitely regulated to match cellular iron stores,
Characterization of Erythroid Differentiation Related Factor (EDRF), a GATA-1 Regulated Molecular Chaperone for á-globin Protein Presenter: Yi Kong Presenter's Affiliation: Children's Hospital of Philadelphia Type of Session: Plenary Background Molecular chaperone proteins are believed to exist which coordinate the exquisitely controlled translation and folding of globin proteins into functional hemoglobin molecules. These proteins have never been identified. In
Expression Profiling of Pediatric Acute Lymphoblastic Leukemia (ALL) Blasts at Diagnosis Accurately Predicts both the Risk of Relapse and of Developing Therapy-Induced ALL Presenter: E. Yeoh PresentAer's Affiliation: National University of Singapore Type of Session: Plenary Background Pediatric patients with ALL (PALL) are typically stratified into risk groups to help direct therapy. 80% of patients are now cured of pediatric ALL with systemic chemotherapy and treatment of the CNS. Despite this high cure
Monitoring the Anti-Tumor Activity of Expanded CD8+ NKT Cells After Allogeneic Bone Marrow Transplantation Using Bioluminescent Imaging Presenter: Matthias Edinger Presenter's Affiliation: Stanford University School of Medicine Type of Session: Plenary Background Biolumiscent imaging is an imaging technique that allows the visualization of labeled cells within a living animal. Cells labeled with the Luc gene emit low levels of light that can be detected and quantified with
Changes in Endogenous Erythropoietin and the Pharmacokinetics of Darbepoetin Alfa in Patients with Non-myeloid Malignancies Receiving or Not Receiving Chemotherapy Presenter: A.C. Heatherington Presenter's Affiliation: Type of Session: Poster Background Several studies have reported an increase in endogenous erythropoietin (EPO) after chemotherapy, however, there is no published data on the pharmacokinetic (PK) properties of recombinant human erythropoietin (rHuEPO) in chemotherapy patients.
Structure of a von Willebrand Factor Cleaving Protease, an ADAMTS Protease Involved in Thrombotic Thrombocytopenic Purpura (TTP) Presenter: Dominic Chung Presenter's Affiliation: Type of Session: Plenary Background Von Willebrand Factor Cleaving Protease (VWFCP) is a plasma metalloprotease that cleaves von Willebrand Factor multimer to smaller sizes. Deficiency of this protease, either congenital or associated with an auto-antibody, is associated with TTP. The
CHEOP (Chop + Etoposide): the New Standard Regimen for Younger Patients with Low Risk (Low LDH) Aggressive Non-Hodgkin's Lymphoma (NHL) Presenter: Michael G. Pfreundlschuh Presenter's Affiliation: Type of Session: Scientific Background Low Risk (normal LDH)aggressive NHL has classically been treated with CHOP chemotherapy given on a 21 day dosing schedule. The objective of this trial was to investigate the use of shorter 14 day treatment intervals with or without the
Acute Myeloid Leukemia in Adolescents and Young Adults (AYAs): A Comparison of Outcomes Between Patients Treated on Childhood or Adult Protocols Presenter: William G. Woods Presenter's Affiliation: Emory University, Atlants, GA and Children's Cancer Group, Arcadia, CA Type of Session: Scientific Background Children with AML are frequently treated with more aggressive regimens than adults, and adults under age 40 are often treated with more aggressive regimens than older adults due to
Concurrent Fludarabine and Total Body Irradiation (F-TBI) for Patients with Advanced Relapsed, Refractory, or Resistant Indolent Non-Hodgkin's Lymphoma (NHL): A Phase I Trial. Presenter: David Eilender Presenter's Affiliation: Wayne State University Type of Session: Poster Background Both chemotherapy (CHT) and radiation therapy (RT) are used in the treatment of non-Hodgkin's lymphoma (NHL). It is well known that when certain chemotherapeutic agents are given with RT there is a synergistic effect. The current
Cytotoxicity of Mevastatin and Other Cholesterol Modulators in Acute Myeloid Leukemia Presenter: Henry Y. Li Presenter's Affiliation: Fred Hutchinson Cancer Research Center Type of Session: Scientific Background The mevalonate pathway is essential to cell survival, producing essential sterols, ubiqinones, retinoids and isoprenoids. HMG-CoA reductase inhibitors are a class of drugs which block the first rate-limiting enzyme
Requestioning the Role of Prolonged Maintenance Chemotherapy in AML: Randomized Trial by the German AML Cooperative Group Updated. Presenter: Thomas Buechner Presenter's Affiliation: German AML Cooperative Group Type of Session: Scientific Background The German AML Cooperative Group (GAMLCG) has previously reported a survival advantage to 3 years of montly maintenance chemotherapy after standard dose thioguanine/araC/daunorubicin (TAD) vs. no further treatment. This was
Thrive I: Efficacy and Tolerability of the Novel, Oral Direct Thrombin Inhibitor Ximelagatran Compared with Standard Therapy for the Treatment of Acute Deep Venous Thrombosis Presenter: Sam Schulman Presenter's Affiliation: Karolinska Hospital, Stockholm, Sweden Type of Session: Scientific Background Ximelagatran is an orally available, direct thrombin inhibitor. It is absorbed and converted to its active form, melagatran. It has a rapid onset, reaching peak serum concentration after 2-3 hours and does not
CHOP Alone Compared to CHOP Plus Radiotherapy for Early Stage Aggressive Non-Hodgkin's Lymphomas: Update of the Southwest Oncology Group (SWOG) Randomized Trial Presenter: T.P. Miller Presenter's Affiliation: Arizona Cancer Center, Tuscon, AZ Type of Session: Scientific Background In 1998, SWOG study 87-36 reported the results of a randomized trial comparing 8 cycles of CHOP chemotherapy with 3 cycles of CHOP + involved field radiotherapy (IFRT). With a median follow up of 4.4 years, there was a
Multiple Resistance Mechanisms Identified through Studies of Cell Lines Derived from Chronic Myelogenous Leukemia Patients Progressing on STI-571 Therapy Presenter: Nicholas J. Donato Presenter's Affiliation: MD Anderson Cancer Center Type of Session: Scientific Background STI-571 is known to be an effective inhibitor of the BCR-ABL fusion protein and therefore has become a common treatment for BCR-ABL positive leukemias. Disease progression while on STI-571 occurs frequently in accelerated
Air Travel, Prothrombotic Mutations and Venous Thrombosis: The MEGA Study Presenter: Frits R. Rosendaal Presenter's Affiliation: Leiden University Medical Center, Leiden, Netherlands Type of Session: Scientific Background Contradictory reports on air travel and deep venous thrombosis (DVT) risk have documented relative risk varying from 0 to 4. Increasing public awareness of mortalities resulting from PE
t(11;18) Is a marker for All Stage Gastric MALT Lymphomas That Will Not Respond o H. Pylori Eradication Presenter: H. Liu Presenter's Affiliation: Universiy College London Type of Session: Scientific Background Eradication of H. Pylori infection leads to complete regression of gastric mucosa associated lymphoid tissue (MALT)lymphoma in greater than 70% of cases. The translocation t(11;18) is the sole chromosomal abberation in gastric MALT
A Randomized Trail of Fludarabine and Mitoxantrone Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment in Patients with Follicular Lymphoma Presenter: Pier Luigi Zinzani Presenter's Affiliation: Type of Session: Scientific Background Fludarabine plus Mitoxantrone (FM) is an effective combination chemotherapy regimen for the treatment of follicular lymphoma. In this study, FM is directly compared to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy
Early Restaging Positron Emmision Tomography (PET) with 18F-Fluorodeoxyglucose (¹⁸FDG)Predicts Outcome in Patients with Aggressive Non-Hodgkin's Lymphoma (NHL) Presenter: Karoline Spaepen Affiliation: Leuven, Belgium Background Positron Emission Tomography (PET) with FDG (a radiolabeled sugar molecule) is a nuclear medicine study that is able to detect areas of active cancer by showing areas of increased sugar metabolism. Materials and Methods NHL, treated on a doxorubicin chemotherapy
Gastric MALT Lymphomas Prospective LY03 Randomized Cooperative Trial: Preliminary Results of the Molecular Follow-up Presenter: F. Bertoni Presenter's Affiliation: Barts and The London, London Type of Session: Scientific Background Gastric MALT lymphoma is most commonly treated with antibiotic therapy directed at H. Pylori infection. Previous studies have shown that eradication of H. pylori can cause complete regression of gastric MALTs. In the current
The Combination of Low D-Dimer Concentration and Non-High Clinical Probability Score is a Safe Strategy to Exclude Deep Venous Thrombosis Presenter: Roger E.G. Schutgens Presenter's Affiliation: St. Antonius Hospital, the Netherlands Type of Session: Scientific Background Compression Ultrasonography (CUS) is considered the gold standard for the diagnosis of deep venous thrombosis (DVT). Though it is highly sensitive, it is expensive and inefficient, given that serial CUS
Final Report of E1484: CHOP vs CHOP + Radiotherapy (RT) for Limited Stage Diffuse Aggressive Lymphoma Presenter: Sandra J. Horning Presenter's Affiliation: Stanford University Type of Session: Scientific Background The objectives of this study were threefold: to determine the rate of complete response (CR) to, and toxicity of, eight cycles of CHOP chemotherapy; to compare 8 cycles of CHOP with 8 cycles of CHOP + involved field radiotherapy
High Levels of Soluble CD20 (sCD20) in patients with Non-Hodgkin's Lymphoma (NHL): Correlation with Clinical Behavior and Contrast with Patients with Hodgkin's Disease (HD) Presenter: M. Albitar Presenter's Affiliation: MD Anderson Cancer Center, Texas Type of Session: Scientific Background CD20 is a Glycoprotein transmembrane receptor found on mature B-cells. Differences in the levels of surface CD20 on B-cells have been observed in different malignancies. Anti-CD20 antibodies are now being used against certain
Combination Therapy with Thalidomide Plus Dexamethasone (THAL/DEX) for Newly Diagnosed Myeloma (MM) Presenter: S. Vincent Rajkumar Presenter's Affiliation: Mayo Clinic, Rochester, MN Type of Session: Scientific Background VAD is standard induction chemotherapy for MM patients prior to undergoing stem cell transplant as part of aggressive therapy for this disease. VAD is cumbersome to administer, requiring central venous access, and also quite
Persistence of Myeloma Protein for More than 1 year after Radiotherapy is an Adverse Prognostic Factor in Solitary Plasmacytoma of Bone Presenter: Richard B. Wilder Presenter's Affiliation: M.D. Anderson Cancer Center Type of Session: Scientific Background Solitary plasmacytoma of bone (SPB) occurs infrequently, therefore no clear prognostic factors for this ailment, when treated with radiotherapy alone, have been established. Evolving criteria regarding the definition of SPB
High incidence of Thalidomide-Associated Deep Vein Thrombosis (DVT) and Pulmonary Emboli (PE) when Chemotherapy is also administered Presenter: Alan Liehten Presenter's Affiliation: University of Chicago Type of Session: Scientific Background Thalidomide is a sedative/anti-emetic that was given to women from 1956-1962. Some 12,000 birth defects have been attributed to the use of this drug. Today thalidomide is used in the treatment of multiple myeloma and leprosy.
Neurocognitive Assessment and detection of Stroke in Patients Diagnosed with Sickle Cell Disease: Neuropsychological Functioning and Magnetic Resonance Imaging (MRI) Presenter: E. Vichinsky Presenter's Affiliation: Children's Hospital, Oakland, California Type of Session: Scientific Background Children who have sickle cell disease(SCD) are at risk for the development stroke or silent infarct, often resulting in cognitive impairment. It has been estimated that approximately 25% of all children with SCD will
Fludarabine Compared with CVP Chemotherapy in Newly diagnosed Patients with Stages III and IV Low Grade Malignant Non-Hodgkin?s Lymphoma. Final Analysis of a Prospective Randomized Phase III Intergroup Study in 381 Patients Presenter: A. Hagenbeek Presenter's Affiliation: Type of Session: Scientific Background In 1993, the EORTC lymphoma group initiated a prospective randomized trial in newly diagnosed, low grade non-Hodgkin?s lymphoma (NHL) patients to investigate the efficacy and toxicity of Fludarabine compared to the conventional regimen of
Single Dose Pegfilgrastin (SD/01) Is as Effective as Daily Filgrastim Following ESHAP Chemotherapy for Subjects wtih Non-Hodgkin's Lymphoma or Hodgkin's Disease: Results of a Randomized, Open-Label Study Presenter: Julie M. Vose Presenter's Affiliation: University of Nebraska Medical Center, Omaha, NE Type of Session: Scientific Background Pegfilgrastim is a pegylated form of filgrastim that has previously been shown to safely and effictively improve neutrophil counts and decrease neutropenia-related complications in patients receiving
Third International Laryngeal Cancer Conference: Call for Posters maxwords){ alert("Sorry, but you have exceeded the 150 word limit. Please reduce the length of your abstract. Thank you.") return false } } //--> This conference is supported by an educational grant from eMedicine.com. Call for Posters The deadline for receipt of abstracts is Wednesday, May 15, 2002. The Abramson Cancer
New Targets and Innovative Strategies in Cancer Treatment: A course for clinicians Conference Dates: February 13-14, 2004 Conference Location: Monte Carlo, Monaco Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: Introduction (Intracellular communication and signaling, Why cancer cells proliferate, Growth factors and growth factor receptors in normal
Organizing Chemotherapy and Hormonal Therapy: The Key Role of Supportive Agents Conference Dates: February 5-6, 2004 Conference Location: Geneva, Switzerland Sponsoring Group: MSKCC, Clinique de Genolier, Imedex Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: Conference Summary - Participants at this meeting will learn about new ways and means to optimize chemotherapy and hormonal
Novel Therapeutic Approaches in the Treatment of Multiple Myeloma and Lymphoma Conference Dates: Friday, February 6, 2004 Conference Location: The St. Regis Hotel, Los Angeles, CA Sponsoring Group: Multiple Myeloma Research Foundation & Lymphoma Research Foundation Conference Web Page URL: www.multiplemyeloma.org/events Topics Covered: Myeloma Specific: At the completion of this program, the participants should be
The American Society of Breast Surgeons 5th Annual Meeting Conference Dates: March 31-April 4, 2004 Conference Location: The Bellagio, Las Vegas, NV Sponsoring Group: Conference Web Page URL: www.breastsurgeons.org Topics Covered: State-of-the-art treatment and diagnosis of breast diseases. Who Should Attend: surgeons with a special interest in breast disease Registration Information:
2nd Annual Atlanta Lung Cancer Symposium Conference Dates: March 19-20, 2004 Conference Location: Atlanta, GA Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/calendars/oncology.htm
Fourth International Laryngeal Cancer Conference Date: March 11-12, 2004 Location: Philadelphia, Pennsylvania, USA Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Sponsors: University of Pennsylvania School of Medicine and Abramson Cancer Center of the University of Pennsylvania Who Should
NCCN 9th Annual Conference: Clinical Practice Guidelines & Outcomes Data in Oncology Conference Dates: March 10, 2004 - March 14, 2004 Conference Location: Westin Diplomat Resort & Spa, Hollywood, FL, USA Sponsoring Group: National Comprehensive Cancer Network Conference Web Page URL: www.nccn.org Topics Covered: The National Comprehensive Cancer Network (NCCN)s 9th Annual Conference: Clinical Practice Guidelines &
Real Men Do Get Cancer: Risks, Prevention and Treatment of Male-Specific Cancers Conference Dates: March 20, 2004 Conference Location: City of Hope National Medical Center, Duarte, CA Sponsoring Group: City of Hope Clinical Cancer Genetics Education Program and Divisions of Medical Oncology & Surgery Conference Web Page URL: www.cityofhope.org/ccgp Topics Covered: This topic will address important advances in
Advances in Oncologic PET Imaging Conference Dates: March 20, 2004 Conference Location: Vincent A. Stabile Research Bldg. Tampa, FL Sponsoring Group: Moffitt Cancer Center Conference Web Page URL: http://www.moffitt.usf.edu/about_moffitt/calendar/index.asp Topics Covered: PET scans Conference Objectives: Review clinical oncologic applications for PET Who Should
Emerging Cancer Treatment Modalities Conference Dates: March 21-23, 2004 Conference Location: Copper Mountain Colorado Sponsoring Group: University of S. Florida and Moffitt Cancer Center Conference Web Page URL: www.moffitt.usf.edu/promotions/modalities Topics Covered: Molecular targeted therapies, clinical drug resistance, immunotherapy, functional genomics, stem cells
Path to Wellness: Coping with Nutrition, Weight and Fitness Issues Related to Breast and Gynecoloical Cancers Conference Dates: Wednesday, March 10, 2004 Conference Location: PENN Medicine at Radnor, 250 King of Prussia Road, Radnor, PA Sponsoring Group: Abramson Cancer Center Topics Covered: Women who have had treatment for breast and gynecologic cancers often find themselves coping with health issues such as weight gain and changes in strength
Focus on Myeloma and Plasma Cell Disorders Conference Dates: April 2-3, 2004 Conference Location: Los Angeles, CA Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: Leading clinical and laboratory investigators will present cutting edge data on the diagnosis and management of multiple myeloma and other plasma cell disorders.
5th Annual Focus on Gynecologic Cancers Conference Dates: Friday, April 2, 2004 Conference Location: Adam's Mark Hotel, City Avenue and Monument Road, Philadelphia, PA Sponsoring Group: The Abramson Cancer Center of the University of Pennsylvania Conference Agenda: A Conference for Women Whose Lives Have Been Touched by Gynecologic Cancer. Registration Information: To
Radiation & Lymphedema - Is There a Connection? Conference Dates: April 14, 2004 Conference Location: Penn Therapy & Fitness, 3624 Market Street, Philadelphia PA Sponsoring Group: Penn Therapy & Fitness Topics Covered: What is lymphedema? Etiology of lymphedema Radiation effects on the lymphatic system Who Should Attend: People with lymphedema and their families
Breast Cancer Genetics: What You and Your Family Need to Know Conference Dates: April 24, 2004, 9:00 a.m.-12:00 p.m. Conference Location: Philadelphia Marriott West, West Conshohocken, PA Sponsoring Group: Living Beyond Breast Cancer Conference Web Page URL: www.lbbc.org Topics Covered: Two cancer genetics experts from the University of Pennsylvania will address questions and concerns about breast
Cancer, Culture and Literacy: Innovative Approaches for Advancing Cancer Communications and Research Conference Dates: May 20-22, 2004 Conference Location: Sheraton Sand Key Resort, Clearwater Beach, Florida Sponsoring Group: H. Lee Moffitt Cancer Center & Research Institute Conference Web Page URL: www.moffitt.usf.edu/promotions/ccl Topics Covered: Health Education Health Literacy Cancer Communications Cancer Control
The First Patient and Survivor Forum: Learning, Laughing and Living in Dallas Conference Dates: May 22-23, 2004 Conference Location: Dallas Marriott Las Colinas, Dallas, Texas Conference Web Page URL: www.curetoday.com/patientmeeting/ Topics Covered: Join survivors from around the country to learn the latest about both sides of the cancer experience: medical and emotional. Conference Objectives: Join survivors
Update in the Multidisciplinary Management of Early-stage Non-small Cell Lung Cancer Conference Dates: Friday, May 14, 2004 Conference Location: Marriott Hotel, 1201 Market Street, Philadelphia, PA Sponsoring Group: University of Pennsylvania School of Medicine Conference Web Page URL: www.med.upenn.eduappscme_events Topics Covered: Early-stage Non-small Cell Lung Cancer Conference Objectives: At the conclusion of
Renew, Relax, Rejoice Conference Dates: May 15, 2004 Conference Location: Bridge Level, Penn Tower Hotel, Philadelphia, PA Sponsoring Group: The Abramson Cancer Center of the University of Pennsylvania Topics Covered: Complementary and Alternative Medical Topics Acupuncture Aromatherapy Qi Gong Tai Chi Shiatsu Myofascial release
World Congress on Gastrointestinal Cancers Formerly PICC - Perspectives in Colorectal Cancer Conference Dates: June 17-19, 2004 Conference Location: Barcelona, Spain Sponsoring Group: Imedex Conference Web Page URL: www.picccongress.com Registration Information: Online at www.imedex.com, tel: +1 770-751-7332, fax: +1 770-751-7334, email: h.drew@imedex.com Continuing
Advances in Neuroblastoma Research 2004 Conference Dates: June 16-19, 2004 Conference Location: Italy, Genova, Magazzini del Cotone Sponsoring Group: Italian Neuroblastoma Association Conference Web Page URL: http://www.anr2004.org Topics Covered: Genetics and molecular biology Translational research Novel therapies Clinical research Microarray technology Spinal
The 11th World Conference on Lung Cancer - IASLC Conference Dates: July 3-6, 2005 Conference Location: Barcelona, Spain Sponsoring Group: International Association for the Study of Lung Cancer Conference Web Page URL: www.2005worldlungcancer.com Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing
World Congress on Gastrointestinal Cancer Conference Dates: June 15-18, 2005 Conference Location: Barcelona, Spain Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.worldgicancer.com Conference Agenda: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
ASCO Review West 2004 Conference Dates: June 26, 2004 Conference Location: Los Angeles, CA Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes ASCO Review East
ASCO Review East 2004 Conference Dates: June 19, 2004 Conference Location: New York, NY Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
WCRF/AICR International Research Conference on Food, Nutrition, and Cancer Conference Dates: July 15-16, 2004 Conference Location: Washington DC Sponsoring Group: World Cancer Research Fund International and American Institute for Cancer Research Conference Web Page URL: www.aicr.org/conference/ Topics Covered: Energy Restriction and Physical Activity Phytochemicals, Vitamins: Interactions and Effects
6th International Conference on Head and Neck Cancer Date: August 7-11, 2004 Location: Washingotn DC, USA Symposium Web Page: www.headandneckcancer.org Sponsors: The American Head and Neck Society Who Should Attend: Recent Doctorates or mid career investigators (PhD, DrPH, MD, DNS, SCD or equivalent) Objectives: Develop an understanding of current issues in the diagnosis in
The 7th World Congress of Psycho-Oncology Conference Dates: August 25-28, 2004 Conference Location: Copenhagen, Denmark Conference Web Page URL: www.ipos2004.dk Topics Covered: The Theme of the Congress is "Understanding diversities - development of strategies for psychosocial oncology." Conference Agenda: The Scientific Programme has been designed to highlight the research
National Conference of Indian Association of Surgical Oncology & International Symposium on Advances in Oncology Conference Dates: September 24-26, 2004 Conference Location: Hotel Clarks Amer, Jaipur Sponsoring Group: SMS Medical College & Rajasthan Cancer Society Jaipur Topics Covered: Surgical Oncology, Advances in Oncology Conference Objectives: Surgical Oncology advances Who Should Attend: Oncologists , Surgeons, ENT, Gynaecologists.
The 4th European Conference: Perspectives in Breast Cancer Conference Dates: September 23-25, 2004 Conference Location: Madrid, Spain Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
Perspectives in Melanoma Conference Dates: September 23-25, 2004 Conference Location: Berlin, Germany Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
The 4th Princess Margaret Hospital Conference on New Developments in Cancer Management Conference Dates: September 22-24, 2004 Conference Location: Toronto, Ontario, Canada Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
The 5th Annual Prespectives on Colorectal Cancer Conference Dates: September 10-11, 2004 Conference Location: Chicago, Illinois Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
Life After Breast Cancer Conference Date: September 11, 2004 Location: Adam's Mark Hotel, Philadelphia, PA Sponsoring Group: Abramson Cancer Center Who Should Attend: Breast cancer survivors and their loved ones Conference Objectives: Patient Education Conference Fees: $20 Continuing Education: No Required Name: Street
Utilizing Integrative Medicine Throughout the Cancer Journey: A Conference for Patients, Survivors and Healthcare Professionals Conference Dates: September 27, 2004Conference Location: Hyatt Regency Philadelphia at Penns Landing Sponsoring Group: Leukemia & Lymphoma Society and Lance Armstrong Foundation Conference Web Page URL: www.lls.org/epa/edprogram Topics Covered: Finding Hope in Integrative Medicine; Mindfulness-Based approaches to well-being; reiki, music
Frankly Speaking About Cancer Treatment Conference Dates: September 18, 2004 Conference Location: The Wellness Community of Philadelphia Sponsoring Group: Amgen Conference Web Page URL: www.twcp.org Topics Covered: Prevent and manage symptoms and side effects. Strengthen the partnership with the health care team Feel more in control by using strategies that integrate mind, body
Medical Update in AML: New Treatments and Blood Stem Cell Transplantation Conference Dates: September 22, 2004 Conference Location: Telephone Conference Sponsoring Group: National Marrow Donor Program, CancerCare and The Leukemia & Lymphoma Society Conference Web Page URL: www.marrow.org/NEWS/EVENTS/aml_workshop.html Topics Covered: An overview of acute myelogenous leukemia (AML), by Dr. Selina Luger An overview
Advances in Non-Hodgkin's Lymphoma (NHL) Treatment Conference Dates: September 10, 2004 Conference Location: Audioconference Sponsoring Group: National Marrow Donor Program, Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research Conference Web Page URL: www.marrow.org/NEWS/CONFERENCES/advances_nhl.html Topics Covered: The program will include: Recent
Molecular Targets for Cancer Therapy Conference Dates: October 1-5, 2004 Conference Location: Don Cesar, St. Petersburg Beach, FL Sponsoring Group: Moffitt Cancer Center Conference Web Page URL: www.moffitt.usf.edu/promotions Topics Covered: The purpose of this meeting is to foster exchange of the most recent findings and ideas in molecular targets for cancer therapy.
The 9th International Conference on Geriatric Oncology: Cancer in the Elderly. The 5th Meeting of SIOG. Conference Dates: October 15-16, 2004 Conference Location: San Francisco, CA Sponsoring Group: SIOG Conference Web Page URL: www.cancerworld.org/siog/default.asp Registration Information: Online at www.imedex.com, tel: +1 770-751-7332, fax: +1 770-751-7334, email: h.drew@imedex.com
The 10th Conference on Cancer therapy with Antibodies and Immunoconjugates Conference Dates: October 21-23, 2004 Conference Location: Princeton, NJ Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
The 10th Annual Perspectives in Breast Cancer Conference Dates: October 15-16, 2004 Conference Location: Boston, MA Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
The 9th International Conference on Geriatric Oncology: Cancer in the Elderly. The 5th Meeting of SIOG Conference Dates: October 14-16, 2004 Conference Location: San Francisco, CA Sponsoring Group: International Society of Geriatric Oncology Conference Web Page URL: www.cancerworld.org Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
Lymphoma & Myeloma 2004 Conference Dates: October 14-16, 2004 Conference Location: New York, NY Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
Perspectives in Thoracic Oncology Conference Dates: October 1-2, 2004 Conference Location: New York, NY Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
New Frontiers in Lymphedema Research and Therapy Conference Dates: October 20-24, 2004 Conference Location: Reno Sponsoring Group: Natitional Lymphedema Network (NLN) Conference Web Page URL: www.lymphnet.org Topics Covered: General and oncological lymphedema Physiology/immunology of the lymphatic system alternative and investigational treatment palliative care Quality
Hepatocellular Carcinoma: Current Status and Challenges for the Future Conference Dates: Saturday, October 2, 2004 Conference Location: The Ace Center, Ridge Pike & Manor Road, Lafayette Hill, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Conference
2004 VICCAN Fall Scientific Meeting Conference Dates: October 22-23, 2004 Conference Location: Stone Mountain, Georgia Sponsoring Group: Cadent Medical Communications and Vanderbilt University School of Medicine Conference Web Page URL: www.thecbce.com Topics Covered: The VICCAN Fall Scientific Meeting is a multi-tumor CME symposium designed for medical, surgical, and radiation
Thyroid Cancer Survivors' 7th International Conference Conference Dates: October 22-24, 2004 Conference Location: Hyatt Deerfield Hotel, 1750 Lake Cook Road, Deerfield, IL 60015 Sponsoring Group: ThyCa: Thyroid Cancer Survivors' Association, Inc. Conference Web Page URL: www.thyca.org Topics Covered: Thyroid cancer research advances and care, including testing, treatment, short-term follow-up,
Keystone Breast Cancer Conference Conference Dates: October 6, 2004 Conference Location: Harrisburg Hilton Sponsoring Group: PA Breast Cancer Coalition Conference Web Page URL: http://www.pabreastcancer.org/kbcc.html Topics Covered: "Grand Rounds for Medical Professionals: Breast Conservation Treatment for Early Stage Breast Cancer and Ductal Carcinoma In Situ (DCIS)" "The
Translational and Therapeutic Advances in Colorectal Cancer Conference Dates: October 28-30, 2004 Conference Location: New York, NY Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com/futureprograms.asp Topics Covered: Individualizing Drug Therapy / Pharmacogenomics EGFR-Targeted Therapies in Colorectal Cancer Targeting Angiogenesis in Colorectal Cancer Optimizing Chemotherapy
Current Role of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC): Which Patients and Why Conference Dates: December 4, 2004 Conference Location: Chicago, IL Sponsoring Group: Conference Web Page URL: www.thecbce.com/futureprograms.asp Topics Covered: Overview of EGFR Small-Molecule TKIs, Update on Recent Clinical Data for Small-Molecule TKIs, Second-Line Options for the Treatment of NSCLC, Clinical Variables of Patient Benefit: Who
The 5th European Conference: Perspectives in Lung Cancer The 5th European Conference: Perspectives in Lung Cancer Conference Dates: November 19-20, 2004 Conference Location: Berlin, Germany Sponsoring Group: Imedex, inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email:
The 4th European Conference: Perspectives in Bladder Cancer Conference Dates: November 12-13, 2004 Conference Location: Seville, Spain Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
Current Role of Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non Small Cell Lung Cancer (NSCLC): Which Patients and Why Conference Date: December 11, 2004 Conference Location: San Francisco, CA Conference Date: January 8, 2005 Conference Location: Atlanta, GA Conference Date: February 5, 2005 Conference Location: Philadelphia, PA Conference Web Page URL: www.thecbce.com/futureprograms.asp Topics Covered: This continuing medical education (CME) activity will
Prognosis After Regional Nodal Recurrence in Patients With Stage I-II Breast Cancer Treated With Breast Conservation Therapy Presenter: Eleanor HarrisPresenter's Affiliation: University of PennsylvaniaType of Session: ScientificBackground Regional nodal recurrences as first sites of failure are rare in early stage breast cancer treated with breast conservation therapy (BCT). They have been reported as first sites of failure in 1-3% of patients, with prognosis after this
ASTRO Addresses Nuclear Radiologic Terrorism After the events of September 11, 2001, The American Society of Therapeutic Radiology and Oncology (ASTRO) Board of Directors put forth a mandate for training courses to prepare professionals for a radiologic terrorist event. In response to the mandate, ASTRO has been working in conjunction with The American College of Radiology (ACR) and The
Correlates of Distant Metastasis and Death in Prostate Cancer Patients Treated with Radiotherapy Presenter: Pollack, AlanPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground Prostate cancer is a slow growing disease that requires a long follow-up to determine data on survival. Due to this phenomenon, many patients die of intercurrent disease unrelated to prostate cancer. Therefore, other endpoints are used,
The Importance of Head and Neck Lymphoscintigraphy in the Determination of Planning Target Volume for Radiation Therapy of Cephalo-Cervical and Aerodigestive Tumors Presenter: F. Campostrini1Presenter's Affiliation: Department of Radiation Oncology, ASL 21, Legnago, ITType of Session: ScientificBackground Cancers of the head and neck region commonly spread throughout the body via the lymphatic system. Radiation therapy can be employed to treat such cancers. Radiation, when used, is typically given to the
Biochemical Relapse Free Survival After External Beam Radiotherapy for Clinical Stage T1-3 Prostate Cancer in the PSA Era: What Should We Expect Presenter: Kuntia, DeepakPresenter's Affiliation: Cleveland ClinicType of Session: ScientificBackground Past studies in prostate cancer reflecting on Relapse Free Survival (RFS) have done so using the development of symptoms-either local or distant (usually by bone pain). It has differed as to whether this included radiographic evidence of disease
Changing Trends in the National Practice for External Beam Radiotherapy for Clinically Localized Prostate Cancer: The 1999 Patterns of Care Survey for Prostate Cancer Presenter: M.J. ZelefskyPresenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY, USAType of Session: ScientificBackground This study is an evaluation of the changing trends in external beam radiotherapy (EBRT) delivery practice for clinically localized prostate cancer based on the 1999 survey from the American College of
Monotherapy for Stage T1/T2 Prostate Cancer: Radical Prostatectomy, External Beam Radiotherapy, or Permanent Prostate Brachytherapy Presenter: L. PottersPresenter's Affiliation: Department of Radiation Oncology, Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, NY, USAType of Session: ScientificBackground Tumors confined to the prostate, stages T1-2N0 are generally managed by radical surgery or radiation therapy. Controversies exist as to the optimal mode of
A Randomized Prospective Trial of Sequential Neutron - Photon vs. Photon-Neutron Irradiation in Organ Confined Prostate Cancer Presenter: J. FormanPresenter's Affiliation: Department of Radiation Oncology, Wayne State University, Detroit, MI, USAType of Session: ScientificBackground Fast neutrons have been examined as a potential modality to improve the results of therapy for organ confined prostate cancer. The biologic properties of neutrons differ from conventional
Should We Treat the Regional Nodes in Patients with Skin Cancer of the Head and Neck with Perineural Invasion Presenter: A. Garcia-SerraPresenter's Affiliation: Department of Radiation Oncology, University of Florida, Gainesville, FL, USAType of Session: ScientificBackground Once the decision to treat a patient with radiation therapy has been made, the next most important isuue is to dermine what area to treat. While increasing the size of the radiation
Axillary Lymph Node Dose With Modern Tangential Breast Radiation Presenter: Daniel ReedPresenter's Affiliation: Dept of Radiation Oncology, Univ of Washington Medical Center, Seattle, WAType of Session: ScientificBackground The computerized tomography (CT) scan has become a valuable tool in defining the location of internal mammary nodes, in the development of dose?volume histograms relating to the radiation
Automated Delineation of Regional Target Volumes for Patients with Head and Neck Cancer Treated Conformally Presenter: J. BarkerPresenter's Affiliation: Department of Radiation Oncology, University of Washington, Seattle, WA, USAType of Session: ScientificBackground One of main challenges in designing radiation treament fields is accurately identifying anatomic structures on planning radiographs. This issue is becoming even more important when conformal
Target Volume Delineation in Intensity-Modulated Radiation Therapy (IMRT) for Head and Neck Cancer and Correlation With Patterns of Failure Presenter: Lee, NancyPresenter's Affiliation: Dept of Radiation Oncology, Univ of California-San Francisco Medical Center, San Francisco, CAType of Session: ScientificBackground IMRT delivers highly focused radiation that closely conforms to the three-dimensional shape of the tumor being treated. Accurate delineation of the diseased tissues is
Impact of Image Coregistration With Computed Tomography (CT), Magnetic Resonance (MR) and Positron Emission Tomography With Fluorodeoxyglucose (FDG-PET) on Delineation of GTV's in Oropharyngeal, Laryngeal and Hypopharyngeal Tumors Presenter: Jean-Francois DaisnePresenter's Affiliation: Head and Neck Onc Prog, Univ Catholique de Louvain, St-Luc Univ Hosp, Brussels, BelgiumType of Session: ScientificBackground The delineation of target volumes for three-dimensional radiotherapy that closely conforms to the target tissues has been traditionally based on computed tomography
Radiation Therapy With or Without Chemotherapy for Cervical Cancer With Periaortic Lymph Node Metastases Presenter: Saad, AymanPresenter's Affiliation: Wayne State UniversityType of Session: ScientificBackground Several large randomized studies have demonstrated increased local control and overall survival in patients with cervical cancer. However, patients with documented spread to the paraaortic lymph nodes have not been actively investigated.
Conflicts of Interest In Science Catherine DeAngelis, MD, Editor of the Journal of the American Medical Association, gave a keynote speech entitled "Conflicts of Interest In Science" at the 44th annual meeting of the American Society Of Therapeutic Radiology and Oncology. Her experiences as editor of the most circulated medical journal have given her a unique perspective on this
Is Previous Transurethral Resection of the Prostate a Contraindication to Brachytherapy Presenter: Moran, BrianPresenter's Affiliation: Chicago Prostate Cancer CenterType of Session: ScientificBackground Transurethral resection of the prostate (TURP) was the most common GU procedure performed in the 1980s and 1990s. The reported incontinence rate from this procedure is 1-2%. In those patients undergoing brachytherapy as treatment
Biochemical Outcomes Following Prostate Brachytherapy with 5-year Minimum Follow-up: The Importance of Patient Selection and Implant Quality Presenter: M.A. KollmeierPresenter's Affiliation: Mount Sinai School of Medicine, New YorkType of Session: ScientificBackground One form of radiation therapy used in the treatment of prostate cancer is brachytherapy. The use of this technique is relatively new, compared to standard external beam therapy. Accordingly, clinicians are still trying
Stereotactic Radiosurgery with Whole Brain Radiation Therapy Improves Survival in Patients with Brain Metastases: Report of Radiation Therapy Oncology Group Phase III Study 95-08 Presenter: Paul SperdutoPresenter's Affiliation: RTOGType of Session: PlenaryBackground Radiation therapy to the whole brain has been the standard treatment for brain metastases. Recently, in good performance status patients, there has been some evidence for better outcomes with the additional use of stereotactic radiosurgery (SRS). This study
Pelvic Radiation With Concurrent Chemotherapy versus Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer: An Update of RTOG 90-01 Presenter: Patricia EifelPresenter's Affiliation: RTOGType of Session: PlenaryBackground There have been several studies documenting the efficacy of chemoradiation over radiation alone in the treatment of locally advanced cervical cancer. One of these studies, published in the NEJM in 1999, was RTOG 90-01, which randomized patients between
Screening Mammography Is Associated with Earlier Stage Disease and Greater Eligibility for Breast Conservation in Women Aged 40 and Older with Breast Cancer Presenter: G.M. FreedmanPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PA, USAType of Session: PlenaryBackground No cancer screening test has been studied more than mammography. Yet, after more than 35 years of trials, many questions remain regarding at what age and at what interval women should be screened. Currently, screening
Significant Relationship Between Hemoglobin (Hb) Levels and Quality of Life (QOL) During Chemoradiation: Findings From an Incremental Analysis of a 442-Patient, Prospective, Community-Based Epoetin Alfa Study Presenter: D. ShashaPresenter's Affiliation: The Charles & Bernice Blitman Department of Radiation Oncology, Beth Israel Medical Center, New York, NY, USAType of Session: ScientificBackground Anemia is a frequent complication of cancer and its associated treatment. Its prevalence and severity are well documented in the medical and radiation
Patterns of Failure for Resected Advanced Head & Neck Cancer Treated by Concurrent Chemotherapy and Radiation Therapy: An Analysis of RTOG 9501/Intergroup Phase III Trial Presenter: Jay CooperPresenter's Affiliation: New York University Medical Center, New York, NYType of Session: PlenaryBackground The most common failure after grossly or microscopically complete surgical resection and post-operative radiation therapy for advanced cancers of the head and neck is local-regional recurrence. This study evaluates
Larynx Preservation and Tumor Control in Stage III and IV Laryngeal Cancer: A Three-Arm Randomized Intergroup Trial; RTOG 91?11 Presenter: Moshe MaorPresenter's Affiliation: M. D. Anderson Cancer Center, Houston, TXType of Session: PlenaryBackground Previously, the Veterans Administration evaluated whether irradiation of patients who respond to induction chemotherapy could safely preserve the larynx in patients with stage III and low-volume stage IV glottic and supraglottic
Brachytherapy Versus Brachytherapy Plus Beam Radiation for Prostate Cancer: Morbidity Outcomes from Two Prospective Randomized Multicenter Trials Presenter: M. GhalyPresenter's Affiliation: Department of Radiation Oncology, New York Methodist Hospital, Weill Medical Collage-Cornell UniversityType of Session: ScientificBackground Localized prostate cancer is typically treated with surgery or radiation therapy. Forms of radiation therapy include external beam, brachytherapy(implantation of
Eighteen-Year Results in the Treatment of Early-Stage Breast Cancer With Breast Conservation Versus Mastectomy Presenter: Matthew PoggiPresenter's Affiliation: Radiation Oncology Branch, NCI, Bethesda, MDType of Session: ScientificBackground Several randomized clinical trials comparing conservative surgery followed by whole breast irradiation to mastectomy for patients with early stage breast cancer have reported long-term outcomes. These studies include
Long-Term Outcome by Risk Factors Using Conformal High Dose Rate Boost for Prostate Cancer Presenter: R. GalalaePresenter's Affiliation: Dept. of Radiation Oncology, Kiel University, GermanyType of Session: ScientificBackground Radiation therapy is widely used in the treatment of prostate cancer. Forms of this treatment include external beam radiation or brachytherapy, or a combination of the two. With brachytherapy, radioactive seeds
Pathologic Evidence of Dose-Response and Dose-Volume Relationships for Prostate Cancer Treated with Combined External Beam Radiotherapy and High-Dose-Rate Brachytherapy Presenter: L. KestinPresenter's Affiliation: Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USAType of Session: ScientificBackground There has been a long-running debate as to if prostate biopsies should be obtained following radiation therapy. In this study, investigators performed a detailed pathologic review of
Randomized Study Comparing Adjuvant Radiotherapy (RT) with Concomitant Chemotherapy (CT) Versus Sequential Treatment After Conservative Surgery for Patients with Stages I and II Breast Carcinoma Presenter: Gilles. CalaisPresenter's Affiliation: Department of Oncology Radiotherapy, CHU, Tours, FranceType of Session: ScientificBackground Both whole breast irradiation and chemotherapy are often indicated after conservative surgery for early stage breast cancer. However, the sequencing of CT and RT after conservative surgery in this group is
Long-Term Complication Risk After Very High Dose Thoracic Radiotherapy Presenter: Mitchell AnscherPresenter's Affiliation: Duke UniversityType of Session: ScientificBackground Although significant gains have been made in the treatment of non-small cell lung cancer (NSCLC) with the use of chemoradiation, patients as a whole still do poorly, with a significant number still failing locally. In order to attempt to
ASTRO 2002 Gold Medal Awards The Gold Medal is the American Society of Therapeutic Radiology and Oncology's (ASTRO) highest honor, bestowed upon revered radiation oncologists, biologists,and physicists. The award is given in recognition of distinguished accomplishments and contributions in the field of radiation oncology. The 2002 recipients are Steven A. Leibel, M.D.,
Phase III Trial of Amisfostine with Chemoradiation for Inoperable Non Small Cell Lung Cancer (NSCLC): Does Amifostine Protect Cancer Cells? Presenter: Ritusko KomakiPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground Several randomized studies have proven improved outcomes with chemoradiation vs. radiation alone in the treatment of inoperable NSCLC. More recently, there has been evidence that concurrent chemoradiation is more efficacious than
Predictors of Survival for Patients With Brain Metastases: Results of a Randomized Phase III Trial Presenter: Walter CurranPresenter's Affiliation: Thomas Jefferson UniversityType of Session: ScientificBackground Brain metastases occur in 20-40% of all patients with cancer. There is a general life expectancy of these patients, though it may vary widely depending on the patient's prognostic factors. This study attempts to evaluate clinical and
Radiotherapy (RT) Patterns of Care Study (PCS) in Lung Carcinoma Presenter: B. MovsasPresenter's Affiliation: Fox Chase Cancer Center (FCCC), Phila, PA, USAType of Session: ScientificBackground This study was designed to determine the national patterns of radiation therapy (RT) practice in patients treated for non-metastatic lung cancer between 1998-1999. Materials and Methods A survey of randomly selected
Use of Complementary and Alternative Medicine in Radiotherapy Patients - Results of a German Multicenter Study Presenter: Micke, OliverPresenter's Affiliation: Department of Radiotherapy, Münster University Hospital, MünsterType of Session: ScientificBackground The use of complementary and alternative medicine (CAM) is a frequent phenomenon among cancer patients. Currently there is only limited knowledge about the patterns of use in patients undergoing
Randomized Prospective Comparison of Stereotactic Radiosurgery (SRS) Followed by Conventional Radiotherapy (RT) with BCNU to RT with BCNU Alone for Selected Patients with Supratentorial Glioblastoma Multiforme (GBM): Report of RTOG 93-05 Protocol. Presenter: L. SouhamiPresenter's Affiliation: McGill University, Montreal, QC, CanadaType of Session: ScientificBackground GBM continues to prove a most challenging tumor to treat. In spite of aggressive therapy local recurrence remains a significant problem. RTOG 9305 is a prospective randomized trial designed to evaluate upfront SRS followed by
Temozolomide Concomitant and Sequential to Radiotherapy as First Line of Treatment in Glioblastoma Multiforme: An Ongoing Multicentric Phase 2 Trial Presenter: L. FatigantePresenter's Affiliation: Department of Oncology, Radiotherapy, Pisa, ITType of Session: ScientificBackground Glioblastoma Multiforme (GBM) is associated with a high rate of local recurrence after primary therapy and a high mortality rate. In spite of aggressive treatment with surgery, radiotherapy and chemotherapy, median
Whole Brain Radiotherapy Alone or in Combination with Temozolomide (TMZ) for Brain Metastases. A Phase III Study Presenter: D. AntonadouPresenter's Affiliation: Radiation Oncology Department, Metaxas Cancer Hospital, Pireus, GRType of Session: ScientificBackground Brain metastases are a common phenomenon in cancer patients and an increasingly important cause of morbidity and mortality. One of the most attractive advantage of using temozolomide, as an
Concurrent Chemo-Radiation Results in Equivalent Local and Overall Outcome as Induction Chemotherapy Followed by Surgery for Clinical Stage IIIA Non-Small Cell Lung Cancer Presenter: N.A. TaylorPresenter's Affiliation: Department of Radiation Oncology, UT M.D. Anderson Cancer Center, Houston, TX, USAType of Session: ScientificBackground In this study, investigators looked at 2 different treatment regimens for clinical stage IIIa non-small cell lung cancer (NSCLC). Materials and Methods This is a retrospective
70 Gy Thoracic Radiotherapy (TRT) is Feasible Concurrent with Chemotherapy for Limited Stage Small Cell Lung Cancer (L-SCLC): Preliminary Analysis of a CALGB Phase II Trial Presenter: J.A. BogartPresenter's Affiliation: Upstate Medical University, Syracuse, NY, USAType of Session: ScientificBackground This study was designed to further investigate the optimal treatment regimen for L-SCLC. A previous randomized intergroup trial showed a survival benefit for twice-daily TRT (total 45 Gy) with chemotherapy, versus
Brachytherapy Alone Versus Whole Breast Radiotherapy After Breast Conserving Surgery: 5-year Results of a Phase I-II Study and Interim Findings of a Phase III Trial Presenter: Csaba PolgarPresenter's Affiliation: Department of Radiotherapy, National Institute of Oncology, Budapest, HungaryType of Session: ScientificBackground Partial breast irradiation (PBI) has recently received alot of attention, especially since the FDA approval of a balloon-type brachytherapy applicator. This therapeutic approach is
Accelerated Partial Breast Irradiation Via Interstitial Brachytherapy as the Sole Radiation Modality for Treatment of Early-Stage Breast Cancer Presenter: Peter Y. ChenPresenter's Affiliation: Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MIType of Session: ScientificBackground In several randomized clinical trials BCT including whole breast irradiation has been found to yield equivalent survival rates when compared to mastectomy in patients with early carcinoma
The Impact of Baseline Nutritional Support on Treatment Outcome in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck Treated with Definitive Radiotherapy: Report of the Radiation Therapy Oncology Group (RTOG) Trial 90-03 Presenter: Barbara EldridgePresenter's Affiliation: RTOGType of Session: ScientificBackground Head and neck cancers and treatment of these cancers are inherently associated with loss of appetite, swallowing dysfunction, and odynophagia. This leads to a decrease in nutritional uptake with obvious problems associated with it. However, there is
Therapeutic Radiation Oncology in the Age of the Internet - Opening Our Eyes to eMedicine Presented by: Alejandro Jadad, MD, DPhil, FRCPC Alejandro (Alex) Jadad, MD, DPhil, FRCPC, director of the Centre for Global eHealth Innovation in Toronto, Canada, has a vision that most of us will find hard to imagine. He envisions a physician in Australia reviewing the case of a patient with a rare tumor, with an expert in the field, in
Long-Term Changes in Pulmonary Function Tests Following Definitive Radiotherapy for Lung Cancer Presenter: Keith MillerPresenter's Affiliation: Duke UniversityType of Session: ScientificBackground The majority of patients with lung cancer present in an inoperable stage and hence require radiation therapy. Thoracic radiation can affect Pulmonary Function Tests (PFT) and cause clinical pneumonitis. Prior studies have had either very short
The Value of Adding Radiation to Tamoxifen in Post-Menopausal Women with Stage I Breast Cancer: A Decision Analysis Presenter: R.S. PungliaPresenter's Affiliation: Joint Center for RadiationTherapyType of Session: ScientificBackground Large randomized trials have proven that radiation therapy (RT) decreases local recurrence in post-lumpectomy patients with breast cancer. However, the effect on the development of distant metastases and overall survival is less
Role of Radiation Therapy in the Management of Craniopharyngiomas in Children and Young Adults Presenter: D.C. Hsiung StrippPresenter's Affiliation: Department of Radiation Oncology, Hospital of the University of PennsylvaniaType of Session: PosterBackground Treatment of craniopharyngioma has as its goal the reduction of the mass, restoration of neurologic function, prevention of recurrence, and prolongation of survival. Surgical resection,
Craniospinal Radiation in the Treatment of Biopsy Proven Intracranial Germinomas: the Children's Hospital of Philadelphia (CHOP)/Hospital of the University of Pennsylvania (HUP) Experience Presenter: A. MaityPresenter's Affiliation: Department of Radiation Oncology, Hospital of the University of PennsylvaniaType of Session: PosterBackground The most optimal therapy for intracranial germinomas remains controversial. While many oncologists have moved towards using focal radiation therapy, the policy at the University of Pennsylvania
Extent of Surgical Resection Predicts a Favorable Outcome for Children with Malignant Gliomas Presenter: M. BucciPresenter's Affiliation: Department of Radiation Oncology, Hospital of the University of PennsylvaniaType of Session: PosterBackground Pediatric patients with high-grade gliomas have been reported to have a better prognosis than their adult counterparts. There is however, relatively very little published data available that
Androgen Deprivation and Late Rectal Bleeding after Radiotherapy for Prostate Carcinoma Presenter: G. SanguinetiPresenter's Affiliation: Department of Radiotherapy, Istituto Nazionale per lo Studio e la Ricerca sul Cancro, Genova, ItalyType of Session: ScientificBackground Previous studies have suggested that adjuvant androgen deprivation (AAD) is associated with altered rectal toxicity when radiation is used in the treatment of
The Hazards of Dose Escalation in Prostate Cancer Radiation Presenter: D.A. KubanPresenter's Affiliation: Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX, USAType of Session: ScientificBackground Numerous previous studies have suggested that there is a dose-response relationship with radiation therapy (RT) used in the treatment of prostate cancer. The current study analyzes the
Toxicity Following 3D Radiation Therapy for Prostate Cancer on RTOG 9406 Dose Level IV Presenter: J.M. MichalskiPresenter's Affiliation: Dept. of Radiation Oncology, Washington University Medical School, St. Louis, MO, USAType of Session: ScientificBackground Numerous previous studies have suggested that there is a dose-response relationship with radiation therapy (RT) used in the treatment of prostate cancer. This study is a
Phase III Trial of Conformal Radiotherapy Following Neoadjuvant Hormone Treatment in Early Prostate Cancer Presenter: Alan HorwichPresenter's Affiliation: The Royal Marsden Hospital & Institute of Cancer Research, Sutton & London, UKType of Session: ScientificBackground There is evidence that a short course of neoadjuvant hormone therapy (NHT) prior to standard dose radiotherapy (RT) can increase local control in patients with clinically localized
Does Short-Term Androgen Deprivation Substitute for Radiation Dose in the Treatment of High Risk Prostate Cancer Presenter: Khanh H. NguyenPresenter's Affiliation: Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PAType of Session: ScientificBackground There are several randomized trials that confirm a clinical and/or biochemical benefit with the use of androgen deprivation (AD) as a component of treatment in high risk prostate cancer,
OncoLink Scientific Update: ASTRO 2002 Highlights OncoLink has gathered a team of physicians to report on the latest advances in the research and treatment of cancer as discussed throughout the 44th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, in New Orleans, Louisiana. This week: Breast Cancer Treatment. Axillary Lymph Node Dose With Modern Tangential
Imatinib (STI571, Gleevac) as Initial Therapy for Patients with Newly Diagnosed Ph + Chronic Myeloid Leukemia (CML): Results of a Randomized Phase III Study vs Interferon-Alpha + Cytarabine (IFN + AraC) Presenter: Richard A. LarsonPresenter's Affiliation: International Randomized IFN vs. STI571 Study GroupType of Session: PlenaryBackground Imatinib is a specific inhibitor of the BCR-ABL tyrosine kinase, which is the oncogene classically associated with Philadelphia chromosome positive chronic myeloid leukemia (CML). It has been shown to produce
Separation of Blood and Lymphatic Vascular Networks Is Regulated by the Hematopoietic Signaling Proteins SLP-76 and Syk. Presenter: Farhad AbtahianPresenter's Affiliation: University of PennsylvaniaType of Session: PlenaryBackground Currently we do not know how blood vessels and lymph vessles form in the fetus. We do know that they begin their development together and at some stage in the fetal development there are molecular signals that are sent to these
Characterization of the Genomic Breakpoint in t(11:18)(q21:q21) of MALT Lymphoma Presenter: Hongxiang LiuPresenter's Affiliation: University College LondonType of Session: ScientificBackground The t(11:18)(q21:q21) is the most frequent chromosomal aberration found in mucosa associated lymphoid tissue (MALT) lymphoma. This translocation fuses the API2 gene to the MALT 1 gene, generating a functional fusion transcript. However,
High Incidence of t(11:18)(q21:q21) in Helicobacter pylori Negative Gastric MALT Lymphoma Presenter: Hongtao YePresenter's Affiliation: University College LondonType of Session: ScientificBackground Gastric mucosa associated lymphoid tissue (MALT) lymphoma is strongly associated with H. pylori infection. Only approximately 10% of cases do not show evidence of H pylori infection. Those MALT lymphoma cases that are associated with H
Thioguanine-Related Veno-Occlusive Disease (VOD) of the Liver in Children with Acute Lymphoblastic Leukemia (ALL): Report from United Kingdom Medical Research Council (UK MRC) Trial ALL97 Presenter: Ajay J. VoraPresenter's Affiliation: Children's Hospital, SheffieldType of Session: ScientificBackground MRC ALL97 randomized non-B ALL patients aged 1-18 to thioguanine (TG) and dexamethasone or mercaptopurine (MP) and prednisolone. Similar to CCG 1952, a small but significant number of patients receiving TG developed VOD of the
Peptide Vaccination with PR1 Elicits Active T Cell Immunity That Induces Cytogenetic Remission in Acute Myelogenous Leukemia. Presenter: Jeffrey J. MolldremPresenter's Affiliation: M.D. AndersonType of Session: PlenaryBackground Despite decades of research there are no FDA approved cancer vaccines. The concept of tumor immunosurveillance has recently become repopularized with recent research showing that tumor specific antigens do indeed exist. There is a known
Results of Myeloablative Allogenic Stem Cell Transplant (SCT) for Severe Sickle Cell Disease in France Presenter: Francoise BernaudinPresenter's Affiliation: SFGM-TC, FranceType of Session: PlenaryBackground Sickle cell disease effects the black population and is responsible for many hospitalizations and a high consumption of red blood cell transfusions. The only definitive cure remains a bone marrow transplant. However, the risks of a allogenic
Long term follow up of an Alemtuzumab (CAMPATH-1H) containing reduced intensity Allogeneic Transplant Regimen for Non-Hodgkins Lymphoma (NHL) Presenter: Emma MorrisPresenter's Affiliation: UK Collaborative Group, United KingdomType of Session: ScientificBackground Campath is an antibody that targets CD 52 which is a T cell marker. Campath has been studied in induction therapies for myeloablative transplants. This study looked at Campath as additional therapy for reduced intensity
Isolated Central Nervous System (ICNS) Relapse in Children With Standard Risk (SR) ALL: Results of CCG-1952. Presenter: Susan LindemulderPresenter's Affiliation: University of Colorado Health Sciences CenterType of Session: ScientificBackground The CCG 1952 trial was designed to assess event free survival and ICNS failure in standard risk ALL patients randomized to different chemotherapy regimens. The ICNS failure rate as well as various related
Primary Pulmonary MALT Lymphomas Show Frequent and Heterogenous Cytogenetic Abnormalities, Including a Previously Unreported MALT1-IGH Translocation Presenter: Ellen D. RemsteinPresenter's Affiliation: Mayo Clinic; Rochester, MNType of Session: ScientificBackground Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B-cell malignant lymphoma that arises in diverse extranodal sites. t(11;18)(q21;q21), which fuses AP12 to MALT1 is specifically associated with MALT lymphoma and is
Double Autologous Transplantation Improves Survival of Multiple Myeloma Patients: Final Analysis of a Prospective Randomized Study of the "Intergroupe Francophone du Myelome" (IFM-94). Presenter: Michel AttalPresenter's Affiliation: Hopital Purpan; Toulouse, FranceType of Session: PlenaryBackground Multiple Myeloma has been a challenging disease with little change in the Median Survival (MS) in the past 20 years; MS averages 30-36 months. With the introduction of high dose chemotherapy with autologous stem cell
Histological and Clinical Prognostic Factors in Follicular Lymphoma: Proposal for a Prognostic Model Presenter: Irit AviviPresenter's Affiliation: University College London; UKType of Session: ScientificBackground Follicular lymphoma (FL) is one of the most common types of non-Hodgkin's lymphoma. Despite this, prognostic models to predict patient's survival are less well established than in intermediate/high grade disease. Histological grading
Treatment of Hypereosinophilic Syndrome (HES) with Imatinib Mesylate Presenter: Jorge E. CortesPresenter's Affiliation: M.D. Anderson Cancer Center; Houston, TXType of Session: ScientificBackground HES is a rare hematologic disorder characterized by persistent eosinophilia associated with organ involvement. The diseasae is very heterogenous but, patients tend to have a poor prognosis. Treatment for HES has
A Combination of Low Dose Thalidomide with Prednisone in Myelofibrosis with Myeloid Metaplasia Presenter: Ruben A. MesaPresenter's Affiliation: Mayo Clinic; Rochester, MNType of Session: ScientificBackground Myelofibriosis with Myeloid Metaplasia (MMM) is a clonal myeloproliferative disorder with varied prognosis and severity. A curative therapy is lacking for this disease, although peripheral stem cell transplant may be an option for a
A Decision Analysis of Allogeneic Stem Cell Transplantation for MDS: Delayed Transplantation for Low Risk MDS Is Associated with Imporved Outcome Presenter: Corey CutlerPresenter's Affiliation: Dana Farber, Boston, MAType of Session: ReportingBackground Therapies for MDS are limited and unrewarding. Allogeneic transplants can provide cure for 25-40% of the pts. Low risk MDS pts have a life expectancy of several years with minimal medical intervention. Eventually however, pts become
Allogeneic Stem Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL) patients <50 years old in first complete remission(CR) A Donor vs no donor comparison in the EORTC ALL-3 Study. Presenter: Boris LabarPresenter's Affiliation: EORTCType of Session: ReportingBackground Allo transplant for ALL has been used for over 20 years but despite its' general application its role in adults remains unclear. The contraversy remains between an allo transplant and an autologous transplant followed by maintenance chemotherapy for this
Consolidation of AML Therapy with Autograft and Allograft Procedures Does not Negate the Poor Prognostic Impact of FLT-3 Internal Tandem Duplications: Results for UK MRC AML 10 and 12 Trials. Presenter: Panagiotis D. KottaridisPresenter's Affiliation: London, UKType of Session: ScientificBackground Currently >80% of AML pts over the age of 60 will attian a complete remission (CR). Those who receive post CR intensification therapy (either with high dose chemotherapy or bone marrow transplant) will have a better overall survival. A
Treatment-Related Myelodysplastic Sydromes (t-MDS) after Autotransplants (AT) for Multiple Myeloma (MM) Presenter: Guido J. TricotPresenter's Affiliation: University of Arkansas for Medical Sciences; Little Rock, ARType of Session: ScientificBackground Overall Survival (OS) in Multiple Myeloma (MM) has increased with the recent onset of tandem transplants. With the increase use of these double transplants, attention must be paid to the late
Radiotherapy is Unnecessary in Elderly Patients With Localized Aggressive Non-Hodgkin's Lymphoma: Results of the GELA LNH 93-4 Study Presenter: Georges FilletPresenter's Affiliation: Hematology, CHU - Sart TilmanType of Session: ScientificBackground CHOP plus local radiotherapy is considered the standard treatment for localized, aggressive Non-Hodgkin's Lymphoma (NHL). It has been shown to be superior to eight cycles of CHOP alone (Miller, NEJM, 1998). To date, there has
N998B: Multicenter Phase II Trial of Thalidomide (Thal) in Adult Patients with Myelodysplastic Syndromes (MDS) Presenter: Alvaro Moreno-AspitiaPresenter's Affiliation: Mayo Clinic, Rochester, MNType of Session: ScientificBackground Bone Marrow specimens in patients with MDS have increased levels of the following cytokines: TNF-á, TGF-â, IL-1, and IFN-ã. Bone Marrow specimens also demonstrate increased neovascularization. For these reasons, thalidomide
Gene Expression Profiles in AIDS-Related Lymphomas (ARL): Burkitt Lymphoma (BL) and Diffuse Large B-Cell Lymphoma-Immunoblastic Variant (DLBCL-IBL) Presenter: Sven de VosPresenter's Affiliation: UCLAType of Session: ScientificBackground Primary CNS lymphoma and other malignant lymphomas continue to be a large problem in patients with AIDS. The most common type of lymphoma in these patients include Burkitt lymphoma (BL) and diffuse large B cell lymphoma, especially that of the immunoblastic
FDG-PET Is Superior to Gallium Scintigraphy in the Staging and Follow-Up of Patients with De Novo Hodgkin's Disease: a Prospective, Blinded Comparison Presenter: Jonathan W. FriedbergPresenter's Affiliation: University of RochesterType of Session: PosterBackground Accurate hodgkin's disease (HD) staging with CT scan and nuclear scintigraphy allows optimal treatment planning and prevents under or over treatment. Persistent positive scintigraphic evidence of disease after therapy predicts
Superiority of Chemotherapy Alone with the ACVBP Regimen over Treatment with Three Cycles of CHOP Plus Radiotherapy in Low Risk Localized Aggressive Lymphoma: The LNH93-1 GELA Study Presenter: Felix ReyesPresenter's Affiliation: GELAType of Session: ScientificBackground Chemoradiation is likely the most common form of treatment in patients with aggressive but localized Non-Hodgkin's Disease (NHL). However, published series appear heterogeneous with respect to prognostic factors. There is the possibility that patients could
Low Dose Decitabine for Elderly High Risk MDS Patients: Who Will Respond? Presenter: P.W. WijermansPresenter's Affiliation: The Hague; NethrelandsType of Session: ScientificBackground MDS is a rare disease with an inevitably fatal outcome. The treatment is cumbersome, especially in the elderly. Previous studies of treatment for this disease in the elderly have demonstrated lower response rates (RR) and shorter
A Multicenter Randomized Trial of Fludarabine and Mitoxantrone (FM) Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment in Patients with Follicular Lymphoma (FL) Presenter: Pier Luigi ZinzaniPresenter's Affiliation: Italian Cooperative Study Group on LymphomaType of Session: ScientificBackground Follicular lymphoma is a low grade lymphoma that typically has a smoldering disease course. Many patients progress to more advanced disease with symptomatic problems. Different therapies have been employed in this
Effects of 40,000 IU Bi-Weekly (BIW) Induction Dose of Epoetin Alfa Followed by 40,000 IU Once Weekly (QW) in Low-Risk Myelodysplastic Syndrome (MDS) Patients. Presenter: Maria A. A. SpiritiPresenter's Affiliation: Italian Fatigue-QoL/MDS Cooperative Group, ItalyType of Session: PosterBackground Anemia is a serious problem in MDS and other hematologic malignancies. >50% of patients with MDS will have anemia at presentation and up to 90% will suffer from it at some point in time during their disease.
Two Cycles ABVD Plus Extended Field Radiotherapy Is Superior to Radiotherapy Alone in Early Stage Hodgkin's Disease: Results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7 Presenter: Markus SieberPresenter's Affiliation: University of CologneType of Session: ScientificBackground Extended Field (EF)Radiotherapy alone has been considered the standard for early stage Hodgkin's Disease (HD) with 90% 10 year Overall Survival (OS). However, 20-25% of these patients suffer a relapse requiring intensive salvage
Phase I-II study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia Presenter: Kanti R. RaiPresenter's Affiliation: Long Island Jewish Medical CenterType of Session: PosterBackground Chronic Lymphocytic Leukemia (CLL) is the most common chronic leukemia in adults. It's course is usually slow and insiduous however treatment options are often limited due to severe anemias and thrombocytopenias. A novel therapy by
Prevalence and Management of Anemia in Patients with Hematologic Malignancies and Solid Tumors: Results from the European Cancer Anemia Survey (ECAS) Presenter: Heinz LudwigPresenter's Affiliation: ECAS Advisory BoardType of Session: PosterBackground Anemia (hgb Large randomized trials show that correction of anemia leads to symptom improvement and improved quality of life (QOL). Unfortunately, the majority of anemic cancer patients receive no treatment for their anemia. (ASH/ASCO guidelines
Quality of Life, Blood Transfusions, and Toxicity, in Anemic Patients with Advanced Cancer Receiving Weekly Erythropoietin While on Chemotherapy: Results from a Phase III Randomized Double-Blind Placebo-Controlled Study. Presenter: Jeff A. SloanPresenter's Affiliation: Mayo ClinicType of Session: PosterBackground Anemia is obviously a large problem in the population of patients who are receiving chemotherapy. This anemia is likely amplified in those patients with advanced cancer. Anemia causes fatigue and jointly affects patients' quality of life (QOL).
High Response Rates and Durable Remissions in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma Treated with Tositumomab and Iodine I-131 Tositumomab (Bexxar) Presenter: Mark S. KaminskiPresenter's Affiliation: University of MichiganType of Session: PosterBackground I-131 Tositumomab is a monoclonal murine antibody directed against the CD20 cell surface protein present on most lymphocytes, including most lymphoma cells. Recent trials of Bexxar in patients with relapsed or refractory low grade
Preliminary Report of a Phase II Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarag)Given in Combination with Cytarabine in Patients with Acute Myelogenous Leukemia Presenter: Michele BaccaraniPresenter's Affiliation: Ospedale S. Orsola; Bologna, ItalyType of Session: PosterBackground Gemtuzumab has been approved in the United States for the treatment of patients aged sixty and above with CD33+ AML in first relapse for those patients without other cytotoxic options. A standard treatment approach for first
Rituximab Treatment Failures: Tositumomab and Iodine I-131 Tositumomab (Bexxar) Can Produce Meaningful Durable Responses Presenter: Sandra J. HorningPresenter's Affiliation: Stanford UniversityType of Session: PosterBackground Rituxan is a chimeric monoclonal antibody (MAb)directed against the CD20 cell surface protein. It effected a 50% overall response rate in the pivotal trial treating relapsed or refractory indolent non-Hodgkin's lymphoma (NHL). Unfortunately,
Duration of Molecular Remission in Patients with Acute Promyelocytic Leukemia (APML) Treated Primarily with Arsenic Tri-oxide Presenter: B GeorgPresenter's Affiliation: Christian Medical College; Vellore, IndiaType of Session: PosterBackground Arsenic trioxide (As2O3) has been shown to be very effective for the treatment of APML. Most data has been with relapsed disease. Optimal protocols for As2O3 remain to be established. There are limited data on the duration of
Bexxar Radioimmunotherapy Produces a Substantial Number of Durable Complete Responses in Patients with Multiply Relapsed or Refractory Low Grade or Transformed Low Grade Non-Hodgkin's Lymphoma Presenter: Mark S. KaminskiPresenter's Affiliation: University of MichiganType of Session: PosterBackground Virtually all patients with low Grade Non-Hodgkin's Lymphoma (LG NHL) relapse. Relapsed or refractory LG NHL is very difficult to treat, as successive treatments after relpase result in lower responses and less durable responses.
Intermediate Dose Melphalan for de novo Multiple Myeloma gives high complete response rate and durable long term survival Presenter: Mathew StreetlyPresenter's Affiliation: Queen Elizabeth Hospital, Woolwich, UKType of Session: PosterBackground Multiple Myeloma remains a disease with extremely high recurrence rates even after agressive chemotherapy. Oral Melphalan has a median survival rate of 2-4 years in those pts who respond. Complete remission is achieved in IV
Zevalin Radioimmunotherapy is Not Associated with an Increased Incidence of Secondary Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Presenter: M.S. CzuczmanPresenter's Affiliation: Roswell Park Cancer InstituteType of Session: PosterBackground Zevalin is an anti-CD 20 monoclonal antibody with bonded Yttrium-90, making it a radioimmunotherapy. It is being used more commonly in the treatment of B cell Non Hodgkin's Lymphoma (NHL). NHL therapy has traditionally been treated with
Oral Fludarabine phosphate as first-line treatment of chronic lymphocytic leukemia Presenter: Jean-Francois RossiPresenter's Affiliation: CHU; Montpellier, FranceType of Session: PosterBackground Fludarabine phosphate is a nucleotide analog of arabinoside which has achieved overall response rates (ORR) of 63-70% in previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL). Treatment regimens typically
Long Term Follow Up of a Phase II study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Aggressive Non-Hodgkins Lymphoma (NHL) Presenter: J.M. VosePresenter's Affiliation: University of Nebraska Medical CenterType of Session: PosterBackground Standard therapy for NHL is combination chemotherapy with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) Rituxan, a mouse/human anti CD 20 antibody has a distinct mechanism of action and is synergistic with CHOP
Epoetin Alfa Treatment Improves Quality of Life and Increases Hemoglobin Levels during Chemotherapy for Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Multiple Myeloma (MM) Patients with Mild-to-Moderate Anemia Presenter: David J. StrausPresenter's Affiliation: Memorial Sloan Kettering Cancer Center/ Procrit Hematologic Malignancies Study GroupType of Session: ScientificBackground Anemia affects up to 80% of patients with hematologic malignancies. While the effects of severe anemia are known, symptoms of more mild anemia is less well-known, mainly
Time to First Progression Is the Best Predictor of Survival Duration in SWOG Standard Dose Chemotherapy Studies Presenter: Brian G.M. DuriePresenter's Affiliation: SWOGType of Session: ScientificBackground Multiple myeloma has been treated with combination chemotherapy for years. Various regimens have various response rates and have been used in the past to determine efficacy. However, reponse (by % regression of disease) has absolutely no correlation with
Zoledronic Acid, Hypocalcemia and Renal Dysfunction in Thalidomide-Treated Myeloma Patients Presenter: Bethan MyersPresenter's Affiliation: Queen's Medical Centre, University Hospital, NottinghamType of Session: ScientificBackground Zoledronic acid (Zometa) is a new bisphosphonate hundreds to thousands of times more potent than it's predescessors. ASCO 2002 guidelines recommend the use of bisphoshonates to prevent progression of lytic
Low-Dose Thalidomide and Dexamethasone Improves Survival in Advanced Multiple Myeloma Presenter: Antonio PalumboPresenter's Affiliation: Divisione di Ematologia dell'Unversita di TorinoType of Session: ScientificBackground The standard treatment for multiple myeloma (MM)for decades had been melphalan and prednisone. High dose chemotherapy and bone marrow transplant has imroved outcomes, but relapses continue to occur and many
Non-Myeloablative Radio-Immunotherapy With a Iodine-131-Tagged Anti-CD30 Antibody (131I-Ki-4) in Patients With Refractory Hodgkin's Lymphoma Presenter: Roland SchnellPresenter's Affiliation: University of CologneType of Session: ScientificBackground Relapsed Hodgkin's Disease (HD) has a poor prognosis. More treatment alternatives are neeeded. HD is a good target for immunotherapy given high expression of surface antigens including CD25 and CD30. HD also tends to be well
Replicating Attenuated Measles Virus Can Be Engineered to Enter Cells Through the CD20 Antigen Presenter: Adele FieldingPresenter's Affiliation: Mayo ClinicType of Session: ScientificBackground In laboratory models of Non-Hodgkin's Lymphoma (NHL), attenuated measles virus (MV) has been found to have therapeutic potential as a replicating, oncolytic virus. There are case reports of lymphoma regression after measles virus infection in
Treatment of Elderly Non-Small Lung Cancer (NSCLC) Patients with 3 Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial Presenter: S. RamalingamPresenter's Affiliation: University of Pittsburgh Cancer InstituteType of Session: PosterBackground Benefit from combination chemotherapy extends to all age patients with advanced NSCLC Elderly patients with good performance status have comparable efficacy with 'standard' platinum-based doublets. There is concern of
Age-Specific Sub-Analysis of ECOG 1594: Fit Elderly Patients (70-80 yrs) with Non-Small Cell Lung Cancer Do As Well As Younger Patients (<70 yrs) Presenter: CJ LangerPresenter's Affiliation: Fox Chase Cancer CenterType of Session: PosterBackground Exclusion of elderly patients from studies of advanced non-small cell lung cancer (NSCLC) has been common due to fear of increased toxicity of platinum-based regimens in these patients. Previous retrospective studies have been mixed regarding the
Pulmonary radiological-, physiological-, and clinical side-effects after adjuvant radiotherapy in breast cancer Presenter: P.A. LindPresenter's Affiliation: Karolinska Institute, SwedenType of Session: PosterBackground Adjuvant radiation therapy used in the treatment of breast cancer has been shown to decrease cancer deaths However, toxicity from radiation therapy leads to an increase in deaths from other causes At least some of these increased deaths are
P53, EGFR, and PTEN as markers of diagnosis and prognosis in patients with anaplastic glioma enrolled in NCCTG clinical trials Presenter: J.C. BucknerPresenter's Affiliation: NCCTGType of Session: ScientificBackground The NCCTG has previously reported survival differences in patients with high grade gliomas. Median survival times were 52 mo, 19 mo, 16 mo, and 11 mo for grade 3 oligoastrocytomas (OA3), anaplastic astrocytomas (AA), grade 4 oligoastrocytomas (OA4), and
Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy: Update Presenter: M. A. EisenbergerPresenter's Affiliation: Johns Hopkins University (JHU)Type of Session: ScientificBackground Post-prostatectomy patients demonstrating biochemical evidence of prostate cancer recurrence have been previously studied with regards to the natural history of disease progression. The original report from Pound et al. (JAMA
A Phase II Study of Docetaxel and Carboplatin as Neoadjuvant Therapy for Patients with Early T and Advanced N Stage Nasopharyngeal Carcinoma(NPC) Presenter: FM JohnsonPresenter's Affiliation: The University of Texas M.D. Anderson Cancer CenterType of Session: PosterBackground Historically, early stage NPC has been treated successfully with radiation therapy. Radiation therapy alone provides excellent locoregional control, but poor systemic control. Concurrent cisplatin and radiation
Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Presenter: M.V. PilepichPresenter's Affiliation: RTOGType of Session: ScientificBackground RTOG 85-31 was one of the first studies investigating adjuvant androgen suppression in the treatment of prostate cancer. Since the publication of this study, many others investigating the use of adjuvant hormones have been performed. Though this was
Randomized Phase III Study of I.V. Vinorelbine plus hormonotherapy versus hormonotherapy alone in hormone refractory prostate cancer (HRPC) Presenter: R.P AbrettPresenter's Affiliation: Groote Schuur Hospital, Cape Town, South AfricaType of Session: ScientificBackground Vinorelbine has been shown to be active in hormone refractory prostate cancer. Controversy exists regarding the proper palliative management of hormone refractory patients who have failed first line hormonal therapy
Two year survival for Concurrent Carboplatin, Paclitaxel, and Hyperfractionated Radiotherapy in Unresectable Head and Neck Cancer. Presenter: D. CarterPresenter's Affiliation: US Oncology, Houston TXType of Session: PosterBackground Several randomized trials and meta-analyses have shown superior local control, disease-free and overall survival for simultaneous chemoradiotherapy compared with radiation alone for patients with locally advanced head and neck cancers. Recent
The role of hormonal treatment for biochemical recurrence in patients following radical prostatectomy Presenter: Z. A. DotanPresenter's Affiliation: Memorial Sloan Kettering Cancer CenterType of Session: ScientificBackground Biochemical failure following radical prostatectomy (RP) is common, occurring in 20-40% of patients. 1/4 to 1/3 of these patients receive secondary therapy evenly divided between local radiation and hormone therapy. The
Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in phase III localized prostate cancer clinical trials? Analysis of RTOG protocol 92-02 Presenter: H.M. SandlerPresenter's Affiliation: RTOGType of Session: ScientificBackground Prostate cancer is a disease with a long natural history, so the use of survival as an endpoint requires a very long follow-up to reach conclusions Therefore, PSA-defined failure has been used as a surrogate endpoint, shortening the time needed for reporting
Vital statistics following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. Presenter: A. V. D'AmicoPresenter's Affiliation: Dana-Farber Cancer InstituteType of Session: ScientificBackground Various algorithms using pre-treatment risk groups to predict for PSA failure in prostate cacner patients currently exist, namely through single-institution studies by Roach et al and D'Amico, et al. The three main components of these
Paclitaxel (T) following doxorubicin/cyclophosphamide(AC) as adjuvant chemotherapy for node positive breast cancer: Results from NSABP B-28 Presenter: E. P. MamounasPresenter's Affiliation: NSABPType of Session: ScientificBackground This prospective randomized trial intended to determine whether the addition of T to AC chemotherpy provided a benefit in node positive patients with operable breast cancer. Though definitive data regarding the benefit of adjuvant taxanes in node
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy Presenter: M. G. Le ArriagadaPresenter's Affiliation: Institut Gustave-RoussyType of Session: ScientificBackground Premenopausal women with early breast cancer receive a significant reduction in overall mortality from adjuvant ovarian suppression (AOS) following surgery, approximately 24% (+/- 7%). However, in the presence of adjuvant chemotherapy,
Older women with node positive (N+) breast cancer (BC) get similar benefits from adjuvant chemotherapy (adj) as younger patients (pts): The Cancer and Leukemia Group B (CALGB) experience Presenter: H. B. MussPresenter's Affiliation: Univ. of Vermont, CALGBType of Session: ScientificBackground This study is an analysis of the benefits and toxicities by age of adjuvant chemotherapy in N+ breast cancer patients. Little data exists regarding the benefit of cytotoxic chemotherapy in elderly (>65) breast cancer patients. The
Chemohormonal therapy in premenopausal node-positive, receptor positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT 0101) Presenter: N. E. DavidsonPresenter's Affiliation: Eastern Cooperative Oncology GroupType of Session: ScientificBackground The benefits of combined chemotherapy and endocrine therapy in premenopausal pts with node-positive, hormone receptor-positive breast cancer are a topic of much research. The benefit of chemotherapy in node-positive breast
Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nscls: RTOG 94-10 Presenter: W.J. CurranPresenter's Affiliation: RTOGType of Session: ScientificBackground There has been a demonstrated survival benefit of chemoradiation over radiation alone in stage III non-small cell lung cancer (NSCLC) This survival benefit has been demonstrated in several studies using sequential chemotherapy followed by radiation therapy.
Induction chemotherapy following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB) Presenter: R. M. HuberPresenter's Affiliation: University of Munich, Germany; BROCAT-GroupType of Session: ScientificBackground Studies of inoperable NSCLC patients have previously shown a small but statistically significant advantage in median survival with combined modality treatment, ie: chemoradiation. This appears to hold true for both
Subsequent neoplasms (SNs) of the central nervous system (CNS) in survivors of childhood cancer: a case/control study from the Children's Cancer Survivor Study (CCSS) Presenter: J.P. NegliaPresenter's Affiliation: University of MinnesotaType of Session: ScientificBackground Childhood cancer patients survivors are known to be at increased risk of subsequent CNS malignancies. An association between subsequent meningiomas and previous irradiation has been shown previously. A 23-fold increased risk of CNS
Isolated CNS relapse of acute lymphoblastic leukemia (ALL) treated with intensive systemic chemotherapy and delayed CNS radiation: A Pediatric Oncology Group Study Presenter: J.C. BarredoPresenter's Affiliation: Medical University of South CarolinaType of Session: ScientificBackground Event-free survival for patients suffering isolated CNS relapse of ALL after initial therapy has improved. The previous POG 9061 study showed an excellent 4 year EFS of 71% with 6 months of intensive chemotherapy and delayed
Late cardiotoxicity of mediastinal irradiation Presenter: JM AdamsPresenter's Affiliation: University of RochesterType of Session: ScientificBackground Most patients with childhood Hodgkin's Disease (HD) survive long-tem and many are treated with mediastinal irradiation (RT). Mediastinal RT is known to cause cardiac fibrosis and possibly increase the risk of fatal myocardial infarctions;
The impact of concurrent versus sequential tamoxifen and radiation therapy in breast cancer patients undergoing breast conservation therapy. Presenter: Vasathi J. ChristnesenPresenter's Affiliation: Hospital of the University of PennsylvaniaType of Session: PosterBackground Hormonal Therapy plays an important role in the adjuvant therapy of breast cancer patients. The optimal sequencing of tamoxifen therapy and radiation (XRT) is not well established. This study was conducted in order
Bladder preservation with induction chemotherapy (carboplatin/paclitaxel) followed by radiotherapy with concurrent paclitaxel. A study of the Hellenic Cooperative Oncology Group Presenter: G. AravantinosPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: PosterBackground Radical cystectomy remains the standard of care treatment for invasive bladder cancer. Comparable results have been obtained with combined chemotherapy and radiation therapy with bladder preservation Previous studies have been
Ten-Year outcomes for elderly women treated with breast-conserving surgery and definitive breast irradiation for early stage breast cancer. Presenter: Sandra L. UrtishakPresenter's Affiliation: Hospital of the University of PennsylvaniaType of Session: PosterBackground Breast cancer is a major cause of morbidity and mortality among elderly women, but it is not well studied in this population. Older women are more often under treated by conventional criteria when compared with younger
Docetaxel and carboplatin once every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer. Interim analysis of a multicenter phase III trial Presenter: H. GroenPresenter's Affiliation: Dutch Chest Physicians AssociationType of Session: ScientificBackground Taxane-based chemotherapy has been shown to have a modest response rate of 10-30% in advanced non-small cell lung cancer (NSCLC). Taxanes are often given in conjunction with platinum-based chemotherapy for these patients.
Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma Presenter: J.P. LeonardPresenter's Affiliation: Weill Medical College of Cornell UniversityType of Session: ScientificBackground Bcl-2 overexpression is involved in inhibition of apoptosis and therefore results in tumor cell growth. Bcl-2 is highly expressed in patients with Mantle Cell lymphoma. Bcl-2 has also been shown to be a major
Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas. Presenter: Owen A. O'ConnorPresenter's Affiliation: Memorial Sloan Kettering Cancer CenterType of Session: ScientificBackground The ubiquitin proteasome pathway plays an essential role in the degradation of most intracellular proteins in eukaryotic cells. The 26S proteasome, a multicatalytic protease, degrades regulatory proteins involved in cell
The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. Presenter: S.K.L.ChiaPresenter's Affiliation: British Columbia Cancer AgencyType of Session: ScientificBackground Metastatic Breast Cancer is an extremely prevalent diagnosis. Median OS for these patients has historically been 12-24 months. No studies have shown population based data indicating improved survival with newer chemotherapeutic agents
Neoadjuvant chemotherapy for primary high grade extremity soft tissue sarcoma: A matched case control study Presenter: S. R. GrobmyerPresenter's Affiliation: Memorial Sloan-Kettering Cancer Center and Dana-Farber Cancer InstituteType of Session: ScientificBackground The investigation of high grade (HG) extremity soft tissue sarcomas (STS) is often challenging secondary to the relative rarity of these tumors. Furthermore, acquiring broad treatment data
Intergroup 0144 - phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leukovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV Presenter: S.R. SmalleyPresenter's Affiliation: SWOGType of Session: ScientificBackground 5-FU based chemoradiotherapy is standard post-operative management of T3-4N0 or node positive rectal cancer patients. Controversy regarding the optimal method of 5-FU delivery exists. The Intergroup 864751 trial suggested improved RFS and OS in patients
Radiation Therapy Oncology Group (RTOG) 9514: A phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in the management of high risk (HR), high grade (HG) soft tissue sarcomas (STS) of the extremities and body wall Presenter: W. G. KraybillPresenter's Affiliation: RTOGType of Session: ScientificBackground The preliminary data from this RTOG phase II trial of neoadjuvant chemotherapy and radiation in high risk soft tissue sarcoma patients was first presented at ASCO a few years ago. This presentation is an update of that data including analysis of all pts
A randomized study of concomitant radiotherapy with cisplatin or carboplatin versus radiotherapy alone in patients with locally advanced non-nasopharygeal head and neck cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase III study Presenter: G FountzilasPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: ScientificBackground The prognosis of locally advanced head and neck cancer (HNC) is poor. More than 50% of patients with locally advanced HNC will recur locally despite optimal treatment and another 15-20% will develop distant metastatic disease.
Phase III dose-randomization study of imatinib mesylate (STI571, Gleevac) for GIST: Intergroup S0003 early results Presenter: RS BenjaminPresenter's Affiliation: Sarcoma IntergroupType of Session: ScientificBackground Imatinib has been shown to have high rates of activity in most gastro-intestinal stromal tumors (GIST) due to its specific activity against the KIT receptor tyrosine kinase which is frequently up-regulated in GIST. High response rates and durable
Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Presenter: D CunninghamPresenter's Affiliation: BOND InvestigatorsType of Session: ScientificBackground Cetuximab is a chimeric anti-EGFR monoclonal antibody that results in the blockade of EGF and TGF-alpha. The downstream results of this blockade results in modulation of reponse to chemotherapy, and effects on cell growth, differentiation, and
Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluoruracil, leucovorin) as first-line therapy in subjects with metastatic CRC Presenter: H HurwitzPresenter's Affiliation: Duke UniversityType of Session: ScientificBackground Vascular endothelial growth factor (VEGF) is frequently overexpressed in cancers and plays an important role in tumor angiogenesis. Bevacizumab (BV)is a recombinant, humanized monoclonal antibody that has direct action against VEGF. Phase II trials
OncoLink TV: Special Live Webcast from ASCO 2003
Early Study Results Promising: Oral Medication Active Against Skin Cancer Abramson Cancer Center Research Presented at ASCO: Abstract #2854 FOR IMMEDIATE RELEASE (Saturday, May 31, 2003, Chicago, IL) - Researchers from the Abramson Cancer Center of the University of Pennsylvania today presented early study results showing that a new kind of drug, a Raf kinase inhibitor, is well tolerated and may prove effective in
Results from a phase II trial of conformal radiation therapy (CRT)for pediatric patients with localized ependymoma and quantification of radiation-related CNS effects Presenter: T.E. MerchantPresenter's Affiliation: St. Jude Children's Research HospitalType of Session: ScientificBackground Radiation therapy (RT) following maximal resection is the standard treatment for localized ependymoma in children. In very young children, avoiding or delaying RT with systemic chemotherapy has been justified by the
Low dose bleomycin every three weeks with cisplatin and etoposide results in excellent event free survival and survival in children and adolescents with gonadal malignant germ cell tumors (MGCT) A POG/CCG Study Presenter: T.A. OlsonPresenter's Affiliation: Children's Oncology GroupType of Session: ScientificBackground Bleomycin is a standard component of multi-drug chemotherapy for MGCT. It is the least effective single agent in this regimen. Concern for the pulmonary toxicity of bleomycin led to the development of this trial which employs reduced
Randomised phase 3 trial of dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC) Presenter: P LoriganPresenter's Affiliation: Manchester Lung Cancer GroupType of Session: ScientificBackground Although SCLC is chemosensitive, it is associated with low rates of cure. Several previous phase II and III trials have attempted to increase dose intensity in an attempt to improve the outcome of these patients. Recently the EORTC has
Age as a continuous variable in predicting outcome for neuroblastoma patients with metastatic disease: Impact of tumor biological features Presenter: R. GeorgePresenter's Affiliation: COGType of Session: ScientificBackground Infants (age 0-12 months) with stage D disease, with single copy n-myc and hyperdiploidy tumors have an excellent prognosis (84% 4 yr EFS vs. 46% 4 year EFS in infants with diploid (i.e. non-hyperdiploid tumors) Older children (>2 years) with metastatic disease
Randomized phase III trial in locally advanced squamous cell carcinoma (SCC) of the esophagus: chemoradiation with and without surgery Presenter: M StahlPresenter's Affiliation: German Oesophageal Cancer Study GroupType of Session: ScientificBackground Treatment of locally advanced esophageal cancer remains difficult. Treatment with surgery alone results in overall survival (OS) of less than 15%. Recent studies have demonstrated improved outcomes by combining surgery with
Surgical variables impact bladder cancer outcomes: A cooperative group report Presenter: H. HerrPresenter's Affiliation: Southwestern Oncology Group, IntergroupType of Session: ScientificBackground The use of neoadjuvant MVAC (methotrexate, vinblastine, adriamycin, cisplatin) followed by cystectomy was shown to be superior to cystectomy alone in patients with muscle invasive bladder cancer in the SWOG 87-10 (INT-0080)
Definitive results of a comparative longitudinal quality of life study using the Spitzer index in the randomized multicentric phase III trial FFCD 9102 (surgery vs. radiochemotherapy in patients with locally advanced esophageal cancer) Presenter: F BonnetainPresenter's Affiliation: Federation Francophone de Cancerologie DigestiveType of Session: ScientificBackground FFCD 9102 was a randomized trial comparing chemoradiation + surgery versus chemoRT alone for locally advanced, but resectable esophageal cancer. The results were previously presented and showed no difference in
Whole Abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group Presenter: M.E. RandallPresenter's Affiliation: GOGType of Session: PlenaryBackground Endometrial cancer is the most common gynecologic cancer diagnosed Treatment for stage III endometrial cancer has ranged from no treatment to chemotherapy alone to radiation therapy of various types This study hoped to further define the optimal treatment for
Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer Presenter: L PusztaiPresenter's Affiliation: MD Anderson Cancer Center, TexasType of Session: PlenaryBackground Multiple different chemotherapy regimens are used in the treatment of breast cancer. One common regimen involves neoadjuvant paclitaxel + FAC (5-FU, doxorubicin, and cyclophosphamide) (T/FAC) which offers modest benefit over FAC alone at
Docetaxel and cisplatin versus M-VAC in advanced urothelial carcinoma: A multicenter, randomized, phase III study conducted by the Hellenic Cooperative Oncology Group Presenter: A. BamiasPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: ScientificBackground Urothelial carcinoma is a relatively common cancer with a significant risk of disease progression and spread. Untreated disease-free survival rates are quite low, generally below 5%. The application of M-VAC chemotherapy
Surveillance of "high-risk" women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial Presenter: C. K. KuhlPresenter's Affiliation: University of Bonn, GermanyType of Session: PlenaryBackground Hereditary breast cancer is associated with a high lifetime risk of developing breast cancer and a relatively early age of onset. As a result, early and intensive surveillance is typically recommended starting at age 30 years or at least 5
A randomized trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastasis Presenter: R. PatchellPresenter's Affiliation: University of KentuckyType of Session: PlenaryBackground Cord compression by metastatic disease is a large problem in cancers that has the propensity to spread to bone. As prostate cancer, breast cancer, and lung cancer all commonly spread to bone, this represents a huge problem Cord compression is
MRI screening for breast cancer in women with high familial and genetic risk: First results of the Dutch MRI screening study (MRISC) Presenter: M. KriegePresenter's Affiliation: University Medical Center RotterdamType of Session: PlenaryBackground Women at high genetic or familial risk for breast cancer undergo careful surveillance. The value of screening in these women is unknown. MRI is a newer modality of breast cancer detection with high sensitivity. It may be able to
Results of a randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC) Presenter: T. LeChevalierPresenter's Affiliation: Institut Gustave RoussyType of Session: PlenaryBackground 1.2 million cases of NSCLC are diagnosed yearly worldwide. 30% of these are resectable but local therapy is not consistently curative. Distant metastases are common. The 1995 MRC lung cancer trial suggested a 5% 5 year OS benefit, but
Docetaxel, Cisplatin, 5-Fluorouracil compare to Cisplatin and 5-fluorouracil for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325) Presenter: J. A. AjaniPresenter's Affiliation: MD Anderson Cancer Center; Houston , TXType of Session: ScientificBackground Gastric cancer is the 2nd most frequent world wide malignancy and is the 2nd most frequent cause of cancer deaths world wide. MGC is incurable with a median survival of 6-9 months Docetaxel, Cisplatin and 5-FU (DCF)is an
Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomized, controlled trial (the MAGIC trial, ISRCTN 9379397) Presenter: W. AllumPresenter's Affiliation: Epsum General Hospital; Surrey, UKType of Session: ScientificBackground The combination of Epirubicin, Cisplatin and infusional 5-FU (ECF) has demonstrated increased RR and statistically significant benefit in advanced oesophagogastric cancer This trial was designed to determine if this benefit could be
Gemcitabine vs. GEMOX (gemcitabine + oxaliplatin) in non-resectable pancreatic adenocarcinoma: Interim results of GERCOR/GISCAD intergroup Phase III Presenter: C. LouvetPresenter's Affiliation: Hospital St. Antoine; Paris, FranceType of Session: ScientificBackground Gemcitabine 1g/m2 in a 30 min infusion remains the reference regimen for non-resectable pancreatic cancer. Oxaliplatin and Gemcitabine have different mechanisms of action and resistance The toxicity profiles of these two drugs is
A Phase III Trial comparing Gemcitabine plus Cisplatin vs. Gemcitabine alone in advanced pancreatic cancer Presenter: V. HeinemannPresenter's Affiliation: University of Munich; Munich, GermanyType of Session: ScientificBackground Pancreatic cancer has a very poor prognosis. Most patients are diagnosed in the metastatic stage. Median survival is 3-4 months with best supportive care. Single agent gemcitabine (Gem) has increased this MS to 5-6
Ribbon Cutting Ceremony Local Native American tribe opens the Ribbon Cutting Ceremony at the 45th Annual Meeting of ASTRO, in Salt Lake City, Utah. Hailee Iverson, a Rocky Mountain Candlelighter member, is assisted by Jami Palmer, osteosarcoma survivor and Miss Utah 2002, at the Ribbon Cutting Ceremony of the 2003 Annual ASTRO Convention. Joel Tepper, MD,
Patterns of Recurrence by Sequence of Chemotherapy and Radiotherapy in Early Stage Breast Cancer Presenter: Lori Pierce, M.D.Presenter's Affiliation: University of MichiganType of Session: ScientificBackground The impact of sequencing of chemotherapy and radiation therapy (RT) for breast conservation therapy (BCT) is unclear. A previous large randomized trial of the sequencing of chemotherapy and RT following surgery showed no difference in
RTOG 9705, A Phase II Trial of Postoperative Adjuvant Paclitaxel/Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small Cell Lung Cancer (NSCLC) Patients - Promising Long Term Survival Results Presenter: Mary V. GrahamPresenter's Affiliation: Phelps County Regional Medical CenterType of Session: ScientificBackground The role of adjuvant chemotherapy in addition to radiotherapy (RT) for resected stage II and IIIA NSCLC patients is unclear. A previously published large randomized trial from ECOG showed a lack of benefit of the addition of
The Role of Mammography and Physical Examination in Detecting Recurrent Tumor and Contralateral Breast Cancer for Patients with Stage I-II Breast Cancer Treated with Breast Conservation Treatment Presenter: Changhu ChenPresenter's Affiliation: University of Pennsylvania and University of ColoradoType of Session: ScientificBackground Breast cancer is the most common malignancy in women Women who want to preserve their breast and are appropriate candidates can receive breast conservation treatment (BCT) which uses lumpectomy combined with
CTRT 99/97 A Randomized Trial of Simultaneous Paclitaxel and Radiotherapy vs. Radiotherapy Alone Following Induction Chemotherapy in Stage III Inoperable NSCLC Presenter: Jochen Willner, MDPresenter's Affiliation: BROCATType of Session: ScientificBackground Combined modality chemoradiation is accepted in today's oncologic community as an effective treatment option for unresectable Stage III NSCLC patients, based on the demonstration of a small but significant survival advantage in several phase III
Metastatic Spinal Cord Compression: A Randomized Trial of Direct Decompressive Surgical Resection Plus Radiotherapy vs. Radiotherapy Alone Presenter: William F. Regine, MDPresenter's Affiliation: University of MarylandType of Session: PlenaryBackground 5-14% of cancer patients will develop spinal cord compression. It is the second most common neurologic complication from cancer after brain metastases and has a very strong negative effect on patient quality-of-life. The respective
Phase III Randomized Trial of 8 Gy in 1 Fraction vs. 30 Gy in 10 Fractions for Palliation of Painful Bone Metastases: Preliminary Results of RTOG 97-14 Presenter: William F. HartsellPresenter's Affiliation: RTOGType of Session: PlenaryBackground Palliation of metastatic disease is a substantial component of radiation oncology, and an important aspect of cancer patient care in general. Severe pain and debilitation resulting from untreated metastases have a significant impact not only on the
Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA and B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597) Presenter: Minesh MehtaPresenter's Affiliation: University of Wisconsin/ ECOGType of Session: ScientificBackground The current standard of care for patients with inoperable NSCLC is combined modality chemotherapy and thoracic irradiation. Research is ongoing, however, to establish the optimal scheduling and dose fractionation of the radiation
A Randomized Trial Comparing Two Fractionation Schedules for Patients with Localized Prostate Cancer Presenter: H. LukkaPresenter's Affiliation: McMaster UniversityType of Session: PlenaryBackground Prostate cancer is the most commonly diagnosed cancer in men External beam radiation therapy is a potentially curative treatment for men with localized prostate cancer Most treatments involve a long course of radiation, with up to 8 weeks of
Ten-Year Results of Dose Escalation with 3-Dimensional Conformal Radiotherapy for Patients with Clinically Localized Prostate Cancer Presenter: Michael ZelefskyPresenter's Affiliation: Memorial Sloan Kettering Cancer CenterType of Session: ScientificBackground Prostate cancer is the most commonly diagnosed cancer in men External Beam Radiotherapy is a potentially curative treatment for patients with localized disease There has been a trend of dose escalation in prostate cancer
Adjuvant versus Neoadjuvant Combined Modality Treatment for Locally Advanced Rectal Cancer: First Results of the German Rectal Cancer Study (CAO/ARO/AIO-94) Presenter: Rolf Sauer, M.D.Presenter's Affiliation: German Rectal Cancer GroupType of Session: PlenaryBackground The addition of adjuvant chemoradiotherapy (CRT) to the surgical resection of stage II-III rectal cancers has been proven to improve the local control and survival of patients when compared to surgery alone. Building on these results
Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Initial results from intergroup trial 0139 (RTOG 93-09) Presenter: Andrew Turrisi, M.D.Presenter's Affiliation: RTOGType of Session: PlenaryBackground Patients with stage IIIa NSCLC have a poor prognosis. Although definitive chemoradiotherapy (especially when delivered concurrently) remains standard for most patients with pathologic N2 disease, small phase III trials support the use of chemotherapy
Pattern of Local Recurence After Conservative Surgery and Whole-Breast Irradiation: Implications for Partial Breast Irradiation Presenter: Gary Freedman, MDPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground The standard treatment with radiation therapy (RT) for breast conservation therapy (BCT) is whole breast irradiation. 75-85% of local recurrences occuring within 10 yrs of BCT are true local recurrences (TLR) meaning they recur within
Improved Sphincter Preservation of Low Rectal Cancer with High Dose Preoperative Radiotherapy: The Lyon R96-02 Randomized Trial Presenter: Jean Pierre GerardPresenter's Affiliation: Centre Antoine-Lacassagne, Nice, FranceType of Session: ScientificBackground Historically, the management of rectal cancer centered around extensive surgical resection, with local disease control being tantamount and sphincter preservation a low priority. Over the years, with the improvement in
A Multi-Institution Prospective Trial of Reduced-Dose Craniospinal Irradiation (23.4 Gy) Followed by Conformal Posterior Fossa (36 Gy) and Primary Site Irradiation (55.8 Gy) and Dose-Intensive Chemotherapy for Average-Risk Medulloblastoma Presenter: Thomas Merchant, MDPresenter's Affiliation: St. Jude Children's Research HospitalType of Session: ScientificBackground Neurocognitive, endocrine, and otic toxicity are of primary concern in treating pediatric patients with radiation therapy (RT). Previous efforts to decrease the dose and volume of RT for patients with average-risk
Androgen Suppression Adjuvant to Radiotherapy in Carcinoma of the Prostate. Long Term Results of Phase III RTOG Study 85-31 Presenter: Miljenko V. PilepichPresenter's Affiliation: RTOGType of Session: ScientificBackground RTOG 85-31 was one of the first studies to evaluate the worth of adding androgen suppression to radiation therapy. It analyzed the effectiveness of adjuvant goserelin in patients with poor prognosis prostate cancer treated with definitive radiotherapy.
Intramural Distal Spread of Rectal Cancer Following Preoperative Radiotherapy: The Results of a Multicentre Randomized Clinical Study Presenter: K. BujkoPresenter's Affiliation: Cancer Centre and Institute of Oncology, Warsaw, PolandType of Session: ScientificBackground Preoperative radiotherapy regimens have generally followed one of two basic schema: 5 fractions of 5 Gy each, followed by immediate surgery, as was employed in the only rectal cancer study to show a survival
The Impact of Regional Nodal Radiation In Patients With Early-Stage Breast Cancer with Clinically Negative Nodes Treated with Breast-Conserving Therapy Presenter: T. VuPresenter's Affiliation: CHUQ, Pavillon Hotel-Dieu de QuebecType of Session: ScientificBackground Breast cancer is the most common cancer in women Axillary dissection is often part of breast conservation therapy (BCT) because it can decrease axillary recurrence, it helps with staging and prognosis, it guides medical oncologists in
Low-Dose Megavoltage Cone-Beam CT for Dose-Guided Radiation Therapy Presenter: Jean PouliotPresenter's Affiliation: UCSFType of Session: ScientificBackground Cone-beam CT scanning is an emerging technology that incorporates flat panel detectors for image acquisition rather than the ring-shaped detectors found in standard CT scanners. It offers the potential for 3-D correlation on fluoroscopy units as well as
Correlation Between External and Internal Markers for Abdominal Tumors: Implications for Respiratory Gating Presenter: D. GiergaPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Treating tumors in the abdomen with radiation can be challenging because patient respirations can cause tumor movement, thus making tumor targeting difficult Many radiation centers are beginning to use gated therapy, which turns the
Implementation of an On-Board Kilovoltage Cone-Beam CT Imaging System fo Clinical Applications Presenter: Daniel LetourneauPresenter's Affiliation: William Beaumont HospitalType of Session: ScientificBackground Cone-beam CT (CBCT) imaging is an emerging technology which uses a flat panel detector in conjuction with a kilovoltage or megavoltage linear accelerator to produce CT images. The ability to produce CT images from these accelators,
Amifostine As Mucosal Protectant in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Intensive Chemotherapy and Thoracic Radiotherapy (RT): Results of the Radiation Therapy Oncology Group (RTOG) 98-01 Study Presenter: Maria Werner-Wasik, MDPresenter's Affiliation: Thomas Jefferson UniversityType of Session: ScientificBackground 20-50% of patients receiving thoracic RT with concurrent chemotherapy experience severe esophagitis. Amifostine (AMI) is a radioprotectant that has been shown to improve esophagitis both in animal models and in early clinical
A Randomized Trial of High and Low Source Strength I-125 Prostate Seed Implants Presenter: Vrinda Narayana, MDPresenter's Affiliation: University of MichiganType of Session: ScientificBackground Prostate brachytherapy is an established treatment modality for early, localized adenocarcinoma of the prostate. Selected patients with low-risk features based on clinical stage, Gleason score, and serum PSA level can undergo permanent
The Role of Prophylactic Tamsulosin (Flomax) in Patients Undergoing Prostate 125-I Seed Implants for Prostate Carcinoma: Final Report of a Double-Blind Placebo-Controlled Randomized Study Presenter: Mohamed Elshaikh, MDPresenter's Affiliation: Cleveland Clinic FoundationType of Session: ScientificBackground Urinary morbidity following radioactive seed implantation for prostate cancer is common. Alpha-blockers with or without steroids following prostate implantation have been used routinely to reduced these symptoms; however, there
Changes of Tumor Motion Patterns During a Course of Radiation Therapy for Lung Cancer Presenter: Kenneth M. Forster, PhDPresenter's Affiliation: MD Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Patient and target immobilization with daily reproducibility are the cornerstones of accurate and precise radiation therapy delivery. The treatment of lung cancers has long posed the challenge of retaining this
IMRT-Physics Aspects Moderator: Theodore L. Phillips, MD., University of California, San Francisco Lynn J. Verhey, PhD., University of California, San Francisco IMRT is now commonly used for patient treatment. Compared to 3D conformal treatment (3DCRT), IMRT requires increased commissioning time, increased treatment time, increased physics and dosimetry time,
Randomized Trials and IMRT: Overkill or Overdue? Moderator: Theodore L. Phillips, MD., University of California, San Francisco Soeren M. Bentzen, PhD., DSc., Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom IMRT is an advanced technology for radiation therapy (RT), using non-uniform radiation beam intensities incident upon the patient.
IMRT for Head and Neck Cancer: Updated Clinical Results Moderator: Theodore L. Phillips, MD., University of California, San Francisco Nancy Lee, MD, Memorial Sloan-Kettering Cancer Center, New York Approximately 150 papers have reported on the outcomes of H&N cancer patients treated with IMRT. The primary endpoints for these trials usually are rates of xerostomia and local control. It is
Economic Issues in 3DCRT and IMRT Moderator: Theodore L. Phillips, MD., University of California, San Francisco Jeffrey M. Michalski, MD, MBA, Washington University, St. Louis There are several key questions regarding a treatment when performing an economic analysis: Can the intervention work? Efficacy (compliance) Does the intervention work? Effectiveness Does the
IMRT: Another Point of View Moderator: Theodore L. Phillips, MD., University of California, San Francisco Edward C. Halperin, MD, Duke University There is a difference between research and therapy. As a field, we have used research and randomized trials selectively if they show a benefit for radiation, but have dismissed its necessity when we do not have the data.
Geometrical Uncertainties and Inverse Treatment Planning for IMRT: An Integrated Approach Instead of Using Planning Margins Presenter: Ben J. HeijmenPresenter's Affiliation: Daniel den Hoed Cancer Center, Rotterdam, The NetherlandsType of Session: ScientificBackground The current approach to IMRT involves a planning treatment volume (PTV)-based approach, which places a ?planning margin? around a physician-defined clinical target volume in order to account for both
Analysis of Local Failure After Breast Conserving Therapy for Locally Advanced Breast Cancer Presenter: Eugenio F. Vines, MDPresenter's Affiliation: Instituto de Radiomedicina, Santiago, ChileType of Session: ScientificBackground Locally advanced breast cancer remains a large problem in developing countries. The standard treatment for LABC remains mastectomy; however, in Chile, patients with LABC who achieve adequate response to
The 11th World Conference on Lung Cancer Conference Dates: July 3-6, 2005 Conference Location: Barcelona, Spain Sponsoring Group: International Association for the Study of Lung Cancer (IASLC) Conference Web Page URL: www.2005worldlungcancer.com Registration Information: Online at www.2005worldlungcancer.com,tel: +1 770-751-7332, fax: +1 770-751-7334, email: h.drew@imedex.com
International Research Conference on Food, Nutrition and Cancer Conference Dates: July 14-25, 2005 Conference Location: Washington, DC Sponsoring Group: World Cancer Research Fund International/American Institute for Cancer Research Conference Web Page URL: www.wcrf.org/home/2005_conference.lasso Topics Covered: Life Course Approach to Cancer Phytochemicals and Nutritional Interactions
Targeted Therapies for the Treatment of Breast Cancer Conference Dates: July 6-9, 2005 Conference Location: Dana Point, California Sponsoring Group: The CBCE (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com/currentactivities.asp Topics Covered: Statement of Need: Rationally designed target-based therapies beyond those targeting the estrogen
Toronto Patient & Family Seminar Conference Dates: July 22 & 23, 2005 Conference Location: The Radisson Admiral Sponsoring Group: The International Myeloma Foundation Topics Covered: Myeloma 101: Getting started New Standards for Front-Line Therapy Advances in Supportive Bone Care Transplantation - 10 years later Novel Therapies and Advances
5th Annual Conference for Young Women Affected by Breast Cancer Conference Dates: February 19-20, 2005 Conference Location: Pennsylvania Convention Center, Philadelphia Sponsoring Group: Living Beyond Breast Cancer and the Young Survival Coalition Conference Web Page URL: www.youngsurvivorsconference.org Topics Covered: This program is the only international educational conference focused on the critical
Current Concepts in the Management of Colorectal Cancer Conference Dates: Friday, February 25, 2005 Conference Location: The Rittenhouse Hotel, 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online.
Fifth Annual Targeted Therapies for the Treatment of Lung Cancer Conference Dates: February 10-12, 2005 Conference Location: Steamboat Springs, ColoradoSponsoring Group: The Dannemiller Memorial Educational Foundation and Cadent Medical CommunicationsConference Web Page URL: http:/www.thecbce.com/futureprograms.aspTopics Covered: After participating in this conference, attendees should be able to: Explain the
Evaluating, Testing and Advancing Oncology Therapies Conference Dates: February 9-11, 2005 Conference Location: Philadelphia, PASponsoring Group: ExL PharmaConference Web Page URL: http://www.exlpharma.com/events/p301/index.phpTopics Covered: ExL Pharma is proud to present Evaluating, Testing and Advancing Oncology Therapies, focusing on Trial Design, Testing Strategies, and Clinical Development
Second Annual Winter Lung Cancer Conference Conference Dates: March 18-20, 2005 Conference Location: Sunny Isles Beach, Florida Sponsoring Group: Cadent Medical Communications Conference Web Page URL: www.thecbce.com Topics Covered: In this symposium, opinion leaders who specialize in medical radiation and surgical oncology will provide updates on the diagnosis, staging, and treatment of
The American Society of Breast Surgeons Sixth Annual Meeting Conference Dates: March 16-20, 2005 Conference Location: The Westin Century Plaza & Spa in Los Angeles, CA Sponsoring Group: The American Society of Breast Surgeons Conference Web Page URL: www.breastsurgeons.org Topics Covered: Clinical trials, mammographic skills, basic and advanced breast ultrasound, oncoplastic surgery, new
Breast Cancer: When Taking Care Means Taking Charge Conference Dates: March 5, 2005 Conference Location: San Francisco Sponsoring Group: Northern California Cancer Center Conference Web Page URL: www.nccc.org Topics Covered: treatment, research, side effect management, disability and insurance benefits, pain management, reconstructive surgery, intimacy and sexuality, quality of life
Focus on Melanoma Conference Dates: March 31, 2005 Conference Location: University of Pennsylvania Biomedical Research Building II/III, Philadelphia PA Sponsoring Group: The Abramson Cancer Center of the University of Pennsylvania Conference Agenda: 2nd Annual Conference For Patients And Families Whose Lives Have Been Affected By Melanoma Conference
Practical Issues in Multidisciplinary Management of Breast Cancer: 29th Annual Symposium of the American Society of Breast Disease Conference Dates: April 14 - 16, 2005 Conference Location: Mandalay Bay Resort and Casino, Las Vegas, Nevada Sponsoring Group: American Society of Breast Disease Conference Web Page URL: www.asbd.org Topics Covered: Topics and Interactive Workshops to include: Is Breast MRI Ready for Prime Time? Oncoplasty in Partial Mastectomy
Fifth Annual New Strategies in Breast Cancer Conference Conference Dates: April 8-10, 2005 Conference Location: Philadelphia, PASponsoring Group: The Center for Biomedical Continuing Education)Conference Web Page URL: www.thecbce.com/futureprograms.aspTopics Covered: Optimizing Imaging Techniques in High-Risk Patients; Targeted Adjuvant Therapy: Where Do We Go From Here?; Genetic Susceptibility and
7th Annual Changing Concepts in Breast Cancer Conference Dates: Friday, April 8, 2005 Conference Location: The Rittenhouse Hotel, 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania and the University of Pennsylvania School of Medicine Office of CME Conference Brochure: Changing Concepts in Breast Cancer Topics
Fostering Wellness in Cancer Survivorship Conference Dates: April 4, 2005 Conference Location: Seton Hall University, South Orange NJ Sponsoring Group: NJ Commission on Cancer Research/ Psychosocial and Nursing Advisory Group Topics Covered: Emerging Issues in Survivorship Research; Effective Surveillance and Monitoring; Psychosocial Adjustment to Survivorhsip; Challenging the notion
9th Annual Cancer Survivors Conference Conference Dates: Saturday, April 30, 2005 Conference Location: Philadelphia, PA Sponsoring Group: American Cancer Society Conference Web Page URL: Conference Brochure Topics Covered: Survivorship; Exercise & Well-being; Spirituality; Integrative Nutrition; Dance/Movement Therapy; Caregivers;
Innovations in Cancer Therapy, 1st International Symposium on Image-Guided Therapies for Cancer Conference Dates: May 1-4, 2005 Conference Location: London, England Sponsoring Group: PRRI Conference Web Page URL: www.cancerinnovations.org Topics Covered: Lung Cancer, Liver Tumors: Imaging, Hepatocellular Carcinoma, Liver Transplantation, Liver Metastases, Renal Cell Carcinoma, Central Venous Pathology and Interventions, Bone Tumors,
Each One Reach One: Working Together To Make A Change Conference Dates: May 26, 2005 Conference Location: Oakland, California Sponsoring Group: Northern California Cancer Center Conference Web Page URL: www.nccc.org Topics Covered: overview of issues, myths and misconceptions about breast cancer in the African American community Conference Objectives: Provide accurate and culturally
Focus on Gynecologic Cancers Conference Dates: Friday, May 6, 2005, 8:30 AM to 4:00 PM Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA 19131 Sponsoring Group: The Abramson Cancer Center of the University of Pennsylvania Conference Brochure: Focus on Gynecologic Cancers Topics Covered: Workshop Sessions: Restoring Vitality Taking
Chicago Patient & Family Seminar Conference Dates: June 10 & 11, 2005 Conference Location: The Hilton Northbrook Sponsoring Group: The International Myeloma Foundation Conference Web Page URL: www.myeloma.org Topics Covered: Myeloma 101: Getting Started New Standards for Front-Line Therapy Advances in Supportive Bone Care Transplantation - 10
Focus on Leukemia, Lymphoma & Myeloma Conference Dates: June 24, 2005 Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: The Leukemia & Lymphoma Society, Greater Delaware Valley Division and the Abramson Cancer Center of the University Conference Brochure: Focus on Leukemia, Lymphoma & Myeloma Topics Covered: The Leukemia &
Los Angeles Patient & Family Seminar Conference Dates: June 24 & 25, 2005 Conference Location: The Sheraton Universal Hotel Sponsoring Group: International Myeloma Foundation Conference Web Page URL: www.Myeloma.org Topics Covered: Myeloma 101: Getting Started New Standards of Frontline Therapies Advances in Supportive Bone Care Transplantation - Ten
4th World Conference on Breast Cancer Conference Dates: June 8-12, 2005 Conference Location: Halifax, Nova Scotia, Canada Sponsoring Group: The World Conference on Breast Cancer Foundation Conference Web Page URL: www.wbco.ca Who Should Attend: Survivors, family members, research scientists, clinicians Conference Agenda: Each day of the conference will expand on three key themes
Oncology World Congress Conference Dates: November 17-19, 2005 Conference Location: New York, New York Sponsoring Group: Elsevier Conference Web Page URL: www.oncologycongress.com Topics Covered: Lung Cancer Pediatric Oncology Neuro Oncology Sarcoma Head & Neck Cancer Bone Metastasis Breast Cancer Patient
Genitourinary Malignancies: Current Perspectives in Bladder, Kidney, and Testis Cancer Conference Dates: Friday, November 4, 2005 Conference Location: The Rittenhouse Hotel, 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Objectives: At the completion of this conference, participants should be able to: Identify risk factors in bladder
1st Annual Moffitt Interdisciplinary GI Tumor Conference Conference Dates: November 17-19, 2005 Conference Location: Don CeSar Resort, St. Pete Beach, FL Sponsoring Group: Moffitt Cancer Center Conference Web Page URL: www.moffitt.usf.edu Topics Covered: Clinical Problems in: Esophageal Cancer, Hepatobiliary Cancer, Pancreatic Cancer, Neuroendocrine Tumors, Colorectal Cancer Conference
Live Webcast - Learn about Diagnosis and Treatment of Lung Cancer and Chemotherapy Expectations and Management of Side Effects Conference Dates: Saturday, November 5, 2005 at 7:00 P.M. (EST) Conference Location: Webcast Sponsoring Group: Lung Cancer Alliance and provided as an educational service by Lilly Oncology Conference Web Page URL: medconference.net/lungcancerawareness Topics Covered: Learn about Diagnosis and Treatment of Lung Cancer and Chemotherapy
Third Biennial Symposium on Biology, Diagnosis and Treatment of Lymphomas Conference Dates: Friday, October 14, 2005 Conference Location: Marriott West, West Conshohocken, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Brochure: Download PDF version of conference brochure. Topics Covered: Non-Hodgkins, Hodgkins, Prognostic Markers, New Targeted Therapies Conference
Defining the Future of Chemotherapy in the Treatment of Early-Stage NSCLC Conference Dates: Aug 1 - Oct 31 2005 Conference Location: N/A Telesession Sponsoring Group: The CBCEtm (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com Topics Covered: Five-year survival for patients with NSCLC is currently only 15%,largely due to the fact that only approximately half of these patients
Second Annual Fall Oncology Conference Conference Dates: 22-23 October 2005 Conference Location: Braselton, GA Sponsoring Group: Vanderbilt University School of Medicine Conference Web Page URL: www.thecbce.com/currentactivities.asp Topics Covered: Educational Objectives: Based on recent clinical study data, assess the efficacy of novel approaches in the treatment of
Emerging Technologies: Changing the Face of Cancer Care Conference Dates: October 28, 2005 Conference Location: NJ Performing Arts Center, Newark, New Jersey Sponsoring Group: Atlantic Health System, New Jersey Commission on Cancer Research Conference Web Page URL: nj.gov/health/ccr/documents/changingfacecancercare.pdf Topics Covered: Advances in understanding the epigenetic and molecular
10th Annual Joint Cancer Conference of the Florida Universities Conference Dates: September 28-October 1, 2006 Conference Location: The Breakers, Palm Beach, FL Sponsoring Group: University of South Florida College of Medicine Conference Web Page URL: www.jcc-fl.org Topics Covered: The Business of Medicine Complementary Therapies Multidisciplinary Approach to Treating Cancer Clinical Trials for the Private
5th International Symposium on Minimal Residual Cancer Conference Dates: September 11-14, 2005 Conference Location: Fairmont Hotel, San Francisco, CA Sponsoring Group: International Symposium on Minimal Residual Cancer Conference Web Page URL: www.ismrc.org Topics Covered: The Detection of Microscopic Disease in Breast Cancer: a Paradigm for Other Solid Tumors ICC- and PCR-based strategies
Fourteenth Annual Life After Breast Cancer Patient Conference Conference Dates: September 16, 2005 Conference Location: Hilton, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Objectives: Patient Education Who Should Attend: Breast Cancer Survivors and Their Loved Ones Conference Brochure: Life After Breast Cancer PDF Conference
Recent Clinical Advances in Pancreatic Cancer Conference Dates: September 28, 2005, 6:00pm Conference Location: Riva, 700 E. Grand Avenue/Navy Pier, Chicago, IL 60611 Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com/futureprograms.asp Who Should Attend: MDs and PAs Conference Agenda: Clinical Overview of Pancreatic Cancer Registration Information: Visit
Novel Therapeutic Approaches in the Treatment of Multiple Myeloma Conference Dates: September 30th, 2005 Conference Location: Marriott Marquis, 1535 Broadway, New York, NY Sponsoring Group: MMRF and New York Medical College Conference Web Page URL: www.nymc.edu/cme/upcoming_events.asp Who Should Attend: Patients, Caregivers, Hematologists, Medical Oncologists, Oncology Nurses, Internists with recently
2005 National Carcinoid-Net Conference Conference Dates: September 22-24, 2005 Conference Location: Philadelphia, PA Sponsoring Group: Carcinoid Cancer Awareness Network & North American Alliance of Patients with Neuroendocrine Tumors Conference Web Page URL: www.naapnet.org/html/2005conference.html Topics Covered: The Philadelphia conference committee has put together a
Facing Prostate Cancer with Information & Support Conference Dates: Saturday September 24, 2005 Conference Location: Holiday Inn, Presidential Boulevard, Philadelphia, PA Sponsoring Group: American Cancer Society Conference Web Page URL: www.cancer.org Conference Objectives: Increase understanding of prostate cancer, treatment options, and managing side effects. Meet experts
Third Annual Therapeutic Advances in the Treatment of Hematological Malignancies Conference Dates: August 3-6, 2005 Conference Location: Santa Monica, California Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com/currentactivities.asp Topics Covered: Description/Statement of Need: Typically, hematologic malignancies are sensitive to chemotherapy and radiation therapy, but a significant proportion of
Mini Allo Transplants for Lymphoma/CLL Faculty Disclosure: Edwin P. Alyea III, MD Nothing to Disclose Presenter: Edwin P. Alyea III, MD Affiliation: Dana Farber Institute Patients with low-grade lymphoma and chronic lymphocytic leukemia (CLL) typically have relatively prolonged disease-free survival, but this does not hold true for more advanced and chemotherapy-refractory
Patient-specific therapeutic vaccines for non-Hodgkin's lymphoma Faculty Disclosure: John M. Timmerman, M.D. The presentation by Dr Timmerman includes discussion of vaccine therapy that has not been approved by the FDA and the use of GM-CSF as an off-label indication. Presenter: John M. Timmerman, M.D. Affiliation: UCLA Despite radiation therapy, chemotherapy, bone marrow and stem cell transplants, and
Experience with decitabine in imatinib resistant CML Faculty Disclosure: Hagop M. Kantarjian, M.D. Supergen - Research Support In this presentation Dr. Kantarjian discusses the use of decitabine for the treatment of CML which has not been approved by the FDA. Presenter: Hagop Kantarjian, MD Affiliation: M.D. Anderson Cancer Center Imatinib has revolutionized the treatment of CML. Higher
High dose imatinib (Gleevac) in CML Faculty Disclosure: Hagop M. Kantarjian, M.D. Novartis - Research Support Supergen - Research Support Presenter: Hagop Kantarjian, MD Affiliation: M.D. Anderson Cancer Center The Philadelphia chromosome and the resultant bcr-abl oncogene cause a majority of cases of CML. Imatinib, a selective bcr-abl tyrosine kinase inhibitor, has
Treatment of Cancer-Related Anemia Faculty Disclosure: Janice Gabrilove, M.D. Amgen - Research Support Ortho Biotech - Research Support, Speakers Bureau Berlex - Speakers Bureau Presenter: Janice Gabrilove, M.D. Affiliation: Mt. Sinai Hospital Cancer-related anemia is a very serious issue that often arises during the management of cancer patients. It has
PTK 787/ZK 222584: Clinical results with a novel angiogenesis inhibitor in colorectal cancer Faculty Disclosure: Peter J. O'Dwyer, M.D. Novartis - Research Support AstraZeneca - Consultant, Speakers Bureau Lilly - Consultant BMS - Consultant Bayer - Consultant, Speakers Bureau Sanofi - Consultant Cell Therapeutics - Consultant 3D - Speakers Bureau GSK - Speakers Bureau This presentation by Dr. O'Dwyer
Modulating IL-2 for Non-Hodgkins' Lymphoma (NHL) Faculty Disclosure: Michael A. Caligiuri, M.D. This presentation by Dr. Caligiuri discusses off-label use of IL-2 for the treatment of NHL. Presenter: Michael A. Caligiuri, M.D. Affiliation: James Cancer Hospital and Ohio State University Manipulating the immune system of a non-Hodgkins' lymphoma to launch an attack on foreign tumor
Adjuvant Multimodality with Gemcitabine versus 5-Fluorouracil in Pancreatic Cancer: Status of U.S. Intergroup Trial Faculty Disclosure: William F. Regine, M.D. Nothing to Disclose Presenter: William F. Regine, M.D. Affiliation: University of Maryland Even with potentially curative resection, 5 year survival for pancreatic cancer patients is less than 20%. Approximately 25 years ago, the Gastrointestinal Study Group found a small survival advantage
Bevacizumab (Avastin) in Colorectal Cancer Faculty Disclosure: Daniel Haller, M.D. Roche - Research Support, Consultant OSI - Research Support Pfizer - Research Support, Consultant This presentation by Dr. Haller discusses the use of bevacizumab in the treatment of colorectal cancer which has not been approved by the FDA. Presenter: Daniel Haller, M.D. Affiliation: University
Alimta and Oxaliplatin in Colorectal Cancer Faculty Disclosure: Howard S. Hochster, M.D. Lilly - Consultant AstraZeneca - Consultant This presentation by Dr Hochster includes discussion on the use of pemetrexed in the treatment of colorectal cancer which has not been approved by the FDA Presenter: Howard S. Hochster, M.D. Affiliation: New York University Pemetrexed is a
Emerging Role of EGF (Epidermal Growth Factor) Receptor-Directed Therapy of Colon Cancer Faculty Disclosure: Howard S. Hochster, M.D. Lilly - Consultant AstraZeneca - Consultant In this presentation by Dr. Hochster there is discussion of cetuximab (C 225) and erlotinib (Tarceva) for the treatment of colorectal cancer which is not FDA approved and gefitinib (Iressa) for the treatment of colorectal cancer which is an off
Update on Gynecologic Oncology Group Studies in Ovarian Cancer Faculty Disclosure: Robert F. Ozols, MD This presentation by Dr. Ozols discusses the use of bevacizumab (Avastin), Erbitux (C225), and PS 341 for the treatment of ovarian cancer which is not approved by the FDA. Also discussed is the off label use of gefitinib (Iressa), thalidomide, and gemcitabine. The standard of care for FIGO stage I/II
Motexafin Gadolinium (MGd) and Concurrent Chemoradiation in Head and Neck Cancer Faculty Disclosure: David M. Brizel, MD In this presentation Dr. Brizel discusses the use of Motexafin Gadolinium (MGd)in the treatment of head and neck cancer which has not been approved by the FDA. Presenter: David M. Brizel, MD Affiliation: Duke University Medical Center Approximately 60% of those patients diagnosed with head and neck
Paclitaxel and Platinum versus Platinum-based Chemotherapy in Relapsed Ovarian Cancer: ICON 4 Presenter: Jonathan A. Ledermann, MD Affiliation: University College, London, UK/ MRC The optimal second-line chemotherapy for platinum-sensitive patients with relapsed ovarian cancer is an issue of ongoing research. Despite advances in therapy over the years, there remain unacceptably high relapse rates in patients following initial
First-Line Therapy for Ovarian Carcinoma: What Next? Faculty Disclosure: Tate Thigpen, MD This presentation by Dr. Thigpen discusses the use of cetuximab, bevacizumab, and PSC 833 for the treatment of ovarian cancer which has not been approved by the FDA. Also discussed are off label uses of trastuzumab, gefitinib, and gemcitabine for the treatment of ovarian cancer. The current standard of care
Adding Carboplatin to Trastuzumab/Paclitaxel in Her2+ Breast Cancer: An Update Presenter: Nicholas Robert, MD Affiliation: US Oncology Research Network The HER family of oncogenes are prevalent in breast cancers. This has allowed for the development of trastuzumab, a monoclonal antibody against the HER2 oncoprotein. Alone or with other agents, trastuzumab has improved survival of many patients with breast cancer that
Duration of Therapy for Ovarian Cancer: How Long is Enough? Presenter: David R. Spriggs, MD Affiliation: MSKCC New York, NY There are little scientific data available on the optimal duration of chemotherapy in the first-line treatment of ovarian cancer. As can be expected, there is even less information available on duration of treatment in recurrent disease, either in platinum-sensitive or
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Head and Neck Cancer Faculty Disclosure: Merrill S. Kies, MD In this presentation by Dr. Kies there is discussion of C225 in the treatment of head and neck cancer which has not been approved by the FDA. Presenter: Merrill S. Kies, MD Affiliation: MDACC The treatment of patients with squamous cell cancer of the head and neck (SCCHN) is challenging both for the
Cox-2 Hormonal Approaches for the Treatment and Prevention of Breast Cancer Faculty Disclosure: Paul E. Goss, MD, PhD In this presentation by Dr. Goss there is discussion of celecoxib for the treatment and prevention of breast cancer which is not approved by the FDA. Presenter: Paul E. Goss, MD, PhD Affiliation: Princess Margaret Hospital The advent of hormonal and chemotherapeutic agents has been a significant
Adjuvant Hormonal Therapy in Premenopausal Women Faculty Disclosure: Gini F. Fleming, MDIn this presentation Dr. Fleming discusses the use of triptorelin for the treatment of breast cancer which is an off label use. Presenter: Gini F. Fleming, MD Affiliation: University of Chicago Long-term follow-up of node-negative breast cancer patients treated with mastectomy alone has shown
Vaccines for Breast Cancer: Real Challenge or Reality? Faculty Disclosure: Nuhad K. Ibrahim, MD This presentation by Dr. Ibrahim discusses the use of the STn vaccine for the treatment of breast cancer which has not been approved by the FDA. Presenter: Nuhad K. Ibrahim, MD Affiliation: M.D. Anderson Cancer Center Vaccine mediated cancer therapies are theoretically attractive for many reasons:
Tumor Markers and the Early Detection of Lung Cancer Presenter: James Mulshine, MD Affiliation: National Cancer Institute Lung cancer has recently outstripped coronary artery disease as the leading cause of smoking related death in the USA. One half of new lung cancers are diagnosed in former smokers. This indicates that smoking cessation alone is insufficient in reducing cancer related
Novel Approaches in Stage III NSCLC Presenter: Hak Choy, MD Affiliation: Vanderbilt University School of Medicine The top cause of cancer-related mortality in the United States among both males and females remains lung cancer. Typically, as many as 80% of cases are non-small cell lung cancer, and of these, at least half present as unresectable, locally advanced disease. For
CT-2103 (Xyotax): Phase II Trial of a Polyglutamated Paclitaxel Conjugate in Advanced NSCLC Faculty Disclosure: Howard A. Burris, III, MDbr>In this presentation Dr. Burris discusses the use of CT-2103 for the treatment of lung cancer which has not been approved by the FDA. Presenter: Howard A. Burris, III, MD Affiliation: Sarah Cannon Cancer Center, Nashville, Tennessee CT-2103 (Xyotax, polyglutamated paclitaxel) has many potential
Molecular Prediction of Response and Survival in NSCLC Presenter: Gerold Bepler, MD PhD Affiliation: H. Lee Moffitt Cancer Center Pharmacogenomic research offers the potential for improving upon the results of conventional treatments in managing lung cancer. Currently, the choice of treatment strategy is typically based on site, histopathology, stage, performance status, convenience, and
Optimized Schedule of Weekly Paclitaxel Alone and With Carboplatin: Elderly Advanced NSCLC Patients Presenter: Chandra Belani, MD Affiliation: University of Pittsburgh Lung cancer continues to be the leading cause of cancer death in the United States, with approximately 80% of cases being NSCLC. The overall survival and median survival time in patients with metastatic disease remains dismal. There have been advances in the treatment of both
Bevacizumab (Avastin) in Advanced Prostate Cancer Faculty Disclosure: Joel Picus, MDThis presentation by Dr. Picus discusses the use of bevacizumab in the treatment of prostate cancer which has not been approved by the FDA. Presenter: Joel Picus, MD Affiliation: Washington University School of Medicine Hormone refractory prostate cancer has a very aggressive natural history with reported
Erlotinib (Tarceva) and Bevacizumab (Avastin): Combination Therapy for NSCLC Faculty Disclosure: Roy S. Herbst, MDThis presentation by Dr. Herbst will discuss the use of bevacizumab and erlotinib in the treatment of lung cancer which has not been approved by the FDA. Presenter: Roy S. Herbst, MD Affiliation: M.D. Anderson Cancer Center Lung cancer remains a difficult disease to treat, causing the most cancer deaths
IImpact and Therapeutic Implications of Anemia in Lung Cancer Presenter: Corey Langer, MD Affiliation: Fox Chase Cancer Center, Philadelphia, PA Anemia in cancer patients is a common problem with a multifactorial etiology. It is well recognized that the presence of malignancy is associated with a blunted response to anemia; as hemoglobin (Hb) levels decrease, the normal compensatory increase in
Erythropoietic Agents: Recent Clinical Data Over the last several decades anemia management has evolved. Use of transfusion is now limited to symptomatic severe anemia. The use of stem cell growth factors to prevent the occurrence of anemia has become the norm. Epoetin alpha (Procrit) and darbepoetin alpha (Aranesp) are the two FDA approved stem cell growth factors approved for the
Neutropenia Control: Optimising Therapeutic Gains Neutropenia is often the dose limiting toxicity in chemotherapy treatment. A great advance came with filgrastin, decreasing the incidence of febrile neutropenia and hospitalizations in patients given the injections following chemotherapy. The use of filgrastin, however, requires daily injections which can be inconvenient or even impossible for
Clinical Updates and New Approaches: Hematologic Malignancies and GI Cancers Program Description and Objectives As our understanding of the underlying molecular abnormalities and pathogenesis of various cancers continues to grow, while simultaneously new chemotherapeutic agents and new biological "targeted agents" continue to proliferate, the ability of the clinical oncologist (i.e., those not focused on research) to
Clinical Updates and New Approaches: Ovarian Cancer, Head and Neck Cancer, and Adjuvant Therapy for Breast Cancer Program Description and Objectives As our understanding of the underlying molecular abnormalities and pathogenesis of various cancers continues to grow, while simultaneously new chemotherapeutic agents and new biological "targeted agents" continue to proliferate, the ability of the clinical oncologist (i.e., those not focused on research) to
Clinical Updates and New Approaches: Prostate Cancer, Lung Cancer, and Clinical Support & Outcomes Program Description and Objectives As our understanding of the underlying molecular abnormalities and pathogenesis of various cancers continues to grow, while simultaneously new chemotherapeutic agents and new biological "targeted agents" continue to proliferate, the ability of the clinical oncologist (i.e., those not focused on research) to
Report card for accelerated FDA approval oncology drugs (1995-2003): is it time for a make-up test? Presenter: S.M. BelknapPresenter's Affiliation: Northwestern University, Chicago, ILType of Session: ScientificBackground The FDA approval process includes multiple pathways. One of these is the accelerated approval that was adopted in 1992 in order to improve access to new drugs. The accelerated approval
Cognitive function, fatigue and menopausal symptoms in women following adjuvant chemotherapy for breast cancer: One and two year follow-up of a prospective controlled study Presenter: N. TchenPresenter's Affiliation: Princess Margaret Hospital, Toronto, CAType of Session: ScientificBackground Adjuvant chemotherapy is given to many beast cancer patients; however, it can result in significant toxicity A previous report from this group showed significantly increased fatigue and menopausal symptoms for women receiving
Traditional versus up-front 18-FDG PET staging of non-small cell lung cancer (NSCLC): A Dutch Co-operative randomized study Presenter: G.J. HerderPresenter's Affiliation: POORT Study Group, NetherlandsType of Session: ScientificBackground The use of FDG-PET scan as an add-on study in non-small-cell-lung-cancer (NSCLC) patients scheduled to undergo surgery has been shown to be a cost-effective and useful tool in guiding patient management. When employed after
Interim report of the JROSG99-1 multi-institutional randomized trial, comparing radiosurgery alone vs. radiosurgery plus whole brain irradiation for 1-4 brain metastases. Presenter: H. AoyamaPresenter's Affiliation: University School of Medicine, Sapporo, JapanType of Session: ScientificBackground Whole brain irradiation has long been the standard of care for the treament of multiple brain metastases. Stereotactic radiosurgery is often combined with whole brain treatment in an effort to increase local
Induction chemotherapy followed by concominant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell cancer: Initial analysis of a randomized phase III trial Presenter: Everett V. VokesPresenter's Affiliation: Cancer and Leukemia Group BType of Session: ScientificBackground Induction chemotherapy has been shown to improve survival in patients with stage IIIB non-small cell lung cancer (NSCLC) compared to radiation (RT) alone Concurrent chemoradiotherapy (CT/XRT) has also been shown to be superior to
Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens Presenter: M.I. ZiaPresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: ScientificBackground Phase I, Phase II and Phase III clinical trials represent the paradigm of clinical drug development. Phase I studies are usually conducted in patients with refractory diseases and the endpoints are safety,
Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400 mg (LD)- an international, intergroup study of the EORTC, ISG and AGITG This presentation discusses the use of imatinib at a dose that has not been approved by the FDA. Presenter: J.R. ZalcbergPresenter's Affiliation: EORTC/ ISG/AGITGType of Session: ScientificBackground This international intergroup has previously demonstrated an improvement in progression-free survival (PFS) with the use of high-dose
Irinotecan plus fluorouracil/leucovorin (IFL) verus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) This presentation discusses an off-label use of irinotecan in the treatment of colon cancer. Presenter: L.B. SaltzPresenter's Affiliation: CALGBType of Session: ScientificBackground Metastatic colorectal cancer is a disease in which the natural history can be markedly altered by the application of effective chemotherapy agents. First-line
Expanded access program (EAP) to investigational drugs Presenter: L. TalaricoPresenter's Affiliation: Food and Drug Administration, Rockville, MDType of Session: ScientificBackground Unapproved drugs which have shown evidence of clinical activity during the conduct of registration trials can be made available to treat patients with serious or immediately life-threatening
Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer: Report of the 22921 EORTC phase III trial. Presenter: J.-F. BossetPresenter's Affiliation: Besancon University Hospital, Besancon, FranceType of Session: ScientificBackground Preoperative radiation treatment is used frequently in cases of resectable rectal cancer due to the advantages of more precise tumor definition, decreased amount of irradiated normal tissue, pathological downstaging,
Long-term use of NSAID reduces the risk of oral cancer Presenter: J. SudboPresenter's Affiliation: Norwegian Radium Hosptial, Oslo, NorwayType of Session: ScientificBackground Oral cavity cancers are often associated with high rates of morbidity and mortality COX-2 may play a role in the development of squamous cell carcinomas (SCCA) of the head and neck Cycloxegenase-2 (COX-2) has been found to
Sentinel node staging of resectable colon cancer: Results of the CALGB 80001. Presenter: M. M. BertagnolliPresenter's Affiliation: Brigham and Women's Hospital, Boston, MAType of Session: ScientificBackground The most important predictor of outcome in resected colon cancer is the locoregional nodal status. Currently, there exists a population of conventionally evaluated node negative patients that performs
A prospective randomized trial of adjuvant vinorelbine and cisplatin in completely resected stage IB and II non-small cell lung cancer. Intergroup JBR10 Presenter: Timothy WintonPresenter's Affiliation: National Cancer Institute of CanadaType of Session: ScientificBackground Recent studies have shown that adjuvant chemotherapy following complete resection of non-small cell lung cancer (NSCLC) improves overall survival The majority of this benefit has been seen in patients with higher stage
Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 Presenter: Gary M. StraussPresenter's Affiliation: Cancer and Leukemia Group BType of Session: ScientificBackground The role of adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC) has been controversial Recently reported studies regarding the role of adjuvant chemotherapy with completely resected NSCLC have been conflicting
June 6 Highlights Today, on this anniversary of D-Day, ASCO was bursting with new information and data. Details of presentations can be found on OncoLink for CME credit, but below is a brief summary of major themes discussed. HEMATOLOGIC MALIGNANCIES There were a number of presentations on hematologic malignancies presented today. For the most part investigators
Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC) This presentation discusses off-label use of bevacizumab for RCC. It also discusses the use of erlotinib for the treatment of RCC which has not been approved by the FDA. Presenter: J.D. HainsworthPresenter's Affiliation: Sarah Cannon Cancer Center/Tennessee Oncology, Nashville, TNType of Session: ScientificBackground The incidence of renal
Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer Presenter: M. YoshimotoPresenter's Affiliation: Cancer Institute Hospital, Tokyo, JapanType of Session: ScientificBackground Many breast cancer patients receive chemotherapy as part of their treatment program A common chemotherapeutic agent used in breast cancer is paclitaxel Response to paclitaxel varies greatly from patient to patient
Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips The cDNA arrays and Gene Chips discussed in this study have not been approved by the FDA for use in patients. Presenter: Lajos PusztaiPresenter's Affiliation: M.D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Gene profiling has increasingly been used in attempts to classify cancer into clinically-relevant subgroups
MRI detection of multi focal breast carcinoma: Report from the International Breast MRI Consortium Presenter: M. D. SchnallPresenter's Affiliation: University of PennsylvaniaType of Session: ScientificBackground Single institution studies have suggested that MRI more accurately determines the extent of cancer within the breast compared to mammography, increasing the ability to detect multi-focal disease and potentially alter the
ABVD vs. Stanford V vs. MOPP-EBV-CAD in advanced Hodgkin's lymphoma. Final results of the IIL HD9601 randomized trial Presenter: M. FedericoPresenter's Affiliation: Intergruppo Italiano LinfomiType of Session: ScientificBackground The standard treatment for advanced Hodgkin's lymphoma (HL) is ABVD chemotherapy 30% of patients with advanced HL do not respond to treatment with ABVD chemotherapy or subsequently relapse Recent studies have shown that Stanford
Randomized intergroup trial of first line treatment for patients </= 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab- early stopping after the first interim analysis This study discusses an off-label use of rituximab for the treatment of NHL. Presenter: M. G. PfreundschuhPresenter's Affiliation: International Intergroup: Germany, Australia, Sweden, UK, Czech Republic, Canada, Poland, ItalyType of Session: ScientificBackground Non-Hodgkin's lymphoma (NHL) is the fifth most common malignancy in the United
Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) This study discusses an off-label use of rituximab for the treatment of MCL. Presenter: W. HiddemannPresenter's Affiliation: Ludwig-Maximilians-University, Munchen, GermanyType of Session: ScientificBackground Mantle cell lymphoma (MCL) accounts for up to 6% of all lymphomas. Most patients present with advanced stage and progress
Does postoperative radiotherapy after radical prostatectomy improve progression-free survival in pT3N0 prostate cancer? (EORTC 22911) Presenter: M. BollaPresenter's Affiliation: CHR de Grenoble, Grenoble, FranceType of Session: ScientificBackground A significant number of patients with clinical T1-2N0M0 prostate cancer are treated with radical prostatectmy. However, after pathologic evaluation, some patients are found to have risk factors for local failure.
Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) This presentation discusses the off-label use of rituximab for the treatment of indolent NHL. Presenter: H.S. HochsterPresenter's Affiliation: ECOG/CALGBType of Session: ScientificBackground Indolent lymphomas (IL), as the name implies, have a "waxing and waning" pattern featuring multiple disease relapses over a large time period. It is not
Association between androgen deprivation therapy and fracture risk: A population-based cohort study in men with non-metastatic prostate cancer. Presenter: M.R. SmithPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Several small retrospective studies have reported that GnRH agonists increase fracture risk in prostate patients. However, the studies have been limited by small sample size, short follow-up, and a potential recall bias. This
The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer Presenter: P.L. NguyenPresenter's Affiliation: Harvard Medical School/ University of PennsylvaniaType of Session: ScientificBackground It has been demonstrated that prolonged delay between cancer diagnosis and the start of radiation therapy (RT) is associated with decreased local control in head and neck cancer. This study sought to evaluate if a
Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): a prospective, multi-institutional trial Presenter: D.F. HayesPresenter's Affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MIType of Session: ScientificBackground The identification of markers that predict resistance to a treatment early in the course of therapy would allow termination of a futile treatment and initiation of an alternative regimen.
What we learned on June 5, 2004 The American Society of Clinical Oncology meeting was a wealth of information today. The take home message of what saw yesterday is discussed below and organized by disease type. Detailed coverage of the abstracts can be found on OncoLink for CME credit. LYMPHOMA A number of abstracts were presented with the unifying theme of trying to devise
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) This presentation discusses the use of erlotinib for the treatment of NSCLC which has not been approved by the FDA. Presenter: U. GatzemeierPresenter's Affiliation: TALENT study investigatorsType of Session: ScientificBackground There is a growing body of preclinical data demonstrating the anti-tumor efficacy of erlotinib (OSI-774),
A randomized comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis following orchiectomy: MRC TE19/EORTC 30982 This presentation discusses off-label use of carboplatin in the treatment of seminoma. Presenter: R.T. OliverPresenter's Affiliation: Medical Research Counsel, EnglandType of Session: ScientificBackground Adjuvant radiation therapy (RT) is an effective treatment for stage I seminoma following orchiectomy; however, it is associated with an
A historical perspective on the American Society of Clinical Oncology (ASCO) In April 1964 seven visionary doctors met for lunch at the Edgewater Bridge Hotel in Chicago. They had this novel idea to of gathering together all physicians treating patients with cancer and sharing their experiences as well as information. There were not many people treating cancer at the time. In fact, oncology was not yet a recognized
Risk-adapted management of stage I seminoma: the second Spanish Germ Cell Cancer Group (GG) study * This presentation discusses off-label use of carboplatin in the treatment of seminoma. Presenter: J. AparicioPresenter's Affiliation: Spanish Germ Cell Cancer GroupType of Session: ScientificBackground Seminoma represents 45% of all germ cell tumors and 70%-80% of patients present with Stage I disease. Management of patients with
A multicenter, phase III randomized trial for stage IIIb/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel This presentation discusses unapproved dosing schedules for carboplatin and paclitaxel. Presenter: C. P. BelaniPresenter's Affiliation: University of Pittsburg Cancer Institute, Pittsburg, PAType of Session: ScientificBackground Previous trials evaluating standard three week dosing of paclitaxel and carboplatin in stage IIIb/IV NSCLC have
Long-term effects of conservation therapy for muscle invasive bladder carcinoma Presenter: P. ChungPresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: ScientificBackground Cystectomy has long been considered the gold standard for treatment of muscle invasive bladder carcinoma. This retrospective study was undertaken to evaluate long term outcomes of radiation-based bladder conservation
SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA) Presenter: D.P. PetrylakPresenter's Affiliation: SWOGType of Session: PlenaryBackground The present-day standard of care in the treatment of AIPCA patients consists of the combination of mitoxantrone and prednisone for palliation of disease-related symptoms. There is no remarkable survival benefit with the use of these agents, and thus the ultimate
Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) : 'the "LUCAS" study This presentation discusses off-label use of cetuximab in the treatment of NSCLC. Presenter: R. RosellPresenter's Affiliation: Institut Catala d'Oncologia, Barcelona, SpainType of Session: ScientificBackground The advent of molecular therapeutics and anti-tumor targetted agents has at its center the much discussed and studied epidermal growth
Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126 This presentation discusses off-label use of gefitinib in BAC. Presenter: H. WestPresenter's Affiliation: Swedish Cancer Institute, Seattle, WAType of Session: ScientificBackground Bronchioloalveolar lung cancer (BAC) is a distinctive subtype of non-small cell lung cancer (NSCLC) with different pathologic, radiographic characteristics, and natural
Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a radomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. Presenter: R. StuppPresenter's Affiliation: University Hospital (CHUV), Lausanne, SwitzerlandType of Session: PlenaryBackground Glioblastoma multiforme is the most malignant and most common primary brain tumor, with a dismal median overall survival of less than one year. Radiation treatment has long been the standard of care in treating GBM.
Preliminary evidence of relationship between genetic markers and oncology patient quality of life Presenter: J.A. SloanPresenter's Affiliation: The North Central Cancer Treatment GroupType of Session: PlenaryBackground Genetic variation has been linked to a number of factors that affect quality of life (QOL) including depression, suicide, alcohol use, tobacco use, and psychiatric disorders The effects of cancer treatment and outcomes have a
A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormone-refractory prostate cancer This article discusses non-FDA approved dosing of docetaxel Presenter: M.A. EisenbergerPresenter's Affiliation: TAX-327 InvestigatorsType of Session: PlenaryBackground Therapy for metastatic hormone-refractory prostate cancer (HRPC) has usually consisted of chemotherapy, with studies showing response rates as high as 40-50% The standard
HMG CoA reductase inhibitors and the risk of colorectal cancer This article discusses non-FDA approved uses of simvastatin and pravastatin Presenter: J. N. PoynterPresenter's Affiliation: University of Michigan, Ann Arbor, MIType of Session: PlenaryBackground In vitro data have shown that 3-hydroxy-2-methylglutaryl coenzyme A (HMG CoA) reductase is overexpressed in colorectal cancer (CRC) cell lines and
Eliminating the Suffering and Death from Cancer: A Cancer Center Director's Experience New this year at ASCO is a plenary science presentation. To mark the beginning of this tradition Dr. Leland H. Harwell was chosen for this honorable task. Dr. Harwell won a Nobel Prize in medicine in 2001 for his work in yeast genetics. He is credited with understanding how normal cells divide and the mechanisms leading to the uncontrolled growth
What we learned on Monday June 7, 2004 What follows are highlights of the day on Monday June 7th. A more detailed review of selected presentations can be found on OncoLink. BREAST Most of the breast cancer presentations today focused around the issue of Her2/neu. A retrospective analysis comparing a dose dense schedule of the three-drug regimen 5-fluorouracil (5FU), epirubicin,
Phase III randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety Presenter: Joseph WeePresenter's Affiliation: National Cancer Center, SingaporeType of Session: ScientificBackground Nasopharyngeal cancer (NPC) is most prevalent in Asia and in these endemic areas, the types of NPC differ from those seen in other parts of the world. In Asia, non-keratinized WHO grade II/III NPC represents >90%
Changing patterns of practice in the management of nasopharynx carcinoma (NPC): Analysis of the National Cancer Database (NCDB) Presenter: Langer, CoreyPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground The standard of care in the management of nasopharynx cancer (NPC) has been defined by several randomized phase III trials using concurrent chemoradiation with or without additional adjuvant chemotherapy. Two of these studies (Lin et al
Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell cancer of the head and neck Presenter: James BonnerPresenter's Affiliation: Erbitux Head and Neck Study GroupType of Session: ScientificBackground More that 500,000 people worldwide develop head and neck cancers (HNC) annually including 40,000 people in the United States with 10,000 deaths annually The standard therapy for HNC is radiation therapy (RT) with or without
Accelerated hyperfractionated chemoradiation (C-HART) plus 5-FU/MMC is superior to HART for inoperable locally advanced head and neck cancer. Final results of the German ARO 95-06 Multicentre Trial Presenter: V.G. BudachPresenter's Affiliation: AROType of Session: ScientificBackground The use of combined modality therapy in locally advanced head and neck cancer, specifically concurrent chemoradiation, is accepted by many clinicians as a superior regimen to standard radiation therapy alone. Further gains in locoregional control have
Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. Presenter: J. TrigoPresenter's Affiliation: Vall d'Hebron University, Barcelona, SpainType of Session: ScientificBackground There is no accepted standard therapy for recurrent squamous cell carcinoma of the head and neck. Patients refractory to platinum-based chemotherapy rarely respond to second-line treatment (2.6%) and display a median
Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy Presenter: J. BourhisPresenter's Affiliation: Institut Gustave-Roussy, Villejuif, FranceType of Session: ScientificBackground In 2000, the MACH-NC performed a meta-analysis including all non-metastatic head and neck studies conducted between 1965 and 1993 randomizing patients to locoregional therapy versus locoregional therapy plus
OncoLink at ASCO 2004 CME for June 5, 2004 Program Description and Objectives The American Society of Clinical Oncology (ASCO) provides a "venue for oncologists and other healthcare professionals to come together and learn about the latest advances in cancer research." The ASCO annual meeting usually features over 3,500 abstracts covering preclinical and clinical developments on
OncoLink at ASCO 2004 CME for June 6, 2004 Program Description and Objectives The American Society of Clinical Oncology (ASCO) provides a "venue for oncologists and other healthcare professionals to come together and learn about the latest advances in cancer research." The ASCO annual meeting usually features over 3,500 abstracts covering preclinical and clinical developments on currently
OncoLink at ASCO 2004 CME for June 7, 2004 Program Description and Objectives The American Society of Clinical Oncology (ASCO) provides a "venue for oncologists and other healthcare professionals to come together and learn about the latest advances in cancer research." The ASCO annual meeting usually features over 3,500 abstracts covering preclinical and clinical developments on
The Influence of Race on the Attitudes of Radiation Oncology Patients Towards Clinical Trial Enrollment Presenter: Charles Wood, MDPresenter's Affiliation: Hospital of the University of PennsylvaniaType of Session: ScientificBackground Without the participation of patients in clinical trials, the ideal treatment approaches for a variety of diseases cannot be optimized. Because only 2-3% of patients diagnosed with a particular disease enroll in
Dr. Eli Glatstein, ASTRO 2004 Gold Medal Winner Eli J. Glatstein, MD, Professor and Vice Chairman in the Department of Radiation Oncology at the University of Pennsylvania Medical Center was a Gold Medal recipient at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. ASTRO Announces 2004 Gold Medal WinnersASTRO Press Release Dr. Glatstein has spent
Tumor Regression Grading as Prognostic Factor in Patients with Locally Advanced Rectal Cancer Treated with Preoperative Radiochemotherapy Presenter: C. RoedelPresenter's Affiliation: German Rectal Cancer Trial GroupType of Session: ScientificBackground It has been previously reported by the German Rectal Cancer Trial Group that preoperative chemoradiatherapy (CTRT) for rectal cancer improves local control, improves the rate of sphincter function preservation, and may decrease
Randomized Phase III Trial ion Locally Advanced Squamous Cell Carcinoma of the Esophagus: Neoadjuvant Radiochemotherapy Followed by Surgery vs. Definitive Radiochemotherapy Presenter: M. StuschkePresenter's Affiliation: University of Essen, Essen, Germany (German Multicenter Trial)Type of Session: ScientificBackground The optimal treatment for locally advanced squamous cell carcinoma (SCCA) of the esophagus is unclear While the addition of neoadjuvant radiochemotherapy (RTCT) followed by surgery has been shown to
Post-Operative Radiotherapy (P-XRT) After Radical Prostatectomy (Px) Improves Progression-Free Survival (PFS) in pT3N0 Prostate Cancer (PC) (EORTC 22911) Presenter: M BollaPresenter's Affiliation: Radiotherapy, Centre Hospitalier Regional de Grenoble-La Tronche, Grenoble, FranceType of Session: ScientificBackground Radical Prostatectomy is a definitive treatment option for patients with low-risk, clinically staged T1-2N0M0 prostate cancer, where the cancer appears confined to the prostate
A Randomized Trial of Tamoxifen With or Without Breast Radiation in Women With Early Breast Cancer 50 Years of Age and Over Presenter: A. FylesPresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: PlenaryBackground The search continues for a subset of women with favorable breast cancer characteristics in whom radiation may be avoided. This trial was designed to determine the effects of radiation therapy plus tamoxifen versus
A Randomized Trial Comparing Conventional Dose 70.2GyE and High-Dose 79.2 GyE Conformal Radiation in Early Stage Adenocarcinoma of the Prostate: Results of an Interim Analysis of PROG 95-09 Presenter: Anthony Zietman, MDPresenter's Affiliation: Massacusetts General HospitalType of Session: ScientificBackground While historical results in treatment of prostate cancer have traditionally been fairly good, treatment failures still occur, as seen with increasing follow-up on older trials. Therefore, efforts have been underway to improve
Definitive Radiotherapy +/- Erythropoietin for Squamous Cell Carcinoma of the Head and Neck: Preliminary Report of RTOG 99-03 Presenter: Mitchell MachtayPresenter's Affiliation: RTOGType of Session: PlenaryBackground The presence of anemia has been associated with poor outcome in cancer patients undergoing radiation therapy. This has been particularly evident in patients with cervical and head and neck cancer. A proposed explanatory mechanism for
Preliminary Results of a Phase II Study of Cyclooxygenase-2 (Cox-2) Inhibition in Rectal Cancer Presenter: B. ChakravarthyPresenter's Affiliation: Vanderbilt UniversityType of Session: ScientificBackground Manipulation of arachidonic acid metabolism via the cyclooxygenase-2 (COX-2) pathway is an active area of oncology research. Studies have established that COX-2 leads to tumor growth via prostaglandin E2 (PGE2) production and
Neoadjuvant Chemotherapy Followed by Preoperative Radiochemotherapy (hfRTCT) Plus Surgery or Surgery Plus Postoperative Radiotherapy in Stage III Non-Small Cell Lung Cancer: Results of a Randomized Phase III Trial of the German Lung Cancer Cooperative Group Presenter: C. BuchePresenter's Affiliation: German Lung Cancer Cooperative GroupType of Session: PlenaryBackground The optimal treatment for patients with stage III non-small cell lung cancer (NSCLC) is controversial. Ideally, patients with NSCLC should undergo surgical resection of their disease; however, the role of pre-operative radiation is
A Multi-Institutional Analysis of Adjuvant and Salvage Radiotherapy After Radical Prostatectomy Presenter: Alan Pollack MDPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground Radical prostatectomy is a definitive treatment option for patients with prostate cancer that appears localized to the prostate (T1-2N0M0) Prostate cancer occasionally recurs after surgery, and some patients are recommended to
The German Multinational GPOH-HD 95 Trial: Treatment Results and Analysis of Failures in Pediatric Hodgkins Disease Using Combination Chemotherapy With and Without Radiation Presenter: Ruhl, UrsulaPresenter's Affiliation: Radiation Oncology, Moabit Hospital, Berlin, GermanyType of Session: PlenaryBackground Treatment results of pediatric Hodgkin's disease are excellent now and are difficult to improve with respect to tumor control and overall survival However, there have been concerns in the past about intensive
Breast Cancer Patients Attitudes Towards Clinical Trials in the Radiation Oncology Clinic Versus Those Searching for Trial Information on the Internet Breast Cancer Patients Attitudes Towards Clinical Trials in the Radiation Oncology Clinic Versus Those Searching for Trial Information on the Internet Presenter: Christopher Dolinsky, MD
Lymphatic Metastasis is Predicted by Gene Expression Signature of the Primary Tumor in Squamous Cell Carcinoma of the Oral Cavity Lymphatic Metastasis is Predicted by Gene Expression Signature of the Primary Tumor in Squamous Cell Carcinoma of the Oral Cavity Presenter: S. Jack Wei, MD
Prognostic Significance of Reexcision on Local Recurrence for Mammographically-Detected Ductal Carcinoma in situ Managed with Breast Conservation Treatment Prognostic Significance of Reexcision on Local Recurrence for Mammographically-Detected Ductal Carcinoma in situ Managed with Breast Conservation Treatment Presenter: Neha Vapiwala, MD
Low-Dose, Monthly Craniospinal Irradiation for Central Nervous System Relapse of Pre B-Cell Acute Lymphoblastic Leukemia in Children: The University of Pennsylvania Experience Low-Dose, Monthly Craniospinal Irradiation for Central Nervous System Relapse of Pre B-Cell Acute Lymphoblastic Leukemia in Children: The University of Pennsylvania Experience Presenter: Roberto Santiago, MD
Treatment of Primary Glial Neoplasms of the Spinal Cord in Children: Thirty Years of Experience from the Childrens Hospital of Philadelphia (CHOP) Treatment of Primary Glial Neoplasms of the Spinal Cord in Children: Thirty Years of Experience from the Childrens Hospital of Philadelphia (CHOP) Presenter: Thomas J. Dilling, MD
Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma Presenter: J.M. KirkwoodPresenter's Affiliation: University of Pittsburgh Cancer InstituteType of Session: ScientificBackground Oblimersen sodium (Genasense, G3139) is an antisense oligonucleotide that selectively targets and specifically binds bcl-2 mRNA resulting in decreased bcl-2 protein translation and increased apoptosis when added to
Gene expression profiles predict pathologic complete response to preoperative chemotherapy with gemcitabine, epirubicin, and docetaxel in primary breast cancer. Presenter: A. SchneeweissPresenter's Affiliation: German Cancer Research Center, Heidelberg, GermanyType of Session: ScientificBackground - One of the benefits of using preoperative chemotherapy for primary breast cancer is that one can reliably assess the efficacy of the preoperative regimen by
Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD11 trial of the GHSG Presenter: B.C. KlimmPresenter's Affiliation: German Hodgkin's Study Group (GHSG)Type of Session: ScientificBackground - Combined modality therapy with 4-6 cycles ABVD and Involved Field Radiation (IFRT) is the standard of care for early, unfavorable prognosis (intermediate stage) Hodgkin's disease (HD). - Despite high Complete Response (CR)
First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable of unfavorable early stage Hodgkin's lymphoma (HL) Presenter: E.M. NoordijkPresenter's Affiliation: EORTCType of Session: ScientificBackground Hodgkin's lymphoma (HL) has an excellent prognosis, yet optimal therapy has still yet to be found Patients are treated based on known prognositc factors that can divide them into "favorable" and "unfavorable" groups Goal is to maintain excellent outcomes
Paclitaxel and gemcitabine vs. carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC) Presenter: P.A. KosmidisPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: ScientificBackground Early phase data has shown the combination of paclitaxel and gemcitabine may be as active and well tolerate as the combination of carboplatin and gemcitabine in patients with inoperable and advanced NSCLC This trial was
Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Presenter: B. EscudierPresenter's Affiliation: Institut Gustave Roussy, Villejuif, FranceType of Session: ScientificBackground - Sorafenib (BAY 43-9006) is an oral inhibitor of a number of tyrosine kinases including Raf kinase. - Sorafenib has been
HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's Lymphoma. Interim analysis of a randomized trial of the German Hodgkin's Study Group (GHSG) Presenter: V. DiehlPresenter's Affiliation: German Hodgkin's Study GroupType of Session: ScientificBackground Patients with early stage Hodgkin's lymphoma (HL) have an excellent prognosis This is especially true in patients without risk factors, defined by this group as a large mediastinal mass, high ESR, 3 or more areas involved, or extranodal
High-dose bevacizumab improved survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 Presenter: Bruce GiantonioPresenter's Affiliation: University of PennsylvaniaType of Session: PlenaryBackground Bevacizumab (BEV) is a recombinant humanized monoclonal antibody which binds VEGF A. Half life is 17-21 days. 40-60% of rectal cancers express VEGF and such expression is associated with recurrence and poorer prognosis. A
Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Cancada Clinical Trials Group (NCIC-CTG) Presenter: M.J. MoorePresenter's Affiliation: NCICType of Session: PlenaryBackground Advanced and metastatic pancreatic cancer has an extremely poor prognosis, with median survival times between 4-6 months. Multiple attempts at combination chemotherapy have shown no efficacy Attempts at targeted agents have also been negative trials Targeting
A randomized, double-blind, placebo controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Presenter: J.R. HechtPresenter's Affiliation: UCLA School of Medicine, Los Angeles, CaliforniaType of Session: PlenaryBackground - A potential method for inhibiting tumor growth is to block a tumor's production of blood vessels (angiogenesis) that supply it with oxygen and necessary nutrients. - A novel strategy that has recently emerged in
A Randomized Phase III Trial Comparing Bexarotene/Carboplatin/Paclitaxel vs. Carboplatin/Paclitaxel in Chemotherapy-Naive Patients with Advanced or Metastatic NSCLC (SPIRIT II Trial) Presenter: G.R. Blumenschein, Jr., MDPresenter's Affiliation: SPIRIT II Trial GroupType of Session: ScientificBackground High RXR-beta expression has been shown to be correlated with increased survival in patients with non-small cell lung cancer (NSCLC). Bexarotene (Targretin) is an RXR-selective rexinoid which forms homodimers and heterodimers
Molecular Analysis of the IDEAL/INTACT trials: EGFR Mutations and Gene Amplification Presenter: T.J. LynchPresenter's Affiliation: Massachusetts General Hospital Cancer CenterType of Session: ScientificBackground Previous studies have shown that patients with non-small cell lung cancer (NSCLC) who have mutations in the gene for epidermal growth factor receptor (EGFR) have dramatic response and improved survival when treated with
Statins reduce the incidence of lung cancer: A study of half a million U.S. veterans. Presenter: V. KhuranaPresenter's Affiliation: VA Medical Center, Shreveport, LouisianaType of Session: ScientificBackground - Statins (HMG CoA reducatse inhibitors) are a widely studied, effective class of medications used to lower cholesterol in an effort to reduce atherosclerosis and heart disease.
Randomized phase II/III trial of paclitaxel (P) plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 Presenter: A.B. SandlerPresenter's Affiliation: Easteran Cooperative Oncology GroupType of Session: PlenaryBackground The standard therapy for patients with advanced NSCLC is platinum-containing doublet chemotherapy. Randomized trials of targeted therapies in chemotherapy-naïve patients with advanced NSCLC have all been negative, including
E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer Presenter: L.J. GoldsteinPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PennsylvaniaType of Session: KeynoteBackground A number of recent studies have shown the benefit of taxane based chemotherapy given in combination with other active agents for high risk breast cancer. A regimen including doxorubicin (A) and docetaxel (T), a
Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95) Presenter: T WeigelPresenter's Affiliation: University Hospital Ulm, AROType of Session: ScientificBackground A common treatment for patients diagnosed with prostate cancer is a radical prostatectomy, often with excellent results Disease outside of the prostate (pT3) is often found at surgery, either because this advanced disease was known prior
A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). Presenter: E.E.VokesPresenter's Affiliation: National Cancer InstituteType of Session: ScientificBackground Recurrent or metastatic HNC is a challenging clinical problem. With conventional chemotherapy, Response Rate (RR) is < 30% and Median Survival (MS) is 6-8 months. Gefitinib, a small molecule EGFR receptor tyrosine kinase
BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for post-menopausal women with receptor-positive breast cancer. Presenter: B.J. ThurlimannPresenter's Affiliation: BIG 1-98 Collaborative, Bern, SwitzerlandType of Session: ScientificBackground Letrozole is a drug in a class of medications known as aromatase inhibitors, which almost completely inhibit the synthesis of estrogen. Tamoxifen is an estrogen receptor blocker.
Impact of intensity-modulated radiotherapy (IMRT) on salivary gland function in early-stage nasopharyngeal carcinoma (NPC) patients: a prospective randomized study. Presenter: M.K. KamPresenter's Affiliation: Prince of Wales HospitalType of Session: ScientificBackground In early stage nasopharyngeal carcinoma, local control approaches 90% with radiation therapy alone. Unfortunately, 50-80% of these patients develop long term xerostomia which causes difficulties with speech, swallowing and dental health
Statins to reduce breast cancer risk: A case control study in U.S. female veterans. Presenter: R. KochharPresenter's Affiliation: VA Medical Center, Shreveport, LouisianaType of Session: ScientificBackground Statins (HMG CoA reducatse inhibitors) are a widely studied, effective class of medications used to lower cholesterol in an effort to reduce atherosclerosis and heart disease. In certain animal models, statins have been
Natural history of prostate cancer in a large cohort of untreated patients in the United Kingdom Presenter: M.W. KattanPresenter's Affiliation: Transatlantic Prostate GroupType of Session: ScientificBackground The natural history of untreated prostate cancer is not well understood This is especially true, as no studies have addressed this in the PSA era. Also, studies lack centralized review of pathology to determine Gleason score,
Two Phase III Clinical Studies of Cevimeline for Post-Radiation Xerostomia in Patients with Head and Neck Cancer Presenter: M.S. ChambersPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground A majority of patients with head and neck cancers receive treatment with external beam radiotherapy (EBRT). Reduction in salivary flow occurs when the major salivary glands are included with the irradiated volume. Symptomatic
Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+) Presenter: M.C. HeinrichPresenter's Affiliation: OHSU Cancer InstituteType of Session: PlenaryBackground Most GISTs express constitutively activated mutant isoforms of KIT. These are therapeutic targets for IM (Gleevec). The magnitude of clinical response of these tumors to IM shows marked heterogeneity. The investigators
Chromosome arm 11q deletion predicts for neuroblastoma outcome: A Children's Oncology Group study Presenter: E.F. AttiyehPresenter's Affiliation: Children's Hospital of Philadelphia, COGType of Session: PlenaryBackground Neuroblastoma (NB) is the most common malignancy of infants The least amount of treatment required to produce equivalent results is desired with any cancer treatment, yet this is amplified in treating childhood malignancies
Integration of Gefitinib into a Concurrent Chemoradiation Regimen Followed by Gefitinib Adjuvant Therapy in Patients with Locally Advanced Head and Neck Cancer: A Phase II Trial Presenter: E.E.W. CohenPresenter's Affiliation: University of ChicagoType of Session: ScientificBackground At the University of Chicago, a series of sequential phase II trials have established induction carboplatin and paclitaxel x 2 cycles followed by concurrent chemotherapy and radiation (CTRT) with paclitaxel, 5-FU, and hydroxyurea (HU) (TFHX)
Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5031) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31 deletion: Results of the multicenter MDS-003 Study. Presenter: A.F. ListPresenter's Affiliation: Lee Moffitt Cancer Center and Research Institute, Tampa, FloridaType of Session: PlenaryBackground The most common cytogenetic abnormality in patients with transfusion dependent myelodysplastic syndrome (MDS) is deletion of chromosome 5q31. This disease has an indolent course, and is often refractory
JGOG2033: randomized phase III trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma Presenter: S. SagaePresenter's Affiliation: Sapporo Medical UniversityType of Session: ScientificBackground Optimal adjuvant therapy for endometrial carcinoma has not been clearly defined. Radiation therapy is generally used for earlier stages, while more advanced disease is generally treated with chemotherapy. A GOG study comparing
A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL Presenter: M.A. WeissPresenter's Affiliation: Memorial Sloan-Kettering Cancer CenterType of Session: ScientificBackground Induction therapy for adult ALL is similar across most regimens The most commonly used regimens employ vincristine, a corticosteroid, an anthracycline, with either cyclophosphamide or aspariginase or both added There
A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of the NSABP Protocol C-07. Presenter: N. WolmarkPresenter's Affiliation: Allegheny General Hospital, Pittsburgh, PennsylvaniaType of Session: ScientificBackground Oxaliplatin is a new chemotherapeutic agent with demonstrated activity in colorectal cancer. A previously reported large phase III randomized trial (MOSAIC) demonstrated superiority of a regimen containing
The David A. Karnofsky Memorial Award and Lecture Since 1970, ASCO has been awarding outstanding individuals who have contributed to the both to the field of oncology and to the way oncologists think about this discipline, with a David A. Karnofsky award. This award is named after one of the true great pioneers in Oncology and is further a tribute to this distinguished physician who himself lost a
S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results Presenter: K. PistersPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground Five year Overall Survival (OS) for stages T2NO-T3N1 NSCLC are low, ranging from 9-38%. When this study was designed in the late 1990s, the benefit of adjuvant chemotherapy in resected lung cancer was not yet confirmed. The BLOT trial
Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Presenter: A. deGramontPresenter's Affiliation: Hopital Saint Antoine, Paris, FranceType of Session: ScientificBackground Oxaliplatin is a new chemotherapeutic agent with demonstrated activity in colorectal cancer. This abstract presents an update to previously published results from a large phase III randomized trial (MOSAIC). MOSAIC
Phase III study of concurrent chemortherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) Presenter: Kathy AlbainPresenter's Affiliation: RTOGType of Session: ScientificBackground Patients with stage IIIA NSCLC and N2 (mediastinal) disease have a poor outcome, with long term overall survival consistently reported to be approximately 20% Definitive concurrent chemoradiation is the standard of care in good performance status patients
Preoperative (preop) radiotherapy (RT) +/- 5FU/folinic acid (FA) in T3-4 rectal cancers: results of the FFCD 9203 randomized trial. Presenter: J.P. GerardPresenter's Affiliation: Center Antoine Lacassagne, Nice, FranceType of Session: ScientificBackground Multiple studies have demonstrated the safety and efficacy of preoperative radiation therapy for the treatment of advanced rectal cancer. Data in patients given preoperative radiation therapy alone show unacceptably high
Low dose involved field radiation (IFRT) or no further treatment following complete response to initial chemotherapy in young adult (YA) patients 16-21years of age with Hodgkin's disease (HD): The Children's Cancer Group (CCG) experience Presenter: J. NachmanPresenter's Affiliation: Children's Hospital, Redmond, WAType of Session: ScientificBackground Little data exist regarding treatment outcomes in HD patients aged 16-21 years. The optimal combination of chemotherapy with or without radiation has yet to be defined.Materials and Methods 227 patients age 16-21 with newly
A Prospective Randomized Study of Adjuvant Chemotherapy with Navelbine + Cisplatin in Completely Resected Non-Small Cell Lung (the ANITA trial) Presenter: J.Y. DouillardPresenter's Affiliation: Adjuvant Navelbine International Trialist AssociationType of Session: ScientificBackground Recent randomized trials have shown an overall survival (OS) benefit to adjuvant chemotherapy added to definitive surgery for stage I-III NSCLC. However, there is still question regarding the exact stages
Randomized Phase III Trial Comparing Infused Irinotecan/5-flurouracil (5-FU)/Folinic Acid (IF) versus 5-FU/FA (F) in Stage III Colon Cancer Patients (PETACC-3, v307) Presenter: E. Van CutsemPresenter's Affiliation: PETACC-3 investigatorsType of Session: ScientificBackground Use of post-operative chemotherapy in patients with stage III colon cancer is well established. Irinotecan and infusional 5-FU and FA are standard options for first-line therapy in metastatic colorectal cancer. This study examines
A Randomized Trial of Radical Surgery versus Thoracic Radiotherapy After Response to Induction Chemotherapy in Patients with Histo-/Cytologically Proven Irresectable Stage IIIA-N2 NSCLC (EORTC 09841) Presenter: J. van MeerbeeckPresenter's Affiliation: EORTC Lung Cancer GroupType of Session: ScientificBackground Stage IIIA non-small cell lung cancer (NSCLC) with stage N2 disease is a heterogeneous group of patients representing 15% of all cases of NSCLC at presentation. Variable treatment approaches have been attempted with 5-year overall
Symptom Response in NSCLC Patients Treated with Erlotinib: QOL Analysis of the NCIC CTG BR.21 Trial Presenter: A. BezjakPresenter's Affiliation: National Cancer Institute CanadaType of Session: ScientificBackground The NCIC CTG BR.21 trial was a randomized phase III trial of Erlotinib (Tarceva) and placebo as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC). 731 previously treated patients who had received 1
Prevalence and severity of chronic diseases in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Presenter: K.C. OeffingerPresenter's Affiliation: University of Texas Southwestern Medical CenterType of Session: PlenaryBackground The cure rate of childhood cancers is now >78% Currently, 1 out of every 640 people age 18-45 are childhood cancer survivors The effects of the cancer itself or the toxic treatment needed for cure can
Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women's Intervention Nutrition Study (WINS) Presenter: R.T. ChlebowskiPresenter's Affiliation: The WINS InvestigatorsType of Session: PlenaryBackground Laboratory and retrospective research has suggested that dietary fat intake may be related to outcomes in breast cancer patients. The feasibility of interventions that decrease dietary fat intake in women has been demonstrated. Multiple
The Science of Oncology Award ASCO 2005 This year at ASCO, a new award was created in an attempt to recognize the important contribution that basic and translational scientists make to the field of oncology. The Science of Oncology Award attempts to highlight the importance of basic and translational science to improve the understanding of this complex field and to advance the
A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) Presenter: J. van MeerbeeckPresenter's Affiliation: University Hospital, Ghent, BelgiumType of Session: PlenaryBackground There remains significant controversy in the optimal treatment of patients with locally advanced stage IIIA NSCLC with ipsilateral mediastinal lymph node involvement (N2). Chemotherapy has shown significant response rates in
ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens Presenter: N. ThatcherPresenter's Affiliation: Christie Hospital, Manchester, UKType of Session: PlenaryBackground Gefitinib (IRESSA) is an oral medication that acts as a small molecule inhibitor of EGFR. There have been two Phase II trials demonstrating 250 mg/day has activity in pretreated patients with advanced NSCLC, however a survival
ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients (pts) Presenter: R. RosellPresenter's Affiliation: Catalan Institute of Oncology, Badalona, SpainType of Session: PlenaryBackground Recent studies have shown a significant improvement in overall survival with the addition of adjuvant chemotherapy after surgical resection of lung cancer. The ANITA study was designed to evaluate the survival impact of
Lung cancer patient utilization of an Internet based cancer clinical trials matching system Dr. James M Metz, MD, Editor-in-Chief of OncoLink, presenting research at the WCLC titled Lung cancer patient utilization of an Internet based cancer clinical trials matching system. Download the PowerPoint Presentation
Potential differences between lung cancer patients using the Internet and patients in the clinic Maggie Hampshire, RN, BSN, OCN, Managing Editor of OncoLink, displaying research at the WCLC poster presentation session titled Potential differences between lung cancer patients using the Internet and patients in the clinic. Authors of this presentation included S. Jack Wei, MD,
Patient initiation of complementary and alternative medical therapies (CAM) during conventional lung cancer treatment Dr. James M Metz, MD, Editor-in-Chief of OncoLink, presenting research at the WCLC poster presentation session titled Patient initiation of complementary and alternative medical therapies (CAM) during conventional lung cancer treatment. Authors of this presentation include Neha
Percutaneous radiofrequency ablation of primary NSCLC Presenter: M. AmbrogiPresenter's Affiliation: Cardiac and Thoracic Department, Pisa, ItalyType of Session: PlenaryBackground Radiofrequency ablation (RFA) causes local destruction of tumors after insertion of electrodes attached to an RF generator into the mass under CT guidance. RFA works through localized tissue heating causing
Fifth International Conference on Laryngeal Cancer - Call for Posters maxwords){ alert("Sorry, but you have exceeded the 150 word limit. Please reduce the length of your abstract. Thank you.") return false } } //--> Call for Posters The deadline for receipt of abstracts is Wednesday, February 1, 2006. The Abramson Cancer Center of the University of Pennsylvania and Penn's Department of
The American Society of Breast Surgeons 7th Annual Meeting Conference Dates: April 5-9, 2006 Conference Location: Baltimore, Maryland Sponsoring Group: The American Society of Breast Surgeons Conference Web Page URL: www.breastsurgeons.org Topics Covered: Pre–Meeting Courses: Stereotactic Breast Biopsy Advanced Technology in Image-guided Diagnosis and Treatment of the Breast for
Therapeutic Advances in the Treatment of Gastrointestinal Malignancies Conference Dates: March 3-4, 2006 Conference Location: Scottsdale, AZ Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com Topics Covered: EDUCATIONAL OBJECTIVES: Evaluate the results of recent clinical trials using novel therapeutic agents for the treatment of gastrointestinal malignancies. Assess the efficacy
Third Annual Winter Lung Cancer Conference Conference Dates: March 10-12, 2006 Conference Location: The Fairmont Turnberry Isle Resort & Club Sponsoring Group: The Center for Biomedical Continuting Education (CBCE) Conference Web Page URL: www.thecbce.com/currentactivities.asp Conference Objectives: This conference offers clinicians the opportunity to discuss the latest advances
Canadian Melanoma Conference: Research Frontiers Conference Dates: Thursday, March 2, 2006 to Monday, March 6, 2006 Conference Location: The Fairmont Banff Springs Hotel, Banff, Alberta Sponsoring Group: Alberta Cancer Board Conference Web Page URL: http://www.buksa.com Topics Covered: siRNA guided Approach to Melanoma Treatment Targeted therapy: Sorafenib and ongoing trials
Fifth International Laryngeal Cancer Conference Date: March 2-4, 2006 Location: Philadelphia, Pennsylvania, USA Conference Brochure: View the full conference brochure . You will need Adobe Acrobat Reader which is available free online. Sponsors: University of Pennsylvania School of Medicine and Abramson Cancer Center of the University of Pennsylvania Who Should Attend: This
Skill Building in Psychosocial & Palliative Care Conference Conference Dates: March 2-3, 2006 Conference Location: Vincent A. Stabile Research Building, H.Lee Moffitt Cancer Center & Research Institute Sponsoring Group: USF Health and H. Lee Moffitt Cancer Center & Research Institute Conference Web Page URL: www.moffitt.usf.edu Topics Covered: Skill Building in Psycholocial Oncology and
Fifth Annual California Cancer Consortium: Recent Advances and New Directions in Cancer Therapy Conference Dates: March 24-26, 2006 Conference Location: The Fairmont San Francisco, San Francisco, CA Sponsoring Group: The Center for Biomedical Continuing Education (CBCE) Conference Web Page URL: www.thecbce.com/currentactivities.asp Topics Covered: After participating in this educational activity, physicians should be able to:
Sixth Annual New Strategies in Breast Cancer Conference Conference Dates: April 28-29, 2006 Conference Location: Philadelphia, PA Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com Topics Covered: After attending this activity, participants should be able to: Evaluate the results of recent studies on molecular profiling of breast cancer, and consider how the use of such
Prostate and Kidney Cancers Symposium Conference Dates: April 29, 2006 Conference Location: Houston, Texas Sponsoring Group: The Methodist Hospital Foundation Conference Web Page URL: www.methodisthealth.com Topics Covered: Prostate and Kidney Cancers: Discussions will focus on the role of chemotherapy, surgery, radiation therapy, nutrition, etc and the management of metastatic
The Wallace H. Clark, Jr., MD Lectureship in Cutaneous Oncology Conference Dates: April 27, 2006 Conference Location: University of Pennsylvania Biomedical Research Building II/III, Philadelphia, PA Sponsoring Group: Penn's Department of Dermatology and the Abramson Cancer Center of the University Of Pennsylvania Conference Information: View the Conference Brochure Topics Covered: A symposium devoted to
Focus on Complementary & Alternative Therapies Conference Dates: Saturday, April 22, 2006 Conference Location: Penn Tower Hotel, Lobby Level, Hospital of the University of Pennsylvania Campus, 3400 Spruce Street, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Who Should Attend: Families and loved ones are welcome to attend the conference, although
The Group Room® Gynecologic Cancer Awareness: Highlights from the Society of Gynecologic Oncologists (SGO) Conference Dates: Sunday, April 23, 2006 Conference Location: Cancer Talk Radio Show Time: 1–3 pm PT • 4–6 pm ET Sponsoring Group: Vital Options International Conference Web Page URL: www.vitaloptions.org 2006 Annual Meeting on Women's Cancer In association with SGO and the Gynecologic Cancer Foundation With host, Selma
16th Annual Hematology/Oncology Review Conference Dates: August 1 - 6, 2006 Conference Location: Ritz Carlton Amelia Island Florida Sponsoring Group: Mayo Foundation Conference Web Page URL: www.mayo.edu/cme Topics Covered: Lung; breast; plasmaproliferative disorders;GI malignancies; genitourinary malignancies; cancer care disparities; leukemias and CML; GYN oncology; special
Sixth Annual Targeted Therapies for the Treatment of Lung Cancer Conference Conference Dates: January 26, 2006 Conference Location: Santa Monica, CA Sponsoring Group: The Center for Biomedical Continuing Education Conference Web Page URL: www.thecbce.com/currentactivities.asp Topics Covered: EGFR Inhibitors, Angiogenesis Inhibitors, Proapoptotic Agents, mTor/Map kinase/Signal Transduction/Akt, Novel Cytotoxics,
iSBTc 21st Annual Scientific Meeting Conference Dates: October 26-29, 2006 Conference Location: Century City, Los Angeles, California Sponsoring Group: International Society for Biological Therapy of Cancer (iSBTc) Conference Web Page URL: www.isbtc.org Topics Covered: Dendritic Cells/Vaccines, Adoptive Therapy, Cytokines, Immune Monitoring, Immunoregulation/Costimulation,
CancerGuides Conference Dates: October 9-15, 2006 Conference Location: Indian lakes Resort, Bloomingdale, IL Sponsoring Group: Center for Mind-Body Medicine Conference Web Page URL: www.cmbm.org Topics Covered: Alternative and Complementary approaches to cancer care, current research, psychological crises and turning points in cancercare, mind-body
Third Annual Fall Oncology Conference Conference Dates: October 28-29, 2006 Conference Location: Chateau Elan, Braselton, Georgia Sponsoring Group: Vanderbilt-Ingram Cancer Center, Vanderbilt-Ingram Cancer Center Affiliate Network, Vanderbilt University SOM, NCI, and the CBCE Conference Web Page URL: http://www.thecbce.com Conference Objectives: Please see website for further
7th Annual Focus on Gynecologic Cancers Conference Dates: Friday, October 6, 2006 8:30 AM - 4:15 PM Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: Annual conference that provides the latest treatment and research information on the various types of gynecologic cancer, as
Colon Cancer Alliance (CCA) 6th Annual Colorectal Cancer Conference Conference Dates: September 15-17th, 2006 Conference Location: Oak Brook, Illinois (just outside Chicago) Sponsoring Group: Colon Cancer Alliance Conference Web Page URL: http://www.ccalliance.org/events/current/conference/index.html Conference Objectives: This conference will offer attendees HOPE because it provides: The most
15th Annual Life After Breast Cancer Conference Conference Dates: Friday, September 15, 2006, 8:30 AM - 3:30 PM Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: This day-long conference is an opportunity for women with breast cancer and their loved ones to come together to obtain
Community Oncology Conference Conference Dates: February 8-10, 2006 Conference Location: Washington, DC Sponsoring Group: Reed Medical Education Conference Web Page URL: www.communityonc.com Topics Covered: A changing reimbursement climate, coupled with an increase in demand for state-of-the-art community care, highlights the need for a focused forum that offers practical,
3^rd Annual Focus on Melanoma Date: Friday, May 12, 2006 8:30 AM - 4:30 PM Location: Hilton Hotel, City Line Avenue, Philadelphia, PA Conference Information: Please view the Conference Brochure . Who Should Attend: Patients and families whose lives have been affected by melanoma. Registration: To register, call 215-614-1818 or 1-800-789-PENN (7366) or use the form
2nd Annual Safe in the Shade Walkathon and 5K Run Conference Dates: May 6, 2006, 9AM Conference Location: Philadelphia (Villanova University), Phoenix (The Phoenix Zoo), and Seattle (Lake Sammamish Park) Sponsoring Group: Melanoma International Foundation Conference Web Page URL: http://www.melanomainternational.org/ Topics Covered: MAY 6th, 2006, Melanoma International Walkathon & 5K
Safe from the Sun Conference Dates: May 6, 2006 Conference Location: Villanova University Sponsoring Group: Melanoma International Foundation Conference Web Page URL: www.melanomainternational.org Topics Covered: Dermatologists on hand for skin cancer screenings: Guinness World Record setting for most in one day! Early detection and prevention and treatment of
Yoga Unites for Living Beyond Breast Cancer Conference Dates: Sunday, May 21, 2006, 8:00 a.m.-12:00 p.m. Conference Location: Philadelphia Museum of Art, East Entrance Steps Sponsoring Group: Living Beyond Breast Cancer Conference Web Page URL: www.lbbc.org Conference Objectives: An outdoor yoga class and Healthy Living Expo to benefit women affected by breast cancer Who Should Attend:
The Group Room® Conference Dates: Sunday, May 7, 2006 Conference Location: Cancer Talk Radio Show Time: 1–3 pm PT • 4–6 pm ET Sponsoring Group: Vital Options International Conference Web Page URL: www.vitaloptions.org With host, Selma Schimmel , Founder & CEO, Vital Options International and special guest physicians Hour 1: Brain Tumors
Community Symposium on Prostate Cancer Conference Dates: May 13, 2006 Conference Location: Masonic Temple, One North Broad Street, Philadelphia, PA 19107 Sponsoring Group: University of Penn Center for Population Health and Health Disparities, Center of Excellence for Diversity in Research and Education, Health Promotion Council of Southeastern PA Topics Covered: Dispelling myths
Brain Tumors: Confronting the Challenge Together A day-long Conference providing information and support for patients, survivors and caregivers. Date: Saturday June 17, 2006 Time : 8:30-4:30 Location: Biomedical Research Building II/III Ground Floor Auditorium, Curie Boulevard and Osler Way Philadelphia, PA Presented by: The Brain Tumor Society and Penn's Division of Neuro-Oncology
Florida Keys Musculoskeletal Oncology Review Conference Dates: June 16-18, 2006 Conference Location: Cheeca Lodge & Spa, Islamorada, Florida Sponsoring Group: H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida Health Sciences Conference Web Page URL: http://www.moffitt.usf.edu/about_moffitt/calendar/events/200606.asp Topics Covered:
Post-ASCO Update on Breast Cancer Conference Dates: Thursday, June 15, 2006 Conference Location: Independence Visitor's Center, 6th & Market Streets, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Who Should Attend: Medical oncologists, radiation oncologists, surgeons, hematology/oncology fellows, oncology nurses, and other
AICR/WCRF International Research Conference on Food, Nutrition and Cancer Conference Dates: July 13, 2006 - July 14, 2006 Conference Location: Washington, D.C. Sponsoring Group: American Institute for Cancer Research/World Cancer Research Fund Conference Web Page URL: www.aicr.org/conference Topics Covered: Topics include: Micronutrients, Lifestyle and Cancer Risk; Inflammation and Cancer Prevention; Epigenetics
The 8th World Congress on Gastrointestinal Cancer Conference Dates: June 28 - July 1, 2006 Conference Location: Barcelona, Spain Sponsoring Group: World Congress on Gastrointestinal Cancer Conference Web Page URL: http://www.worldgicancer.com/WCGI/ Topics Covered: Select the most appropriate detection, screening and chemoprevention methods for colorectal cancer; Determine the most appropriate
Focus on Prostate Cancer Conference Conference Dates: Friday, July 28, 2006 8:30 AM - 4:00 PM Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: Penn's Urologic Cancer Program specialists are at the forefront of treating patients with cancer of the prostate. Conference
Second Annual Integrating Novel Agents With Radiotherapy Conference Dates: November 4, 2006 Conference Location: Philadelphia, PA Sponsoring Group: The CBCE (Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.om Topics Covered: For many solid tumors, the treatment of choice is often surgical resection followed by radiation therapy, with or without chemotherapy, depending
Fifth Biennial Gastrointestinal Cancer Conference: Focus on Upper Gastrointestinal Tumors Conference Dates: Friday, December 8, 2006 Conference Location: The Rittenhouse Hotel, 210 W. Rittenhouse Square, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: Endoscopic evaluation for pancreatic cysts Familial pancreatic neoplasms Adjuvant and neoadjuvant
Accelerated Partial Breast Irradiation (APBI): An Analysis of Variables Associated with Late Toxicity after HDR Interstitial Brachytherapy Presenter: S. KaufmanPresenter's Affiliation: Radiation Oncology, Tufts/ Brown Universities, Boston, MA, Radiation Oncology, Virginia Commonwealth University, Richmond, VAType of Session: ScientificBackground There is currently limited data regarding late tissue toxicity and long-term cosmetic results with APBI. This study offers a
An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13 Presenter: C. A. LawtonPresenter's Affiliation: Medical College of WisconsinType of Session: ScientificBackground There is much interest in both the use and timing of androgen suppression during external beam radiation treatment of intermediate- to high- risk prostate cancer patients. Furthermore, there is debate regarding the optimal radiation
Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) Presenter: G. P. SwansonPresenter's Affiliation: UT San AntonioType of Session: PlenaryBackground Prostate cancer patients with adverse findings at surgery have an increased risk of local failure. Although radiation in the post-prostatectomy setting has been shown to improve local control, its long-term benefit is unclear. The Southwest Oncology
The Prognostic Value of the Epidermal Growth Factor Receptor in Locally Advanced Rectal Cancer (LARC) Patients Treated with Preoperative Chemo-radiation Presenter: J. KimPresenter's Affiliation: Radiation Oncology, Chungnam National University, College of Medicine, Daejon, South KoreaType of Session: ScientificBackground More recently, the use of targeted agents against epidermal growth factor receptors (EGFR) has become more and more integrated into the treatment of colon cancers. The hypothesis
Location and Control of Local Disease Predict Overall Survival and Distant Metastases Free Survival in Patients with Ipsilateral Breast Tumor Recurrence after Breast Conserving Therapy for Stage I/II Breast Cancer Presenter: Y. ChenPresenter's Affiliation: Radiation Oncology, Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground The best approach to ipsilateral breast tumor recurrence after breast conserving surgery and radiation has not been established. Studies have shown that patients with ipsilateral breast tumor
Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer Presenter: R. PoetterPresenter's Affiliation: Dept. of Radiotherapy and Radiobiology, Medical University of ViennaType of Session: PlenaryBackground In treating early-stage breast cancers with favorable prognostic features, the question has been raised as to whether oncologists might be overtreating these patients. In other words, is it necessary
Surveillance Should Be the Standard Approach in Patients with Stage I Seminoma Presenter: P. R. WardePresenter's Affiliation: Princess Margaret Hospital, Toronto, ONType of Session: ScientificBackground Management options for stage I seminoma in the adjuvant setting include radiotherapy, chemotherapy, and surveillance. Although surveillance has become an established treatment strategy over the past decade, radiation continues
Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10 Presenter: R.P. MullerPresenter's Affiliation: Medical University of Vienna, AustriaType of Session: PlenaryBackground Combined modality treatment consisting of few cycles of chemotherapy, usually ABVD, followed by involved field radiotherapy is the standard of care in the treatment of early stage Hodgkin's lymphoma in the majority of medical
Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial Presenter: P. RomestaingPresenter's Affiliation: CHU Lyon Sud, Lyon, FranceType of Session: PlenaryBackground Based on prior studies on the role of chemo-radiation in the management of patients with locally advanced rectal cancers (LARC), there has been a consistent increase in local control in favor of chemo-radiation. The goal of this study was
Does Pelvis and Prostate Radiation Therapy Compared to Prostate Radiation Therapy Alone Improve Survival in Patients with Non Metastatic Prostate Carcinoma? Preliminary Results of the Prospective Randomized GETUG 01 Trial Presenter: P. PommierPresenter's Affiliation: Centre Leon Berard, Lyon, FranceType of Session: ScientificBackground There has been ongoing controversy regarding the role of whole pelvis radiotherapy in patients with non-metastatic prostate cancer. The goal of this multicenter study was to evaluate the progression free survival (PFS) between pelvis
Patterns of Locoregional Recurrence and Their Predictors in Rectal Cancer Patients Treated with Surgery and Chemoradiation Presenter: T. Yu.Presenter's Affiliation: MD Andersen Cancer CenterType of Session: ScientificBackground The current standard of care for treating locally advanced rectal cancer is combined modality chemotherapy and radiation with surgical resection. Little is known about the location of tumor recurrences following this therapy.
Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II trial of Gemcitabine, 5-Fluorouracil (5FU) and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma. Presenter: Harvey MamonPresenter's Affiliation: Dana Farber/Brigham and Women's Cancer Center, Boston, MAType of Session: ScientificBackground The median survival for locally advanced, unresectable pancreatic cancer is quite low after chemotherapy and radiation (around 9 months). GITSG trials from the 1980s showed a benefit to adding
Radiation Therapy (RT) as a Chemosensitizer of Gemcitabine (G) in Patients with Metastatic/Unresectable Tumors of the Gastrointestinal (GI) Tract - a Phase I/II Study Exploring a New Treatment Paradigm Presenter: W. F. Regine, MDPresenter's Affiliation: University of Maryland, Baltimore, MDType of Session: ScientificBackground Gemcitabine is one of the most active chemotherapy drugs for the treatment of metastatic/unresectable pancreatic cancer. In the laboratory, it can be demonstrated that very low doses of radiation (< 1Gy) can
ASTRO Patient Summary: Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10 This study looked at patients with early stage (I and II) Hodgkin's disease. There is some controversy over the dose of radiation therapy and the number of cycles of standard chemotherapy (ABVD regimen) these patients should receive. Patients were assigned to some combination of radiation therapy at either 30 Gy (higher dose) or 20 Gy (lower dose)
ASTRO Patient Summary: Surveillance Should Be the Standard Approach in Patients with Stage I Seminoma Surveillance Should Be the Standard Approach in Patients with Stage I Seminoma Stage I testicular cancer (seminoma) is managed by first-line surgery (orchiectomy) and then, most commonly, observation without additional therapy. Many centers offer these patients radiation as added protection, with little data to back up this therapy. Radiation
ASTRO Patient Summary: An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13 An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13 Prostate cancer is often treated with radiation and hormone deprivation therapies (or "total androgen suppression"), but there is no consensus among experts in
ASTRO Patient Summary: Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) This study looked at prostate cancer patients who were found to have "adverse pathologic features" (invasion beyond the prostate or positive surgical margins) after surgical removal of the prostate. There are two
ASTRO Patient Summary: Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial This study examined patients with T3 or T4 rectal adenocarcinoma with no metastases. Patients were assigned to receive either preoperative radiation (RT) or preoperative radiation and 4 cycles of chemotherapy with 5-FU
ASTRO Patient Summary: Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer This presentation reviewed a recent study involving postmenopausal women with early stage, hormone receptor positive breast cancer (ER+ or PR+). Some have wondered if treating these patients with lumpectomy, radiation and
Objective Versus Subjective Assessment of Single Photon Emission Computed Tomography (SPECT) Cardiac Perfusion Scans to Assess for Radiation Therapy (RT) Induced Cardiac Injury Presenter: Robert G. Prosnitz, MDPresenter's Affiliation: Duke University Medical Center, Durham, NCType of Session: PlenaryBackground Radiation therapy has been used in the treatment of breast cancer for many years. Multiple clinical trials that compared surgery to surgery plus radiation have consistently demonstrated that the addition
Adaptive Planning and Delivery to Account for Anatomical Changes Induced by Radiation Therapy of Head and Neck Cancer Presenter: M.B. SharpePresenter's Affiliation: Princess Margaret Hospital, Toronto, ONType of Session: PlenaryBackground Radiation-induced changes manifested during treatment can theoretically increase the risk of local failure and alter predicted normal tissue toxicity. For this reason, a framework is necessary to assess and potentially intervene
The Influence of Intrafraction Movement on Margins for Prostate Radiotherapy Presenter: D. W. LitzenbergPresenter's Affiliation: University of MichiganType of Session: PlenaryBackground As set-up and interfraction errors are being reduced by in-room imaging guidance, the importance of intrafraction errors increases. Unfortunately, little data exists documenting the significance of intrafraction target movement. The
Long-Term Outcomes of RTOG 90-03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma Presenter: A. TrottiPresenter's Affiliation: Moffitt Cancer Center at Univ. South Florida, Tampa, FLType of Session: ScientificBackground In the late 1980's, a variety of radiation dose fractionation schedules were in use at different institutions. The standard of care at the time was to treat patients once daily with radiation. A
Dosimetric Correlation of Acute and Late Xerostomia with Patients Treated with IMRT and Chemotherapy Presenter: A.K. BhatnagarPresenter's Affiliation: Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PAType of Session: ScientificBackground One of the greatest determinants of quality of life following radiation for head and neck cancer is xerostomia. There are limited data for dose-volume relationships of the parotid
A Phase I Clinical Trial Assessing Temozolamide and Tamoxifen with Concomitant Radiotherapy for the Treatment of High-Grade Gliomas Presenter: T.W. FlanneryPresenter's Affiliation: Radiation Oncology, University of Maryland, Baltimore, MDType of Session: ScientificBackground One of the many recent advances in the management of high grade gliomas includes the slight survival advantage seen with the use of concurrent temozolamide and radiation for glioblastoma multiforme (GBM).
Dose-Dependent Effects of Radiation Therapy on Cerebral Blood Flow, Metabolism and Neurocognitive Dysfunction Presenter: C.A. HahnPresenter's Affiliation: Radiation Oncology, Duke University Medical Center, Durham, NCType of Session: ScientificBackground Radiation therapy can cause neurocognitive dysfunction in patients treated for brain tumors. Frequent reported side effects include subtle neurocognitive dysfunction, short term memory impairment,
Radiation is an Important Component of Therapy for Patients with Stage III Breast Cancer Who Achieve a Pathological Complete Response after Neoadjuvant Chemotherapy Presenter: SE McGuirePresenter's Affiliation: Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Neoadjuvant chemotherapy is the standard for locally advanced breast cancer and for large operable breast cancer. A pathological complete response rate of 15-20% after neoadjuvant
Concurrent Trastuzumab and Radiation Therapy (RT) in the Adjuvant Treatment of Breast Cancer Presenter: J. R. BellonPresenter's Affiliation: Dana-Farber Cancer InstituteType of Session: ScientificBackground Her-2-Neu is overexpressed in approximately 25% of breast cancer patients and confers a worse prognosis. Adjuvant trastuzumab improves outcome in node-positive breast cancer patients with Her-2-Neu positivity and high risk node-negative
The Association Between the Mean Heart Dose, Mean Lung Dose, Tumor Location and RT-associated Heart and Lung Toxicity Presenter: L.B. MarksPresenter's Affiliation: Radiation Oncology, Duke University Medical Center, Durham, NCType of Session: ScientificBackground One of the side effects of lung irradiation is radiation pneumonitis, which can be manifested as dyspnea. However, dyspnea can be one of the presenting symptoms of cardiac disease and might cause
Long-Term Results of a Prospective Trial of Mantle Irradiation (RT) Alone for Early-Stage Hodgkin's Disease (HD) Presenter: Andrea NgPresenter's Affiliation: Brigham and Women's Hospital, Boston, MAType of Session: ScientificBackground The historical approach to the management of early stage Hodgkin's disease was radiation alone. Recently, the standard of care has become a combination of chemotherapy and radiation therapy in an effort to decrease
Volume of Abnormal Tumor Tissue on FDG-PET -A Predictor of Progression-free Survival in Hodgkin's Lymphoma? Presenter: Martin HutchingsPresenter's Affiliation: Copenhagen University Hosptial, Copenhagen, DenmarkType of Session: ScientificBackground Pre-treatment tumor volume is a well characterized independent risk factor for developing tumor recurrence in Hodgkin's Lymphoma. PET scans offer quantitative data regarding the glucose utilization
Lobular Carcinoma in Situ (LCIS) in Association with Invasive Breast Cancer: Does LCIS Predict for Local Recurrence? Presenter: S. JollyPresenter's Affiliation: Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, Pathology, William Beaumont Hospital, Royal Oak, MIType of Session: ScientificBackground More than 5% of malignant breast cancers have a component of LCIS. The association of LCIS with invasive breast cancer for patients
ASTRO Patient Summary: A Phase I Clinical Trial Assessing Temozolamide and Tamoxifen with Concomitant Radiotherapy for the Treatment of High-Grade Gliomas A Phase I Clinical Trial Assessing Temozolamide and Tamoxifen with Concomitant Radiotherapy for the Treatment of High-Grade Gliomas There are limited therapies available for patients with high-grade gliomas. One particular problem is finding medications that are able to cross the blood-brain barrier in amounts significant enough to treat the
ASTRO Patient Summary: Long-Term Outcomes of RTOG 90-03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma Long-Term Outcomes of RTOG 90-03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma Traditionally, radiation has been administered once a day for 5 days a week. In the late 1980's, some centers had been performing variations of
ASTRO Patient Summary: Radiation is an Important Component of Therapy for Patients with Stage III Breast Cancer Who Achieve a Pathological Complete Response after Neoadjuvant Chemotherapy Radiation is an Important Component of Therapy for Patients with Stage III Breast Cancer Who Achieve a Pathological Complete Response after Neoadjuvant Chemotherapy Patients who present with locally advanced breast cancer (spread to local lymph nodes or local tissue) or large operable tumors are usually treated with chemotherapy prior to surgical
ASTRO Patient Summary: Long-Term Results of a Prospective Trial of Mantle Irradiation (RT) Alone for Early-Stage Hodgkin's Disease (HD) Long-Term Results of a Prospective Trial of Mantle Irradiation (RT) Alone for Early-Stage Hodgkin's Disease (HD) Historically, patients with early stage Hodgkin's Disease were treated with radiation therapy alone. More recently, chemotherapy has been added to the standard regimen for these patients. This study treated 87 patients with stage I to
ASTRO Patient Summary: Concurrent Trastuzumab and Radiation Therapy (RT) in the Adjuvant Treatment of Breast Cancer Concurrent Trastuzumab and Radiation Therapy (RT) in the Adjuvant Treatment of Breast Cancer Patients with Her2/neu positive breast cancer are considered to have higher risk disease, but have an additional therapy option in trastuzumab (Herceptin). Doctors would like to administer trastuzumab during the same time period as the radiation therapy,
ASTRO Patient Summary: Objective Versus Subjective Assessment of Single Photon Emission Computed Tomography (SPECT) Cardiac Perfusion Scans to Assess for Radiation Therapy (RT) Induced Cardiac Injury Objective Versus Subjective Assessment of Single Photon Emission Computed Tomography (SPECT) Cardiac Perfusion Scans to Assess for Radiation Therapy (RT) Induced Cardiac Injury It has long been known that women who receive radiation to the left breast have portions of heart tissue exposed to radiation, and can develop cardiac complications as a
ASTRO Patient Summary: The Influence of Intrafraction Movement on Margins for Prostate Radiotherapy The Influence of Intrafraction Movement on Margins for Prostate Radiotherapy When a patient is set up for radiation treatment, the physician applies pinpoint skin marks called "tattoos" to guide the x-ray beams each day and to assure that the correct area is being targeted. It is normal for there to be some movement of the radiation target within
Is Anemia a Cause of Radiation Treatment Failure in Patients with Squamous Carcinoma of the Cervix? Presenter: P.J. EifelPresenter's Affiliation: Department of Radiation Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, Gynecologic OncologyType of Session: ScientificBackground Previous studies have shown that anemia is an independent poor prognostic factor in cervical cancer. In addition, anemia may affect a patient's
A Phase I-II Study of COX-2 Inhibitor, Celebrex (Celecoxib) and Chemoradiation in Patients With Locally Advanced Cervical Cancer: Primary Endpoint Analysis of RTOG 0128 Presenter: Presenter: D.K.GaffneyPresenter's Affiliation: Radiation Oncology, University of Utah, Salt Lake City, UT, Statistics, RTOG, Philadelphia, PA, Radiation Oncology, Thomas Jefferson Univ., Philadelphia, PA, Obstetrics/Gynecology, Wake Forest Univ.,Type of Session: ScientificBackground Cyclooxygenase 2 (COX-2) is an enzyme induced by
Integrity of Parotid Gland Delineation for H&N IMRT: What are we sparing? Presenter: T.S. HongPresenter's Affiliation: Department of Human Oncology, University of Wisconsin Medical School, Madison, WI, Department of Medical Physics, University of Wisconsin Medical School, Madison, WI, Department of Radiology, UniversiType of Session: ScientificBackground Parotid–sparing head and neck (H&N) IMRT affords
Subcutaneous (SbQ) Versus Intravenous (IV) Administration of Amifostine for Head and Neck (HN) Cancer Patients Receiving Radiotherapy (RT): Preliminary Results of the GORTEC 2000-02 Randomized Trial Presenter: E. BardetPresenter's Affiliation: Crlcc, Nantes, FranceType of Session: ScientificBackground There are several advantages offered by SbQ amifostine over IV amifostine including easier administration and a favorable window between drug injection and radiation delivery. This trial tested the hypothesis that SbQ amifostine was associated
Initial Report of a Prospective Phase II Trial of Stereotactic Body Radiation Therapy for Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer Presenter: R. TimmermanPresenter's Affiliation: UT-Southwestern Medical CenterType of Session: ScientificBackground Patients with medically inoperable stage I non-small cell lung cancer are potentially amenable to stereotactic body radiation therapy (SBRT), as therapeutic options in this population are limited, and local tumor control alone may
Clinical Application of Positron Emission Tomography (PET) in Designing Radiation Fields in Non-Small Cell Lung Cancer (NSCLC) Patients Presenter: Charles G. Wood, MDPresenter's Affiliation: University of Pennsylvania, Dept. of Radiation Oncology, Philadelphia, PAType of Session: ScientificBackground PET scans offer quantitative data regarding the glucose utilization of both tumor and normal tissue. PET scans have become commonplace in the staging of non small cell lung
Exclusive High-Dose Rate Brachytherapy (HDR-BT) for Limited Non-small Cell Lung Carcinoma: Results of a French Study in 199 Patients Presenter: M.A. MahePresenter's Affiliation: Radiotherapy, Centre Oscar Lambret, Lille, FranceType of Session: ScientificBackground The standard of care for treatment of early stage lung cancer is surgery with or without chemotherapy. HDR-BT is an alternative option for patients with contraindications to surgery. This study was undertaken to
Preliminary Analysis of RTOG 9902: Increased Toxicity Observed with the Use of Adjuvant Chemotherapy Presenter: H.M. SandlerPresenter's Affiliation: University of Michigan, Ann Arbor, MIType of Session: ScientificBackground The current standard of care for patients with high risk prostate cancer includes local radiotherapy in conjunction with long-term androgen ablation (LTAA). However, recurrence and metastasis following treatment continues to
Hypofractionated Intensity Modulated Radiotherapy (70 Gy at 2.5Gy Per Fraction) for Localized Prostate Cancer: Long-Term Outcome Results Presenter: V.V. ThakkarPresenter's Affiliation: Department of Radiation Oncology, The Cleveland Clinic Foundation, Cleveland, OHType of Session: ScientificBackground The principle of α /β has always been instrumental in guiding radiation therapy fractionation and doses. With the prostate having an α /β of 1.5-3, while the
Impact of Computed Tomography and 18F-Deoxyglucose-Hybrid Positron Emission Tomography Image Fusion on Conformal Radiotherapy in Non-Small Cell Lung Cancer Presenter: E. Deniaud-Alexandre.Presenter's Affiliation: Tenon Hospital, Paris, FranceType of Session: ScientificBackground PET scans offer quantitative data regarding the glucose utilization of both tumor and normal tissue. PET scans have become commonplace in the staging of non small cell lung cancer (NSCLC) Recently, computer
Use of Postoperative Radiotherapy (PORT) for Resectable Non-Small Cell Lung Cancer (NSCLC). Presenter: J. E. Bekelman, MDPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, NY, NYType of Session: ScientificBackground In 1998, the PORT meta-analysis of nine clinical trials (2128 patients) concluded that when compared to surgery alone, the use of post-operative radiation therapy (PORT) for NSCLC patients with N0 and N1
ASTRO 2005 Breast Cancer Highlights OncoLink selected breast cancer topics from the Annual Meeting of the American Society for Therapeutic Radiology And Oncology October 16-20, 2005, held in Denver, Colorado. Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer Location and Control of Local Disease Predict
ASTRO 2005 Lung Cancer Highlights OncoLink selected lung cancer topics from the Annual Meeting of the American Society for Therapeutic Radiology And Oncology October 16-20, 2005, held in Denver, Colorado. The Association Between the Mean Heart Dose, Mean Lung Dose, Tumor Location and RT-associated Heart and Lung Toxicity Clinical Application of Positron Emission Tomography (PET)
Preoperative concurrent chemoradiotherapy (CT-RT) improves local control in T3-4 rectal cancers. Results of the FFCD 9203 randomized trial Presenter: J GerardPresenter's Affiliation: Centre Antoine Lacassagne, Nice, FranceType of Session: ScientificBackground There has been a dramatic shift over the past few years to using preoperative radiation therapy for rectal cancer as opposed to using it in the postoperative setting. Some of the initial studies that showed a benefit to
The Role of Chemotherapy and Biologic Therapy in the Treatment of Metastatic Colorectal Cancer Colorectal cancer (CRC) is the third most common cancer diagnosed in men and women in the US, with an estimated annual incidence of almost 150,000 new cases. In terms of cancer-related deaths in the US, it ranks second (after lung cancer), with about 60,000 deaths yearly. Worldwide, the incidence and mortality are 800,000 and 500,000 respectively.
PTK787: A Small Molecule Inhibitor of VEGF-Receptors Presenter: J. Randolph Hecht, MDPresenter's Affiliation: UCLA GI Oncology Program, Los Angeles, CaliforniaType of Session: ScientificBackground Growing tumors need access to nutrients and a blood supply, and the process of new blood vessel formation is called angiogenesis. Considerable research has demonstrated the importance of
Gemcitabine and Erlotinib in Pancreatic Cancer Presenter: Malcolm Moore, MDPresenter's Affiliation: Princess Margaret HospitalType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer-related deaths. In 2005, there will be an estimated 35,400 new cases and 35,000 deaths in the United States and Canada. The 5-year survival is dismal, hovering
Bevacizumab (Avastin) Plus Oxaliplatin-Based Combination Chemotherapy:Update on Recent Trials Presenter: Howard S. Hochster, MD.Presenter's Affiliation: New York University Cancer Institute, New York, New YorkType of Session: ScientificBackground 5-Fluorouracil (5FU) is a very old chemotherapy drug for colorectal cancer, and recent research has demonstrated that the use of 5FU in combination with other drugs like oxaliplatin and
Approaches to Imatinib-resistant GIST Gastrointestinal stromal tumors (GIST) are the most common sarcomas, with about 3000 - 3,500 cases reported each year. The standard of care for locaized GIST is surgical resection. Unfortunately, the recurrence rate can be as high as 60-80% in some series of high-risk GIST patients (pts). The standard of care in metastatic GIST is
Adjuvant Therapy for Rectal Cancer Presenter: Bruce D. Minsky, MDPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, New York, New YorkType of Session: ScientificBackground Based on data published in the Journal of Clinical Oncology, it has become apparent that 5-year follow-up data are not sufficient for rectal cancer clinical trials. The standard
Ixabepilone in Breast Cancer Presenter: Sandra M. Swain, MDPresenter's Affiliation: National Cancer InstituteType of Session: ScientificBackground Microtubules are formed from a protein called tubulin. Microtubules form the skeleton of cells, and have to be broken down for a cell to divide. Certain chemotherapy drugs are actually microtubule-stabilizing
Experience with ABI-007 (Abraxane) in Head and Neck Cancers ABI-007 (brand name Abraxane™) is a protein-bound form of the popular chemotherapy drug paclitaxel (brand name Taxol®)). Standard paclitaxel is formulated with ethanol and a substance called Cremophor EL (polyoxyethylated castor oil) in order to improve drug delivery. However, these additives are felt
Panitumumab, A Fully-Human IgG2 Antibody Treatment for Colorectal Cancer Overexpression of epidermal growth factor receptor (EGFR) is seen in many human malignancies, including colorectal cancer. The cellular pathways that are triggered by EGFR activation are involved in cell growth and proliferation. Thus, inhibiting EGFR by blocking the binding of ligand to the receptor can inhibit these
Role of Ras Inhibitors in the Management of Breast Cancer Presenter: Joseph A. Sparano, MDPresenter's Affiliation: Albert Einstein Cancer Center, Bronx, New YorkType of Session: ScientificBackground G proteins are a superfamily of >100 proteins which are widely distributed in mammalian cells. They regulate a variety of cellular functions, and are classified into 5 families. The names
Preoperative Therapy with Trastuzumab Presenter: Eric P. Winer, MDPresenter's Affiliation: Dana Farber Cancer Institute, Boston, MAType of Session: ScientificBackground The NSABP B-18 trial randomized women with locally advanced breast cancers to receive either preoperative adriamycin and cyclophosphamide (AC), or the same regimen given post-operatively. That trial
Pemetrexed in Extensive Stage Small Cell Lung Cancer Small cell lung cancer (SCLC) represents about 20% of all lung cancers diagnosed in the US, with about 25,000 to 30,000 new cases each year. Of these cases, about two-thirds are considered "extensive stage" (ES), and combination chemotherapy is considered the standard of care. Specifically, the standard chemotherapy regimen is cisplatin
Oral Topotecan Plus Supportive Care Offers Survival Benefit Compared To Supportive Care Alone Presenter: Mary O'Brien, MDPresenter's Affiliation: Royal Marsden Hospital, UKType of Session: ScientificBackground Controlled, randomized trials are considered the gold standard of evidence-based medicine. For patients (pts) with small cell lung cancer (SCLC) that has relapsed after initial chemotherapy, second-line
The Role of AGT in Guiding Therapy of Malignant Glioma AGT is a human protein that modifies DNA in both normal and tumor cells in order to protect it from damage by certain chemotherapy drugs. In both petri dishes and animal studies, AGT has been observed to prevent the death of cancer cells that are in the presence of cancer cell-killing chemotherapy.
Docetaxel Combination Therapy in Prostate Cancer Presenter: Daniel Petrylak, MDPresenter's Affiliation: Columbia University, New York, New YorkType of Session: ScientificBackground SWOG 9916 compared doctaxel/estramustine to mitoxantrone/prednisone for patients with metastatic, hormone-refractory prostate cancer, and found an improvement in overall survival in the docetaxel arm
Bevacizumab/Erlotinib Combinations in the Treatment of Metastatic Renal Cell Carcinoma (RCC) Presenter: John D. Hainsworth, M.D.Presenter's Affiliation: Sarah Cannon Research Institute, Nashville, TNType of Session: ScientificBackground Most clear cell renal cancers have mutations or inactivations of the von Hippel Landau (VHL gene). As a result, multiple tumor growth-signaling agents are overexpressed, including VEGF, EGF,
Motexafin Gadolinium (MGd): Targeting Oxidative Stress Pathways for the Treatment of Non-Hodgkin's Lymphoma Presenter: Andrew M. Evans, DO, MSCIPresenter's Affiliation: Northwestern University, Chicago, IllinoisType of Session: ScientificBackground Motexafin Gadolinium (MGd or Xcytrin) is a novel anti-cancer agent which disrupts redox- dependent pathways by targeting oxidative stress-related proteins. This agent has been shown to work
Pancreatic Cancer: Progress on the Horizon Presented by: Shannon Holloway, MHS , PA -C, New York Presbyterian Weill Cornell Medical Center Pancreatic cancer accounts for 30,500 new cases annually, with a dismal 5-year survival rate of 15% when respectable, down to 1.8% when distant metastases are present. Approximately 80-95% of cases are unresectable at diagnosis, leading to the poor
Trastuzumab Adjuvant Therapy in Breast Cancer: Bringing the Promise of Clinical Results to Patients Presented by: Tamsin Mulrooney, PhD(c), MS, ARNP, OCN, Norris Cotton Cancer Center at Dartmouth Hitchcock Medical Center Tammy presented the data, recently discussed at ASCO 2005 and published in the New England Journal of Medicine, that many clinicians called stunning and predicted will transform the way many women with breast cancer are
Relative Dose Intensity: Improving Cancer Treatment and Outcomes Presented by: Cheryl Lenhart, RN, BSN, HRM, Western Pennsylvania Cancer Institute, West Penn Allegheny Health System Relative dose intensity is a term that refers to the amount of a particular chemotherapy given over a specific time (i.e. paclitaxel 175mg/m2 every three weeks) in relation to what was ordered (or is considered standard). The
Hormonal Therapies in Breast Cancer Maureen Major , MS , RN from Memorial Sloan-Kettering Cancer Center started the morning by updating the group on the latest studies in hormonal therapies for the treatment of early stage breast cancer. There are approximately 215,900 cases of breast cancer annually, with 40,110 deaths. Although lung cancer now accounts for more deaths in women,
Moleculoar Targets In Cancer Therapy, Fourth Biennial Meeting Conference Dates: January 25-28, 2007 Conference Location: Sheraton Sand Key Resort, Clearwater Beach, Florida Sponsoring Group: University of South Florida College and the H. Lee Moffitt Cancer Center & Research Institute Conference Web Page URL: http//www.moffitt.usf.edu/continuinged/mt2007 Topics Covered: Mechanism and Therapeutic
New Directions in the Treatment of Breast Cancer: Updates from the 29th Annual San Antonio Breast Cancer Symposium (SABCS) Conference Dates: February 1, 2007 Conference Location: Seattle, WA Conference Dates: February 5, 2007 Conference Location: Pittsburgh, PA Conference Dates: February 6, 2007 Conference Location: Cleveland, OH Conference Dates: February 7, 2007 Conference Location: Southfield, MI Conference Dates: February 8, 2007 Conference
Breast Highlights: Highlights from the 30th Annual San Antonio Breast Cancer Conference Dates: February 9, 2008 Conference Location: New York, New York Conference Dates: February 16, 2008 Conference Location: Chicago, IL Sponsoring Group: The American School of Oncology Conference Web Page URL: http://www.asoncology.com/Appweb/AsOncologyRegistration/frmPmMeetingWebList.asp Topics Covered: Breast Highlights:
Fourth Annual Winter Lung Cancer Conference Conference Dates: March 16-18, 2007 Conference Location: The Eden Roc Renaissance Resort & Spa, Miami Beach, Florida Sponsoring Group: CBCE (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com Topics Covered: Please log onto www.thecbce.com to download conference brochure. Conference Objectives: For
8th Annual Wallace H. Clark, Jr., MD Lectureship in Cutaneous Oncology & Melanoma Symposium Conference Dates: Thursday, March 29, 2007 Conference Location: University of Pennsylvania Biomedical Research Building II/III, Ground Floor Auditorium, Curie Blvd., and Osler Way, Phila., PA Sponsoring Group: Penn's Department of Dermatology and the Abramson Cancer Center of the University of Pennsylvania Conference Objectives: After
Focus on Gastrointestinal Cancers Conference Conference Dates: Friday, March 14, 2007 Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: Covers the range of gastrointestinal cancers including: colon, rectum, pancreas, liver and bile duct, as well as esophageal and stomach.
Skill Building in Psychosocial Oncology and Palliative Care Conference Dates: March 29-30, 2007 Conference Location: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida Sponsoring Group: H. Lee Moffitt Cancer Center & Research Institute & USF Conference Web Page URL: www.moffitt.org/continuinged - Click on Calendar of Events - Click on to the Month of March Topics Covered: The purpose
2nd Annual Moffitt Interdisplinary GI Oncology Conference Conference Dates: March 10-11, 2007 Conference Location: Sheraton Sand Key Resort, Clearwater Beach, Florida Sponsoring Group: H. Lee Moffitt Cancer Center & Research Institute & USF Health Conference Web Page URL: www.moffitt.org/continuinged/gionc Topics Covered: This course will review new advances in the treatment, early detection and
Navigating the Health Care System for Prostate Cancer Care Conference Dates: March 31, 2007 Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA 19131 Sponsoring Group: University of Pennsylvania Center for Population Health and Health Disparities Topics Covered: A panel of guests including a Urologist, Radiation Oncologist, Internist and Social Worker will answer questions about
Trends and Challenges in Community Oncology: A Focus on Lung Cancer Conference Dates: Thursday, November 13, 2007 Conference Location: Lynnwood Convention Center Sponsoring Group: Oncology Today and Puget Sound Cancer Centers Topics Covered: Hosted by community oncology practices, the CME/CE accredited series of multidisciplinary case-based meetings, Trends and Challenges in Community Oncology: A Focus on Lung
Fourth Biennial Prostate Cancer Conference: Focus on Current Aspects in Diagnosis and Treatment Conference Dates: Friday, November 2, 2007 Conference Location: Rittenhouse Hotel, 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: Univeristy of Pennsylvania School of Medicine/Office of Continuing Medical Education Topics Covered: Robotic surgery, genetics, prevention, PET scanning, radiation therapy, proton therapy,
2007 International Melanoma Congress Conference Dates: November 1-4, 2007 Conference Location: New York Marriott Financial Center, New York, NY Conference Web Page URL: http://www.melanomacongress07.net/main/index.php Topics Covered: Why melanocytes develop into melanoma Why are melanomas so metastatic Why melanomas don't die Wiring of melanoma –
Specialists' Symposium on Advanced Management of Lung Cancer Conference Dates: November 16-17, 2007 Conference Location: Portland, Oregon Sponsoring Group: Providence Cancer Center Conference Web Page URL: Sixth Annual Providence Thoracic Oncology Symposium Website Topics Covered: Endobronchial Ultrasound Preoperative Evaluation for Lung Cancer Stereotactic Radio Surgery for Lung Cancer
Hematological Malignancies Conference Dates: November 14-15, 2007 Conference Location: Newark, New Jersey Sponsoring Group: Healthcare Education Services Conference Web Page URL: http://www.healthtech.com/Healthcare_education/hema_malignancies/Index.asp Topics Covered: This course reviews the hematological system and provides an overview on the spectrum of
12th Annual Perspectives in Thoracic Oncology Conference Dates: November 16-17, 2007 Conference Location: New York, New York USA Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Conference Objectives: Review and synthesize the latest information on the complex biology and treatment of lung cancer Who Should Attend: oncologists, internists, other physicians,
4th International Congress on Cancer Therapeutics and The 7th Princess Margaret Hospital Conference: New Developments in Cancer Management Conference Dates: November 15-17, 2007 Conference Location: Metro Toronto Convention Center Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Conference Objectives: Updating attendees on standard cancer therapies and new experimental programs Who Should Attend: physicians, physicians-in-training, and healthcare
4th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes Conference Dates: November 8-10, 2007 Conference Location: New York, New York USA Sponsoring Group: Imedex Conference Web Page URL: Imedex.com Conference Objectives: MDS and MPD Who Should Attend: hematologists, oncologists, internists, other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists)
Great Debates in GI Malignancies Conference Dates: November 16-17, 2007 Conference Location: Santa Monica, California, USA Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Who Should Attend: Oncologists, other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) Registration Information: Please register at
1st International Betty Ford Breast Cancer Treatment and Survivorship Symposium Conference Dates: April 05, 2007 - April 07, 2007 Conference Location: Vail, Colorado Sponsoring Group: Postgraduate Institute for Medicine, Medical Education Strategies & Communications, Shaw Regional Cancer Center Conference Web Page URL: www.mesc-edu.com/BreastCancer Topics Covered: Some topics include information on drug treatment
Seventh Annual New Strategies in Breast Cancer Conference Conference Dates: April 13-14, 2007 Conference Location: The Rittenhouse Hotel, Philadelphia, PA Sponsoring Group: The Center for Biomedical Continuing Education Conference Web Page URL: www.thecbce.com Conference Objectives: Please see website for further details Who Should Attend: This activity is intended for medical oncologists,
Focus on Head and Neck Cancers Conference Dates: April 13, 2007 Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Web Page URL: www.penncancer.com/events.cfm Topics Covered: An Educational Conference for Those Affected by Head and Neck Cancer Conference Agenda: See
Kidney & Prostate Cancer Symposium Conference Dates: April 28, 2007 Conference Location: The Methodist Hospital, Houston, Texas Sponsoring Group: The Methodist Hospital (TMH) Topics Covered: Renowned physician-scientists from TMH, UT and Baylor College of Medicine will cover a wealth of info on Kidney and Prostate Cancers and their treatment options. Conference Objectives:
1st Annual International Medical Assembly at the United Nations: Meeting the Global Challenge of Cancer Conference Dates: April 3-5, 2007 Conference Location: United Nations Headquarters, New York, New York Sponsoring Group: United Nations Conference Web Page URL: www.medicalassemblyun.org Topics Covered: In this conference, we will: Explore ways and means for abating the spread of cancer worldwide Examine the challenges that
Multiple Myeloma Patient Care: Treatment Options and Nursing Considerations Conference Dates: April 26, 2007 Conference Location: Mandalay Bay North Convention Center - Las Vegas, NV Sponsoring Group: MMRF, PIM and Curatio CME Institute Conference Web Page URL: http://events.axis-healthcare.com/profile/web/index.cfm?PKwebID=0x543579a9 Topics Covered: This symposium seeks to provide oncology nurses with a
Oncology Congress Conference Dates: September 7-9, 2007 Conference Location: Hilton San Francisco Sponsoring Group: Reed Medical Education Conference Web Page URL: www.oncologycongress.com Topics Covered: Updates on prevention, diagnosis and treatment of bladder cancer, breast cancer, cervical cancer, colon cancer, head and neck cancers, leukemia, lung cancer,
Chicago Supportive Oncology Conference Conference Dates: September 27-29, 2007 Conference Location: Hyatt Regency Chicago, Chicago, IL Sponsoring Group: Reed Medical Education Conference Web Page URL: www.chicagosupportiveoncology.com Topics Covered: Survivorship, Emesis, Cancer-Related Pain, Neuro-Oncology, Geriatrics, Communication Skills, Managing Toxicities of Targeted
Mind-Body Medicine Professional Training Program Conference Dates: September 28 - October 3, 2007 Conference Location: New Orleans, LA Sponsoring Group: The Center for Mind-Body Medicine Conference Web Page URL: www.cmbm.org/mbm Conference Objectives: To present a strong theoretical and experiential grounding in mind-body medicine concepts and practices, a review of the most important
Translational Medicine in Oncology: Bridging the Gap Between Basic Science and the Clinic Conference Dates: September 27-28, 2007 Conference Location: Hilton Garden Inn at Albany Medical Center, Albany, New York Sponsoring Group: Albany Medical College, New York Oncology Hematology, PA, and Oncology Today Conference Web Page URL: http://www.nyohpc.com Topics Covered: Oncologists are expected to assimilate a vast amount of rapidly
2007 Update on Breast Cancer: Presented by the Abramson Cancer Center of the University of Pennsylvania: Coverage of the American Society of Clinical Oncology Annual Meeting Conference Dates: Thursday, June 21, 2007 5:30 PM - 9:00 PM Conference Location: University of Pennsylvania Museum of Archaeology and Anthropology (Lower Egyptian Gallery) Sponsoring Group: University of Pennsylvania School of Medicine Conference Brochure: View the conference brochure Conference Objectives: Identify chemotherapy
Second Annual Biological Basis of Breast Cancer Conference Conference Dates: June 30 - July 1, 2007 Conference Location: The Fairmont Miramar Hotel, Santa Monica, CA Sponsoring Group: The Center for Biomedical Continuing Education (CBCE) Conference Web Page URL: www.thecbce.com Who Should Attend: This activity is intended for medical oncologists, advanced practitioners, pharmacists, physician
Skeletal Complications of Malignancy V Conference Dates: October 25-27, 2007 Conference Location: Sheraton at Society Hill, Philadelphia, PA Sponsoring Group: Paget Foundation and University of Michigan School of Medicine Conference Web Page URL: www.paget.org Topics Covered: Cancer Stem Cells and Bone, Cancer Cell Dormancy and Bone Metastasis, Novel Targets for Bone
1st Annual Total Cancer Care Summit: The Future of Personalized Medicine Conference Dates: October 24, 2007 Conference Location: October 28, 2007 Sponsoring Group: H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida College of Medicine Conference Web Page URL: www.moffitt.org/continuinged/tcc Topics Covered: Session topics include: Introduction to Personalized Medicine, Linking
16th Annual Life After Breast Cancer Conference Conference Dates: Friday, October 12, 2007 Conference Location: Hilton Hotel, 4200 City Line Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Website: 16th Annual Life After Breast Cancer Conference Topics Covered: Save the Date flier Who Should Attend: The Sixteenth
Lung Cancer 2007: A Multidisciplinary Approach Conference Dates: October 20, 2007 Conference Location: Houston, Texas Sponsoring Group: Texas Oncology Sugar Land and Oncology Today Conference Web Page URL: http://www.lungcancer2007.com Topics Covered: The CME/CE accredited program, Lung Cancer Care in 2007: A Multidisciplinary Approach, offers a unique opportunity for community-based
Lung Cancer in 2007: A Multidisciplinary Approach Conference Dates: October 6, 2007 Conference Location: Minneapolis, Minnesota Sponsoring Group: Minnesota Oncology Hematology, PA Conference Web Page URL: http://www.lungcancer2007.com Topics Covered: The CME/CE accredited program, Lung Cancer Care in 2007: A Multidisciplinary Approach, offers a unique opportunity for community-based
Lymphoma & Myeloma Conference Dates: October 18-20, 2007 Conference Location: New York, New York USA Sponsoring Group: Imedex Conference Web Page URL: Imedex.com Topics Covered: Lymphoma Classification, Aggressive Lumphoma, Follicular Lymphomas Conference Objectives: Lymphoma and Myeloma Who Should Attend: hematologists, oncologists, internists, other
Great Debates in Breast Cancer Conference Dates: October 26-27 Conference Location: New York, New York USA Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Who Should Attend: oncologists, other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) Registration Information: Please register at www.imedex.com or call
Melanoma 101 Teleconference Conference Dates: Thursday October 18, 2007, 12-1PM Conference Location: Free Teleconference Sponsoring Group: Melanoma Research Foundation Conference Web Page URL: http://www.melanoma.org/Contents.aspx?TeleConfId=218&ContentId=218&Categoryid=99 Topics Covered: Topics to be covered include: Melanoma risk factors What is the optimal
Current Role of Hormonal Therapies for Breast Cancer Conference Dates: Wed. October 17, 2007, 7-8pm(CT) Conference Location: Teleconference Sponsoring Group: Y-ME National Breast Cancer Organization Conference Web Page URL: www.y-me.org/sharering Conference Objectives: Discuss role of hormonal therapies, risks and benefits, and new developments Who Should Attend: People wth breast cancer
Clinical Controversies in Multiple Myeloma Conference Dates: May 17, 2007 Conference Location: Four Seasons Hotel Chicago Sponsoring Group: MMRF and Northwestern Univ. Feinberg School of Medicine Conference Web Page URL: www.multiplemyeloma.org/symposia Topics Covered: Identify the prognostic indicators and diagnostic approaches to multiple myeloma. Discuss the latest
Days of Molecular Medicine 2007 Conference Dates: May 22-24 Conference Location: Cambridge Massachusetts Sponsoring Group: Massachusetts General Hospital and The Karolinska Institute Conference Web Page URL: www.massgeneral.org/cvrc/meetings_molecular_reg.html Topics Covered: "Emerging Technologies of Cancer Biology" as well as "Cancer and Cardiovascular
Fourth Annual Focus on Melanoma Conference Dates: May 11, 2007 Conference Location: Hilton Hotel, City Line Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Who Should Attend: Patients and families whose lives have been affected by melanoma. Conference Agenda: Join us for this informative patient and family conference
Fifth Annual Therapeutic Advances in GI Malignancies Conference Conference Dates: July 13-14, 2007 Conference Location: The Island Hotel, Newport Beach, CA Sponsoring Group: The Center for Biomedical Continuing Education (CBCE) Conference Web Page URL: www.thecbce.com Who Should Attend: This activity is designed for community oncologists, radiation oncologists, oncology nurses, research
Conference for Women Living With Advanced Breast Cancer: Enhancing Your Health and Quality of Life Conference Dates: Saturday, July 14, 2007 Conference Location: Philadelphia Marriott West, West Conshohocken, Pennsylvania Sponsoring Group: Living Beyond Breast Cancer Conference Web Page URL: www.lbbc.org/news-detail.asp?news_id=1387 Topics Covered: Medical Treatments and Research Developments; Understanding Symptom and Side-Effect
34th Annual Williamburg Conference on Heart Disease Conference Dates: December 2-4, 2007 Conference Location: Williamsburg, Virginia, USA Sponsoring Group: Imdex Conference Web Page URL: www.imedex.com Conference Objectives: The primary focus is on coronary artery disease, its treatment and its prevention Who Should Attend: cardiologists, internists, generalists, and cardiovascular
Sixth Annual Advances in the Inflammatory Bowel Diseases Conference Dates: December 6-9, 2007 Conference Location: Aventura, Florida, USA Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Conference Objectives: The scientific agenda follows a two-track format where clinicians and researchers participate in separate sessions, coming together for presentations on advances in the
Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10 Presenter: C. Pepe Presenter's Affiliation: Princess Margaret Hospital, Toronto, Canada Type of Session: Scientific Background There is a high incidence of lung cancer in the elderly. The elderly are under-represented in clinical trials. There is a significant survival benefit with adjuvant chemotherapy after resection of early
A Phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. Presenter: Roy S. HerbstPresenter's Affiliation: M. D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Death receptors, such as TNF-alpha receptor, Fas, and TRAIL-R (TNF-alpha Related Apoptosis Inducing Ligand Receptor)-1 and –2, can stimulate the extrinsic apoptotic pathway in tumor cells when activated by
Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. Presenter: J.P. PignonPresenter's Affiliation: Institut Gustave-Roussy, Villejuif, FranceType of Session: ScientificBackground Lung cancer is the number one cause of cancer death in America. A meta-analysis published in 1995 demonstrated a small but significant survival benefit with adjuvant cisplatin based chemotherapy in
HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors Presenter: A. PatanaikPresenter's Affiliation: Cancer Therapy and Research Center, San Antonio, TXType of Session: ScientificBackground Death receptors, such as TNF-alpha receptor, Fas, and TRAIL-R (TNF-alpha Related Apoptosis Inducing Ligand Receptor)-1 and –2, can stimulate the extrinsic apoptotic pathway in tumor cells when activated
Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Presenter: G.M. Strauss Presenter's Affiliation: CALGB Type of Session: Scientific Background Lung cancer is the number one cause of cancer death in America. A meta-analysis published in 1995 demonstrated a marginally significant survival benefit with adjuvant cisplatin based chemotherapy in patients who received surgery for their
Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial. Presenter: Minesh P. MehtaPresenter's Affiliation: University of Wisconsin, Madison, WIType of Session: ScientificBackground Motexafin gadolinium (MGd) is a radiosensitizer that is MRI-detectable and selectively localizes in tumors. It can induce redox stress and is an inhibitor of thioredoxin reductase, an enzyme whose overexpression is
Outcome of clear cell sarcoma of the kidney (CCSK) treated on the National Wilms Tumor Study-5 (NWTS) Presenter: Breslow EJ et al.Presenter's Affiliation: Children's National Medical Center, Washington D.C.Type of Session: ScientificBackground CCSK originally described in early 1970s and characterized by tendency to metastasize to bone as well as propensity for late relapses Improvements in overall survival (OS) have been demonstrated
Site of metastases does not influence the clinical outcome of children with metastatic Germ Cell Tumors (GCT). A report from the Children's Oncology Group (COG) Presenter: Malogolowkin MH et al.Presenter's Affiliation: Children's Oncology Group, Arcadia, CAType of Session: ScientificBackground A previous protocol had randomized patients with either extragonadal GCT or high-risk gonadal GCT to high-dose versus standard-dose cisplatin/etoposide/bleomycin combination chemotherapy (PEB) This study
Dactinomycin (A) and vincristine (V) with or without cyclophosphamide (C) and radiation therapy (RT) for newly diagnosed patients with low-risk embryonal/botryoid rhabdomyosarcoma (RMS). An IRS-V report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (STS COG) Presenter: Walterhouse JL et al.Presenter's Affiliation: Children's Hospital of Los Angeles, Los Angeles, CAType of Session: ScientificBackground The IRS-III and –IV studies defined 3 risk groups of rhabdomyosarcoma patients: low-risk (35%), intermediate-risk (50%), and high-risk (15%) Low-risk patients have favorable histology,
The impact of FLIPI on outcome of frontline treatment with single-agent I-131 tositumomab for follicular lymphoma (FL) Presenter: M.S. Kaminski Presenter's Affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MI Type of Session: Scientific Background Follicular lymphoma is an indolent Non-Hodgkin's lymphoma that usually presents in an advanced stage. Follicular lymphomas usually express CD20, a B-cell marker. An antibody to
The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation. Presenter: A.J.Al-Tourah Presenter's Affiliation: BC Cancer Agency Fraser Valley Centre, Surrey, BC, Canada Type of Session: Keynote Background Follicular lymphoma is an indolent Non-Hodgkin's lymphoma that usually presents in an advanced stage. Follicular lymphomas usually express CD20, a B-cell marker. Transformation is defined as
Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy Presenter: A.J. Stephenson Presenter's Affiliation: Cleveland Clinic, Cleveland, OH Type of Session: Keynote Background Following radical prostatectomy, 25% of patients experience a rising PSA. Risk factors for metastatic disease include a rapid PSA doubling time, high grade Gleason, and a short disease-free interval. High risk
Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study. Presenter: P. PaschkaPresenter's Affiliation: Ohio State University, Columbus, OHType of Session: PlenaryBackground Core binding factor acute myeloid leukemia (CBF AML) is a specific subtype of leukemia. CBF AML has 2 of the most prevalent cytogenetic subtypes of primary AML, t(8;21) and inv(16) These genomic aberrations disrupt
Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP or autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma (MM) Presenter: Facon TPresenter's Affiliation: CHU, Lille, FranceType of Session: PlenaryBackground MP is the standard treatment for newly diagnosed elderly patients with MM, conferring a median overall survival (OS) of 3 years THAL has demonstrated activity in relapsed MM, and is currently being used with MP as well as stem cell
Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01 Presenter: Calais GPresenter's Affiliation: Centre Henry S. Kaplan, Tours, FranceType of Session: ScientificBackground Induction chemotherapy followed by radiation treatment (RT) provides a potential for functional laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancer PF is the standard induction
Postoperative concurrent radiochemotherapy (RCT) versus radiotherapy (RT) in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96-3 Presenter: Fietkau RPresenter's Affiliation: University of Rostock, Rostock, GermanyType of Session: ScientificBackground Characteristics of high-risk SCCA of the head and neck on surgical pathology include, but are not limited to, involvement of 3 or more lymph nodes (LN), extracapsular extension of disease (ECE), and microscopically
Induction cisplatin (P) and fluorouracil (F) with or without docetaxel (T) followed by chemoradiation (CTRT) and surgical resection as indicated for locally advanced squamous cell carcinoma (LASCC) of the head & neck: preliminary results from the TAX 324 study Presenter: Posner MRPresenter's Affiliation: Dana-Farber Cancer Institute, Boston, MAType of Session: ScientificBackground PF induction chemotherapy has thus far proven to be the sole induction chemotherapeutic regimen to be effective in locally advanced squamous cell carcinoma and has been shown to confer an absolute 5% overall survival (OS)
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Presenter: Robert J. MotzerPresenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NYType of Session: PlenaryBackground Clear cell renal cell carcinoma (RCC) is characterized by mutation or silencing of the VHL gene, which in turn leads to increased activity of hypoxia inducible factor (HIF). This in turn leads to
A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) Presenter: Gary HudesPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PAType of Session: PlenaryBackground Several recent advances in the treatment of advanced RCC using targeted therapy have been made Sorafenib, a multikinase inhibitor that targets Raf kinase and angiogenesis receptor tyrosine kinases, doubled
Phase III trial of intermittent MAB vs continuous MAB Presenter: F.M. Calais Da SilvaPresenter's Affiliation: Hospital Desterro, Lisbon, PortugalType of Session: ScientificBackground Androgen deprivation relieves symptoms and causes a reduction of PSA level in men with locally advanced and metastatic prostate cancer. Men with metastatic prostate cancer have a median progression free
Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma Presenter: U. GatzemeierPresenter's Affiliation: Hospital Grosshansdorf, Grosshansdorf/Hamburg, GermanyType of Session: ScientificBackground The Raf/MEK/ERK pathway is an attractive target in NSCLC 20% Ras mutations which are upstream of Raf EGFR is upstream of Raf, and inhibitors have shown activity in
RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma Presenter: William F. ReginePresenter's Affiliation: University of Maryland, Baltimore, MDType of Session: ScientificBackground Adenocarcinoma of the pancreas, even when resectable, has a poor prognosis. Failures occur both locoregionally and systemically. Adjuvant treatment of resected pancreas adenocarcinoma is
Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal Presenter: J.A. AjaniPresenter's Affiliation: M.D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground The current standard treatment of squamous cell carcinoma of the anus is concurrent chemoradiation (CRT) with 5-FU and mitomycin-C The 5-yr disease free survival (DFS) is ~65% Mitomycin-C has an undesirable
Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831 Presenter: M.Y. Halyard Presenter's Affiliation: Mayo Clinic, Rochester, MN Type of Session: Scientific Background Breast cancer affects more than 200,000 American women every year and is responsible for 40,000 deaths. Some of the effective therapies for breast cancer can potentially cause heart failure including anthracyclines,
Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5FU/cisplatin (FP) as first line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. Presenter: Y. KangPresenter's Affiliation: Asan Medical Center, Seoul, KoreaType of Session: ScientificBackground Capecitabine is an oral fluropyrimidine with proven efficacy and favorable safety in metastatic colorectal cancer. Because it is given orally, patients who receive capecitabine are spared a central line and hospitalization
The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study Presenter: D. L. WickerhamPresenter's Affiliation: National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PAType of Session: PlenaryBackground The NSABP-P1 study demonstrated that tamoxifen given to high-risk pre- and post-menopausal women decreased the risk of both invasive and non-invasive breast cancers There
Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781 Presenter: Tepper JEPresenter's Affiliation: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NCType of Session: ScientificBackground There is disagreement regarding the proper treatment of resectable esophageal carcinoma The purpose of this study was to compare surgical resection alone versus neoadjuvant chemoradiation followed
The Women's Health Initiative randomized trial of calcium plus vitamin D: Effects on breast cancer and arthralgias. Presenter: R. T. ChlebowskiPresenter's Affiliation: Los Angeles Biomedical Research Institute, Torrance, CAType of Session: PlenaryBackground In 12 of 16 retrospective observational studies, calcium (Ca) and vitamin D (D) have been associated with reduced breast cancer risk, decreased breast density, and decreased arthralgias Question:
Patient Summary: Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10 There have been several studies showing the benefit of chemotherapy in surgically resected non small cell lung cancer (NSCLC). Unfortunately, most studies have limited numbers of elderly patients enrolled in
Patient Summary: Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633 Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. The CALGB 9633 trial randomized patients with stage IB non small cell lung cancer NSCLC to either carboplatin/paclitaxel or no further therapy. This study had been stopped early because the investigators saw a
Patient Summary: Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients This study pooled the results (also called meta-analysis) of multiple studies of non small cell lung cancer treated with chemotherapy after surgical resection. In particular, this group looked at studies using cisplatin alone or
Patient Summary: Outcome of clear cell sarcoma of the kidney (CCSK) treated on the National Wilms Tumor Study-5 (NWTS) Outcome of clear cell sarcoma of the kidney (CCSK) treated on the National Wilms Tumor Study-5 (NWTS) Clear cell sarcoma of the kidney was first described in the 1970's and has a tendency to metastasize to the bone and can relapse long after treatment. The Wilm's Tumor Study has been looking at various combinations of chemotherapy to treat this
Patient Summary: The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study The STAR trial included post-menopausal women with a high risk of developing breast cancer (Gail model risk 1.66%). Women were randomized to receive tamoxifen 20mg daily for 5 years or raloxifene 60mg daily for 5 years. Tamoxifen and
Patient Summary: The Women's Health Initiative randomized trial of calcium plus vitamin D: Effects on breast cancer and arthralgias The Women's Health Initiative randomized trial of calcium plus vitamin D: Effects on breast cancer and arthralgias. This study looked at the question: would calcium and vitamin D supplements decrease risk of breast cancer ? 32,282 women were randomized to receive either 1000 mg calcium carbonate and 400 IU vitamin D or placebo. The women were
Patient Summary: Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781 Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781 There is some controversy over the best treatment for surgically resectable esophageal cancer , so this study looked to compare surgery alone to chemotherapy followed by surgery (neoadjuvant chemotherapy). Eligible patients had stage I-III disease,
Patient Summary: Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831 Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831 NCCTG N9831 is a 3-arm randomized Phase III trial involving stage I-IIA breast cancer patients comparing the safety and efficacy of doxorubicin / cyclophosphamide (AC) followed by weekly paclitaxel
Patient Summary: Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5FU/cisplatin (FP) as first line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5FU/cisplatin (FP) as first line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. This study looked to prove that Xeloda (a newer oral chemotherapy) and cisplatin (XP) are as effective as intravenous therapy with 5-FU and
Patient Summary: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). This study looked at one of the recently approved drugs for renal cell carcinoma, Sutent (sunitinib malate), and compared it to standard therapy with interferon-alpha
Patient Summary: Phase III trial of intermittent MAB vs continuous MAB Phase III trial of intermittent MAB vs continuous MAB This trial began with 766 patients with locally advanced or metastatic prostate cancer. These men were initially treated with three months of therapy consisting of 2 weeks of 200mg cyproterone acetate (CPA), and then monthly injections of an LHRH agonist with continued daily CPA. O f these
Patient Summary: Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy When a patient has a rising PSA after radical prostatectomy, they are often recommended hormone therapy, but this is not without side effects. These investigators wondered if they could predict which patients will respond to salvage radiation
Patient Summary: Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01 Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01 Chemotherapy followed by radiation treatment (RT) provides a potential for laryngeal preservation in patients with locally
A phase III, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer Presenter: Marc Peeters Presenter's Affiliation: Ghent University Hospital, Ghent, Belgium Type of Session: Clinical Plenary Background Epidermal growth factor receptor (EGFR) signaling contributes to tumor growth, and overexpression of EGFR is associated with worse prognosis in metastatic colorectal cancer. Cetuximab (Erbitux) is a
Development of the ABL kinase inhibitor dasatinib (BMS-354825) in imatinib-resistant Philadelphia chromosome-positive leukemias Presenter: Charles L. Sawyers Presenter's Affiliation: University of California at Los Angeles, Los Angeles, CA Type of Session: Clinical Plenary Background Chronic myeloid leukemia (CML) is associated with the 9;22 reciprocal chromosomal translocation (aka the Philadelphia chromosome). This translocation results in the fusion protein,
Chemoprevention of colorectal adenomas with celecoxib in an international, randomized, placebo-controlled, double-blind trial Presenter: Nadir Arber Presenter's Affiliation: Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel Presenter's Financial Interest Disclosure: Pfizer and GI View Type of Session: Clinical Plenary Background Cyclooxygenase-2 (COX-2) converts arachidonic acids to prostaglandin endoperoxides, which in turn are converted to biologically
Celecoxib reduces sporadic colorectal adenomas: Results from the Adenoma Prevention with Celecoxib (APC) trial Presenter: Monica M. Bertagnolli Presenter's Affiliation: Brigham and Women's Hospital, Boston, MA Type of Session: Clinical Plenary Background Cyclooxygenase-2 (COX-2) converts arachidonic acid to prostaglandin endoperoxides, which in turn are converted to biologically active mediators that mediate inflammation and other biologic
A Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre- and Post-chemoradiation (CRT) 5-FU vs. Gemcitabine (G) for Resected Pancreatic Adenocarcionma Presenter: Abrams, R et al.Presenter's Affiliation: University of Maryland School of MedicineType of Session: ScientificBackground Pancreatic cancer is a very difficult cancer to treat and cure A previously published phase II trial of locally advanced and/or metastatic pancreatic cancer demonstrated improved outcomes with gemcitabine
Long-Term Survival Results of a Phase III Intergroup Trial (RTOG 95-01) of Surgery Followed by Radiotherapy vs. Radiochemotherapy for Resectable High Risk Squamous Cell Carcinoma of the Head and Neck Presenter: Jay S. Cooper, MDPresenter's Affiliation: Maimonides Cancer Center; NY, NYType of Session: ScientificBackground Preliminary results of this study suggested a benefit in locoregional control and disease-free survival in patients with high-risk head and neck cancer receiving concurrent cisplatin and radiotherapy following resection.
Intra-arterial vs. Intravenous Chemoradiation for Advanced Head and Neck Cancer, Early Results of a Multi-institutional Trial Presenter: C. R. N. Rasch, M.D., Ph.D.Presenter's Affiliation: NetherlandsType of Session: PlenaryBackground The addition of concurrent cisplatin-based chemotherapy to definitive radiotherapy for locally advanced squamous cell carcinoma of the head and neck (HNSCC) improves local control and survival. Cisplatin has significant systemic
Impact of Radiation on Survival After Complete Resection of Non Small Cell Lung Cancer: Descriptive Analysis in the Randomized Adjuvant Chemotherapy Trial Anita 1 Presenter: Jean-Yves Douillard, M.D., Ph.D.Presenter's Affiliation: Centre Rene Gauducheau, FranceType of Session: PlenaryBackground Post-operative radiotherapy ( PORT ) in lung cancer is a controversial topic. The PORT Meta-analysis previously demonstrated that radiotherapy was actually detrimental in certain patients. The PORT Meta-analysis has
Phase III Randomized Study of Intensity Modulated Radiation Therapy vs. Standard Wedging Adjuvant Breast Radiotherapy Presenter: Jean-Philippe Pignol, M.D.Presenter's Affiliation: Sunnybrook and Women's College Health Sciences Centre, Toronto , Ontario , CanadaType of Session: PlenaryBackground The current standard adjuvant treatment of localized breast cancer is whole breast radiotherapy Prior to using modern 3-D planning techniques, opposed tangent
The 2006 Worldwide Overview of the Effects of Local Treatments for Early Breast Cancer On Long-term Outcome? "Meta-analysis of the Randomized Trials of Radiotherapy After Mastectomy With Axillary Clearance" Presenter: Paul McGale, PhDPresenter's Affiliation: Clinical Trial Service Unit, United KingdomType of Session: PlenaryBackground Randomized trials have shown that post-mastectomy radiation therapy ( PMRT ) confers both a local control and survival benefit in certain patient populations. It is generally accepted that patients with 4 or
Motexafin Gadolinium (MGd) Combined With Prompt Whole Brain Radiation Therapy Prolongs Time to Neurologic Progression in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases: Results of a Randomized Phase 3 Trial Presenter: M.P. MehtaPresenter's Affiliation: University of Wisconsin, Madison, WIType of Session: ScientificBackground Motexafin gadolinium (MGd) is a radiosensitizer that is MRI-detectable and selectively localizes in tumors. MGd is an inhibitor of thioredoxin reductase, an enzyme whose overexpression is correlated with poor
Intergroup RTOG 9811: Phase III Comparison of Chemoradiation With 5-FU and Mitomycin Vs. 5-FU and Cisplatin for Anal Canal Carcinoma: Impact on Disease-Free, Overall and Colostomy-Free Survival Presenter: L.L. GundersonPresenter's Affiliation: Mayo Clinic Cancer Center ? Arizona, Scottsdale, AZType of Session: ScientificBackground Anal cancer is frequently a loco-regional disease The RTOG 8704/ECOG 1289 study showed the superiority of RT/5-FU/Mitomycin C over RT/5FU The current standard treatment of squamous cell
Long-Term Results of a Randomized Trial of Tamoxifen With or Without Radiation in Women Over 50 Years of Age With T1/2 N0 Breast Cancer Presenter: A. FylesPresenter's Affiliation: Princess Margaret HospitalType of Session: ScientificBackground Multiple studies have attempted to define a population of women with early stage breast cancer in whom the inclusion of radiation as a part of breast conservation treatment is not necessary This report represents long-term results
Long-term Toxicity Outcomes After High-Dose Conformal Radiotherapy for Clinically Localized Prostate Cancer Presenter: A. ShippyPresenter's Affiliation: Memorial Sloan-Kettering Cancer CenterType of Session: ScientificBackground Higher doses of radiotherapy have been shown in prospective randomized trials to correlate with improved clinical outcomes in prostate cancer patients Toxicity has also been found to increase with increasing dose,
Accelerated Versus Conventional Fractionated Radiotherapy in Squamous Cell Carcinoma of the Head and Neck (SCCHN: A Randomized International Multicenter Trial with 908 Patients Conducted by the IAEA-ACC Study Group Presenter: J. OvergaardPresenter's Affiliation: Aarhus University Hospital, DenmarkType of Session: ScientificBackground Multiple prospective randomized trials have suggested that accelerated fractionation schedules may increase the efficacy of radiation therapy for SCCHN Because these trials have been performed in Europe and the United
Long-term Neck Control Rates After Complete Response to Chemoradiation in Patients with Advanced Head and Neck Cancer Presenter: R. RenganPresenter's Affiliation: Memorial Sloan-Kettering Cancer CenterType of Session: ScientificBackground The indications for planned neck dissection in patients with advanced head and neck cancer who achieve a complete response to chemoradiation are unclear This study sought to evaluate outcomes in advanced head and neck
The 2006 Worldwide Overview of the Effects of Local Treatments for Early Breast Cancer On Long-term Outcome? "Meta-analysis of the Randomized Trials of Radiotherapy After Mastectomy With Axillary Clearance" The 2006 Worldwide Overview of the Effects of Local Treatments for Early Breast Cancer On Long-term Outcome? "Meta-analysis of the Randomized Trials of Radiotherapy After Mastectomy With Axillary Clearance" It is well understood that radiation therapy after mastectomy ( PMRT ) improves survival and decreases recurrence rates in women
Impact of Radiation on Survival After Complete Resection of Non-Small Cell Lung Cancer: Descriptive Analysis in the Randomized Adjuvant Chemotherapy Trial Anita 1 Impact of Radiation on Survival After Complete Resection of Non-Small Cell Lung Cancer: Descriptive Analysis in the Randomized Adjuvant Chemotherapy Trial Anita 1 This analysis was done on a study designed to look at the benefit of chemotherapy for early stage lung cancers. The researchers have analyzed the use of radiation therapy in the
A Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre- and Post-chemoradiation (CRT) 5-FU vs. Gemcitabine (G) for Resected Pancreatic Adenocarcionma Intra-arterial vs. Intravenous Chemoradiation for Advanced Head and Neck Cancer, Early Results of a Multi-institutional Trial Locally advanced squamous cell head and neck cancer is often treated with a combination of cisplatin chemotherapy and radiation therapy. The dose of cisplatin is limited by the side effects it causes. By giving
Analyzing Serial Hypoxia Images from 18 FMISO-PET: Modeling Transient and Chronic Hypoxia Presenter: Kelin Wang, PhDPresenter's Affiliation: Memorial Sloan-Kettering, New York, NYType of Session: PlenaryBackground Oxygen is an important mediator of radiation-induced DNA damage. Thus, tumor hypoxia impedes the ability of radiation to kill tumor cells. Tumor hypoxia has been demonstrated by many groups using hypoxia markers
The Prediction of Radiation-Induced Liver Dysfunction Using a Local Dose and Regional Venous Perfusion Model Presenter: Y. CaoPresenter's Affiliation: University of Michigan, Ann Arbor, MIType of Session: PlenaryBackground High-dose conformal radiation therapy with chemotherapy can prolong the survival of patients with unresectable liver tumors. Radiation-induced liver disease (RILD) limits the ability to safely deliver high doses.
Biochemical Recurrence and Late Toxicity Following External Beam Radiotherapy Combined With Permanent Source Prostate Brachytherapy: Analysis of RTOG 0019 Presenter: W. LeePresenter's Affiliation: Wake Forest University School of MedicineType of Session: ScientificBackground Previous clinical trials have shown the benefits of dose escalation with external beam radiation for patients with prostate cancer. One strategy to deliver higher radiation doses to the prostate is to combine external
Quantitative Characterization of Radiation Dose Dependent Changes in Normal- Appearing White Matter of Cerebral Tumor Patients Using Diffusion Tensor Imaging Presenter: V. NageshPresenter's Affiliation: University of Michigan, Ann Arbor, MIType of Session: PlenaryBackground Radiation effects on normal brain tissue can include neuroinflammation, demyelination, disruption of the blood-brain barrier, cerebral edema, and white matter necrosis. Hypothesis: Radiation causes demyelination and
Analysis of V20 and Radiation Pneumonitis on SWOG 0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Non-small Cell Lung Cancer Presenter: L.E. Gaspar Presenter's Affiliation: University of Colorado at Denver Health Sciences Center Type of Session: Scientific Background SWOG 0023 was a prospective, randomized, multi-institutional phase III trial evaluating the use of external beam radiotherapy with concurrent cisplatin/etoposide chemotherapy, followed by
10 Year Follow-Up of RTOG 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer Presenter: G. HanksPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground Multiple large randomized trials have demonstrated a clinical benefit with the addition of androgen deprivation to external beam radiotherapy for treatment of locally advanced prostate cancer This report represents long-term
Analysis of V20 and Radiation Pneumonitis on SWOG 0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Non-small Cell Lung Cancer Analysis of V20 and Radiation Pneumonitis on SWOG 0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Non-small Cell Lung Cancer SWOG 0023 was a phase III trial evaluating the use of radiation therapy given with cisplatin and etoposide chemotherapy, followed by docetaxel chemotherapy, and then gefitinib
Biochemical Recurrence and Late Toxicity Following External Beam Radiotherapy Combined With Permanent Source Prostate Brachytherapy: Analysis of RTOG 0019 Biochemical Recurrence and Late Toxicity Following External Beam Radiotherapy Combined With Permanent Source Prostate Brachytherapy: Analysis of RTOG 0019 Previous clinical trials have demonstrated the benefits of higher doses of external beam radiation therapy for patients with prostate cancer. One strategy to deliver higher radiation doses to
Patterns of Failure Following the Brachytherapy Management of Prostate Cancer Patterns of Failure Following the Brachytherapy Management of Prostate Cancer There are relatively few studies with long-term outcomes for men who have been treated with radioactive seed implant (brachytherapy) for prostate cancer. It is important to understand treatment failures after brachytherapy in order to decide which patients should be
Phase II Study of Proton Radiotherapy for Spine and Paraspinal Sarcoma Presenter: Thomas F. DelaneyPresenter's Affiliation: Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground Sarcomas located in the spinal axis have a poor prognosis, as local control of the disease is difficult to achieve: obtaining clear surgical margins is challenging high radiation
A Comparison of 3-D Conformal Proton Therapy, Intensity Modulated Proton Therapy, and Intensity Modulated Photon Therapy for Retroperitoneal Sarcoma Presenter: Christine S. ChungPresenter's Affiliation: Harvard Radiation Oncology Program, Boston, MAType of Session: ScientificBackground The treatment of retroperitoneal sarcoma usually involves a combination of surgery and radiotherapy. Post-operative radiotherapy can entail treating very large, complex volumes located in close
Impact of Prophylactic Cranial Irradiation on Neurocognitive Function in Patients With Small Cell Lung Carcinoma Presenter: D.R. GrosshansPresenter's Affiliation: MD Andersen Cancer Center, Houston, TXType of Session: ScientificBackground Numerous reports have shown that limited-stage small cell lung cancer patients who receive prophylactic cranial irradiation (PCI), after achieving a clinical complete response from definitive thoracic treatment, have
Elective Nodal Irradiation in the Treatment of Non-Small Cell Lung Cancer Presenter: K.E. RosenzweigPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, NY, NYType of Session: ScientificBackground It is difficult to know which nodal regions need irradiation when treating lung cancer with radiotherapy. At the Memorial Sloan Kettering Cancer Center, physicians decided to omit treating clinically
Cardiac Morbidity and Mortality After Breast Conservation Treatment in Early-stage Breast Cancer Patients With Pre-existing Cardiac Disease Presenter: R. GuttPresenter's Affiliation: University of MarylandType of Session: ScientificBackground Patients with left-sided breast cancer have been shown to have an increase in the subsequent development of coronary artery disease (CAD) and myocardial infarction (MI), but no increase in mortality versus patients with right-sided breast
Role of PI3K/Akt Signaling in TRAIL and Radiation-induced Gastrointestinal (GI) Apoptosis Presenter: J. PlastarasPresenter's Affiliation: University of PennsylvaniaType of Session: ScientificBackground Activation of the PI3K/Akt pathway leads to tumorigenesis, progression, and resistance to therapy; inhibition of the PI3K/Akt pathway has been shown to radiosensitize tumor cells in vitro and in animal models The results of
Adjuvant Chemoradiation for Adenocarcinoma of the Pancreas: The Johns Hopkins Experience Adjuvant Chemoradiation for Adenocarcinoma of the Pancreas: The Johns Hopkins Experience At the time of diagnosis, 15% to 20% of patients will have resectable pancreatic cancers. The 5-year survival for patients after surgical resection is between 20% and 25%. The use of chemotherapy and radiation therapy following surgery is controversial, with
Cetuximab in Combination With Capecitabine, Oxaliplatin, and Concomitant Radiotherapy (Cet-Capox-RT) as Preoperative Therapy for Rectal Cancer Cetuximab in Combination With Capecitabine, Oxaliplatin, and Concomitant Radiotherapy (Cet-Capox-RT) as Preoperative Therapy for Rectal Cancer Cetuximab is a monoclonal antibody to the EGF-receptor and has been shown to improve outcomes in metastatic colorectal cancer and in combination with radiation therapy for head and neck cancers. Previous
The Breast Cancer Epigenome Presenter: M. Esteller Affiliation: Spanish National Cancer Centre (CNIO), Madrid, Spain Background Epigenetics is the study of information related to DNA that does not depend on the DNA sequence itself. Examples include methylation of DNA itself, modification of histones, and micro-RNA expression. In general, the progression of normal
Combined Clinical Trial Results Of A HER2/Neu (E75) Vaccine For Prevention Of Recurrence In High-Risk Breast Cancer Patients Presenter: G. E. Peoples Affiliation: Walter Reed Army Medical Center, Washington, DC Background Immunotherapy to treat cancer has been a popular idea for decades. Interferon therapy is FDA-approved and has been used in a variety of settings, such as in renal cell cancer. Cancer vaccines can potentially harness specific immune responses,
A Sharp Decrease In Breast Cancer Incidence In The United States In 2003 Presenter: P. M. Ravdin Affiliation: M.D. Anderson Cancer Center, Houston, TX Background The incidence of breast cancer over time may reflect a differences in etiologic factors and screening practices. For example, after the wide-spread institution of mammography, there was bump in the incidence of breast cancer The incidence of
Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33 Presenter: E. Mamounas Affiliation: NSABP Operations & Biostatistical Centers, Pittsburgh, PA Background For hormone receptor positive breast cancers, 5 years of adjuvant tamoxifen had been the standard. Aromatase inhibitors (AIs) were tested in three different settings: AI x 5 yr vs. Tamoxifen x 5 yr Sequential Tam/AI (2-3 yr
Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer Presenter: W. Gradishar Affiliation: Robert H. Lurie Comprehensive Cancer Center of Northwestern University Background Recent trial results have shown that adjuvant first-line aromatase inhibitors give superior disease free survival compared to tamoxifen in hormone receptor-positive breast cancer When these women recur, it is unclear
Impact of radiation dose on local control, fibrosis and survival after breast conserving treatment: 10 years results of the EORTC trial 22881-10882 Presenter: H. Bartelink Affiliation: The Netherlands Cancer Institute, Amsterdam, Netherlands Background After lumpectomy and whole breast irradiation, the tumor bed is a major site of recurrence Several trials, including this one, demonstrated that boosting the tumor bed with additional radiation, either by insterstitial
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up Presenter: K.S. Hughes Affiliation: Massachusetts General Hospital, Boston, MA Background After lumpectomy for early breast cancer, adjuvant breast irradiation reduces local recurrence by about two-thirds. The EBCTCG overview has shown a survival benefit from adjuvant radiation, noting that for every 4 local recurrences that are
Five year results of Intergroup Study E5194: local excision alone (without radiation treatment) for selected patients with ductal carcinoma in situ (DCIS) Presenter: L. Hughes Affiliation: Eastern Cooperative Oncology Group Background Based on results of large randomized trials studying adjuvant treatment for excised ductal carcinoma in situ, adjuvant breast radiation is the gold standard to reduce the risk of local recurrence Retrospective analyses have attempted to identify favorable
Axillary lymph node nanometastases are prognostic factors for metastatic relapse in breast cancer patients Presenter: S. Alberti Affiliation: University of Chieti, Chieti, Italy Background There is a wide range of outcomes after diagnosis and treatment for early stage breast cancer. The unexplained heterogeneity of outcomes may be a result of inaccurately under staged axillary lymph node metastases Routine pathologic analysis of axillary
OncoLink Professor On-Call: Lawrence Solin, MD provides exclusive expert review and insights from the recent San Antonio Breast Cancer Symposia for OncoLink The 29th Annual San Antonio Breast Cancer Symposium was held from Thursday, December 14 through Sunday, December 17, 2006. A wide range of topics was discussed. This symposium is widely considered to be one of the major breast cancer conferences in the world. As such, much of the scientific information presented at this symposium is quickly
Monitoring Response to Imatinib By Fluorescence In Situ Hibridization (FISH) and Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) In Chronic Myeloid Leukemia (CML) Patients (PTS) In Chronic Phase (CP): Experience of Argentina and Uruguay Presenter: Pavlovsky, CPresenter's Affiliation: FUNDALEU (Argentina)Type of Session: ScientificBackground The impressive efficacy of imatinib in CML is well-established and is correlated directly with transcription levels of its target, bcr-abl. Higher doses of imatinib are indicated in pts with rising levels of bcr/abl transcripts. RQ-PCR is
Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report Presenter: Milone, G.Presenter's Affiliation: Instituto de Investigaciones Hematologicas, Buenos Aires, ArgentinaType of Session: ScientificBackground Advanced stage (Stage III/IV) indolent NHL is generally thought to be incurable, but can be treated successfully with single- and multi-agent chemotherapy regimens as well as anti-CD20 immunotherapy
Molecular Evaluation of Telomere length in patients with mantle cell lymphoma (MCL) Presenter: Cottliar, A.Presenter's Affiliation: Academia Nacional de Medicina, ArgentinaType of Session: ScientificBackground Mantle cell lymphoma (MCL) is a rare (6% of NHL), but aggressive NHL with median survival of 3-4 years. MCL is genetically characterized by the t(11;14)(q13;q32) translocation (Cyclin D1:IgH) and up-regulation of Cyclin
Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib and Prognosis Presenter: Silveira, RAPresenter's Affiliation: UNICAMP, BrazilType of Session: ScientificBackground Imatanib (Gleevec) has been established as first line treatment in Chronic Myeloid Leukemia (CML). Resistance to Imatinib frequently occurs in Acute Blast Crisis (ABC). More than 70 mutations in BRC/ABL have been identified and
Cutaneous Lymphomas: Experience of a single institution in Lima-Perú Presenter: Beltran-Gárate, B.Presenter's Affiliation: Hospital Rebagliati, PeruType of Session: ScientificBackground It has been demonstrated that geographic variations can predict for the clinical behavior and pathologic characteristics of malignant lymphomas. Adult T -cell leukemia/lymphoma (ATLL) is an aggressive lymphoma associated with the
Analysis of 511 Lymphoma Cases in Uruguay Presenter: Gualco, G. (in Spanish)Presenter's Affiliation: Hospital Militar, Laboratorio de Anatomía Patológica, UruguayType of Session: ScientificBackground The incidence and demographic distribution of Hodgkin's lymphoma (HL) and non-Hodgkin lymphomas (NHL) vary throughout the world. The incidences are particularly high in North America, and
Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL): A Single Centre Experience Presenter: Pavlovsky, M APresenter's Affiliation: FUNDALEU, ArgentinaType of Session: ScientificBackground Chronic lymphocytic leukemia (CLL) is an indolent neoplasm of B-cell origin, that is usually CD20+, CD5+, and CD23+. It is similar to small lymphocytic lymphoma (SLL) where the disease burden is predominantly in lymph nodes and the bone marrow
Safety of Intrathecal Rituximab as Prophylaxis or Treatment in CD20+ Acute Lymphoblastic Leukemia (ALL) and Aggressive Lymphoma (AL): Report from a Mexican Pilot Study Presenter: Villela, L.Presenter's Affiliation: Instituto Nacional de Ciencias Médicas y Nutrición, MexicoType of Session: ScientificBackground CNS involvement in acute lymphoblastic leukemia (ALL) and aggressive lymphoma (AL) is a poor prognostic indicator. Systemic rituximab is a safe and effective agent in patients with B-cell
Results of the "Mexican method" to conduct allogeneic hematopoietic stem cell transplantation Presenter: Ruiz-Argüelles, GJPresenter's Affiliation: Centro de Hematologia y Medicina Interna de Puebla, MexicoType of Session: ScientificBackground Myeloablative allogeneic bone marrow transplantation is used for several hematopoietic diseases, and is extremely expensive. Non-myeloablative transplants, sometimes called
Alemtuzumab in the treatment of steroid refractory acute graft-versus-host disease Presenter: Gómez-Almaguer, DPresenter's Affiliation: Hospital Universitario de Nuevo León, MexicoType of Session: ScientificBackground Corticosteroid therapy is the mainstay of treatment for graft versus host disease (“GVHD). This condition is typically manifested by gut, skin, and liver toxicity. Unfortunately, steroid medications have
Results in the Treatment With Chemotherapy in Acute Myeloid Leukemias. Experience of 20 Years Presenter: Hernández, C.Presenter's Affiliation: Hospital Hermanos Ameijeiras, CubaType of Session: ScientificBackground Acute myeloid leukemia (AML) represents 80% of the total number of acute leukemias that affect the adult Cuban population. Yet despite this high prevalence, its prognosis remains very unfavorable. This paper was
Allogeneic Stem Cell Transplant with TBI/CY/Cytarabine Conditioning for Childhood Philadelphia-Positive ALL Presenter: Yoo, K.H.Presenter's Affiliation: Samsung Medical Center, KoreaType of Session: ScientificBackground Allogeneic stem cell transplantation (ASCT) is generally felt to be the optimal curative treatment of Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ ALL). The standard conditioning regimen to prepare these patients for
A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group Presenter: Cacchione, RPresenter's Affiliation: CEMIC ArgentinaType of Session: ScientificBackground Non-Hodgkin’s Lymphoma (NHL) represents a diverse group of malignancies and has a variable presentation, ranging from indolent to aggressive. Diffuse large B-cell lymphoma (DLBCL) is the most common histological
Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance (MGUS): Experience of One Institution Presenter: Sackmann, FPresenter's Affiliation: FUNDALEU, ArgentinaType of Session: ScientificBackground MGUS has a prevalence of 1 to 3%. MGUS generally has an indolent course, however some patients (pts) will progress to a malignant neoplasm. Identifying prognostic factors that can identify pts who will progress is important.
Acute Promyelocytic Leukemia, Twelve Years Experience at the University Hospital,San Juan, Puerto Rico Presenter: Lopez-Enriquez, A.Presenter's Affiliation: University of Puerto Rico, Puerto RicoType of Session: ScientificBackground Acute Promyelocytic Leukemias (APL) are a unique entity in the field of carcinogenesis. They result from maturation arrest of cells at the promyelocyte stage, and are associated with a reciprocal chromosomal
Expression of CD56 As A Prognostic Factor in Multiple Myeloma Presenter: Almeida, E. B.Presenter's Affiliation: Department of Internal Medicine and Hematology/Hemotherapy Center, State University of Campinas UNICAMP, BrazilType of Session: ScientificBackground Multiple myeloma (MM) is characterized by the absence of specific B-cell antigens, such as CD19 Aberrant expression of CD56 is the most
Prognostic Value of Different Profiles of the Early Response to Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Presenter: Semochkin, S.V.Presenter's Affiliation: Federal scientific clinical center for pediatric hematology, oncology and immunology, RussiaType of Session: ScientificBackground The early response of patients during induction therapy is essential for patient risk-stratification in childhood acute lymphoblastic leukemia (ALL), and has long been
Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia (ALL). Presenter: Gómez-Almaguer, DPresenter's Affiliation: Hospital Universitario de Nuevo León, MexicoType of Session: ScientificBackground Adult acute lymphoblastic leukemia (ALL) is associated with a far worse prognosis than in the pediatric population. Despite the optimal use of the antileukemic agents, reported cure rates range from
Acute Myeloid Leukemia in the Elderly, Intensive or Maintenance Therapy? Our Experience in Patients Over 65 Years Presenter: Mettivier, VPresenter's Affiliation: Haematology Division A.Cardarelli Hospital, ItalyType of Session: ScientificBackground The use of intensive chemotherapy in the treatment of acute myeloid leukemia (AML) in patients older than age > 65 years is debatable. Numerous previous studies have suggested that intensive
FLT3 gene internal tandem duplication (ITD) mutations in patients with acute myeloid leukemia (AML) Presenter: Arana-Trejo, RMPresenter's Affiliation: Genética, Hospital General de México and Laboratorio de OncoHematologia, SC, MexicoType of Session: ScientificBackground FMS-like tyrosine kinase 3 (FLT3) is a Class III receptor tyrosine kinase, that is mainly expressed by early myeloid and lymphoid progenitor cells. FLT3 consists of 2
In Vitro CD4+ T Cells Expansion: Induction of Regulatory T Cells with Sirolimus and CD3/CD28 Dynabeads Presenter: Borelli, GPresenter's Affiliation: Department of Cellular Therapy, Rikshospitalet-Radiumhospitalet HFType of Session: ScientificBackground T regulatory cells (Treg) are a subset of T lymphocytes defined by CD4+CD25+ markers and high FOXP3 expression. They play a key role in self-reactivity and alloreactivity control. Treg
Acute Lymphoblastic Leukemia (ALL): Detection of Prognostically Significance Fusion-Genes By Multiplex-Polymerase Chain Reaction (M-PCR) Presenter: Manrique, G.Presenter's Affiliation: ASESP, UruguayType of Session: ScientificBackground Acute lymphoblastic leukemia (ALL) is associated with a very poor prognosis in adults compared to the pediatric population. In children, the TEL/AML1 translocation is associated with improved response to therapy and is considered a good
Acute Promyelocytic Leukemia (APL): Genetic Characterization of 78 Argentinian And Uruguayan Patients Presenter: Uriarte, M.R.Presenter's Affiliation: ASESP, UruguayType of Session: ScientificBackground Acute Promyelocytic Leukemia (APL) requires accurate and rapid diagnosis of PML-RAR transcript for implementation of specific therapy, prognostic assessment and molecular relapse of disease (MRD) monitoring. There have been three
Correlation Between the Uptake of Tc-99m-sesta MIBI and Prognostic Factors in Patients with Multiple Myeloma Presenter: Bacovsky, J.M.Presenter's Affiliation: University of Olomouc, Czech RepublicType of Session: ScientificBackground Multiple myeloma (MM) is a malignant disease characterized by clonal proliferation and accumulation of transformed B-line elements. MM cells can produce monoclonal immunoglobulin (MIG) that can be detected in the
siRNA-Inhibition OF E2A-PBX1 in Pre-B Leukemia Cells Presenter: Casagrande, GPresenter's Affiliation: University of Padova - Lab. Pediatric Onco-Hematology, ItalyType of Session: ScientificBackground The t(1;19)(q23;p13) chromosomal translocation is detected in ~5-6% of childhood pre-B acute lymphoblastic leukemias (ALLs) and usually results in E2A-PBX1 gene expression. The role of this
Alemtuzumab in the treatment of steroid refractory acute graft-versus-host disease Transplant patients take immunosuppressive medications for several years after undergoing transplantation. Graft Versus Host Disease (GVHD) is a common complication after allogeneic transplant that can have negative effects on the skin, liver, and gastrointestinal tract. The most common treatment for both preventing and treating a GVHD flare is
Acute Myeloid Leukemia in the Elderly, Intensive or Maintenance Therapy? Our Experience in Patients Over 65 Years When AML develops in people over the age of 65, the optimal choice of therapy is debatable. Intensive chemotherapy for AML is highly toxic, and there is great concern over causing more harm than good with this regimen. Many of these patients thus end up treated with a maintenance program of less toxic therapy. This study looked at 54 patients with
Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 Patients from the Nordic Area Multiple myeloma is commonly treated with stem cell transplantation in younger patients. A randomized study in 1996 found that double (or “tandem”) transplants resulted in an increase in overall survival, from 21% to 42% of patients. As a result, many institutions perform tandem transplants for these patients. This study aimed to assess the long
Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report Advanced stage (Stage III/IV) indolent NHL is generally thought to be incurable, but can be treated successfully with chemotherapy as well as immunotherapy with or without linked radionuclides. Fludarabine (F) chemotherapy is at least as effective, as conventional therapies such as cyclophosphamide, vincristine, prednisone (CVP) for the first and
A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group The purpose of this prospective study was to address the efficacy of Yttrium ibritumomab tiuxetan (Zevalin) in patients with relapsed or refractory lymphomas who had already failed rituximab. Rituximab is a monocloncal antibody that targets CD20, which is found on the surface of lymphoma cells. Zevalin is rituximab with the addition of a
Aberrant Methylation of Tumor Suppressor Genes (TSG) In Myeloma Multiple (MM) and Chronic Lymphocytic Leukemia (CLL) Presenter: Chena, C. and Stanganelli, C.Presenter's Affiliation: Academia Nacional de Medicina, ArgentinaType of Session: ScientificBackground Multiple myeloma (MM) is a clonal B-cell neoplasm that results from a number of mutations. Monoclonal gammopathy of unknown significance (MGUS) is considered to be a precursor of MM. Chronic
Prognostic Value of CD38 Expression by Fluorescence Intensity Histogram in Chronic Lymphocytic Leukemia Presenter: Barreto, W. G.Presenter's Affiliation: Universidade Federal de São PauloType of Session: ScientificBackground Chronic Lymphocytic Leukemia (CLL) is the most prevalent form of leukemia in the Western World. CLL has a variable clinical course and CLL cells appear to proliferate at variable rates.
Incidence of Human Papillomavirus (HPV)-Related Head and Neck Cancers in the U.S. from 1998-2003: Pre-HPV Vaccine Licensure Presenter: M. SaraiyaPresenter's Affiliation: Centers for Disease ControlType of Session: ScientificBackground The majority of head and neck cancers are related to alcohol and tobacco use (75%). However, human papillomavirus (HPV) has been shown to be related to between 15-25% of head and neck cancers worldwide. In certain head and neck
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. Presenter: Hanna, N.H.Presenter's Affiliation: Indiana University, Indianapolis, INType of Session: ScientificBackground Concurrent platinum-based chemotherapy and thoracic radiation treatment (RT) has become a standard of care in the treatment of unresectable non-small cell lung cancer (NSCLC). This treatment methodology is based on studies
Incidence Trends for Human Papillomavirus-Related (HPV-R) and Unrelated (HPV-U) Head and Neck Squamous Cell Carcinoma (HNSCC) in the United States (US) Scientific Session: Incidence Trends for Human Papillomavirus-Related (HPV-R) and Unrelated (HPV-U) Head and Neck Squamous Cell Carcinoma (HNSCC) in the United States (US) With the recent approval of a vaccine for HPV and a second approval pending, there has been much discussion of how these vaccines may affect other cancers in addition to
Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG E2303) Scientific Session: Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG E2303) The combination of C225 and radiation has been proven superior to radiation alone for the treatment of
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 Scientific Session: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 Chemotherapy (containing a platinum drug) combined with chest radiation (RT) has become a standard
Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) Scientific Session: Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) Bevacizumab (Avastin), a monoclonal antibody directed against the vascular endothelial growth factor
S0216: A Southwest Oncology Group (SWOG) phase II trial of docetaxel (T), cisplatin (P), and fluorouracil (F) induction followed by accelerated fractionation/concomitant boost (AF/CB) radiotherapy (RT) and concurrent cisplatin for advanced head and neck squamous cell cancer (HNSCC) Presenter: D. AdelsteinPresenter's Affiliation: Cleveland Clinic, Cleveland, OHType of Session: ScientificBackground Several phase III cooperative studies have established radiation therapy and concurrent single agent cisplatin as a clear treatment standard for squamous head and neck cancer. Cooperative group trials (RTOG 9003) and
The cognitive effects of modafinil in breast cancer survivors: A randomized clinical trial Presenter: Kohli, S.Presenter's Affiliation: University of Rochester, Rochester, NYType of Session: ScientificBackground As the number of cancer survivors continues to increase, after-effects of cancer and its treatments have become increasingly important. Cognitive changes and impairment after cancer treatment, often referred to as
A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA. Presenter: Soori, G.S.Presenter's Affiliation: Mayo Clinic College of Medicine, Rochester, MN.Type of Session: ScientificBackground Fatigue is an extremely important issue for cancer patients, recently having been reported to occur in 58% of patients undergoing cancer treatment, as compared to pain, encountered by 22%, and nausea and
Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer Presenter: M. O. MeyersPresenter's Affiliation: Duke University Medical CenterType of Session: ScientificBackground It is well known that lymph node metastasis is associated with a worse outcome in rectal cancer. It has generally been accepted that 12 lymph nodes are needed for proper nodal staging. However, only 37% of patients in the SEER
Phase III Trial of Ixabepilone plus Capecitabine Compared to Capecitabine Alone in Patients with Metastatic Breast Cancer (MBC) Previously Treated or Resistant to an Anthracycline and Resistant to Taxanes. Presenter: L.T. VahdatPresenter's Affiliation: Weill Cornell Medical CollegeType of Session: ScientificBackground Currently, the standard of care for the systemic treatment of breast cancer involves treatment with anthracyclines and taxanes. The use of the anthracyclines and taxanes is increasing and more patients are developing resistance to
Risk based care in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) Presenter: Nathan, P.C.Presenter's Affiliation: The Hospital for Sick Children, Toronto, ON, CanadaType of Session: ScientificBackground An estimated 270,000 childhood cancer survivors (CCS) were residing in the United Stages in 1997. As survival rates after childhood cancer continue to increase, this number is expected to grow: Currently,
The journey from cancer patient to cancer survivor: A 5-year longitudinal study Presenter: Snyder, C.F.Presenter's Affiliation: Johns Hopkins School of Medicine, Baltimore, MDType of Session: ScientificBackground Over 10 million cancer survivors currently reside in the United States, and this number is estimated to continue to rise at a rate of approximately 3% each year. Cancer survivors require attentive medical
Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: Results of the randomised MRC ASTEC and NCIC CTG EN.5 trial Presenter: J. OrtonPresenter's Affiliation: Medical Research Council Clinical Trials Unit, London, UKType of Session: ScientificBackground Endometrial cancer is the most common gynecologic cancer among women in North America and affects over 40,000 women per year. 75% of endometrial cancer cases present with disease confined to the
Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: First results of a randomized phase III trial Presenter: M. StahlPresenter's Affiliation: University of Essen, GermanyType of Session: ScientificBackground Neoadjuvant chemoradiation is frequently used in the treatment of localized adenocarcinomas of the esophagus. Prior studies (CALGB 9781) have demonstrated the superiority of trimodality therapy compared with surgery alone in
A randomized phase III study on adjuvant treatment with radiation (RT) +/- chemotherapy (CT) in early stage high risk endometrial cancer (NSGO-EC-9501/EORTC 55991) Presenter: T. HogbergPresenter's Affiliation: Nordic Society of Gynecologic Oncology, Odense, DenmarkType of Session: ScientificBackground Endometrial cancer is the most common gynecologic cancer among women in North America, affecting over 40,000 women per year. 75% of endometrial cancer cases present with disease confined to the
A Double-Blind, Placebo Controlled, Randomized Phase III trial of Gemcitabine (G) plus Bevacizumab (B) Versus Gemcitabine Plus Placebo (P) in Patients (pts) with Advanced Pancreatic Cancer (PC): A Preliminary Analysis of Cancer and Leukemia Group B (CALGB) Presenter: H. L. KindlerPresenter's Affiliation: University of Chicago Medical CenterType of Session: ScientificBackground Advanced pancreatic cancer continues to have an extremely poor prognosis. Gemcitabine is the cornerstone of treatment and objective response rates of 5-10% are seen when gemcitibine is used alone. Treatment with
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer Presenter: Perez, E.A.Presenter's Affiliation: Mayo Clinic, Jacksonville, FL.Type of Session: ScientificBackground Up to 25% of women diagnosed with early-stage breast cancers have tumors which demonstrate overexpression of human epidermal growth factor receptor 2 (HER-2). Trastuzumab (Herceptin) is a monoclonal antibody directed against the
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years Presenter: Aimery De GramontPresenter's Affiliation: Hopital St. Antoine, Paris, FranceType of Session: ScientificBackground Oxaliplatin is a chemotherapeutic agent with demonstrated activity in colorectal cancer. This abstract presents a 6 year update to previously published results from a large phase III randomized trial (MOSAIC).
Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials Presenter: William ShapiroPresenter's Affiliation: Barrow Neurological Institute, Phoenix AZType of Session: ScientificBackground Motexafin gadolinium (MGd) is a radiosensitizer that is MRI-detectable and selectively localizes in tumors. MGd is an inhibitor of thioredoxin reductase, an enzyme whose overexpression is correlated with poor
Cumulative False-Positives (FP) in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial Presenter: J. H. MillerPresenter's Affiliation: National Institutes of HealthType of Session: ScientificBackground Cancer screening tests are recommended to the general public, however, the burden of multiple screening tests is not clear. Prior studies have examined the risk benefit ratios of individual screening tests, but in clinical
Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. Presenter: C. N. SternbergPresenter's Affiliation: San Camillo Forlanini Hospital, Rome, ItalyType of Session: ScientificBackground Previously there had only been a limited role for chemotherapy in the treatment of prostate cancer. In 2004 docetaxol was approved as first line treatment for hormone refractory prostate cancer (HRPC). The
Diurnal rhythms (DR) in gene expression in human oral mucosa: Implications for gender differences in toxicity, response and survival and optimal timing of targeted therapy (Rx) Presenter: Bjarnason, G.A.Presenter's Affiliation: Toronto-Sunnybrook Regional Cancer Center, Toronto, ON, Canada.Type of Session: ScientificBackground Diurnal rhythms (DR) have been suggested to be implicated in tumor growth and response to cancer treatment, and have been observed to play a role in pathophysiology of many other human
Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710 Presenter: B. L. PowellPresenter's Affiliation: Wake Forest UniversityType of Session: PlenaryBackground Acute promyelocytic leukemia (APL) was originally described in 1957. APL is defined by a fusion gene unique to this disease, which most commonly involves the fusion of the retinoic acid receptor-alpha (RAR a) and the promyelocytic leukemia
A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs. placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma Presenter: Bernard EscudierPresenter's Affiliation: Institut Gustave Roussy, Villejuif, FranceType of Session: PlenaryBackground Until recently, treatment of metastatic renal cell carcinoma (RCC) included immunotherapy as the standard of care. Treatment with interferon (IFN) provided modest clinical benefit and toxicity with an expected
Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases Presenter: Bernard NordlingerPresenter's Affiliation: Hospital Ambroise Pare, Boulogne Cedex, FranceType of Session: PlenaryBackground Liver metastases are observed in 40 to 50% of patients with newly diagnosed colorectal cancer worldwide. When resected, 5 year survival is close to 35%, but disease relapse is common. The benefit
Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC) Presenter: Llovet, J.Presenter's Affiliation: Mount Sinai School of Medicine, New York, NYType of Session: PlenaryBackground Hepatocellular carcinoma (HCC) represents the 5th most common cancer across the globe. Over 600,000 new cases are diagnosed each year, 370,000 of which occur in East Asia, 32,000 in Europe, and 19,000 in the
Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710 Scientific Session: Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710 Acute promyelocytic leukemia (APL) comprises approximately 10% of acute leukemias and is initially
A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs. placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma Scientific Session: A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs. placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma This was a phase III, randomized study for patients with metastatic renal cell cancer. Patients were randomized to receive either interferon-alpha
Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961 Scientific Session: Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961 The optimal duration of hormone therapy for locally advanced prostate cancer remains controversial. Since the EORTC
A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993) Scientific Session: A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993) At diagnosis, patients with small cell lung cancer (SCLC) have a high rate of brain metastasis (around 20%), and this number rises to >50% at 2 years.
Cigarette smoking during irinotecan therapy: Effects on pharmacokinetics and neutropenia Scientific Session: Cigarette smoking during irinotecan therapy: Effects on pharmacokinetics and neutropenia Cytochrome P450 enzymes in the liver are important for the detoxification of many drugs and substances. Exposure to cigarette smoke can affect the expression of cytochrome P450 enzymes and has been demonstrated to affect the levels and
Traditional Chinese Medicine in the Management of Treatment Related Pneumonitis-Rational and Evidence Presenter: Zhongxing Liao, MD. Presenter's Affiliation: MD Anderson Cancer Center Type of Session: Scientific Background Locally advanced lung cancer continues to have an extremely poor prognosis. Approximately 171,900 new cases of lung cancer are diagnosed annually. Greater than 50% of patients present with regional disease
Diagnostic and Screening X-Rays: Estimated Risks and Benefits Presenter: Amy Berrington de Gonzalez Presenter's Affiliation: Johns Hopkins University Type of Session: Scientific Background Diagnostic X-rays provide a great medical benefit to patients with only a small risk of secondary cancers. This increase in risk of secondary malignancy has been shown in prior studies: Example: The increased
Protons and Other Charged Particles: What Is the Potential Impact on Radiotherapy Practice? Presenter: Jay S. Loffler Presenter's Affiliation: Harvard University Type of Session: Scientific Background There are treatment limitations which are independent of radiation. Limitations in diagnostic imaging to define the tumor How sensitive the tumor is to radiation How close the tumor is to normal organs Is the tumor truly
Secondary Cancers After Radiotherapy: An Increasing or Decreasing Concern? Presenter: Eric J. Hall Presenter's Affiliation: Columbia University Type of Session: Scientific Background Approximately 10% of patients presenting to US cancer centers have secondary malignancies. This may be due to an increase genetic susceptibility to cancer or continued life style habits which put patients at increased risk for
Chemotherapy Foundation Symposium XXVI Innovative Cancer Therapy for Tomorrow Conference Dates: November 4 - November 8, 2008 Conference Location: Marriott Marquis Hotel, New York City Sponsoring Group: Mount Sinai School Of Medicine Conference Web Page URL: www.chemotherapyfoundationsymposium.org Topics Covered: Pediatric Oncology, Hematologic malignancies, GI Cancers, Gynecological cancers, Head and neck cancers,
Multidrug Resistance and ABC Transporters Conference Dates: November 5, 2008 Conference Location: Baltimore, Maryland Sponsoring Group: Abcam, Inc. Conference Web Page URL: http://www.abcam.com/Baltimore Topics Covered: The meeting will cover multidrug resistance in cancer and ABC transporters - basic, clinical, regulation and drug-drug interaction aspects. Conference Objectives:
School of Breast Oncology (SOBO) Conference Dates: November 6-9 2008 Conference Location: Atlanta, GA Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/sobo/live_meeting/index.php Topics Covered: Over the past decade, an increasing number of oncologists have concentrated their practices on breast cancer, a trend that
The American Society of Breast Surgeons 9th Annual Meeting Conference Dates: April 30 - May 4, 2008 Conference Location: New York Marriott Marquis Sponsoring Group: The American Society of Breast Surgeons Conference Web Page URL: www.breastsurgeons.org Topics Covered: Radiotherapy Systemic Therapy SLN Biopsy Image Guided Breast Procedures Breast Pathology Who Should
Fourth Annual Multidisciplinary Interactive Thoracic Oncology Conference Conference Dates: April 11-12, 2008 Conference Location: Seattle, WA Sponsoring Group: The CBCE Conference Web Page URL: http://www.thecbce.com Conference Objectives: After attending this activity, participants should be able to: Describe the standard of care for patients with early-stage NSCLC, and discuss recent trials incorporating
Eighth Annual New Strategies in Breast Cancer Conference Dates: April 4-5, 2008 Conference Location: Philadelphia, Pennsylvania Sponsoring Group: CBCE™ (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com Topics Covered: Please visit www.thecbce.com for the topics covered during this program, or send an e-mail to info@theCBCE.com. Conference
Rise to Action - Washington, DC Conference Dates: April 12 & 13, 2008 Conference Location: Georgetown University Conference Center Sponsoring Group: Children's Cause for Cancer Advocacy Conference Web Page URL: http://www.childrenscause.org/ Topics Covered: Late Effects; Health Insurance; Education & Employment; Fertility Concerns; Intimacy & Sexuality; Advocacy; Family &
Focus 18 on Fungal Infections Conference Dates: March 6-8, 2007 Conference Location: San Antonio, Texas, USA Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Conference Objectives: Spotlight on both clinical and laboratory aspects of antifungal therapy and a variety of educational tools Who Should Attend: physicians, laboratory technologists, and
Perspectives in Central Nervous System Malignancies IV <p><b>Conference Dates:</b> March 28-29, 2008 <br> <b>Conference Location:</b> Berlin, Germany</p> <p><b>Sponsoring Group:</b> Imedex</p> <p><b>Conference Web Page URL:</b> <a href="http://www.imedex.com"
9th European Congress: Perspectives in Lung Cancer Conference Dates: March 14-15, 2008 Conference Location: Torino, Italy Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Conference Objectives: Lung Cancer Who Should Attend: oncologists, internists, other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) Registration
Fifth Annual Winter Lung Cancer Conference Conference Dates: March 14, 2008 - March 16, 2008 Conference Location: Trump International Sonesta Beach Resort, Sunny Isles Beach, Florida Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com Who Should Attend: Medical, surgical, and radiation oncologists; Thoracic surgeons; Pulmonologists; Nurses; Pharmacists; Advanced
6th Annual Therapeutic Advances in Gastrointestinal Malignancies Conference Dates: March 14, 2008 Conference Location: Sunny Isles Beach, FL Sponsoring Group: The Center for Biomedical Continuing Education Conference Web Page URL: www.thecbce.com Topics Covered: Educational Objectives After participating in this educational activity, attendees should be able to: 1. Discuss clinical trial data integrating
Seventh Annual Recent Advances and New Directions in Cancer Therapy Conference, in Partnership With the California Cancer Consortium Conference Dates: March 28-30, 2008 Conference Location: San Francisco, CA Sponsoring Group: The CBCE™ (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com Topics Covered: Please visit www.thecbce.com or e-mail info@thecbce.com for information regarding the topics covered. Conference Objectives:
5th European Congress: Perspectives in Gynecologic Oncology Conference Dates: January 18-19, 2008 Conference Location: Cannes, France Sponsoring Group: Schering-Plough Conference Web Page URL: www.imedex.com/announcements/317.asp Topics Covered: Cervical Cancer Endometrial Cancer and Vulvar Cancer Ovarian Neoplasm I Ovarian Neoplasm II Conference Objectives: Assess the impact of recently
Highlights: Highlights from the 30th Annual San Antonio Breast Cancer Symposium Conference Dates: January 19, 2008 Conference Location: New York, New York Conference Dates: January 26, 2008 Conference Location: Santa Monica Sponsoring Group: The American School of Oncology Conference Web Page URL: http://www.asoncology.com/Appweb/AsOncologyRegistration/frmPmMeetingWebList.asp Topics Covered: Breast Highlights:
A CME/CNE Regional Dinner Program Series: New Molecular Targets and Novel Agents for the Treatment of Advanced Renal Cell Carcinoma: From Rational Design to Clinical Efficacy Conference Dates: January 14-30, 2008 Conference Location: Nationwide Sponsoring Group: The CBCE Conference Web Page URL: http://www.thecbce.com/rcc Topics Covered: This interactive dinner discussion/presentation forum, including key abstracts presented at the 43rd American Society of Clinical Oncology Annual Meeting, will utilize multiple
4th European Congress on Hematologic Malignancies from Clinical Science to Clinical Practice Conference Dates: February 22-24, 2008 Conference Location: Paris, France Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Conference Objectives: Provide a forum to review state-of-the-art and present new data on the diagnosis and management of myeloma, lymphoma and related disorders Who Should Attend: hematologists,
10th International Symposium on Febrile Neutropenia Conference Dates: February 8-9, 2008 Conference Location: Brussels, Belgium Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Who Should Attend: Oncologists, other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) Registration Information: Please register at www.imedex.com or call
Third Symposium on Upper Gastrointestinal Malignancies Conference Dates: September 6, 2008 Conference Location: Philadelphia, PA Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/gastrointestinal/upper_gi_0908_1102034/index.php Topics Covered: The Third Symposium on Upper Gastrointestinal Malignancies is designed to update practicing
Fifth Annual Symposium on Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia Conference Dates: September 19-20, 2008 Conference Location: Phoenix, AZ Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/hematologic/5th_mll/index.php Topics Covered: The Fifth Annual Symposium on Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia is designed to
12th Annual Fall Oncology Conference: Clinical Challenges in Cancer Medicine Held in Conjunction With the Ninth Annual Medical Oncology Fellows Forum Conference Dates: September 19-21, 2008 Conference Location: Hilton Head, SC Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/multi_disease/12th_fall_oncology_1102037/index.php Topics Covered: The 12th Annual Fall Oncology Conference: Clinical Challenges in Cancer Medicine Held in
Health Care Systems of the Future Conference Dates: September 26, 2008 Conference Location: San Francisco, CA Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://healthsystems.cancerconferences.com/index.php Topics Covered: This activity is presented by Physicians’ Education Resource in conjunction with the UCSF Helen Diller Family
14th Annual Perspectives in Breast Cancer Conference Dates: September 26-27, 2008 Conference Location: New York, New York Sponsoring Group: Imedex Conference Web Page URL: http://www.imedex.com/appweb/announcements/a042-01.asp Topics Covered: Surgery/Radiotherapy, Translational Research, Early and locally advanced disease, Advanced/metastatic disease, Adjuvant therapy Conference
10th World Congress on Gastrointestinal Cancer Conference Dates: June 25-28, 2008 Conference Location: Barcelona, Spain Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Who Should Attend: oncologists, other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) Registration Information: Please register at www.imedex.com or call
iSBTc 23rd Annual Meeting Conference Dates: October 31-November 2, 2008 Conference Location: Westin Horton Plaza- San Diego, CA Sponsoring Group: International Society for Biological Therapy of Cancer Conference Web Page URL: http://www.isbtc.org/meetings/am08/ Topics Covered: Adoptive Transfer Cancer Stem Cells and the Host Response Co-Stimulation
Workshop on Inflammation in Cancer Development Conference Dates: October 30, 2008 Conference Location: Westin Horton Plaza- San Diego, CA Sponsoring Group: International Society for Biological Therapy of Cancer Conference Web Page URL: http://www.isbtc.org/meetings/am08/workshop08/ Conference Objectives: This small group, interactive workshop will assemble thought-leaders in the field to
Primer on Tumor Immunology and Biological Therapy of Cancer Conference Dates: October 30, 2008 Conference Location: Westin Horton Plaza- San Diego, CA Sponsoring Group: International Society for Biological Therapy of Cancer Conference Web Page URL: http://www.isbtc.org/meetings/am08/primer08/ Topics Covered: Adoptive T Cell Therapy Anti-Angiogenic Therapies Antibody Therapy of
Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy 2008 Conference Dates: October 3-5, 2008 Conference Location: New York, NY Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/breast_cancer/adjuvant_1008_1102027/index.php Topics Covered: The Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy 2008 3-day congress is dedicated to
Seventh International Colorectal Cancer Congress Conference Dates: October 16-18, 2008 Conference Location: Aventura, FL Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/gastrointestinal/7th_ccc/index.php Topics Covered: The Seventh International Colorectal Cancer Congress is dedicated to an in-depth discussion of the best care
Annual Symposium for Nurses and Pharmacists Specializing in Oncology: Assessing and Managing Side Effects in the Era of Targeted Therapies Conference Dates: October 25, 2008 Conference Location: Dallas, TX Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/multi_disease/nursephysician_symposium/index.php Topics Covered: The Annual Symposium for Nurses and Pharmacists Specializing in Oncology: Assessing and Managing Side
8th Princess Margaret Hospital Conference, Developments in Cancer Management: Conquering Cancer in our Lifetime Conference Dates: October 16 -18, 2008 Conference Location: Toronto, Ontario, Canada – Hilton, Toronto Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/appweb/announcements/a038-01.asp Organizers: Pamela Catton, MD, Ronald Feld, MD, and Richard Hill, PhD The 8th Princess Margaret Hospital Objectives: New Developments
Introduction to Oncology and Chemotherapy Conference Dates: October 29-30, 2008 Conference Location: San Diego, CA Sponsoring Group: Healthcare Education Services / CHI Conference Web Page URL: http://www.healthtech.com/Conferences_Overview.aspx?id=76030 Topics Covered: Cancer: Terminology and classification Introduction to anti-cancer drugs Side effects of
Cellular Responses to DNA Damage 2008 Conference Dates: Thursday, May 29, 2008 Conference Location: Boston, Massachusetts Sponsoring Group: Abcam, Inc. Conference Web Page URL: http://www.abcam.com/dnadamage08 Topics Covered: - Higher order chromatin structures and double strand break repair. - Chromatin remodeling complexes implicated in the repair of DNA breaks. - Chromatin
Seventh International Congress on Targeted Therapies in Cancer Conference Dates: August 22-24, 2008 Conference Location: Washington, DC Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/other_solid_tumors/7th_targeted_therapies_2032/index.php Topics Covered: The Seventh International Congress on Targeted Therapies in Cancer has been designed to
Seventh International Congress on the Future of Breast Cancer Conference Dates: July 23-26, 2008 Conference Location: Koloa, HI Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/breast_cancer/7th_bcc/index.php Topics Covered: The Seventh International Congress on the Future of Breast Cancer is an international educational and scientific meeting
Fourth Annual Multidisciplinary Symposium on Head and Neck Cancer Conference Dates: December 6, 2008 Conference Location: Philadelphia, PA Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/thoracic/4th_headneck_1208_1102042/index.php Topics Covered: The purpose of the Fourth Annual Multidisciplinary Symposium on Head and Neck Cancer is to provide an
Is Long-Term Survival in Glioblastoma Possible? Updated Results of the EORTC/NCIC Phase III Randomized Trial on Radiotherapy (RT) and Concomitant and Adjuvant Temozolomide (TMZ) versus RT Alone Scientific Session: Is Long-Term Survival in Glioblastoma Possible? Updated Results of the EORTC/NCIC Phase III Randomized Trial on Radiotherapy (RT) and Concomitant and Adjuvant Temozolomide (TMZ) versus RT Alone Stupp et al. (New England Journal 2005) reported improvement in 2-year survival in patients with GBM treated with concurrent radiation
Can Adjuvant Neck Dissection be Deferred in Locally Advanced Head and Neck Cancer Patients with Complete Response to Definitive Chemoradiotherapy? Scientific Session: Can Adjuvant Neck Dissection be Deferred in Locally Advanced Head and Neck Cancer Patients wtih Complete Response to Definitive Chemoradiotherapy? Patients with locally advanced squamous cell cancer of the head and neck are typically treated with a combination of chemotherapy and radiation therapy. This therapy can achieve a
Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplatin and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer Scientific Session: Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplating and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer There is no consensus on standard therapy for locally advanced pancreatic
Dose to the Larynx Predicts for Swallowing Complications Following IMRT and Chemotherapy Scientific Session: Dose to the Larynx Predicts for Swallowing Complications Following IMRT and Chemotherapy The combination of chemotherapy and radiation therapy has improved survival for people with head and neck cancers, but this has led to an increase in toxicity. Two concerning side effect are aspiration (breathing food or drink into the
Comparison of Health Related Quality of Life (HRQOL) in Men Treated With Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer Scientific Session: Comparison of Health Related Quality of Life (HRQOL) in Men Treated With Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer Although no large, randomized trials have directly compared outcomes between the two leading treatment options for patients with low-risk prostate cancer, historical
Update of the Results of the Dutch Multicenter Dose Escalation Trial of Radiotherapy for Localized Prostate Cancer Scientific Session: Update of the Results of the Dutch Multicenter Dose Escalation Trial of Radiotherapy for Localized Prostate Cancer Improved radiation techniques (IMRT and 3D conformal radiation therapy) have allowed for higher doses of radiation to be given in the treatment of prostate cancer. This study updated a previous report which showed
Neurocognitive Impact of Whole Brain Radiation on Patients With Brain Metastases: Secondary Analysis of RTOG BR-0018 Scientific Session: Neurocognitive Impact of Whole Brain Radiation on Patients With Brain Metastases: Secondary Analysis of RTOG BR-0018 This is the second report from a study on the ability to evaluate neurocognitive functioning after whole brain radiotherapy. This report specifically addresses the results of these evaluations. Participants were
Prophylactic Cranial Irradiation (PCI) in Extensive Stage Small Cell Lung Cancer (ES-SCLC) (EORTC 22993-08993) Presenter: Bernard J. Slotman, MD, PhDPresenter's Affiliation: VU University Medical Center, EORTC Radiation Oncology and Lung Cancer GroupsType of Session: ScientificBackground At the time of diagnosis, approximately 20% of patients with small cell lung cancer (SCLC) have brain metastases, and at least 50% will develop brain metastases at
A Phase III Trial to Compare Standard Versus Accelerated Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Compliance and Toxicity Presenter: Kian Ang, MD, PhDPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground The definitive treatment of locally advanced head and neck cancer with radiation has evolved greatly over the past 15 years. Various treatment regimens have been employed such as hyperfractionated radiation (EORTC 22791)
Phase II Randomized Trial of Surgery Followed by Chemoradiation Plus Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234) Presenter: Paul Harari, MDPresenter's Affiliation: University of WisconsinType of Session: ScientificBackground Prior studies have demonstrated an improvement in local control and overall survival in post operative, high risk patients with locally advanced squamous cell carcinoma of the head and neck treated with concurrent chemotherapy and
Can Adjuvant Neck Dissection be Deferred in Locally Advanced Head and Neck Cancer Patients wtih Complete Response to Definitive Chemoradiotherapy? Presenter: S. YovinoPresenter's Affiliation: University of Maryland Medical System, Baltimore, MDType of Session: ScientificBackground With recent advances in radiotherapy techniques and their use with concurrent chemotherapy, patients with locally advanced squamous cell carcinoma of the head and neck who are felt to be at risk for
Post-resectional CA 19-9 Values >90 are Associated With Significantly Worse Survival in Patients With Pancreatic Carcinoma Treated With Adjuvant Therapy on RTOG 9704 - Implications for Current and Future Trials Presenter: William F. Regine, MDPresenter's Affiliation: University of Maryland Medical Center, Radiation Therapy Oncology GroupType of Session: ScientificBackground The CONKO-001 phase III trial (Oettle H, et al. JAMA. 2007;297(3):267-77) recently reported that adjuvant Gemcitabine without radiation resulted in improved disease free survival
The Impact of Boost Dose and Margins on the Local Recurrence Rate in Breast Conserving Therapy: Results From the EORTC Boost-No Boost Trial Presenter: H. JonesPresenter's Affiliation: Holzer Cancer Center for Cancer Care, Gallipolis, OHType of Session: PlenaryBackground Breast conserving therapy (BCT), which consists of lumpectomy followed by adjuvant radiation treatment (RT), is currently a standard option for patients with early-stage breast cancer. Although
Which Lung Volumes to Use for Radiotherapy Planning of Lung Cancer: Inspiration, Expiration, Averaged, or Free-breathing? Presenter: Yixiu Kang, MDPresenter's Affiliation: M.D. Anderson Cancer CenterType of Session: PlenaryBackground Local control in patients with early stage non-small cell lung cancer (NSCLC) after conventional radiotherapy has historically been poor. Doses of up to 70 Gy delivered with 3D conformal radiotherapy achieve local control in
Is Long-Term Survival in Glioblastoma Possible? Updated Results of the EORTC/NCIC Phase III Randomized Trial on Radiotherapy (RT) and Concomitant and Adjuvant Temozolomide (TMZ) versus RT Alone Presenter: Rene-Olivier Mirimanoff , MDPresenter's Affiliation: University Hospital Lausanne, Lausanne, SwitzerlandType of Session: PlenaryBackground Glioblastoma Multiforme (GBM) is a devastating malignancy with poor survival even with full surgical resection and radiation. Previously Stupp et al. (NEJM 2005) reported improvement in 2
The Integrin-TGFbeta Axis: Inhibition of Integrin Alpha v Beta6 Prevents Radiation-Induced Lung Fibrosis. Presenter: S. ChengPresenter's Affiliation: New York University Medical Center, New York, NYType of Session: ScientificBackground Over 175,000 new cases of thoracic malignancies are diagnosed in the United States each year, and over half of them require treatment with radiation at some point. Treatment of thoracic malignancies is
A Small Molecular Inhibitor of TGFß Protects Against the Development of Radiation Induced Lung Injury Presenter: Mitchell S. Anscher, MDPresenter's Affiliation: Virginia Commonwealth University Medical Center, Richmond, VAType of Session: PlenaryBackground One of the primary limitations that inhibits dose escalation in the treatment of lung cancer is the risk of pulmonary toxicity, such as pulmonary fibrosis. Finding new agents to
Characterization of Pancreatic Tumor Motion Using 4D MRI: Surrogates for Tumor Position Should be Used With Caution Presenter: Mary Feng, MDPresenter's Affiliation: University of Michigan Medical CenterType of Session: PlenaryBackground Pancreatic cancer is associated with poor outcomes and limited long-term survival, and there are numerous challenges that treating physicians encounter. Less than 20% of patients are operable at the time of
Breast Magnetic Resonance Imaging in the Management of Early Breast Cancer: Implications for Partial Breast Irradiation Presenter: R.D. TendulkarPresenter's Affiliation: Cleveland Clinic, Cleveland, OHType of Session: ScientificBackground For patients with early stage breast cancer, breast conserving treatment (BCT), consisting of lumpectomy followed by breast irradiation is currently a standard of care. Current radiotherapy techniques involve delivery of
Image Guidance for External Beam Partial Breast Irradiation Presenter: S.H. Wahab, MDPresenter's Affiliation: Washington UniversityType of Session: ScientificBackground Partial Breast Irradiation (PBI) is currently being investigated in several studies, and at present, the ideal system to use for proper setup is still not established. PBI is more susceptible to random setup errors compared with
Comparison of Health Related Quality of Life (HRQOL) in Men Treated With Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer Presenter: Varagur M. Venkatesan, MDPresenter's Affiliation: London Regional Cancer Program, London Health Sciences CentreType of Session: ScientificBackground Although no large, randomized trials have directly compared outcomes between the two leading treatment modalities for patients with low-risk prostate cancer, historical comparisons
Breast Cancer After Supradiaphragmatic Irradiation for Hodgkin's Disease; Risk Analysis and Possible Surveillance Strategies Presenter: M. A. Alm El-Dina, MDPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Radiation therapy imparts an antitumor effect through the formation of free radiations. Radiation can also have effects on normal tissues. It can also induce cancer in long-term cancer survivors,
A Phase II Trial of Conformal Radiation Therapy for Pediatric Low-Grade Glioma: 5-year Disease Control and Functional Outcomes Presenter: T. E. MerchantPresenter's Affiliation: St. Jude Children's Research Hospital, Memphis, TNType of Session: ScientificBackground Central nervous system (CNS) tumors represent the most common solid tumor of childhood, and are the most common cause of cancer-related death in this population. Low-grade gliomas are a subset of
Dose to the Larynx Predicts for Swallowing Complications Following IMRT and Chemotherapy Presenter: Hale B. Caglar, MDPresenter's Affiliation: Head and Neck Oncology Program Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MAType of Session: ScientificBackground The combination of chemotherapy and radiation therapy has improved survival and local control outcomes in patients with head and neck
Current and Future Applications of Proton Therapy: It's All About the Therapeutic Ratio The following is a summary of a presentation by Nancy P. Mendenhall, MD from a panel session at the ASTRO 2007 Annual Meeting. The clinical concepts underlying proton beam radiotherapy are the same principles that have governed our use of x-ray therapy since its inception. For the most part, we are lacking large, randomized, prospective trials
Socioeconomic Aspects of Proton Therapy The following is a summary of a presentation by Timothy Williams, MD from a panel session at the ASTRO 2007 Annual Meeting. The last two decades have seen an era of unparalleled technical developments in the field of radiation oncology. Three-dimensional conformal radiation therapy and intensity modulated radiation therapy (IMRT) have become the
New Technical Developments in Proton Therapy The following is a summary of a presentation by James McDonough, Ph.D. from a panel session at the ASTRO 2007 Annual Meeting. Current Status of Protons in America There are currently five high energy proton facilities in the United States The first was in Loma Linda and started in 1990 and has the largest experience
Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplating and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer Presenter: C.H. Crane substituting for F. MornexPresenter's Affiliation: Centre Hospitalier Lyon Sud, Lyon Pierre Benite, FranceType of Session: ScientificBackground Pancreatic cancer is the fourth most common malignancy in the United States, and the annual incidence rate is almost identical to the mortality rate. In 2007, over 37,000
Chest Wall Radiation Alone for Breast Cancer Patients With 1-3 Positive Lymph Nodes Treated by Mastectomy Presenter: Shannon M. MacDonald, MDPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Numerous studies have demonstrated that the administration of adjuvant comprehensive postmastectomy radiation, which includes radiation to the chest wall and supraclavicular region, reduces locoregional recurrences
Percent Necrosis in Extremity Soft Tissue Sarcoma After Preoperative Radiation Alone Versus Preoperative Radiation and Chemotherapy Presenter: Karl Haglund MD, PhDPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Prior studies have found that treatment related necrosis is a prognostic marker in bone sarcomas. Retrospective studies of soft tissue sarcomas from UCLA suggested that in soft tissue sarcomas of the extremities,
A Phase II Study of a Paclitaxel Based Chemoradiation Regimen With Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer: Initial Reporting of RTOG 0246 Presenter: Stephen Swisher, MDPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground Prior studies (RTOG 8501) have demonstrated that chemoradiation is more effective than radiation alone in the treatment of esophageal cancer. However, in this study the majority of patients had squamous cell carcinoma and
Outcome After Stereotactic Radiotherapy in 'High-Risk' Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Presenter: F. J. LagerwaardPresenter's Affiliation: VU University Medical Center, Amsterdam, The NetherlandsType of Session: ScientificBackground Surgical treatment with lobectomy or pneumonectomy is recognized as the optimal treatment for stage I non-small cell lung cancer (NSCLC) (Kraev A, Chest, 2007); however, many patients with this
Toxicity Analysis of RTOG 0236 Using Stereotactic Body Radiotherapy to Treat Medically Inoperable Early Stage Lung Cancer Patients Presenter: Robert Timmerman, MDPresenter's Affiliation: University of Texas SouthwesternType of Session: ScientificBackground The treatment of patients with non-small cell lung cancer (NSCLC) who are unable to undergo surgery can be very difficult as these patients often have poor lung function which limits radiation dose and volumes.
Statin Use and Clinical Outcomes after High-Dose Radiotherapy for Prostate Cancer Presenter: M. ZelefskyPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, New York, NYType of Session: ScientificBackground Clinical and laboratory work has suggested that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly known as statins, may have anti-cancer activity. These drugs have been demonstrated
Prospective Trial of Individual Optimal Positioning (Prone Versus Supine) for Whole Breast Radiotherapy: Results of the First 168 Patients Presenter: Silvia C. Formenti, MDPresenter's Affiliation: New York University Medical CenterType of Session: ScientificBackground External beam radiation therapy as part of breast conservation therapy for early stage breast cancer has traditionally used tangential fields to treat the whole breast of patients in the supine position. Newer
Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vascualture Presenter: James Murphy, MDPresenter's Affiliation: University of MichiganType of Session: ScientificBackground Rapamycin is an FDA approved immunosuppressant used in organ transplant, especially renal. It was derived from a soil sample from the island of Rapa Nui. Rapamycin was originally used as an antifungal but rejected due to
Update of the Results of the Dutch Multicenter Dose Escalation Trial of Radiotherapy for Localized Prostate Cancer Presenter: Abrahim Al-Mamgani, MDPresenter's Affiliation: Erasmus Medical Center, Rotterdam, The NetherlandsType of Session: ScientificBackground With the increased use of three-dimensional conformal radiotherapy (3D-CRT) and intensity modulated radiation therapy (IMRT), radiation oncologists have been able to treat patients with prostate
Neurocognitive Impact of Whole Brain Radiation on Patients With Brain Metastases: Secondary Analysis of RTOG BR-0018 Presenter: Young Kwok, MDPresenter's Affiliation: University of Maryland Medical CenterType of Session: ScientificBackground In studies involving the treatment of patients with brain metastases, survival and time to progression may not fully describe therapeutic effects. Since both brain metastases and the treatment modalities for these
Impact of Postoperative Radiation Therapy on Postmastectomy Breast Reconstruction Presenter: L.C. KeilerPresenter's Affiliation: University Hospital of Cleveland, Cleveland, OHType of Session: ScientificBackground Despite improvements in early-detection of breast cancer, many patients still present with disease requiring surgical intervention with mastectomy. Post-mastectomy radiation treatment (PMRT) is recommended
Bortezomib/dexamethasone versus VAD as Induction Prior to Autologous Stem Cell Transplant (ASCT) in Previously Untreated Multiple Myeloma (MM): Updated Data from IFM 2005/01 Trial Presenter: Harousseau J.L.Presenter's Affiliation: Hoteldieu Hospital, Nantes, FranceType of Session: ScientificBackground Multiple Myeloma (MM) remains an incurable condition, with a median survival of 48-68 months. Autologous stem cell transplant (ASCT) is the standard of care for MM patients aged ≤65 years old and is associated
Deforolimus Trial 106-A Phase I Trial Evaluating 7 Regimes of Oral Deforolimus (AP23573, MK-8669) Presenter: Mita M.M.Presenter's Affiliation: University of Texas Health and Science Center, San AntonioType of Session: ScientificBackground Prior studies have validated mTOR as a target in cancer therapy. mTOR is a downstream target of the PI3K/Akt pathway and mTOR has effects both downstream and upstream of Akt. Hence mTOR
Randomized Phase III Study of Capecitabine, Oxaliplatin, and Bevacizumab with or without Cetuximab in Advanced Colorectal Cancer (ACC), the CAIRO2 Study of the Dutch Colorectal Cancer Group (DCCG) Presenter: Punt C.J.Presenter's Affiliation: UMC St Radboud, Nijmegen, NetherlandsType of Session: ScientificBackground Prior studies have found an overall survival benefit in patients with advanced colorectal cancers (ACC) treated with fluoropyrimidine-based chemotherapy combined with bevacizumab (bev), as compared to
RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase III study Presenter: R.J. MotzerPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, New York, NYType of Session: ScientificBackground Treatment of metastatic renal cell carcinoma (RCC) has changed dramatically over the past several years with the availability of targeted agents. As the role of angiogenesis and tumor proliferation in
Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONCEPT trial Presenter: A. Grothey Presenter's Affiliation: Mayo Clinic Type of Session: Scientific Background Oxaliplatin is widely used as a 1st line treatment for metastatic colorectal cancer (mCRC). The addition of Bevacizumab has also been shown to improve efficacy, and these 2 agents are often used in combination. Although oxaliplatin is relatively
Long-term outcomes among survivors of childhood central nervous system tumors: A report from the childhood cancer survivor study Presenter: G. T. ArmstrongPresenter's Affiliation: St. Jude Children's Research Hospital, Memphis, TNType of Session: ScientificBackground Over 270,000 childhood cancer survivors reside in the United States, and this number is expected to grow as survival rates after childhood cancer continue to increase. Currently, one in 640 adults
Bortezomib/dexamethasone versus VAD as Induction Prior to Autologous Stem Cell Transplant (ASCT) in Previously Untreated Multiple Myeloma (MM): Updated Data from IFM 2005/01 Trial Bortezomib/dexamethasone versus VAD as Induction Prior to Autologous Stem Cell Transplant (ASCT) in Previously Untreated Multiple Myeloma (MM): Updated Data from IFM 2005/01 Trial The use of autologous stem cell transplant in treating multiple myeloma patients over 65 years of age has become standard therapy. Traditionally, the VAD chemotherapy
BRCA1 mRNA expression in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy BRCA1 mRNA expression in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy Improved overall survival has been demonstrated with the use of cisplatin-based chemotherapy given prior to radical cystectomy in patients with locally advanced bladder cancer, as compared to radical cystectomy alone (Lancet, 2003).
Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double blind NCCTG trial N04C7 Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double blind NCCTG trial N04C7 The addition of oxaliplatin to the arsenal of therapies for GI cancers has had a profound effect on survival, but not without additional side
Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity Non-small cell lung cancer (NSCLC) remains the number one cause of cancer death in both men and women in the United States. The greatly increased risk of NSCLC development
Evaluation of chromosome 17 (Chr-17) polysomy in Her2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib Evaluation of chromosome 17 (Chr-17) polysomy in Her2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib Researchers believe that having multiple copies of a cromosome (i.e. 3 or more, a condition known as polysomy), specifically of chromosome 17, may result in higher
A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 Previous studies have shown a benefit to adding oxaliplatin to the standard 5-FU and leucovorin in adjuvant therapy for stage II or III colon cancer. This report is an update of the results of a phase III study
RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase III study RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase III study RAD001 (Everolimus) is an oral targeted therapy medication that inhibits mTOR, which regulates cell proliferation (growth) and angiogenesis (development of blood
Initial Safety Report of NSABP C-08, a Randomized Phase III Study of Modified 5-Flurouracil (5-FU/leucovorin (LCV) and oxalliplatin (OX) (mFOLFOX6) with or without Bevacizumab (bev) in the Adjuvant Treatment of Patients with Stage II/III Colon Cancer Presenter: Allegra, C.J.Presenter's Affiliation: University of FloridaType of Session: ScientificBackground There is a rationale for combining antiangiogenic agents, such as bevacizumab, with cytotoxic chemotherapy, such as mFOLFOX6, in the treatment of solid tumors. The tumor vasculature is thought to be disorganized and leaky,
Sentinel Lymph Node Biopsy Improves Survival Among SEER Patients with Melanoma Presenter: Gimotty P. Presenter's Affiliation: University of Pennsylvania Type of Session: Scientific Background Regional lymph node metastases increase the risk of melanoma-specific death. Sentinel lymph node biopsy (SLNB) provides prognostic information in patients with malignant melanoma (MM); however, its therapeutic role is not well
A Phase II multicenter, randomized trial to compare anastrazole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) Presenter: M. CristofanilliPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground It is well known that hormonal receptor status is an important prognostic factor in metastatic breast cancer patients and has clinical implications for hormonal therapies. 55% of metastatic breast cancer patients are
Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial Presenter: R.A. NoutPresenter's Affiliation: Leiden University Medical Center, Leiden, NetherlandsType of Session: ScientificBackground Endometrial carcinoma represents the most common gynecologic malignancy in the United States, and the second most common cause of gynecologic cancer death. Tumor grade (1 -3), histology, and depth of
A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group (GOG) study Presenter: B. J. MonkPresenter's Affiliation: University of California, Irvine, Orange, CAType of Session: ScientificBackground Cervical cancer represents the third most common gynecologic malignancy in the United States. Although screening via Pap smear has significantly decreased the prevalence of advanced and metastatic cervical
Randomized Trial of Standard Versus Higher Dose Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Cancer (SCLC) Complete Responders (CR): Primary End Point Analysis (PCI99-01, EORTC 22003-08004, RTOG 0212) Presenter: Le Pechoux C.Presenter's Affiliation: Institute Gustav Roussy, Villejuif, FranceType of Session: ScientificBackground The use of prophylactic cranial irradiation (PCI) in patients with limited stage small cell lung cancer (SCLC) has been shown to provide an overall survival benefit (3-year overall survival of 20.7% with PCI versus
Adjuvant ovarian suppression combined with tamoxifen or anastrazole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: First efficacy results from ABCSG Presenter: M. GnantPresenter's Affiliation: Medical University of ViennaType of Session: ScientificBackground In hormone receptor-positive breast cancers, growth of the tumor is stimulated by estrogens. Decreasing the production of estrogens therefore leads to suppression of recurrence, and drugs such as tamoxifen and aromatase
KRAS Status and Efficacy in the First –Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI with or without Cetuximab: The Crystal Experience Presenter: Van Cutsem E. Presenter's Affiliation: University Hospital Gasthuisberg, Leuven, Belgium Type of Session: Plenary Background Cetuximab is a chimeric antibody which blocks epidermal growth factor (EGF) signaling by binding to the EGF receptor (EGFR). The EGFR has several downstream targets, including the PI3K/Akt pathway and
Randomised, double-blind, placebo controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO Randomised, double-blind, placebo controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO Bevacizumab is a monoclonal antibody that targets VEGF, which allows it to inhibit angiogenesis (growth of blood
A randomized phase III trial of four cisplatin (CIS)- containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group (GOG) study A randomized phase III trial of four cisplatin (CIS)- containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group (GOG) study Several studies have demonstrated varying degrees of benefit to adding a second chemotherapy to cisplatin when treating advanced cervical cancer. This GOG
Randomized Trial of Standard Versus Higher Dose Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Cancer (SCLC) Complete Responders (CR): Primary End Point Analysis (PCI99-01, EORTC 22003-08004, RTOG 0212) Randomized Trial of Standard Versus Higher Dose Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Cancer (SCLC) Complete Responders (CR): Primary End Point Analysis (PCI99-01, EORTC 22003-08004, RTOG 0212) The use of prophylactic cranial irradiation (PCI) in patients with limited stage small cell lung cancer (SCLC) has been
SO124: A Randomized Phase III Trial Comparing Irinotecan/Cisplatin (IP) with Etoposide/Cisplatin (EP) in Patients (pts) with Previously Untreated Extensive Stage Small Cell Lung Cancer (E-SCLC) SO124: A Randomized Phase III Trial Comparing Irinotecan/Cisplatin (IP) with Etoposide/Cisplatin (EP) in Patients (pts) with Previously Untreated Extensive Stage Small Cell Lung Cancer (E-SCLC) The combination of etoposide and cisplatin (EP) is the most widely used chemotherapy regimen for small cell lung cancer. Two large studies looked at using
FLEX: A randomized,multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) FLEX: A randomized,multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) Epidermal growth factor (EGFR) is over expressed in 80% of lung cancers. Cetuximab is a monoclonal antibody that interferes with
KRAS Status and Efficacy in the First –Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI with or without Cetuximab: The Crystal Experience KRAS Status and Efficacy in the First –Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI with or without Cetuximab: The Crystal Experience Cetuximab is a targeted therapy agent that blocks epidermal growth factor receptor (EGFR) and that is used in the treatment of colon cancers. EGFR has several
Radiotherapy versus carboplatin for Stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214) Radiotherapy versus carboplatin for Stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214) Seminoma (the most common type of testicular cancer) has traditionally been treated with orchiectomy followed by radiation therapy. Follow-up of these patients found that the radiation therapy resulted in higher risk of
Cancer-related fatigue interferes with activities of daily living among 753 patiens receiving chemotherapy: A URCC CCOP study Presenter: K.M. MustianPresenter's Affiliation: University of Rochester Cacner Center, Rochester, NYType of Session: ScientificBackground Cancer-related fatigue (CRF) is common in cancer patients, and may be under-diagnosed, under-recognized, and under-treated (Savard, 2001). Cancer-related fatigue is in all likelihood multifactorial,
A phase II randomized, placebo-controlled, double blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP study Presenter: G. R. MorrowPresenter's Affiliation: U. of Rochester Medical Center, Rochester, NYType of Session: ScientificBackground Cancer-related fatigue (CRF) is one of the most common side effects of cancer and its treatment, and has been shown to affect nearly 70-100% of cancer patients in previous studies. It usually comes
ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon Presenter: Picozzi R.A.Presenter's Affiliation: Virginia Mason Medical Center, Seattle WashingtonType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer death in the United States and in 2007, over 37,000 cases were diagnosed, and over 33,000 deaths documented (Jemal, CA Cancer J Clin, 2007).
Randomized Phase III Trial of Sorafenib Versus Placebo in Asian Patients with Advanced Hepatocellular Carcinoma Presenter: Cheng A.Presenter's Affiliation: National Taiwan University Hospital, Taipei, TaiwanType of Session: ScientificBackground Hepatocellular carcinoma (HCC) is the 8th most common cancer in the world, but yet it is the number three cause of cancer deaths worldwide. The areas with the highest incidence of HCC are East and Southeast Asia
CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) Presenter: Neumann J.P.Presenter's Affiliation: Charite School of Medicine, Berlin, GermanyType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer death in the United States, and in 2007, over 37,000 cases were diagnosed, and over 33,000 deaths documented . Surgery is the only curative
A phase III randomized study comparing the effects of oxandrolone (Ox) and megastrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy Presenter: G. J. LesserPresenter's Affiliation: Wake Forest University, Winston-Salem, NCType of Session: ScientificBackground A study by DeWys, et. al. in 1980 showed that unintentional weight loss in cancer patients is a significant problem and is a poor prognostic factor. It is associated with decreased survival and QOL, and increased
Electronic self-report assessment for cancer (ESRA-C): Results of a randomized clinical trial Presenter: D.L. BerryPresenter's Affiliation: University of Washington, Seattle, WAType of Session: ScientificBackground As the healthcare milieu continuously evolves, healthcare providers are faced with the difficulties of shrinking resources, which may ultimately impact upon the amount of time spent with patients during individual clinic
ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon Surgery is considered the only curative therapy for pancreatic cancer. However, 50-80% of patients will develop recurrence after surgery. For this reason, patients also receive adjuvant (meaning
Cancer-related fatigue interferes with activities of daily living among 753 patients receiving chemotherapy: A URCC CCOP study Cancer-related fatigue interferes with activities of daily living among 753 patients receiving chemotherapy: A URCC CCOP study Cancer-related fatigue is unfortunately a very common problem with few to no effective solutions. This study looked to evaluate rates of fatigue and how they interfere with activities of daily living (ADLs) (such as
CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) This study has previously reported (Oettle H., et al. JAMA 2007) that the use of post-operative gemcitabine in patients with pancreatic cancer
Effect of paroxetine on depression and insomnia in 547 fatigued cancer patients undergoing chemotherapy Effect of paroxetine on depression and insomnia in 547 fatigued cancer patients undergoing chemotherapy Depression and insomnia are two common issues in people with cancer. Studies have found that approximately 30% of people with cancer report insomnia and they are 2.5 times as likely to have insomnia compared with the general population. This
Effects of aerobic exercise training on physical performance during myeloablative therapy Effects of aerobic exercise training on physical performance during myeloablative therapy The benefits of exercise for people undergoing cancer therapy have been shown in previous studies. These include improvements in lung and heart function, increased strength and improvements in fatigue levels. The purpose of this study was to evaluate
A phase II randomized, placebo-controlled, double blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP study A phase II randomized, placebo-controlled, double blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP study Cancer-related fatigue (CRF) is one of the most common side effects of cancer and its treatment, and has been shown to affect nearly 70-100% of cancer patients in previous studies. This
A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy A study by DeWys, et. al. in 1980 showed that unintentional weight loss in cancer patients is a significant problem
Prophylaxis of recurrent chemotherapy-induced oral mucositis: A phase II multicenter, randomized, placebo-controlled trial of recombinant human intestinal trefoil factor (rhITF) Prophylaxis of recurrent chemotherapy-induced oral mucositis: A phase II multicenter, randomized, placebo-controlled trial of recombinant human intestinal trefoil factor (rhITF) Oral mucositis is a common, debilitating symptom affecting many patients on high-dose chemotherapy. It is an inflammation of the mucous membranes of the mouth, and can
A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer: E4201 A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer: E4201 Prior studies of gemcitabine with radiation therapy in pancreatic cancer have concluded that the drug adds toxicity, with little, if any benefit. But, gemcitabine if known
Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer “Chemobrain” or “chemofog” was originally described by the female breast cancer population, and refers to symptoms of decreased cognitive acuity described by patients. Often, these symptoms include
Adjuvant Chemoradiation Therapy after Surgical Resection for 1092 Cases of Pancreatic Adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic Collaborative Study of Pancreatic Cancer Presenter: C. C. HsuPresenter's Affiliation: Johns Hopkins Hospital, Baltimore, MDType of Session: ScientificBackground Despite aggressive multimodality treatment, pancreatic cancer is associated with a high rate of mortality. Even the 15-20% of patients who present with resectable disease experience 5-year survivals of only 10-25%.
Recurrence and Survival in the American Society of Breast Surgeons (ASBS) MammoSite RTS Registry Trial Presenter: P.D. BeitschPresenter's Affiliation: American Society of Breast Surgeons, Dallas, TXType of Session: ScientificBackground Large trials examining outcomes for early-stage breast cancer patients have demonstrated that lumpectomy followed by radiotherapy is equivalent to mastectomy. Local recurrence rates remain higher
Initial Efficacy Results of RTOG 0319: Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I/II Breast Carcinoma Presenter: F.A. ViciniPresenter's Affiliation: William Beaumont Hospital, Royal Oak, MIType of Session: ScientificBackground Breast conservation treatment, consisting of lumpectomy followed by radiotherapy, has been demonstrated in large trials to be equivalent to mastectomy for treatment of early-stage breast cancer (Fisher B, NEJM, 2002).
Postoperative Adjuvant Gemcitabine Plus Oxaliplatin (GemOx)Chemotherapy in Patients with Pancreatic Adenocarcinoma: Final Results of a Single Arm Multicenter Phase II Study Presenter: Francoise Mornex Presenter's Affiliation: Centre Hospitalier Lyon Sud, Lyon, France Type of Session: Scientific Background Pancreas cancer treated with surgery alone has produced disappointing results including high rates of positive margins and rapid development of distant metastases At the time of initiation of this study,
Comparative Analysis of Second Malignancy Risk in Patients Treated with Proton Therapy versus Conventional Photon Therapy Presenter: T. YockPresenter's Affiliation: Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground Proton radiotherapy is rapidly gaining favor as a treatment modality in the setting of many cancers. Due largely to the physical nature of protons as particulate matter, proton radiation can improve dose distribution
The Impact of Short Course Pre-Operative Radiotherapy on Patients’ Quality of Life: Data from the MRC CR07/ NCIC CO16 Randomised Clinical Trial in Patients with Rectal Cancer Presenter: D. Sebag-Montefiore, MDPresenter's Affiliation: Medical Research Council Clinical Trial Unit, CR07 Trial Management GroupType of Session: PlenaryBackground The current standard of care for treatment rectal cancer involves surgery; however, there is a high incidence of local recurrence seen after surgery due to failure to remove all
A Phase III Prospective Randomized Trial Comparing Radiosurgery With Versus Without Whole Brain Radiotherapy for 1-3 Newly Diagnosed Brain Metastases Presenter: Eric Chang, MDPresenter's Affiliation: MD Anderson Cancer Center, TexasType of Session: PlenaryBackground Brain metastases occur in 20% to 40% of all patients with cancer, and there are approximately 170,000 new cases of brain metastases per year reported in the United States. They generally are associated with a poor prognosis and
A Randomized Trial Comparing Antiandrogens with or without Radiotherapy in the Treatment of Locally Advanced Prostate Cancer: Survival and QOL Outcome Presenter: Anders WidmarkPresenter's Affiliation: Umeå University, SwedenType of Session: ScientificBackground Hormonal therapy has become a standard addition to definitive radiation therapy for higher risk and locally advanced prostate cancer. Luteinizing hormone-releasing hormone (LHRH) antagonist administration, a form of medical
Long-term Results of a Randomized Trial of Accelerated Hypofractionated Whole Breast Irradiation Following Breast Conserving Surgery in Women with Node-Negative Breast Cancer Presenter: T.J. WhelanPresenter's Affiliation: Juravinski Cancer Centre and McMaster University, Hamilton, ON, CanadaType of Session: PlenaryBackground Large, well-designed trials have demonstrated that lumpectomy followed by whole breast radiotherapy is equivalent to mastectomy as treatment for early-stage breast cancer (Fisher B, NEJM,
Independent Interfraction Motion and Deformation of Pelvic Nodes and Prostate in Image Guided Concurrent Irradiation of Prostate and Pelvic Nodes Presenter: Adam CurreyPresenter's Affiliation: Medical College of WisconsinType of Session: ScientificBackground Patients with high risk prostate cancer are known to be at increased risk for occult nodal involvement In approximately 15% of cases, interfraction motion of the prostate exceeds 1cm Daily target localization is now
Pain and Rib Fracture after Stereotactic Radiotherapy for Peripheral Non-small Cell Lung Cancer (NSCLC) Presenter: A. M. BradePresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: ScientificBackground The current standard of care for operable patients with early stage lung cancer has been well established as surgical resection +/- adjuvant chemotherapy, with local control rates close to 90%. Treatment
Brachial Plexopathy (BP) from Stereotactic Body Radiotherapy (SBRT) in Early-Stage NSCLC Presenter: J.A. Forquer, MDPresenter's Affiliation: Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, INType of Session: ScientificBackground Brachial plexopathy (BP) is a type of peripheral neuropathy which is caused by impaired function or damage of the brachial plexus, the nerves that control
Induction Chemotherapy versus Chemoradiotherapy for Stage III Non-small Cell Lung Cancer Presenter: Kristin HigginsPresenter's Affiliation: Duke University, North CarolinaType of Session: ScientificBackground Stage IIIa non-small cell lung cancer with N2 disease represents a heterogenous group of patients ranging from microscopic lymph node involvement on staging mediastinoscopy to bulky mediastinal disease on initial staging
Results of the Phase III ENRICH (RT-016) Study of Efaproxiral Administered Concurrently with Whole Brain Radiation Therapy (WBRT) in Women with Brain Metastases from Breast Cancer Presenter: J. H. SuhPresenter's Affiliation: Cleveland Clinic, Cleveland, OHType of Session: ScientificBackground Brain metastasis is a common and deadly complication of many cancers, including lung, breast, renal cell, melanoma, and others. 170,000 individuals are diagnosed with new brain metastases annually in the United States.
The Incidence of Stroke in Patients with Head and Neck Cancer with or without Radiotherapy Presenter: D.J. HuangPresenter's Affiliation: Mount Sinai School of Medicine, New York, NYType of Session: ScientificBackground Radiotherapy is an essential component of treatment for many cancers of the head and neck, and may be delivered in combination with surgery and/ or chemotherapy. As the number of cancer survivors living in the
The Risk of Developing a Neutron-induced Second Malignancy for Pediatric Proton Therapy Patients Presenter: Harald PaganettiPresenter's Affiliation: Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground Second malignancies and other late toxicities are a major concern when treating pediatric cancer patients with radiation therapy. The physical properties of the proton beam offer the potential for
CaP Calculator: An Online Decision Support Tool to Improve Evidence-based Doctor-Patient Communication for Clinically Localized Prostate Cancer Presenter: M.S. KatzPresenter's Affiliation: Saints Medical Center, Lowell, MAType of Session: ScientificBackground Prostate cancer is the most commonly diagnosed cancer in men living in the United States, and most patients have localized disease at the time of diagnosis. At the time of prostate cancer diagnosis, patients are faced with
Stereotactic Body Radiosurgery for 121 Cases of Spinal Metastases Treated at M.D. Anderson Cancer Center Presenter: E. L. ChangPresenter's Affiliation: M.D. Anderson Cancer CenterType of Session: ScientificBackground · Spinal metastases commonly develop in patients with cancer, and can often cause extreme back pain, weakness, autonomic dysfunction, and difficulty with
Final Report of a Canadian Phase III Trial of 3 vs. 8 months Neoadjuvant Androgen Deprivation Prior to 66 Gray External Beam Radiotherapy for Clinically Localized Prostate Cancer. Presenter: J. M. Crook, MDPresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: ScientificBackground Data from prior RTOG and EORTC trials indicate that the combination of hormonal therapy to radiation treatment for prostate cancer may improve survival in certain subsets of patients. However,
Long-term Quality of Life after Chemoradiation for Anal Cancer Presenter: Prajnan DasPresenter's Affiliation: UT MD Anderson Cancer Center, Houston, TXType of Session: ScientificBackground There are an estimated 4700 cases/year of anal cancer in the US. Definitive radiation therapy with concurrent chemotherapy represents the standard of care for squamous cell carcinoma of the anus. RTOG 9811
A Prospective Phase I/II Study using Proton Beam Radiation to Deliver 82GyE to Men with Localized Prostate Cancer: Preliminary Results of ACR 0312 Presenter: Anthony ZietmanPresenter's Affiliation: Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground Prospective randomized studies have shown dose escalation to be effective in prostate cancer A previous study of dose escalation to 79.2 Gy utilized conformal photon therapy to 50.4 with a proton boost to the
Acupuncture for the Treatment of Vasomotor Symptoms in Breast Cancer Patients Receiving Hormone Suppression Treatment Presenter: E. M. Walker, MDPresenter's Affiliation: Henry Ford Health System Department of Radiation Oncology, Detroit, MIType of Session: ScientificBackground Anti-estrogen hormonal therapy given as treatment for breast cancer can induce early menopause, and often causes patients to experience debilitating vasomotor symptoms, mainly hot
Radiation Therapy for High Risk Prostate Cancer: Do Patients 70 Years or Older Benefit from Combined Androgen Deprivation Therapy? Presenter: J. S. Silverman, MDPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PAType of Session: ScientificBackground It has been well established from previous research that long-term (2 to 3 years) of androgen deprivation therapy (ADT) significantly improves survival in men with high-risk prostate cancer. ADT is now widely
Psychological Distress in Long-term Survivors of Adult-onset Cancer: Results from a National Survey Presenter: K. E. HoffmanPresenter's Affiliation: Harvard Radiation Oncology Program, Harvard Medical School, Boston, MAType of Session: ScientificBackground The number of cancer survivors has increased steadily over the past four decades, and an estimated 12 million cancer survivors are living in the United States currently (MMWR, 2004).
Tolerance to High Dose Proton Therapy of Normal CNS Structures in Children Presenter: J.L HabrandPresenter's Affiliation: Institut Curie-Centre de Protontherapie d’Orsay, Orsay, FranceType of Session: ScientificBackground Cancers of the central nervous system are the most common solid tumors arising within the pediatric population, and most children with brain tumors require radiotherapy as part of their
Outcomes using IMRT Tumor-bed Boost for Medulloblastoma Presenter: W.R. PolkingtonPresenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NYType of Session: ScientificBackground Medulloblastoma, a primary neuroendocrine tumor arising in the posterior fossa, represents the second most common pediatric central nervous system (CNS) tumor, and accounts for 20% of pediatric CNS tumor
A Novel Technique for Predicting Which Head and Neck Patients Will Require Adaptive Therapy Presenter: Carley HarrisPresenter's Affiliation: Thompson Cancer Survival Center, Knoxville, TNType of Session: ScientificBackground Background: With the advent of IGRT, it is now feasible to actively measure geometric changes in tumor volume and normal tissues Patients treated for head and neck malignancies often undergo significant
Acute Esophageal Reactions from Proton Beam Therapy and Concurrent Chemotherapy for Non-Small Cell Lung Cancer: Reduction in Incidence and Severity Despite Higher Doses Presenter: R. KomakiPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground In the United States, concurrent chemotherapy and radiation therapy is standard for unresectable NSCLC. However, there is significantly increased toxicity with concurrent radiochemotherapy as opposed to sequential treatment. There
Preliminary Results of Proton Radiotherapy for Esophageal Cancer Presenter: Suwen LiuPresenter's Affiliation: Wanjie Proton Therapy Center, Zibo, ChinaType of Session: ScientificBackground China has the highest incidence of esophageal cancer in the world with a rate of 479 per 100,000 people. Radiation therapy plays an important role in the treatment of this disease. However, standard radiation therapy is
Proton Beam Therapy for the Treatment of Hepatocellular Carcinoma (HCC) Presenter: Jiamin LiPresenter's Affiliation: Wanjie Proton Therapy Center, Zibo, ChinaType of Session: ScientificBackground Hepatocellur Carcinoma (HCC) is one of the most common cancers in China and the 4th leading cause of cancer death world wide. Most patients present with advanced stage and 80% are not eligible for surgery at the time of
Proton Beam Therapy for Clival Chordomas Presenter: K. TsuboiPresenter's Affiliation: University of Tsukuba, Tokyo University HospitalType of Session: ScientificBackground Clival Chordomas are rare tumors that arise from the embryonic notochord. These particular chordomas are located at the base of skull. These tumors are characterized by slow growth, with local
Dose Escalation in Pediatric Brain Tumors with Radiation Therapy. A dosimetric Evaluation on The Potential Role of Proton Beam Therapy Presenter: J.L. HabrandPresenter's Affiliation: Centre De Proton Therapie d'Orsay, Orsay, FranceType of Session: ScientificBackground Historically, local control of most pediatric brain tumors following surgery and conventional radiation have been disappointing. Extrapolating from adult brain tumor data it seems that dose escalation
Preliminary Experience with Proton Radiotherapy for Pelvic Bone Sarcomas Presenter: T. DelaneyPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Surgery is commonly used for the definitive treatment of pelvic bone sarcomas. However, acceptable surgical margins are difficult to achieve in this location. Furthermore, surgical morbidity can be quite high in that
Separating the Rectum from the Prostate during Proton Beam Radiotherapy of Prostate Cancer Patients Reduces Rectal Side Effects Presenter: K. NilssonPresenter's Affiliation: Uppsala University, SwedenType of Session: ScientificBackground Radiation therapy is one of the mainstays of treatment for localized prostate cancer. Common side effects of this treatment include acute and late rectal toxicity. Many investigators and clinicians have attempted to reduce
Opening and Closing Ceremonies Opening Celebration from PTCOG 46 in Zibo, China Closing Ceremony from PTCOG 46 in Wanjie, China
Images from Wanjie Hospital Proton Therapy Center Weijing Sun, MD at the Wanjie Hospital Proton Therapy Center Gantry Treatment Room at the Wanjie Hospital Proton Therapy Center Fixed Beam Treatment Room at the Wanjie Hospital Proton Therapy Center
Treatment of Skull Base Tumors With Proton Therapy Presenter: Norbert J. Liebsch Affiliation: Massachusetts General Hospital Introduction The treatment of base of skull tumors is extremely complex. Surgical resection is difficult due to toxicity associated with large resections. External beam radiation with photons can reduce the recurrence rates, however the results are still not optimal.
Craniopharyngioma in Childhood: Proton Radiotherapy and Treatment Planning With Special Attention to the Cyst Size Presenter: Claudia Linsenmeier Affiliation: Massachusetts General Hospital Introduction Craniopharyngioma accounts for 5-8% of central nervous system tumors in children. It classically has a bimodal age distribution of 5-14 years and > 65 years. Endocrine deficits are common at both presentation and at the completion of treatment for this
Proton Therapy of Uveal Melanomas: Thirty years Experience Presenter: Evangelos Gragoudas, MD Affiliation: Massachusetts Eye and Ear Infirmary Introduction Uveal melanoma is a rare malignancy with a rate in the United States of 6 cases per million per year. However, it is the most common intraocular primary malignancy. This tumor is a threat to both the sight and life of the patient. Radiation therapy
Preliminary results of proton beam therapy for esophageal carcinoma Presenter: Jiamin Li, Suwen Liu, Jianguang Zhang Affiliation: Wanjie Proton Therapy Center, Zibo Wanjie Hospital, Boshan, Zibo, Shandong Province, China Background Esophageal cancer has historically been treated with a combination of surgery (when possible), photon radiotherapy, and chemotherapy Radiation therapy doses to the esophagus
The protection of the small intestine and colon from carbon ion particle irradiation by means of Gore-Tex soft tissue patches for patients with pelvic tumors Presenter: Shigeru Yamada, MD Affiliation: Division of Radiation Medicine, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan Other Authors: Tadashi Kamada, Ryusuke Hara, Hirotoshi Kato, Shigeo Yasuda, Masayuki Kano, Shingo Kato, Reiko Ima, Hirohiko Tsujii Background Recurrent pelvic
Increase in proton RBE in the last few millimeters of the SOBP (Spread Out Bragg Peak) as observed in intestine (preliminary data) Presenter: John Gueulette, PhD Affiliation: Universite catholique de Louvain, Brussels, Belgium Other Authors: Joel Martinez, Blanche-Marie De Coster, Julyan Symons, Jacobus Slabbert Background The RBE (relative biological effectiveness) of proton beam radiotherapy is generally accepted to be about 1.1 compared with x-rays (RBE = 1.0), and
Proton beam therapy for bone and soft tissue sarcomas: 35-year single institutional retrospective review Presenter: S. Goldberg Affiliation: Harvard Medical School, Mass General Hospital, Boston, MA Other Authors: A. Agarwal, T. DeLaney, M. Niemerko, A. Niemerko, H. Suit Background Bone and soft tissue extremity sarcoma is usually treated with a combination of surgery and radiation Proton radiation has been used post-operatively in
Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas Presenter: Azusa HasegawaPresenter's Affiliation: Research Center for Charged Particle TherapyType of Session: ScientificBackground Chordomas are rare, slow growing, locally aggressive neoplasms of bone that arise from embryonic remnants of the notochord. They typically occur in the axial skeleton and arise most commonly in the skull
Reduction of Bone Marrow Suppression for Patients with Stage III NSCLC Treated by Protons and Chemotherapy Compared with IMRT and Chemotherapy Presenter: Ritsuko Komaki, MDPresenter's Affiliation: M.D. Anderson Cancer CenterType of Session: ScientificBackground The concurrent use of chemoradiation is the standard of care for patients with stage III non-small cell lung cancer (NSCLC). Because of the toxicities associated with chemoradiation these patients are at increased risk for bone
Craniopharyngioma: Early Response Evaluation of Patients Treated with Protons at the Midwest Proton Radiotherapy Institute in Bloomington, Indiana. Presenter: Markus Fitzek, MDPresenter's Affiliation: Midwest Proton Radiotherapy Institute, Bloomington, IN and Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, INType of Session: ScientificBackground Craniopharyngioma is a benign tumor that represents the most common pituitary tumor in children.
Pelvic Proton Radiotherapy for High-Risk Prostate Cancer Presenter: Bhishamjit S. Chera, M.D. Presenter's Affiliation: University of Florida Department of Radiation Oncology, Gainesville, FL Type of Session: Scientific Background Treatment options for prostate cancer in the current era are largely based on risk assessment and stratification. Patients with clinical stage T3 – T4 disease,
Particle and Proton Radiotherapy in Treatment of Pediatric Oncology Patients Presenter: Torunn Yock, M.D.Presenter's Affiliation: Harvard University, Massachusetts General Hospital Frances Burr Northeast Proton CenterType of Session: ReportingDr. Torunn Yock is a pediatric radiation oncologist practicing at Massachusetts General Hospital (MGH). At MGH, approximately 60 patients per day are treated with proton radiotherapy
Carbon Ion Radiotherapy in Germany: Update on the Clinical Results from 394 patients Treated at the University of Heidelberg and on the Future Perspectives at the Heidelberg Ion Therapy Center (HIT) Presenter: Stephanie e. CombsPresenter's Affiliation: University of HeidelbergType of Session: ScientificBackground Chordomas (C) are rare, slow growing tumors which are thought to arise from remnants of the notochord. Though slow growing, they can be locally aggressive and tend to involve the axial skeleton, often involving the base of
Efficacy and Safety of Spot Scanning Proton Radiation Therapy for Skull Base Tumors: First Long Term Report of the PSI Experience Presenter: Carmen AresPresenter's Affiliation: Paul Scherrer InstituteType of Session: ScientificBackground Chordomas (C) are rare, slow growing tumors which are thought to arise from remnants of the notochord. Though slow growing, they can be locally aggressive and tend to involve the axial skeleton, often involving the base of
Dosimetric Advantages of Proton Simultaneous In-Field Boost (PSIB) Technique for Treating Lung Cancer Presenter: Lei Dong, PhDPresenter's Affiliation: Division of Radiation Oncology, the University of Texas M.D. Anderson Cancer CenterType of Session: ScientificBackground Despite continued efforts of behalf of the oncology community, prognosis for patients with locally advanced non-small cell lung cancer (NSCLC) remains poor. Radiotherapy
Changes in the Rectal Volume and Prostate Localization with Placement of a Rectum Emptying Tube Presenter: Hiroshi Fuji, MD Presenter's Affiliation: Shizuka Cancer Center Type of Session: Scientific Background One of the primary advantages of protons is the ability to control the range of protons which limits the dose beyond the distal boarder of the treatment field. However, the range and hence the location of the distal edge of
Use of Particle Therapy in Treatment of Sarcomas Presenter: Eugen Hug, M.D.Presenter's Affiliation: Paul Scherrer InstituteType of Session: Scientific Introduction Dr. Eugen Hug initiated his discussion of the indications for particle based radiotherapy in treatment of sarcomas by explaining his assessment of the need for improvements in treatment of both adult and pediatric sarcomas. He noted
Analysis of Visual Loss Due to Radiation-Induced Optic Neuropathy After Particle Therapy for Head and Neck and Skull Base Tumors Adjacent to Optic Nerves. Presenter: Yusuke Demizu Presenter's Affiliation: Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan Type of Session: Scientific Background Use of radiotherapy for treatment of tumors of the head and neck is made complicated by the proximity of vital structures, including the optic chiasm and optic nerves. Clearly,
Designing a Multileaf Collimator for Proton Therapy Presenter: C Ainsley, S Avery, R Maughan, J McDonough, J Metz, R Scheurermann, Z TochnerPresenter's Affiliation: Department of Radiation Oncology, University of PennsylvaniaType of Session: PosterBackground Multileaf collimator (MLC) systems are frequently used to deliver photon-based radiation, and allow conformal shaping of treatment
Does Proton Beam Radiotherapy (PBT) Reduce Treatment Related Pneumonitis (TRP) Compared to Intensity Modulated Radiation Therapy (IMRT) in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Concurrent Chemotherapy? Presenter: Ritsuko KOmaki, MD Presenter's Affiliation: M.D. Anderson Cancer Center Type of Session: Scientific Background The risk of radiation pneumonitis limits both the dose of radiation that can be delivered as well as the volume of the thorax that can be treated. It appears that the dose of radiation, the amount of lung radiated, and the
Comparison of Proton and Photon Radiation Treatment Plans for the Adjuvant Treatment of Pancreatic Cancer Including Comprehensive Nodal Radiation Presenter: Mark Ingram Presenter's Affiliation: University of Pennsylvania Type of Session: Poster Background Pancreatic cancer is the fourth leading cause of death and most patients present with unresectable disease. The five year survival is poor even in patients who can be resected (5 year survival ~10%) and is even worse in patients who
Effectiveness of Rectal Balloon as an Internal Immobilization Device for Proton Therapy of Prostate Cancer Presenter: Andrew Lee, M.D., M.P.H.Presenter's Affiliation: Division of Radiation Oncology, The University of Texas M.D. Anderson Cancer CenterType of Session: ScientificBackground Radiotherapy for prostate cancer depends largely on the technical ability to deliver adequate dose to the prostate without severe bladder and rectal
Head and Neck Cancer and Proton Therapy Presenter: William Mendenhall, MD Presenter's Affiliation: University of Florida Type of Session: Reporting There are several potential advantages to proton treatment compared with IMRT in the treatment of patients with head and neck cancers. The major advantage is likely to be a decrease in the late side effects associated with radiation
Panel Discussion: Randomized Trials vs. Prospective Registry Presenter: Andre Konski, M.D. and Andrew Lee, M.D. Presenter's Affiliation: Fox Chase Cancer Center and M. D. Anderson Cancer Center Type of Session: Reporting Drs. Konski and Lee engaged in a panel discussion of the most efficient and appropriate ways in which to gather clinical data regarding patients undergoing proton-and particle-based
15 years of Proton Radiosurgery Experience at the Ithemba Labs, Long Term Results for AVM’s, Meningiomas, and Acoustic Neuromas Presenter: Frederick Vernimmen Presenter's Affiliation: Stellenbosch University Type of Session: Scientific Background There are a number of benign diseases which can be treated with radiation and the present study is a review of the long term outcomes in patients treated with protons for AVM, meningiomas and acoustic neuromas at Ithemba
Clinical Trials in Particle Therapy Presenter: Bhadrasen Vikram, MD Presenter's Affiliation: National Cancer Institute Type of Session: Reporting Background Dr. Vikram started his presentation with several pictures which demonstrated the precision with which radiation can be delivered to single cells. He showed a picture of several carbon ion beams hitting a single cell within a
Lung Cancer and Proton Therapy Presenter: Joe Chang, MD, PhD Presenter's Affiliation: MD Anderson Cancer Center Type of Session: Reporting Background Dr. Chang’s presentation focused on the use of image guided proton therapy in the treatment of non-small cell lung cancer. He discussed ways to decrease inter and intra-fraction tumor motion as well as how changes in
Images from PTCOG 2008 View a slideshow of images from the Particle Therapy Cooperative Group (PTCOG) 47 Conference from Jacksonville, Florida, May 19-24, 2008.
6th European Congress: Perspectives in Gynecologic Oncology Conference Dates: 30-31 January 2009 Conference Location: Nice, France Sponsoring Group: Imedex, LLC Conference Web Page URL: http://www.imedex.com/appweb/announcements/a049-01.asp Conference Objectives: This multidisciplinary program features a comprehensive overview of current research and treatment of ovarian, vulvar, cervical and
Beyond Treatment: Challenges & Solutions for Cancer Survivors...Employment Law Conference Dates: January 15, 2009 Conference Location: teleconference Sponsoring Group: Legal Clinic for the Disabled, St. Mary's Medical Center, American Cancer Society, Leukemia & Lymphoma Society Topics Covered: Topics include: who is covered by the ADA, reasonable accommodation, the scope and limits of protections under the ADA, who
Mitosis and Cancer Symposium Conference Dates: February 26 - 27 , 2009 Conference Location: Amsterdam, The Netherlands Sponsoring Group: Abcam Conference Web Page URL: www.abcam.com/mitosiscancer Topics Covered: - Cellular responses to checkpoint activation in G2 and mitosis - Targeting mitotic pathways in cancer therapy - The mitotic checkpoint and cancer Conference
Beyond Treatment: Challenges & Solutions for Cancer Survivors...Social Security Disability Conference Dates: February 19, 2009 Conference Location: teleconference Sponsoring Group: Legal Clinic for the Disabled, St. Mary's Medical Center, American Cancer Society, Leukemia & Lymphoma Society Topics Covered: Eligibility for SSD and SSI, available benefits, applying for benefits and the appeals process. Conference Objectives:
Targeted Therapies for Advanced Renal Cell Carcinoma: New Standards of Care Conference Dates: February 26, 2009 Conference Location: Orlando, FL Sponsoring Group: The Center for Biomedical Continuing Education Conference Web Page URL:www.thecbce.com/renalcell2009 Topics Covered: renal cell carcinoma, gene mutations, cellular signaling defects, metastasectomy, cytoreductive nephrectomy Conference Objectives:
9th Annual Conference for Young Women Affected by Breast Cancer Conference Dates: February 27-March 1, 2009 Conference Location: Hilton Anatole, Dallas, TX Sponsoring Group: Living Beyond Breast Cancer & Young Survival Coalition Conference Web Page URL: www.youngsurvivorsconference.org Topics Covered: Understand how various treatments can impact fertility — and what options can help you maintain
Beyond Treatment: Challenges & Solutions for Cancer Survivors...Finding Work Conference Dates: March 19, 2009 Conference Location: teleconference Sponsoring Group: Legal Clinic for the Disabled, St. Mary's Medical Center, American Cancer Society, Leukemia & Lymphoma Society Topics Covered: Information to help unemployed or under employed cancer survivors find work. Available resources, how to avoid problems, advice
Eighth Annual Recent Advances and New Directions in Cancer Conference Dates: March 27-29, 2009 Conference Location: The InterContinental, San Francisco, CA Sponsoring Group: CBCE (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com/ccc2009 Topics Covered: The rapidity of recent advances in the use of targeted agents, molecular biomarkers, and expression profiling in
Spring Refresher Course Conference Dates: March 13-15, 2009 Conference Location: Doubletree San Diego Mission Valley, San Diego, Calif. Sponsoring Group: ASTRO Conference Web Page URL: www.astro.org/Meetings/UpcomingMeetings/SpringRefresher/ Topics Covered: The ASTRO Spring Refresher Course Program is designed to update the practicing radiation oncologist, medical
Molecular Mechanisms of Aging and Age-Related Diseases Conference Dates: March 3-6, 2009 Conference Location: Puerto Vallarta, Mexico Sponsoring Group: Abcam Conference Web Page URL: www.abcam.com/go.cfm?p=2812 Topics Covered: Diseases of aging I: metabolic syndromes Diseases of aging II: cancer Diseases of aging III: neurodegeneration Organismal aging: vertebrates The
The Eighth International Symposium on Sympathetic Surgery (ISSS): Approaching Clinical Care With Clinical Science and VATS 2009: The Seventh International Symposium on Video-Assisted Thoracic Surgery Conference Dates: March 25-29, 2009 Conference Location: New York, NY Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com/ISSSVATS Conference Objectives: Please see website for further information Who Should Attend: Surgical Oncologists, Medical Oncologists, Physicians, Physican Assistants, Healthcare Professional Conference
Sixth Annual Winter Lung Cancer Conference Conference Dates: March 6-8, 2009 Conference Location: Trump International Sonesta Beach Resort in Sunny Isles Beach, FL Sponsoring Group: CBCE (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com/wlcc Conference Objectives: Please see website for further information. Who Should Attend: This activity is
Ninth Annual New Strategies in Breast Cancer Conference Conference Dates: April 3-4, 2009 Conference Location: Philadelphia, PA Sponsoring Group: The CBCE (The Center for Biomedical Continuing Education) Conference Web Page URL: http://www.thecbce.com/nsbc2009 Topics Covered: In this 2-day intensive review, clinical experts will discuss recent progress in the detection, prevention, diagnosis,
Great Debates and Updates in GI Malignancies Conference Dates: April 3-4, 2009 Conference Location: New York, NY Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/appweb/announcements/a046-01.asp Conference Objectives: After attending this symposium, participants should be able to: Determine the benefits and risks of surgical management of gastrointestinal cancers
Medical Developments and Issues to Consider Conference Dates: April 23, 2009 Conference Location: Anywhere (teleconference/webinar) Sponsoring Group: Cancer and Careers Conference Web Page URL: www.cancerandcareers.org/healthcare_professionals Topics Covered: Relating medical developments and other issues for cancer survivors to their experiences in the workplace. Who Should
Immune Tolerance in Cancer and Autoimmune Disease Conference Dates: May 06 - 09, 2009 Conference Location: Antigua Sponsoring Group: Abcam, Inc. Conference Web Page URL: www.abcam.com/go.cfm?p=3321 Conference Objectives: Immune Tolerance in Cancer and Autoimmune Disease: how to break it, and how to (re-)make it. Conference Agenda: Immune Tolerance in Cancer and Autoimmune Disease: how to
ASTRO's Advances in Technology: IGRT and SBRT Symposium Conference Dates: May 15-17, 2009 Conference Location: Doral Golf Resort and Spa, Miami Sponsoring Group: ASTRO Conference Web Page URL: www.astro.org/Meetings/UpcomingMeetings/IGRTSymposium/ Topics Covered: Program Objectives Present a snapshot of current IGRT and SBRT technologies. Discuss how to safely implement IGRT and SBRT.
Legal Questions Answered Conference Dates: May 28, 2009 Conference Location: Anywhere (teleconference/webinar) Sponsoring Group: Cancer and Careers Conference Web Page URL: www.cancerandcareers.org/healthcare_professionals Topics Covered: Legal issues as they relate to cancer survivors who are working through treatment. Who Should Attend: Healthcare
Apoptosis and Cancer: The Bcl-2 family of proteins Conference Dates: June 25-26, 2009 Conference Location: Dartmouth College, New Hampshire Sponsoring Group: Abcam Conference Web Page URL: www.abcam.com/go.cfm?p=2733&Cl=2282 Topics Covered: The Bcl-2 family of proteins (Bcl-2-like proteins, Bax/Bak, BH3-only proteins): -Regulation and role in apoptosis and tumorigenesis
Great Debates and Updates in Breast Cancer Conference Dates: June 19-20, 2009 Conference Location: San Francisco, CA Sponsoring Group: Imedex, LLC Conference Web Page URL: www.imedex.com/appweb/announcements/A048-01.asp Topics Covered: Chemoprevention of breast cancer Selecting techniques for breast cancer surgery Confusion and controversies in radiation therapy
2009 Update on Breast Cancer: Coverage of the American Society of Clinical Oncology's Annual Meeting Conference Dates: Thursday, June 11, 2009 Conference Location: The Hub Cira Center, 2929 Arch Street, Mezzanine Level, Philadelphia, PA Sponsoring Group: University of Pennsylvania School of Medicine/ CME Conference Web Page URL: www.oncolink.org/conference/asco Topics Covered: Adjuvant chemotherapy, adjuvant hormonal therapy, surgery,
Re-entering the Workforce, after short and long absences Conference Dates: June 25, 2009 Conference Location: Anywhere (teleconference/webinar) Sponsoring Group: Cancer and Careers Conference Web Page URL: www.cancerandcareers.org/healthcare_professionals Topics Covered: How to guide cancer survivors through their journey back into the workforce. Who Should Attend: Healthcare Professionals
The 11th Annual "Celebration of Hope" Conference Dates: June 5, 2009, 9:30 A.M. - 2:30 P.M. Conference Location: The Hyatt Regency Philadelphia at Penn's Landing 201 South Columbus Blvd. Philadelphia, Pennsylvania, 19106 Sponsoring Group: The Wellness Community of Philadelphia Conference Web Page URL: www.twcp.org/CelebrationofHope2009.htm Who Should Attend: People with
Cancer Transitions: Moving Beyond Treatment Conference Dates:Thursdays, October 1, 8, 15, 22, 29 And November 5, 2009 Conference Location: The Suzanne Morgan Center at Ridgeland, Chamounix Drive, West Fairmount Park, Philadelphia, Pennsylvania 19131 Sponsoring Group: The Wellness Community of Philadelphia Conference Web Page URL: twcp.org Topics Covered: This is a six-week
Cancer in Africa - The New Reality Conference Dates: November 11-14, 2009 Conference Location: Dar Es Salaam, Tanzania Sponsoring Group: AORTIC (African Organisation for Research and Training in Cancer) Conference Web Page URL: www.aortic2009.org Topics Covered: The AORTIC 2009 conference will have a strong focus on cancer control. The main themes will be cancer treatment,
Breast Cancer Support for Lesbians and Bisexual Women and their Families Conference Dates: November 1, 2009 (8am-5:30pm) Conference Location: Gilda's Club, Warminster, PA Sponsoring Group: Gilda's Club Delaware Valley Conference Web Page URL: http://www.gildasclubdelval.org/events.htm Topics Covered: Breast cancer support networking Self-Advocacy Nutrition Survivorship Issues Intimacy and cancer and much more!
Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR): preliminary results of the MIRROR study from the Dutch breast cancer trialists’ group (BOOG) Presenter: E. Mamounas Affiliation: NSABP Operations & Biostatistical Centers, Pittsburgh, PA Background Decisions regarding use of chemotherapy and radiotherapy in the treatment of breast cancer patients may be partially based on axillary lymph node status. In recent years, more extensive pathologic examination of lymph nodes has
Cetuximab-based neoadjuvant chemoradiation and surgical resection in patients with locally advanced esophageal and gastric cancer Presenter: H.J. Wanebo, Brown University Oncology Group, Providence, Rhode Island Background Although surgical treatments remain a mainstay of definitive treatments for esophageal and gastric cancers, several groups have demonstrated benefit to multimodality treatments (Krasna, 2006). Although up-front surgical procedures are often performed
Relative Outcomes for Asian-Americans with Gastric Adenocarcinoma Presenter: B.A. Mailey, City of Hope, Duarte, CA Background Reported outcomes for patients with gastric cancer have historically been better in Japan and other Asian countries than in the United States and Europe. These differences have been widely discussed. Although surgical differences may potentially have an impact, efforts in the
Final safety findings from a randomized phase III trial of preoperative FU-based chemoradiation +/- weekly oxaliplatin as neoadjuvant therapy for patients with locally advanced rectal cancer: the STAR (Studio Terapia Adiuvante Retto)-01 randomized trial Presenter: C. Aschele on behalf of STAR Network Investigators Background Beginning in the mid-1990s, with the publication of results from the German CAO/ARO/AIO 94 trial, a paradigm shift from treatment of locally advanced rectal cancer with up-front surgery to administration of preoperative chemoradiotherapy took place. This change was based
Use of endoscopic ultrasonography in screening patients at high-risk for pancreatic cancer Presenter: J. Poley, University Medical Center, Rotterdam, Netherlands Background Screening of the general population for certain malignancies, including breast cancer, prostate cancer, colon cancer, and cervix cancer has become standard of care within the United States and in many countries abroad. The feasibility and cost-effectiveness of
Effect of extended preoperative chemotherapy on pathologic response and pathologic livery insufficiency after hepatic resection of colorectal liver metastases Presenter: D. Zorzi, MD Anderson Cancer Center, Houston, TX Background Recent advances in detection and treatment of liver metastasis from colon cancer have resulted in improved outcomes for patients in this disease setting. Most patients are treated with multimodality treatment, and chemotherapy is often given neoadjuvantly, prior to
European Multidisciplinary Colorectal Cancer Congress Conference Dates: March 28-30, 2010 Conference Location: Nice, France Sponsoring Group: ESMO, ESSO, ESTRO, ESP, ESGAR Conference Web Page URL: www.colorectal2010.org Topics Covered: All aspects of diagostic & treatment of colorectal cancer Conference Objectives: offer a real multidisciplanary approach for the treatment of colorectal
Practical Advice and Tools to Balance Cancer and Employment Conference Dates: March 4, 2010 Conference Location: Teleconference Sponsoring Group: Cancer and Careers Conference Web Page URL: www.cancerandcareers.org/healthcare_professionals/ Who Should Attend: Oncology nurses, social workers, patient navigators, etc. Registration Information:
Los Angeles Neuroendocrine Tumor Patient Education Seminar Conference Dates: March 27, 2010, 1-5:30PM Conference Location: Los Angelos Sponsoring Group: Caring for Carcinoid Conference Web Page URL: www.caringforcarcinoid.org/fundraising/laevent.asp Who Should Attend: Patients, Family Members Conference Agenda: On March 27th, come join your fellow neuroendocrine tumor patients for an
Chemotherapy Foundation Symposium, Innovative Cancer Therapy for Tomorrow Conference Dates: November 9-13, 2010 Conference Location: Marriott Marquis, NYC Sponsoring Group: Mount Sinai School of Medicine and The Chemotherapy Foundation Conference Web Page URL: chemotherapyfoundationsymposium.org Topics Covered: New agents, clinical trials, targeted therapies, biotherapies, hematology, breast, GI,
The 2010 AICR Annual Research Conference on Food, Nutrition, Physical Activity and Cancer Conference Dates: October 21-22, 2010 Conference Location: Capital Hilton, Washington, DC Sponsoring Group: American institute for Cancer Research Conference Web Page URL: www.aicr.org/conference Topics Covered: Cancer, Nutrition, Food, Physical Activity Conference Objectives: Research Conference on Food, Nutrition, Physical
Survivor Caregiver Boston Regional Seminar Conference Dates: Saturday, November 20, 2010 Conference Location: Dana-Farber Cancer Institute Sponsoring Group: Colon Cancer Alliance Conference Web Page URL: www.ccalliance.org Topics Covered: Take control of your cancer and your life! Conversations about Colorectal Cancer Regional Seminars, presented by the Colon Cancer Alliance, are
2010 School of Breast Oncology Conference Dates: 11/11/2010 - 11/14/2010 Conference Location: Emory University Conference Center Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/558 Conference Objectives: This curriculum-based program focuses exclusively on breast cancer clinical management. The intensive
Sixth Annual New York Lung Cancer Symposium Conference Dates: November 9, 2010 Conference Location: The Westin New York at Times Square Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/565 Topics Covered: Assess molecular profiling of lung cancer based on tumor
5th Annual Bear Discoveries Research Symposium Dates: November 19, 2010 Location: Chicago, IL Sponsoring Group: Bear Necessities Pediatric Cancer Foundation Web Page URL: www.bearnecessities.org/Symposium/Index.html Topics Covered: Pediatric Hematology/Oncology Research Objectives: Distinguish between differences in clinical approaches as they apply to cancer research. Identify new
Eleventh Annual Wallace H. Clark Jr., MD Lectureship in Cutaneous Oncology Melanoma Symposium Conference Dates: April 29, 2010 Conference Location: University of Pennsylvania, Biomedical Research Building II/III, Ground Floor Auditorium, Curie Blvd. Osler Circle, Philadelphia, PA Sponsoring Group: University of Pennsylvania School of Medicine and Abramson Cancer Center of the University of Pennsylvania Conference Web Page URL:
Re-entering the Workforce After Short and Long Absences Conference Dates: April 1, 2010 Conference Location: Teleconference Sponsoring Group: Cancer and Careers Conference Web Page URL: www.cancerandcareers.org/healthcare_professionals/ Who Should Attend: Oncology nurses, social workers, patient navigators, etc. Registration Information:
Legal and Insurance Issues to Consider Conference Dates: May 6, 2010 Conference Location: TeleconferenceSponsoring Group: Cancer and CareersConference Web Page URL: www.cancerandcareers.org/healthcare_professionals/Who Should Attend: Oncology nurses, social workers, patient navigators, etc.Registration Information: www.cancerandcareers.org/healthcare_professionals/Conference Fees:
The Role of Multi-gene Predictors in Early Breast Cancer Conference Dates: May 1, 2010 Conference Location: WTTW-CH 11 Studios, Chicago, IL Sponsoring Group: ONECONSORTIUM Oncology Education Conference Web Page URL: http://www.oneconsortium.org/registration Conference Objectives: Evaluate the results of recent studies on molecular profiling of breast cancer and apply the knowledge
7th Annual Focus on Melanoma Conference: What’s New in Melanoma and News You Can Use Date/Time: Friday, May 14, 2010, 7:30am – 2:30pm Location: Hilton Hotel 4200 City Avenue Philadelphia, PA Audience: Open to All Sponsor: Cancer - Abramson Cancer Center Cost: This event is free. Registration: This conference is FREE of charge. A $20 donation (non-tax deductible) is suggested to support the
Ninth Annual Recent Advances and New Directions in Cancer Therapy Conference, in Cooperation With the California Cancer Consortium Conference Dates: May 14-16, 2010 Conference Location: Pasadena Sponsoring Group: Physicians’ Education Resource in conjunction with the California Cancer Consortium Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/543 Topics Covered: At the conclusion of this
Discussions on Emerging Concepts and Controversies in the Treatment of Patients With Advanced Non–Small Cell Lung Cancer Conference Dates: June 19, 2010 Conference Location: Chicago, Illinois Sponsoring Group: Jointly sponsored by University of Nebraska Medical Center, Center for Continuing Education and oneconsortium Conference Web Page URL: www.thecbce.com/lungtownhall Topics Covered: This interactive, town hall program focuses on the latest
Latest Advances in the Diagnosis Treatment of Malignant Gliomas Conference Dates: on-line web archive 7/30/10-7/30/11 Conference Location: Web archive Sponsoring Group: University of Pennsylvania School of Medicine; Presented by Abramson Cancer Center of the University of Pennsylvania Topics Covered: Advanced imaging, latest advances in surgery, update in chemotherapy, and radiation oncology
11th International Lung Cancer Congress Conference Dates: July 8-11, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/510 Conference Objectives: An update of research efforts from major Cooperative Groups from the United
10th International Congress on Genitourinary Malignancies Conference Dates: July 16-17, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/525 Conference Objectives: A comprehensive review of current therapeutic strategies for the treatment
Ninth International Congress on the Future of Breast Cancer Conference Dates: July 22-25, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/520 Conference Objectives: An international educational and scientific meeting that focuses on the
Ninth International Congress on Targeted Therapies in Cancer Conference Dates: August 20-22, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/529 Topics Covered: At the conclusion of this congress, you should be able to: Discuss
Cancer Metabolism: Pathways to the Future Conference Dates: September 19-21, 2010 Conference Location: Edinburgh Sponsoring Group: Eyal Gottlieb and Karen Vousden (The Beatson Institute for Cancer Research, UK) Conference Web Page URL: www.abcam.com/index.html?pageconfig=resource&rid=12304 Topics Covered: - All the major aspects of metabolic transformation in cancer - Potential
4th Annual Perspectives in Genitourinary Oncology: A Case-Based Approach to Enhance Patient Management of Prostate, Renal and Bladder Cancers Conference Dates: September 24-25, 2010 Conference Location: Chicago, Illinois Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/AppWeb/announcements/a179-01.asp Topics Covered: Concurrent break-out discussions for oncologists and urologists on the management of prostate, bladder, and renal cancers Role of adjuvant
Seventh Annual Symposium on Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia Conference Dates: September 24-25, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/560 Topics Covered: At the conclusion of this symposium, you should be able to:
14th Annual Fall Oncology Conference: Clinical Challenges in Cancer Medicine Conference Dates: September 24-26, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource in conjunction with Duke Oncology Network Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/545 Topics Covered: Topics to be included:
CFCF Neuroendocrine Tumor Patient Education Conference Conference Dates: September 25, 2010 Conference Location: Stanford University, CA Sponsoring Group: The Caring for Carcinoid Foundation Conference Web Page URL: cfcf.eventbrite.comTopics Covered: Please join us to learn more about the latest developments in research and treatment for neuroendocrine tumors. Each expert speaker will give a brief
MENA Oncology Conference Conference Dates: October 22-23, 2010 Conference Location: Cairo, Egypt Sponsoring Group: Fleming Gulf Conference Web Page URL: www.fleminggulf.com/life-science/middle-east/mena-oncology-conference Topics Covered: Regional Perspective on Breast CancerThe Challenges facing national cancer control plansEarly detection and Screening of Breast
Survivor Caregiver Chicago Regional Seminar Conference Dates: Saturday, October 2, 2010 Conference Location: Northwestern Memorial Hospital Sponsoring Group: Colon Cancer Alliance Conference Web Page URL: support.ccalliance.org/site/Calendar/1084759641?view=Detail=100181 Topics Covered: Take control of your cancer and your life! Conversations about Colorectal Cancer Regional Seminars,
Seventh Annual Current Trends in Genitourinary Malignancies Conference Dates: October 16, 2010 Conference Location: The Westin New York at Times Square - 270 W. 43rd St. at 8th Ave., New York, NY 10036 Sponsoring Group: Physicians' Education Resource Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/589 Topics Covered: androgen deprivation
Ninth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy Conference Dates: October 8-10, 2010 Conference Location: Sheraton New York Hotel Towers Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/530 Topics Covered: The Ninth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that
Expert Perspectives: Integrating New Data Into Best Practices for Breast Cancer Conference Dates: October 1, 2010 - October 1, 2010 Conference Location: 201 Waterfront St., National Harbor, MD 20745 Sponsoring Group: Physicians' Education Resource Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/590 Topics Covered: Evaluate the utility of gene profiling
CMC - Liver Tumor Seminar Conference Dates: October 18, 2010 Conference Location: Carolinas Medical Center - Mercy Auditorium Sponsoring Group: YES! Beat Liver Tumors Conference Web Page URL: www.yeslunchandlearn.com Topics Covered: Cutting edge treatments for cancers of the liver. Conference Objectives: To provide a multidisciplinary treatment algorithm for
Radiosurgery for Prostate Dates: 10/30/10 Location: Sunnyvale, CA Sponsoring Group: The Accuray Training Department, in partnership with Dr. Alan Katz and Dr. Michael Santoro Web Page URL: http://www.accuray.com/clinicaleducation/prostate.aspx Topics Covered: Throughout the course, the practical aspects of hypo-fractionated prostate radiosurgery will be emphasized.
The Future of Cancer Research: Accelerating Scientific Innovation Dates: October 26, 2010 Location: Chemical Heritage Foundation, Philadelphia, PA Sponsoring Group: President's Cancer Panel Web Page URL: pcp.cancer.gov Topics Covered: Future of Cancer Research Subject of Public Forum in Philadelphia, PA Second of Four Meetings in National Series The President's Cancer Panel will conduct an open forum
Value of adjuvant radiation therapy in breast cancer patients with one to three positive lymph nodes undergoing a modified radical mastectomy and systemic therapy Presenter: S. DawoodPresenter's Affiliation: M.D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground The Early Breast Cancer Trialists’ Collaborative Group Overview (Lancet 2005), a meta-analysis of 78 randomized trials, including 42,000 women, showed that radiation therapy (RT) after breast-conserving surgery
A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study Presenter: Groen, M. M. Hochstenbag, J. W. van Putten, A. Vincent, O. Dalesio, B. Biesma, H. J. Smit, A. Termeer, B. E. van den Borne, F. M. SchramelPresenter's Affiliation: University Medical Center Gron, NetherlandsType of Session: ScientificBackground Cyclooxygenase-2 (COX-2) is an enzyme responsible for the conversion of arachidonic acid
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) Presenter: N. J. RobertPresenter's Affiliation: US Oncology GroupType of Session: ScientificBackground Bevacizumab (B) is a humanized monoclonal antibody which inhibits VEGF, a known central mediator of angiogenesis. Two previous large phase III trials, E2100 and AVARO, have demonstrated that B in combination with weekly paclitaxel or
Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-?2a (IFN) in metastatic renal cell carcinoma (mRCC) Presenter: B.J. Escudier, et al.Presenter's Affiliation: Institut Gustave Roussy, Villejuif, FranceType of Session: ScientificBackground Renal cell carcinoma (RCC) is diagnosed in more than 120,000 patients in the United States and Europe every year. The most common histology is clear cell carcinoma. The 5-year survival rate for
Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine Presenter: M.L. Disis, L. G. Salazar, A. Coveler, J. Waisman, D. Higgins, J. Childs, N. Bates, Y. DangPresenter's Affiliation: University of Washington, Seattle, WA; Breastlink, Los Angeles, CAType of Session: ScientificBackground HER2/neu (also known as ErB-2) is a protein member of the ErbB protein family more commonly referred to as the
National survey of physicians practice patterns: Fertility preservation and cancer patients Title: National survey of physicians practice patterns: Fertility preservation and cancer patientsReviewer: Arpi Thukral, MD Presenter: G. QuinnAffiliation: Moffitt Cancer Center The treatment of cancer often poses a threat to fertility for young patients of child-bearing age. Approximately 450,000 cancer survivors in the U.S. are of
Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients Title: Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patientsReviewer: Arpi Thukral, MD Presenter: J. L. Ryan, PhD, MPH Affiliation: URCC CCOP Nausea is one side effect that almost every person facing cancer therapy fears. It affects their
Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863) Title: Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)Reviewer: Arpi Thukral, MD Presenter: Suresh. S. Ramalingam, MD Affiliation: Emory University This
A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08 Title: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08 Reviewer: Geoffrey Geiger MD Presenter: N. Wolmark, G. Yothers, M. J. O'Connell, S. Sharif, J. N. Atkins, T. E. Seay, L. Feherenbacher, S. O'Reilly, C. J. Allegra Affiliation: NSABP Pittsburg,
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results Title: Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial resultsPresenter: S. J. Schuster, MD Affiliation: University of Pennsylvania Non-Hodgkin's Lymphoma (NHL) is the 6th most common type of cancer in the US. There will be approximately 65,980 news cases diagnosed in the US in
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial Title: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial Reviewer: Arpi Thukral, MD Presenter: Joyce O'Shaughnessy, MD Affiliation: US Oncology Group PARP is an
A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) Title: A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) Reviewer: Geoffrey Geiger MD Presenter: G. J. Rustin, M. E. van der Burg Affiliation: On behalf of the MRC and EORTC collaborators Ovarian
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214 Title: A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214 Reviewer: Arpi Thukral, MD Presenter: Elizabeth M. Gore, MD Affiliation: Medical College of Wisconsin The brain is a frequent site of
Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy Title: Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy Reviewer: Arpi Thukral, MD Presenter: M. M. O'Brien Affiliation: Stanford University There has been a steady improvement in the survival rates of pediatric patients with Hodgkin's disease as more
Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC) Title: Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC) Reviewer: Geoffrey Geiger, MD Author(s): M.D. Vincent, C. Butts, L. Seymour, K. Ding, B. Graham, P. Twumasi-Ankrah, D. Gandara, J. Schiller, M. Green,
Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) Title: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) Reviewer: Geoffrey Geiger, MD Author(s): B. J. Escudier, J. Bellmunt, S. Negrier, B. Melichar, S. Bracarda, A. Ravaud, S. Golding, S. Jethwa, on behalf of the
First results of a phase III multi-centre randomized controlled trial of intensity modulated vs. conventional radiotherapy in head and neck cancer: PARSPORT (CRUK/03/005) Title: First results of a phase III multi-centre randomized controlled trial of intensity modulated vs. conventional radiotherapy in head and neck cancer: PARSPORT (CRUK/03/005) Reviewer: Christine E. Hill-Kayser, MD Presenter: Christopher Nutting on behalf of the PARSPORT Trial Management Group, Cancer Research UK Radiation therapy is a
Sexual function in male lymphoma survivors in relationship to age, gonadal hormones and psychosocial issues, and compared to matched controls Title: Sexual function in male lymphoma survivors in relationship to age, gonadal hormones and psychosocial issues, and compared to matched controls Reviewer: Christine Hill-Kayser, MD Presenter: Cecilie E. Kiserud Affilation: The Norwegian Radium Hospital, Oslo, Norway Sexual function is a common concern of cancer survivors. This study
Neuroprotective effect of paroxetine hydrochloride among 781 cancer patients receiving chemotherapy: A URCC CCOP study Title: Neuroprotective effect of paroxetine hydrochloride among 781 cancer patients receiving chemotherapy: A URCC CCOP study Reviewer: Christine Hill-Kayser, MD Presenter: Pascal Jean-Pierre, PhD, MPH Affiliation: University of Rochester Medical Center Many cancer survivors report difficulty with neurocognitive functioning, often called
A Randomized Phase III Study Comparing Concurrent Gemcitabine plus Cisplatin and Radiation followed by Adjuvant Gemcitabine plus Cisplatin versus Concurrent Cisplatin and Radiation in Patients with Stage IIB to IVA Carcinoma of the Cervix Title: A Randomized Phase III Study Comparing Concurrent Gemcitabine plus Cisplatin and Radiation followed by Adjuvant Gemcitabine plus Cisplatin versus Concurrent Cisplatin and Radiation in Patients with Stage IIB to IVA Carcinoma of the Cervix Reviewer: Christine Hill-Kayser, MD Presenter: Alfonso Duenas-Gonzalez Affiliation: Unidad de
Surveillance and screening for new neoplasms in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) Title: Surveillance and screening for new neoplasms in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) Reviewer: Christine Hill-Kayser, MD Presenter: Paul Nathan, MD, MSc Affiliation: The Hospital for Sick Children, Toronto, Canada Due to numerous clinical trials in pediatric oncology, the
Routine Preventive Care and Cancer Surveillance in Long-Term Survivors (LTS) of Colorectal Cancer: Results from NSABP Protocol LTS-01 Title: Routine Preventive Care and Cancer Surveillance in Long-Term Survivors (LTS) of Colorectal Cancer: Results from NSABP Protocol LTS-01 Reviewer: Presenter: Hiroko Kunitake, MD Affiliation: David Geffen School of Medicine at UCLA Over 11 million cancer survivors currently reside in the United States, and this number is estimated to
Clinical outcomes of proton beam therapy for early stage non-small cell lung cancer. A retrospective analysis of Shizuoka experiences Presenter: S. Murayama, H. FujiPresenter's Affiliation: Proton therapy division, Shizuoka Cancer Center Hospital, Nagaizumi, Shizuoka, JapanType of Session: ScientificBackground The standard of care for patients with operable stage non-small cell lung carcinomas (NSCLC) remains surgical resection. The best surgical series have
Spot-Scanning Proton Radiation Therapy for Extra-cranial Chordoma Presenter: A StaabPresenter's Affiliation: Paul Scherrer Institute, Villagen, SwitzerlandType of Session: ScientificBackground Chordomas represent a group of rare, locally aggressive tumors, felt to arise from notochord remnants; they most often occur in the regions of the skull base or spinal column Although complete resection with or
Proton Therapy for Early-Stage Lung Cancer at Loma Linda University Medical Center Presenter: D. BushPresenter's Affiliation: Loma Linda University Medical CenterType of Session: ScientificBackground Non-small cell lung cancer (NSCLC) remains the most frequent cause of cancer-related death in the United States, and is a prominent cause of death worldwide. Survival correlates with disease stage at diagnosis, and
Proton Therapy for Lung Cancer at Loma Linda University Medical Center (LLUMC), Locally Advanced Disease Presenter: D. BushPresenter's Affiliation: Loma Linda, USAType of Session: ScientificBackground Despite aggressive treatment with chemoradiation, outcomes in patients with locally advanced NSCLC remain poor, with a median survival of approximately 18 months. There have been several advancements that have been made over time that have
Surgical Organ Displacement for Proton Radiotherapy Presenter: Dr. J JessephPresenter's Affiliation: Proton Radiotherapy Institute, Indiana University, Bloomington, IndianaType of Session: ScientificBackground Compared with photon based therapy, proton therapy has the potential to greatly reduce dose to normal structures. Nonetheless, there are still situations where the successful
Definitive high dose photon/proton radiotherapy for unresected chordomas Presenter: Y-L. Chen, W. Kobayashi, S. Childs, A. Rosenberg, G.P. Nielsen, D. Rosenthal, H. Suit, T. DeLaneyPresenter's Affiliation: Massachusetts General Hospital, Boston, USAType of Session: ScientificBackground Chordomas are rare and slow-growing but locally aggressive malignancies arising from embryonic notochordal elements. Areas
Intrafractional and Interfractional Range Variation in Charged Particle Therapy of Lung Cancer Presenter: S. Mori, L. Dong, G. Starkschall, R. Mohan, J.D. Cox, T. ChenPresenter's Affiliation: National Institute of Radiological Sciences, Chiba, JapanType of Session: ScientificBackground The difference between charged particle and photon beams is their finite penetration and sensitivity to tissue density variations along a given pathway
Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas Presenter: Dr. Tadashi KamadaPresenter's Affiliation: Research Center for Charged Particle Therapy, Chiba, JapanType of Session: ScientificBackground The results from a phase I/II dose escalation study using carbon ion therapy in the treatment of bone and soft tissue sarcomas are presented here. Many patients in this study had osteosarcomas,
Particle Therapy for Sarcomas Presenter: T. DelaneyPresenter's Affiliation: Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground Sarcomas of bone and soft tissues represent only 1% of adult malignancies. They generally require multidisciplinary treatment, with a combination of surgery and radiotherapy, with or without chemotherapy:
Proton Radiation Therapy for Patients with Prostate Cancer Presenter: C. RossiPresenter's Affiliation: Loma Linda, USAType of Session: ScientificBackground The most effective treatment for clinically localized prostate cancer remains controversial, as no randomized trials comparing radiation therapy to surgical resection have been performed. Options for the treatment of clinically localized
Proton treatment of prostate cancer in the presence of unilateral hip replacement Presenter: M. Fitzek, K. Shahnazi, J. Simmons, A. ThorntonPresenter's Affiliation: Midwest Proton Radiotherapy Institute, Bloomington, IN, USAType of Session: ScientificBackground Options for the treatment of clinically localized prostate cancer include radical prostatectomy and radiation therapy, and the latter can be delivered via
Novel Techniques in Proton Treatment and Challenges with Heavy Ion Radiotherapy Presenter: Dr. K. HerfarthPresenter's Affiliation: Heidelberg, GermanyType of Session: Scientific This presentation is a discussion of the current research projects that are ongoing at the Heidelberg heavy ion facility, as well as planned future studies. The presentation began with a discussion of data that support the use of dose escalation in
Multi-Institutional Phase II Study of Proton Beam Therapy for Organ Confined Prostate Cancer in Japan, Focusing on the Incidence of Late Rectal Toxicities Presenter: Dr. K. NiheiPresenter's Affiliation: Shizuoka Cancer Center, Shizuoka, JapanType of Session: ScientificBackground At present, IMRT is the predominant modality used to treat prostate cancer using radiation Dose escalation has been shown to provide higher rates of biochemical free survival in numerous studies (Zietman et al.,
Interfractional Variation in the Set-up of Pelvic Bony Anatomy and Soft Tissue, and Their Implications in Proton Therapy of the Prostate Presenter: A. TrofimovPresenter's Affiliation: Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground As proton therapy becomes more widely available, more and more patients with prostate cancers receive definitive radiation using protons. Multiple dosimetric studies have demonstrated potential for improved
Late Effects of Particle Radiation Presenter: E. BlakelyPresenter's Affiliation: Berkeley Laboratory, San Francisco, CaliforniaType of Session: ScientificBackground Dr. Blakely gave a comprehensive discussion of the published literature regarding late effects of radiation with protons and other particles. Populations at risk for such late effects include both patients requiring
Proton Therapy of Nasal Cavity and Paranasal Sinus Tumors: The UFPTI Experience Presenter: Dr. R. MalyapaPresenter's Affiliation: University of Florida Proton Therapy Institute, Jacksonville, Florida, USAType of Session: ScientificBackground Compared with 3D conformal radiation therapy, a number of studies have suggested that IMRT is able to attenuate treatment-related toxicity in patients with nasopharyngeal cancer
Proton radiation therapy of ocular melanoma at PSI - long-term clinical exam Presenter: G. Goitein, A. Schalenbourg, J. Verwey, A. Bolsi, C. Ares, L. Chamot, E. Hug, L. ZografosPresenter's Affiliation: Paul Scherrer Institute (PSI) Villigen, Switzerland Type of Session: ScientificBackground There are approximately 2200 cases of eye/orbit malignancies per year. The most common primary intraocular malignancy in
Particle Therapy for Bone and Soft Tissue Sarcomas: A Retrospective Study Presenter: Y. Demizu , M. Murakami, D. Miyawaki, M. Mima, K. Terashima, T. Arimura, Y. Niwa, Y. Hishikawa Presenter's Affiliation: Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, JapanType of Session: ScientificBackground Bone and soft tissue sarcomas (BSTSs) represent nearly 10,000 cases of newly diagnosed malignant disease
Carbon Ion Radiotherapy for Head and Neck Tumors Invading the Skull Base Presenter: A. Hasegawa, J. E. Mizoe, K. Jingu, H. Bessho, T. Kamada, H. TsujiiPresenter's Affiliation: Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, JapanType of Session: ScientificBackground A limiting factor in the treatment of malignancies of the skull base is the proximity to critical
Proton Radiotherapy for Pediatric Ewing's Sarcomas: Initial Clinical Outcomes of 29 Patients Presenter: B. RombiPresenter's Affiliation: Trento, ItalyType of Session: ScientificBackground Ewing’s sarcoma represents the second most common bone tumor in children; the Ewing’s family of tumors includes osseous Ewing’s sarcoma, extraosseous Ewing’s sarcoma, peripheral neuroendocrine tumors (PNET), and Askin’s
Proton therapy of ocular tumors for very young children under general anesthesia Presenter: J. HeufelderPresenter's Affiliation: Berlin, GermanyType of Session: ScientificBackground Ocular tumors represent an important subset of pediatric malignancies, often affecting very young children. Most children with retinoblastoma and other ocular tumors go on to be cured of their disease; however, treatments are not without
Carbon Ion Therapy for Patients with Pancreas Cancer Presenter: Dr. S. YamadaPresenter's Affiliation: Chiba University, Chiba JapanType of Session: ScientificBackground The treatment of pancreatic cancer remains a therapeutic challenge. The majority of patients are unresectable at the time of diagnosis and even in those patients who are resectable, trimodality therapy still has poor outcomes
Hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme Presenter: Dr. K. TsuboiPresenter's Affiliation: Proton Medical Research Center, University of Tsukuba, Tsukuba, JapanType of Session: ScientificBackground Despite aggressive multimodality treatment, outcomes in glioblastoma (GBM) remains poor, with a two year survival of approximately 25% (Stupp, NEJM, 2005) In order to try and improve
Stereotactic Body Radiation Therapy for Medically Inoperable Early-stage Lung Cancer Patients: Analysis of RTOG 0236 Presenter: R.D. Timmerman Presenter's Affiliation: University of Texas Southwestern Medical Center, Dallas, TXType of Session: ScientificBackground Lung cancer remains the most frequent cause of cancer death among men and women in North America. Approximately 75% of patients with bronchogenic carcinoma are diagnosed with non-small cell
Adjuvant Radiotherapy Improves Regional (Lymph Node Field) Control in Melanoma Patients after Lymphadenectomy: Results of an Intergroup Randomized Trial (TROG 02.01/ANZMTG 01.02) Presenter: B. BurmeisterPresenter's Affiliation: Princess Alexandra Hospital, Brisbane, AustraliaType of Session: PlenaryBackground Approximately 80% of patients with melanoma who undergo lymphadenectomy have high-risk features. Of these high risk patients, approximately 30-50% fail locally following surgical resection. Adjuvant
Phase III Study of Prophylactic Cranial Irradiation vs. Observation in Patients with Stage III Non–small-cell Lung Cancer: Neurocognitive and Quality of Life Analysis of RTOG 0214 Presenter: B. Movsas Presenter's Affiliation: Presenter's Affiliation: Henry Ford Hospital, Detroit, MIType of Session: PlenaryBackground Fifty percent of patients with locally advanced non-small cell lung cancer (NSCLC) develop central nervous system (CNS) metastases at some time during the course of their disease, with the CNS as
Short-term Endocrine Therapy Prior to and During Radiation Therapy Improves Overall Survival in Patients with T1b – T2b Adenocarcinomas of the Prostate and PSA ? 20: Initial Results of RTOG 94-08 Presenter: Christopher JonesPresenter's Affiliation: Radiological Associates of Sacramento, Sacramento, CAType of Session: PlenaryBackground The potential benefits of the addition of androgen deprivation treatment to radiotherapy in definitive treatment of prostate cancer have been recognized for the past three decades.
Randomized Phase III Trial of Radical Radiotherapy with Concurrent Carbogen and Nicotinamide in Locally-advanced Bladder Cancer Presenter: P. HoskinPresenter's Affiliation: Mount Vernon Cancer Centre, Northwood, United KingdomType of Session: ScientificBackground Although radical cystectomy is generally considered to be the standard treatment for patients with muscle-invasive bladder cancer, radiation therapy has been shown to allow for high rates of
Ten-year Results of a Randomized Trial of Internal Mammary Chain Irradiation after Mastectomy Presenter: P. RomestaingPresenter's Affiliation: Centre De Radiotherapie Charcot, Ste Foy Les Lyon, FranceType of Session: PlenaryBackground Radiation delivery to nodal regions following mastectomy for breast cancer remains controversial. Among clinical discussion points remains the question of the need for delivery
Results of a Prospective Study Delivering Limited Margin Radiotherapy for Pediatric Patients with Ewing’s Sarcoma Family of Tumors Presenter: M.J. KrasinPresenter's Affiliation: St. Jude Children’s Research Hospital, Memphis, TNType of Session: ScientificBackground The Ewing’s sarcoma represents the 2nd most common bone tumor in children, following osteosarcoma. The Ewing’s sarcoma family of tumors includes Ewing’s sarcoma of
RTOG 0529: A Phase II Evaluation of Dose-painted IMRT in Combination with 5-Fluorouracil and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal Presenter: Dr. Lisa KachnicPresenter's Affiliation: Radiation Therapy Oncology Group, Philadelphia, PAType of Session: ScientificBackground Definitive chemoradiotherapy with 5-Fluorouracil (5FU) and mitomycin-C (MMC) is considered the standard of care for patients with cancers of the anal canal. Superiority of this
First Report of Real-time Tumor Tracking in the Treatment of Pancreatic Cancer using the Calypso System Presenter: James M. Metz, MDPresenter's Affiliation: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PAType of Session: ScientificBackground In the United States, surgery followed by combined modality therapy with chemotherapy and radiation therapy remains the standard of care for the approximately 10-20% of patients
Survival Impact of Prophylactic Cranial Irradiation in Limited-stage Small-cell Lung Cancer Presenter: M.E. GiulianiPresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: ScientificBackground Among patients with small-cell lung cancer (SCLC), approximately 10-15% are found to have brain metastasis at diagnosis. In total, approximately 30-60% of patients develop brain
Five-year Results of the Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre- and Postchemoradiation (CRT) 5-FU vs. Gemcitabine (G) For Resected Pancreatic Adenocarcinoma: Implications for Future International Trial Design Presenter: William F. Regine, MDPresenter's Affiliation: University of Maryland Medical Center, Baltimore, MDType of Session: ScientificBackground Due to the often advanced stage of presentation among patients with pancreatic adenocarcinoma, only 15-20% with head of the pancreas lesions and fewer with body and tail lesions are
Changes in Left Ventricular Function after Radiation Therapy and Trastuzumab: Analysis of North Central Cancer Treatment Group Phase III Trial N9831 Presenter: M. HalyardPresenter's Affiliation: Mayo Clinic, Scottsdale, AZType of Session: ScientificBackground Radiotherapy for breast cancer has recently been associated with increased risk of coronary artery disease in patients receiving radiotherapy to the left breast or chest wall (Harris EE, JCO, 2006). Since
Second Tumors in Pediatric Patients Treated with Radiotherapy to the Central Nervous System Presenter: Thomas GallowayPresenter's Affiliation: University of Florida Shands Cancer Center, Gainesville, FLType of Session: ScientificBackground Second malignant neoplasm (SMN) is a well-recognized risk of cancer treatments, including radiotherapy and chemotherapy, and this risk has been demonstrated to be increased in
Five-year Analysis of Treatment Efficacy and Cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in Patients Treated with Accelerated Partial Breast Irradiation (APBI) Presenter: F.A. ViciniPresenter's Affiliation: William Beaumont Hospital, Royal Oak, MIType of Session: ScientificBackground For patients undergoing breast conserving surgery with lumpectomy or quadrantectomy, adjuvant whole breast radiation therapy has consistently been demonstrated to significantly decrease ipsilateral breast
Outcomes following Accelerated Partial Breast Irradiation in Patients with ASTRO Consensus Statement Cautionary Features Presenter: D.R. McHaffiePresenter's Affiliation: Presenter's Affiliation: Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WIType of Session: ScientificBackground Over the past several years, patients are increasingly being offered accelerated partial-breast irradiation (APBI) as
What do Patients want from Their Radiation Oncologist? Final Results from a Prospective Randomized Trial Presenter: Ajay BatnagarPresenter's Affiliation: Cancer Treatment Services International, Casa Grande, AZType of Session: ScientificBackground Adequate patient-physician relationships are very important for achieving good communication, and ultimately the best outcomes possible. In the oncologic setting, physician guidance
Cardiac Complications and Mortality in Men with Prostate Cancer Treated with Brachytherapy with or without Neoadjuvant Hormonal Therapy Presenter: A. NandaPresenter's Affiliation: Harvard Radiation Oncology Program, Boston, MAType of Session: ScientificBackground Multiple studies have demonstrated benefit in biochemical and disease-free survival in men with intermediate and high-risk prostate cancer receiving androgen ablation therapy in combination with
The Four-Year Beam Delivery Experience at the M.D. Anderson Cancer Center Proton Therapy Center Houston Presenter: Dr. Kazumichi Suzuki Presenter's Affiliation: The University of Texas M. D. Anderson Cancer Center, Proton Therapy Center Houston, Houston, TX Background The M.D. Anderson Cancer Center began delivering proton radiotherapy in May, 2006, and, since that time, > 1800 patients have been treated at their center. The
Reduction of Normal Tissue (NT) Toxicity in Patients with Locally Advanced (LA) NSCLC treated with Concurrent Chemotherapy (ChT) and Proton Beam Therapy (PBT) compared to Intensity Modulated Radiation Therapy (IMRT) Presenter: Ritsuko Komaki, MD Presenter's Affiliation: University of Texas M.D. Anderson Cancer Center Background Lung cancer is the leading cause of cancer mortality with a 5 year overall survival of 15%. Local control with standard photon therapy is less than 50%. Improvements in radiation treatment planning and delivery, in
Proton therapy in Pediatric Malignancies: Update of the Orsay Experience Presenter: Dr. Jean-Louis Habrand Presenter's Affiliation: Institut Curie Centre De Protontherapie d'Orsay, Division of Medicine and Biophysics, Orsay, France Background Properties of proton and other particle radiation allow delivery of radiation dose with sparing of normal tissues. The heavy charged nature of protons used therapeutically
Construction, Commissioning, and First Treatments at the ProCure Oklahoma City and Chicago Proton Therapy Facilities Presented by: Andries N. Schreuder Presenter's Affiliation: ProCure Treatment Centers, Department of Medical Physics and Technology, Bloomington, IN Background ProCure Treatment Centers, Inc., was founded in 2005 to provide cancer patients increased access to proton therapy. The first ProCure facility opened in Oklahoma City and treated
Particle Therapy for metastatic liver tumors: evaluation of clinical differences between proton and carbon ion therapies Presenter: Kazuki Terashima Presenter's Affiliation: Hyogo Ion Beam Medical Center, Department of Radiology, Tatsuno, Japan Background The liver is inherently sensitive to radiation therapy, thus limiting the use of external beam photon therapy in treating primary tumors and isolated metastases. The unique physical properties of proton
Proton Beam Therapy Reduced Bone Marrow Suppression Compared with IMRT for Patients with Stage III NSCLC Receiving Concurrent Chemotherapy Presented by: Ritsuko Komaki, MD Presenter's Affiliation: University of Texas M.D. Anderson Cancer Center Background Lung cancer is the leading cause of cancer mortality, with a 5-year overall survival of 15%. Improvements in radiation treatment planning and delivery, in addition to combined modality treatment, have led to an increase
Proton-Based Radiotherapy for Unresectable or Incompletely Resected Osteosarcoma Presenter: Dr. Thomas F. Delaney Presenter Affiliation: Massachusetts General Hospital, Francis H. Burr Proton Therapy Center, Boston, MA Background Osteosarcoma represents the most common primary tumor of bone affecting adolescents and young adults. Early treatment paradigms in the 1960's consisted of aggressive local control with
Requirements for Development and Expansion of Particle Therapy Presenter: Andrew K. Lee Presenter Affiliation: The University of Texas M.D. Anderson Cancer Center, Department of Radiation Oncology, Houston, TX Introduction Dr. Lee provided a discussion of indications for expansion of particle therapy, with a focus on the United States, as well as ways in which the radiation community may support
Clinical Results of Spot-Scanning based Proton Radiotherapy: Experience at the Paul Scherrer Institute since 1996 Presenter: E.B. Hug Presenter Affiliation: Paul Scherrer Institute, Center for Proton Therapy, Villagen, Swiss Confederation Background Spot scanning based proton therapy was pioneered at the Paul Scherrer Institute (PSI) and has been in routine clinical use there since 1996. PSI remains the only facility with long-term experience in
Requirements for the Development and Expansion of Particle Therapy Presenter: Nancy Mendenhall, MD Presenter Affiliation: University of Florida Proton Therapy Institute, Jacksonville, Florida Background Dose delivered to normal tissues is an important barrier to dose distribution in radiation oncology. Particle therapy “moves the field of external beam radiation forward” by changing the photon
Systematic Review and Meta-Analysis of Best Available Photon, Proton, and Carbon-Ion Radiotherapy in Various Head and Neck Cancers Presenter: Dr. Janneke Grutters for Dr. Bram Ramaekers Presenter's Affiliation: Maastricht Radiation Oncology (MAASTRO), Maastricht, The Netherlands Background Cancers of the head and neck represent a heterogeneous group of malignancies. Although these cancers can and do metastasize to distant sites, local control has been demonstrated
Proton Radiotherapy for Cardiac and Pulmonary Vessel Sarcomas Presenter: Dr. Yen-Lin Chen Presenter's Affiliation: Massachusetts General Hospital, Radiation Oncology, Boston Background Although cardiac and pulmonary vessel sarcomas are rare, they are not unheard of, and pose significant treatment conundrums. The mainstay of treatment is surgical resection, but gross total resection is rarely
A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study Presenter: K.G. Tournoy, MD Affiliation: Ghent University Hospital, Ghent, Belgium Background Prognosis of patients with non-small cell lung cancer (NSCLC) depends heavily on nodal staging (Rusch, Journal of Thoracic Oncology 2007, 2:603-12) Appropriate treatment of NSCLC depends on accurate mediastinal lymph node staging. Non-operative
Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer Presenter: V. Westeel, MD, on behalf of the Intergroupe Francophone de Cancerologie Thoracique Background This is an update of a previously reported French Phase III randomized trial (DePierre, JCO 2002) comparing neo-adjuvant chemotherapy followed by surgery to surgery alone for patients with resectable non-small cell lung cancer (NSCLC).
Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study Presenter: T. Cloughesy for the BRAIN Investigators Affiliations: University of California, Los Angeles Neuro-Oncology Program, Los Angeles, CA Background Glioblastoma Multiforme (GBM) is the most common primary malignant brain tumor accounting for 40% of primary CNS Malignancies Primary therapy for GBM typically consists of maximally
A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 Presenter: G.D. Goss, MD Affiliation: The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada Background Platinum-based adjuvant chemotherapy in completely resected NSCLC had demonstrated a modest survival benefit of 5% at 5 years when this study was initiated. EGFR expression in NSCLC has been correlated with aggressive morphology and
Limited-stage diffuse large B-cell lymphoma (DLBCL) treated with abbreviated systemic therapy and consolidation radiotherapy: Involved field radiotherapy (IFRT) versus involved nodal radiotherapy (INRT≤5cm) Presenter: B. A. Campbell Affiliation: British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL), and accounts for approximately 30-35% of patients with NHL. Limited stage DLBCL is defined as Ann
Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial Presenter: E. Thiel Affiliation: Department of Hematology, Charite Campus Benjamin Franklin, Berlin, Germany Background Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma (NHL). It is restricted entirely to the brain, leptomeninges, eyes, and rarely the spinal cord. It accounts for
Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ) Presentor: A. Malmstrom Affiliation: Unit of Advanced Palliative Home Care, Linköping, Sweden Background Glioblastoma Multiforme (GBM) is the most common primary malignant brain tumor, accounting for 40% of primary CNS Malignancies The incidence of GBM increases with age and approximately 50% of patients diagnosed with GBM are > 65
Long-term survival among 298 Hodgkin lymphoma (HL) patients who develop breast cancer (BC): A population-based study Presenter: M. T. Milano, Department of Radiation Oncology, University of Rochester, Rochester, NY Background Second malignant neoplasms are the leading cause of death among long-term survivors of Hodgkin lymphoma (HL) (Hoppe et al. Ann Oncol, 1997). Breast cancer (BC) is the most common solid tumor diagnosed among female HL survivors.
Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer Background In locally advanced prostate cancer, the combination of radiation therapy (RT) and androgen deprivation therapy (ADT) has been demonstrated to provide superior outcomes when compared to RT or ADT alone (Bolla, Lancet, 2002). Indications and methodology for delivery of ADT remain uncertain and at times controversial. Outstanding
Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group (GOG) study Presenter: Robert Burger, MD for the Gynecologic Oncology Group and Fox Chase Cancer Center, Philadelphia, PA Background Ovarian cancer is the most common gynecologic cancer, and is the 4th leading cause of cancer death in women. Annually, 22, 000 women are diagnosed with ovarian cancer and 15,000 women die of this disease per
A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma Presenter: Steven O'Day, The Angeles Clinic and Research Institute, Los Angeles, CA. Background Advanced melanoma (Stage III/IV) has an increasing global incidence. Many patients are diagnosed at a relatively young age, and the disease carries a poor prognosis. Despite multiple trials of experimental therapeutics, there are few good
Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC) Presenter: E. A. Quoix, on behalf of IFCT; Hôpitaux Universitaires, Strasbourg, France Background Lung cancer is the most common cause of cancer mortality in the US, accounting for 30% of cancer-related deaths in men and 26% of cancer-related deaths in women. Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung
Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) Presenter: Y. Bang, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Background Efficacy of conventional chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) appeared to reach a plateau in the mid-1990s, at the same time that targeted therapeutics began to enter clinical trials.
Neurocognitive outcomes after proton radiation for pediatric brain tumors Presenter: M. B. Pulsifer, Massachusetts General Hospital, Boston, MA; Children's Hospital Medical Center, Boston, MA; Harvard Medical School, Boston, MA Background Pediatric brain tumors account for 20% of all pediatric cancers, and treatment generally involves surgery, chemotherapy, and/or radiation therapy. Radiation therapy, which is
Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients Presenter: S. H. Giordano, University of Texas M. D. Anderson Cancer Center, Houston, TX Background Diabetes and obesity are very prevalent in the US population and the incidence of these disorders continues to rise. The National Institute of Health estimated that in 2007, 7.8% of Americans had either diagnosed or undiagnosed
A phase II trial of proton radiotherapy for medulloblastoma: Preliminary results Presenter: T. I. Yock, Massachusetts General Hospital, Boston, MA; Children's Hospital Medical Center, Boston, MA; Harvard Medical School, Boston, MA Background Medulloblastoma (MB) is the most common malignant brain tumor occurring in children, accounting for 20% of all pediatric CNS tumors. It commonly arises in the posterior fossa, and has
Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer Presenter: K. S. Hughes, CALBG, ECOG, RTOG, Massachusetts General Hospital, Boston, MA Background The Early Breast Cancer Trialists’ Collaborative Group Overview (Lancet, 2005), showed that radiation therapy (RT) after breast-conserving surgery (BCS) produced significant absolute improvements in 5-year LR (17-19% benefit) and 15-year breast
Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN) Presenter: K. J. Harrington, Royal Marsden Hospital, UK Background Lapatinib is an oral small-molecule dual tyrosine kinase (TK) inhibitor of EGFR (epidermal growth factor receptor), which targets Her2 receptors. This drug has been approved for use in treatment of locally advanced metastatic Her 2+ breast cancer.
Factors influencing the uptake of the human papillomavirus (HPV) vaccine to prevent cervical cancer (CC) Presenter: J. Y. Lai, PhD; Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada Background Cervical cancer is a major cause of cancer morbidity and mortality worldwide, with an estimated 11,270 new cases in the United States in 2009. Gardasil is a vaccine that has been developed to immunize patients against
TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy Presenter: S. Lee, University College Hospital/UCL Cancer Institute, London, United KingdomBackground Patients with poor performance status (PS) represent 30-50% of those presenting with advanced (Stage IIIB/IV) NSCLC, and are under-studied. These patients are often not candidates for standard first line chemotherapy (platinum-based doublet
Chronic medical conditions, health status, and health care practices at 25 years in 5-year survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study Presenter: A. M. Termuhlen, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, OH Background Wilms tumor (WT) is the most common pediatric abdominal tumor. The development of more effective therapy for WT has translated into marked improvements in overall survival since the 1960's, and currently
Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial Presenter: G. Pfeiler, MD, Medical University of Vienna Background In hormone receptor positive breast cancers, drugs such as Tamoxifen and aromatase inhibitors decrease the production of estrogens, and have been shown to lead to suppression of tumor recurrence. Tamoxifen is an orally active selective estrogen
Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003 Authors: M. L. Gillison, The Ohio State University, Columbus, OH Background There is a growing body of evidence that Human Papillomavirus (HPV) infection plays an important role in the pathogenesis of a subset of head and neck squamous cell carcinomas (SCC). HPV related tumors are characterized by the presence of HPV DNA within the
Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial Presenter: J. S. Temel, Massachusetts General Hospital, Boston, MA. Background Patients with metastatic NSCLC often have a high symptom burden from the time of initial diagnosis, which greatly affects their quality of life. These patients are often subjected to aggressive care at the end of life, which can contribute to patient distress,
A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome Presenter: K. Ang, University of Texas M. D. Anderson Cancer Center, Houston, TX Background Accelerated fractionation of radiotherapy and concurrent chemoradiotherapy have both been shown to improve outcomes in locally advanced HNC patients compared to standard fractionated radiotherapy alone. RTOG 9003 was a phase III randomized
Contrasting effects of religious/spiritual support from religious communities versus medical teams on advanced cancer patient end-of-life care It will come of no surprise to patients and their families that religious and spiritual concerns are important to the majority (76-88%) of patients facing a life-threatening illness. Support of a patient’s religious or spiritual (R/S) needs by the medical team (nurses, physicians and chaplains) is associated with less aggressive care at the end of
Effect of YOCAS yoga on sleep, fatigue, and quality of life: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors Most any person going through cancer diagnosis and treatment will tell you their sleep has been affected. Poor sleep, in turn, leads to worse quality of life (QOL) and difficulty carrying out life’s daily activities. While medications can help a person sleep, many patients are hesitant to take yet another pill and practitioners worry about sleep
15th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma Conference Dates: February 17-20, 2011 Conference Location: The Fairmont Château Whistler, 4599 Château Blvd., Whistler, British Columbia, Canada V0N 1B4 Sponsoring Group: Physicians' Education Resource Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/592 Topics
Best Practices & Strategies for Oncology Nurse Navigation Leadership Dates: February 16-17, 2012 Location: Orlando, FL Web Page URL: https://www.mindstreamedu.com/conference-pages/nn1 Topics Covered: Join us at our National Event on ";Best Practices for Oncology Nurse Navigation Leadership" focused on exploring the latest strategies and best practices for Establishing a Competitive Nurse Navigation
12th European Conference: Perspectives in Lung Cancer Conference Dates: March 11-12, 2011 Conference Location: Lingotto Conference and Exhibition Centre Sponsoring Group: Imedex Conference Web Page URL: www.perspectivesinlungcancer.com Topics Covered: Lung Cancer Who Should Attend: This educational activity is intended for medical and radiation oncologists, thoracic surgeons, pulmonologists,
Immunochemotherapy: Correcting Immune Escape in Cancer Conference Dates: March 10-11, 2011 Conference Location: Philadelphia, USA Sponsoring Group: Abcam Conference Web Page URL: www.abcam.com/philadelphia Topics Covered: Immunological effects of chemotherapy. Inflammatory tumor microenvironment and immune suppression. Intrinsic and extrinsic barriers to cancer. Therapeutic strategies. Conference
Scientific and Clinical Update in Geriatric Oncology: A New Battlefront Dates: March 9, 2012 Location: Philadelphia, PA Sponsoring Group: Kimmel Cancer Center at Jefferson, Kimmel Cancer Center Network and the Rothman Institute Web Page URL: www.kimmelcancercenter.org Topics Covered: The Scientific and Clinical Update in Geriatric Oncology: The New Battlefront is designed to provide comprehensive updates in basic
AICR/AADE Webinar: ‘The Diabetes-Cancer Connection: From Research to Practice Dates: March 20, 2012 Time: 1:00 pm ET Location: Washington, DC Sponsoring Group: American Institute for Cancer Research Web Page URL: http://www.aicr.org/health-professionals/ Topics Covered: Diabetes, Cancer, Nutrition, Diet Objectives: Join leading experts in a lively overview of the research, dietary recommendations for each disease, and
Apoptosis and Cancer Dates: June 14-15, 2012 Location: Cambridge, UK Web Page URL: http://www.abcam.com/cambridgecancer Topics Covered: BCL2 Family P53 Family Death Receptors and Inflammation IAP's Who Should Attend: All researchers/scientists from academia and industry Agenda: A failure of cells to undergo apoptosis is a common feature of many
JAK Inhibition in Cancer: Exploring a Novel Pathway Dates: Saturday, June 2, 2012 Location: Chicago, IL Web Page URL: www.peerviewpress.com/JAK Objectives: Please see website for further information. Who Should Attend: This activity has been designed to meet the educational needs of oncologists and hematologist-oncologists engaged in the management of patients with cancer.. Fees: Please see
Breast Cancer Coordinated Care - BC3 Dates: July 19-21, 2012 Location: JW Marriott Washington, DC Sponsoring Group: Georgetown University Hospital Web Page URL: www.bc3conference.com Topics Covered: Breast Conservation Therapy Oncoplastic Surgery Surgical Challenges in the Management of Breast Cancer Post-Mastectomy Radiation Therapy Coordinating Reconstruction with Post-Mastectomy
2012 World Cancer Congress Dates: August 27-30, 2012 Location: Montréal, Canada Sponsoring Group: Union for International Cancer Control (UICC) Web Page: www.worldcancercongress.org Topics Covered: Track 1 Prevention and early detection Session topics include: Digital media in cancer prevention and tobacco control Countering the tobacco industry Education and
Sydney Cancer Conference 2012 Dates: September 27-28, 2012 Location: Sydney, Australia Sponsoring Group: University of Sydney Web Page URL: sydney.edu.au/cancer-research/SCC2012/ Topics Covered: The Sydney Cancer Conference 2012 theme is From Discovery to Implementation covering basic cancer research, biomedical cancer research, Clinical and public health research, and
2012 ASH Consultative Hematology Course (CHC) Dates: September 28, 2012 Location: Chicago, IL Web Page URL: www.hematology.org/Meetings/Consultative-Hematology-Course/8501.aspx Topics Covered: The program will focus on non-malignant hematology. Objectives: The one-day program, geared toward North American community practitioners, will cover commonly encountered clinical problems that
Practical Advice & Tools to Balance Cancer & Employment Dates: September 13, 2012, 3PM ET Location: Teleconference/Webinar Sponsoring Group: Cancer and Careers Web Page URL: www.cancerandcareers.org/en/community/events/healthcare-professionals Information: Take a Break and Earn a CEU! Don't miss the Fall 2012 sessions of Cancer and Careers' FREE educational series for healthcare professionals at
3rd International Symposium on Focused Ultrasound Dates: October 14-17, 2012 Location: Bethesda North Marriott Hotel and Conference Center Sponsoring Group: Focused Ultrasound Foundation Web Page URL: www.fusfoundation.org/Symposium Topics Covered: Organized by the Focused Ultrasound Foundation, the Symposium is a global forum covering state-of-the-art clinical applications of image-guided
2012 ASH State-of-the-Art Symposium Dates: October 12-13, 2012 Location: Los Angeles, CA Web Page URL: www.hematology.org/Meetings/State-of-the-Art-Symposium/ Topics Covered: Topics will include thrombocytopenia, myelodysplastic syndromes, and lymphoma. Objectives: This year's program will focus on the newest treatment options for hematologic malignancies with a special focus on
Celebration of Hope Dates: Friday, October 5, 2012 Location: Hilton Philadelphia City Avenue Sponsoring Group: Cancer Support Community of Philadelphia Web Page URL: www.cancersupport-phila.org/CelebrationofHope2012.htm Topics Covered: Fitness and Cancer, Competing with Cancer, Eating Well with Cancer, NIA exercise Objectives: Provide inspiration, education and
Legal & Insurance Issues to Consider Dates:October 11, 2012 Location: Teleconference/Webinar Sponsoring Group: Cancer and Careers Web Page URL: www.cancerandcareers.org/en/community/events/healthcare-professionals Information: Take a Break and Earn a CEU! Don't miss the Fall 2012 sessions of Cancer and Careers' FREE educational series for healthcare professionals at 3 PM ET.
Philadelphia Free To Breathe 5K Run/Walk/Rally Dates: November 4, 2012 Location: Memorial Park, near the Please Touch Museum, Philadelphia, PA Sponsoring Group: PA Lung Cancer Partnership Web Page: www.freetobreathe.org Topics Covered: This event provides an opportunity for lung cancer advocates, survivors and the community to come together to raise awareness and support to fight this
2012 Science of Global Prostate Cancer Disparities Conference: The Global Burden of Prostate Cancer: Economic, Clinical and Humanistic Outcomes Dates: November 1-4, 2012 Location: Nassau, The Bahamas Sponsoring Group: University of Florida, University of West Indies Website:cancer.ufl.edu/research/symposia-and-conferences-2/symposia-and-conferences/ Objectives: The goals of this conference are to: Provide opportunities for mutual learning, knowledge transfer, and collaborations among
Ask The Experts: Legal and Career Advice Dates: 5/23, 7/19, 10/24 Location: Teleconference Sponsoring Group: Cancer and Careers Web Page URL: http://www.cancerandcareers.org/en/community/events/ask-the-experts Topics Covered: A teleconference series presented by Cancer and Careers, your resource for balancing work and cancer. How do I deal with the gap on my resume from taking time off
The AICR Annual Research Conference 2012 on Food, Nutrition, Physical Activity Cancer Dates: November 1-2, 2012 Location: Capital Hilton Hotel, Washington, DC Conference URL: www.aicr.org/conference
Global Conference on Perioperative Medicine: Care of the Elderly and the Cancer Patient Dates: November 28 - December 2, 2012 Location: The University of Texas MD Anderson Cancer Center, Houston-Texas Sponsoring Group: Department of Anesthesiology & Perioperative Medicine Web Page URL: http://www.mdanderson.org/anesthesiology Topics Covered: At the conclusion of the meeting participants should be able to: Understand the
Re-Entering the Workforce after Short & Long Absences Dates: November 15, 2012 Location: Teleconference/Webinar Sponsoring Group: Cancer and Careers Web Page URL: www.cancerandcareers.org/en/community/events/healthcare-professionals Information: Take a Break and Earn a CEU! Don't miss the Fall 2012 sessions of Cancer and Careers' FREE educational series for healthcare professionals at 3 PM ET.
ASH 2012 Annual Meeting Dates: December 8-11, 2012 Location: Atlanta, Georgia Sponsoring Group: The American Society of Hematology Web Page URL: http://www.hematology.org/Meetings/Annual-Meeting/ Objectives: The goal of the ASH annual meeting is to present the best new scientific research in all areas of hematology. Fees: Advance Registration: $440 for members and
Proton Radiotherapy for Pediatric Medulloblastoma: Improved Early Ototoxicity Authors: B. J. Moeller, M. Chintagumpala, J. J. Philip, S. Y. Woo, J. E. Wolff, A. Mahajan Institution: M.D. Anderson Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX; University of Louisville School of Medicine, Louisville, KY Background Medulloblastoma represents approximately 1 in 5 pediatric central nervous system
Gamma Knife Radiosurgery (GKRS) in the Management of Parkinson's Disease and Essential Tremor: Long-term Follow-up Report of 192 Cases Authors: C. Frentress, R.J Mark, H. Smith, D. Jacques, R. Young, B. Copcutt, C. Chen, P.J. Anderson, M. Nair. Background Tremor secondary to Parkinson's disease (PD) and Essential Tremor (ET) are often progressive in nature and without effective treatment may result in significant disability for affected patients. Medication is typically
Brain Metastases from Breast Cancer: Recursive Partitioning Analysis of Prognostic Factors Including Molecular Subtypes and Treatment Authors: R. Le Scodan, C. Massard, L. Jouanneau, F. Coussy, M. Gutierrez, Y. Kirova, A. Labib, E. Mouret-Fourme Institution: Institut Curie, Hopital Rene Huguenin, Saint Cloud, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Site Ulm, Paris, France Background Approximately 20-40% of all cancer patients will develop
Initial Report of UCCRC 3443: A Prospective Study on the Utility of Magnetic Resonance Imaging (MRI) in Determining Candidacy for Partial Breast Irradiation (PBI) Authors: P.L. Dorn, H. Al-Hallaq, M. Goldberg, Y. Hassan, N. Jaskowiak, G. Newstead, S.J. Chmura. Background For several decades, whole breast irradiation (WBI) has been used after breast conserving surgery as a means of reducing risk of ipsilateral breast tumor recurrence. The efficacy of whole breast irradiation has been demonstrated in
Poor Pulmonary Function is not Associated with Increased Rates of Toxicity or Decreased Overall Survival after Stereotactic Body Radiotherapy for Early Stage Non-small Cell Lung Cancer: Results of a Multi-Institutional Analysis Authors: M. Guckenberger1, J. Belderbos2, A. Hope3, L. L. Kestin4, M. Werner-Wasik5, J. J. Sonke2, Y. Xiao5, D. Yan4, J. Wilbert1,I. S. Grills4 Institution: 1Julius-Maximilians University, Wuerzburg, Germany 2The Netherlands Cancer Institute, Amsterdam, Netherlands 3PrincessMargaret Hospital and University of Toronto, Toronto, ON, Canada
QRRO 2007 Practice Survey Documents Dramatic Technical Changes in How Radiotherapy for Operable Breast Cancer is Delivered Authors: J.R. White1, N. Khalid2, M.L. Tao3, L.J. Pierce4, A. DeRobertis5, C. Crozier2, J.B. Owen2 and J.F. Wilson1 Institution: 1Medical College of Wisconsin, Milwaukee, WI 2American College of Radiology, Philadelphia, PA 3Epic Care, Orinda, CA 4University of Michigan Medical School, Ann Arbor, MI 5Massachusetts General
A Phase II Trial of Stereotactic Body Radiation Therapy for Operable T1N0M0 Non-small Cell Lung Cancer: Japan Clinical Oncology Group (JCOG0403) Authors: Y. Nagata, M. Hiraoka, T. Shibata, H. Onishi, M. Kokubo, K. Karasawa, Y. Shioyama, R. Onimaru, E. Kunieda, S. Ishikura Institution: Hiroshima University,, Hiroshima, Japan, Kyoto University, Kyoto, Japan, JCOG Data Center, National Cancer Center, Tokyo, Japan, Yamanashi University, Yamanashi, Japan, Institute of Biomedical Research and
Intergroup Randomized Phase 3 Study of Androgen Deprivation Therapy (ADT) + Radiation Therapy (RT) in Locally Advanced Prostate Cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, and INT: T94-0110; NCT00002633) Authors: M.D. Mason, P.R. Warde, M.R. Sydes, M.K. Gospodarowicz, G.P. Swanson, P. Kirkbride, E. Kostashuk, J. Hetherington, K. Ding, W. Parulekar Affiliations: Cardiff University. Cardiff, UK. Princess Margaret Hospital and University of Toronto. Toronto, ON. Clinical Trials Unit, Medical Research Council. London, UK. University of Texas Health
The TME Trial after a Median Follow-up of 11 Years Authors: C. A. Marijnen1, W. van Gijn1, I. D. Nagtegaal2, E. Klein Kranenbarg1, H. Putter1, T. Wiggers3, H. J. T. Rutten4, L. Pahlman5,B. Glimelius5, C. J. H. van de Velde1 Institution: 1 Leiden University Medical Center, Leiden, Netherlands 2 University Medical Center St. Radboud, Nijmegen, Netherlands 3 University Medical Center
Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) Randomized HD11 Trial Authors: H. T. Eich, R. P. Mueller, V. Diehl, H. Gorgen, H. Mueller-Hermelink, B. Schmidt, Grosu, J. Karstens, N. Willich, A. Engert Institutions: Department of Radiation Oncology, University of Cologne, Cologne, Germany; Clinic for Internal Medicine, University of Cologne, Cologne, Germany; Institute of Pathology, University of Wurzburg,
10-year results of Adjuvant Radiotherapy after Radical Prostatectomy in pT3N0 Prostate Cancer Authors: M. Bolla1, H. Van Poppel2, B. Tombal3, K. Vekemans4, L. Da Pozzo5, T. M. De Reijke6, A. Verbaeys7, J. F. Bosset8, R. Van Velthoven9, L. Collette10 Institution: 1 CHU de Grenoble - A Michallon, Grenoble, France 2 Leuven University Hospital - UZ Gasthuisberg, Leuven, Belgium 3 Cliniques Universitaires Saint Luc, Brussels,
Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Level Authors: W.U. Shipley, D. Hunt, H. Lukka, P. Major, N.M. Heney, D. Grignon, M. Patel, J. Bahary, C. Lawton, H. Sandler. Affiliations: Massachusetts General Hospital. Boston MA. RTOG Statistical Center. Philadelphia, PA. Mcmaster University Juravinski Cancer Center. Hamilton, ON Indiana University. Indianapolis, IN. University of
Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) is the New Standard of Care in the Treatment of Patients with Early Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) Trial HD10 Authors: R. P. Mueller, H. T. Eich, A. Plutschow, J. Debus, M. Bamberg, K. Wilborn, M. Eble, H. Muller-Hermelink, V. Diehl, A. Engert Institutions: Radioonkologie, Klinikum der Universitaet zu Koeln, Koeln, Germany; Medical Oncology, Klinikum der Universitaet zu Koeln, Koeln, Germany; Radioonkologie, Universitat Heidelberg, Heidelberg, Germany;
An Updated Report on the Pathologic Complete Response and Survival Outcome of Southwest Oncology Group (SWOG S0536): A Phase II Trial of Oxaliplatin (oxp) Plus Protracted Infusion 5-Fluorouracil (PIFU) and External Beam Radiation (EBRT) Prior to Surgery for Potentially Curable Esophageal Adenocarcinoma (EA) with Molecular Correlates Authors: L.P. Leichman, B. Goldman, C.R. Thomas, K.G. Billingsley, C.L. Corless, H. Lenz, S. Iqbal, J.K. Benedetti, P.J. Gold, C.D. Blanke. Affiliations: Aptium Gastrointestinal Cancer Consortium. Palm Springs, CA. Southwest Oncology Group. Seattle, WA. Oregon Health Sciences University. Portland, OR. University of Southern California. Los
Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004) Authors: N. James1, S. Hussain1, E. Hall2, P. Jenkins3, J. Tremlett4, C. Rawlings5, M. Crundwell6, R. Waters2, R. A. Huddart2 Institution: 1 University of Birmingham, Birmingham, United Kingdom 2 Institute of Cancer Research, Sutton, United Kingdom 3 Cheltenham General Hospital, Cheltenham, United Kingdom 4 Brighton and Susgender
Outcome of Radiotherapy Alone in HPV Associated Oropharyngeal Cancer Authors: B. O'Sullivan, S. Huang, B. Perez-Ordonez, F. Liu, C. Massey, I. Weinreb, E. Chen, B. Cummings, J. Kim, J. Waldron Affiliations: Princess Margaret Hospital / University of Toronto, Toronto, ON, Canada Background There is a growing body of evidence that Human Papillomavirus (HPV) infection plays an important role in the pathogenesis
Triple-Negative Breast Cancer is Associated with Higher Risk of Local Recurrence after 3D-Conformal External Beam Accelerated Partial Breast Irradiation (3D-APBI) Authors: I. M. Pashtan, M. Ancukiewicz, J. Y.Wo, A. E. Hirsch, B. L. Smith, S. N. Powell, A. Recht, A. G. Taghian. Affiliations: Harvard Radiation Oncology Program, Boston, MA. Massachusetts General Hospital, Boston, MA. Boston Medical Center, Boston, MA. Memorial Sloan-Kettering Cancer Center, New York, NY. Beth Israel Deaconess Medical Center,
Patient Reported Cosmetic Outcomes and Complications after Breast Conserving Treatment Authors: C. E. Hill-Kayser, C. Vachani, M. K. Hampshire, G. A. Di Lullo, J. M. Metz Institution: University of Pennsylvania Medical Center, Philadelphia, PA Background Over the past 30 years, much work in treatment of breast cancer has contributed to improvement of cosmetic and functional outcomes. Over 50% of women with breast cancer
Pelvic Fracture after Radiation Therapy for Localized Prostate Cancer: A Population Based Study Authors: D. M. Housman, C. J. Savage, M. J. Zelefsky, E. B. Elkin Institution: Memorial Sloan-Kettering Cancer Center, New York, NY Background Prostate cancer is the most common malignancy in men; most are diagnosed over age 65, when age-related bone density is already decreasing and pelvic fracture is a source of morbidity and mortality.
Toxicity of Phase I Radiation Oncology Trials: Worldwide Experience Authors: C. Glass1, R. B. Den2, A. P. Dicker2, Y. R. Lawrence2 Institution: 1 Jefferson Medical College, Philadelphia, PA 2 Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA Background Informed consent involves understanding the risks and benefits of trial enrollment, but
Carbon Ion Radiotherapy for Primary Malignant Bone Tumors of the Sacrum Authors: T. Kamada, R. Imai, H. Tsuji, T. Imaizumi, H. Tsujii Institution: National Institute of Radiological Sciences, Chiba, Japan Background Primary malignant bone tumors of the sacrum are extremely rare, and their management complex because of the proximity of these tumors to sacral nerve roots as well as the important weight bearing
Comparison of Health-related Quality of Life 5 Years after Brachytherapy (BT) or Radical Prostatectomy (RP): The SPIRIT (Surgical Prostatectomy vs. Interstitial Radiotherapy Intervention Trial) Cohort (ACOSOG Z0070) Authors: J. M. Crook, A. Gomez-Iturriaga, K. Wallace, S. Fung, S. Alibhai, M. Jewett, N. Fleshner Institutions: University of British Columbia, Kelowna, BC, Canada; Cruces Hospital, Barakaldo, Spain; Princess Margaret Hospital, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada Background Worldwide, prostate cancer is the
Long-term Survival and Competing Causes of Death in Men with Stage I Seminoma Authors: C. J. Beard, M. Chen, N. D. Arvold, P. L. Nguyen, A. K. Ng, K. E. Hoffman Institutions: Dana-Farber Cancer Institute, Boston, MA; University of Connecticut, Storrs, CT; Harvard Radiation Oncology Program, Boston, MA; The University of Texas M. D. Anderson Cancer Center, Houston, TX Background Testicular cancer is the most common
A Dose-response Relationship for the Incidence of Radiation-related Heart Disease Authors: S. C. Darby, D. Brønnum, C. Correa, M. Ewertz, G. Gagliardi, B. Gigante, P. McGale, A. Nisbet, C. Taylor, P. Hall. Affiliations: University of Oxford, Oxford, United Kingdom. Aalborg Hospital, Aalborg, Denmark. University of Odense, Odense, Denmark. Karolinska University Hospital, Stockholm, Sweden. Karolinska Institutet, Stockholm,
The Effect of Radiotherapy on Local Regional Recurrence among Patients with Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Authors: C. E. Fasola, K. D. Godette, M. W. McDonald, R. M. O'Regan, A. B. Zelnak, J. C. Landry, M. A. Torres. Affiliations: Emory University School of Medicine, Atlanta, GA. Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. Department of Radiation Oncology, Indiana University School of Medicine,
Hematologic Toxicity on RTOG 0418: A Phase II Study of Post-operative IMRT for Gynecologic Cancer Authors: A. H. Klopp1, J. Moughan2, L. Portelance3, B. E. Miller4, M. R. Salehpour1, D. D'Souza5, L. Souhami3, W. Small6, R. Gaur7, A. Jhingran1 Institution: 1 M.D. Anderson Cancer Center, Houston, TX 2 RTOG Statistical Center, Philadelphia, PA 3 McGill University Health Centre, Montreal, QC, Canada 4 Wake Forest University
High-dose, Spot Scanning Based Proton Therapy For Paraspinal / Retroperitoneal Neoplasms and Small Bowel Tolerance: Dose Distribution Analysis in a Patient Cohort Authors: R. A. Schneider, V. Vitolo, F. Albertini, T. Koch, C. Ares, A. Lomax, G. Goitein, E. B. Hug. Affiliations: Paul Scherrer Institute, Villigen PSI, Switzerland. Fondazione CNAO, Pavia, Italy. University of Zurich, Zurich, Switzerland. Background Mesenchymal tumors require high doses of radiation when treated either in the adjuvant or
Radiation Induced Rib Fractures after Hypofractionated Stereotactic Body Radiation Therapy: The Risk Factors and Dose-Volume Relationship Authors: K. Asai, Y. Shioyama, S. Ohga, T. Nonoshita, T. Yoshitake, K. Ohnishi, K. Terashima, K. Matsumoto, H. Hirata, H. Honda. Affilations: Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Phase I/II study of Proton-based Short Course Chemoradiation and Early Surgery for Adenocarcinoma of the Pancreas Authors: T. S. Hong, D. P. Ryan, L. S. Blaszkowsky, H. J. Mamon, R. C. Wadlow, E. L. Kwak, C. R. Ferrone, J. Adams, B. Yeap, B. Winrich Institution: Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA Background Pancreatic cancer is overwhelmingly adenocarcinomatous in origin
Five Year Results of US Intergroup/RTOG 9704 with Postoperative Ca 19-9 #90 and Comparison to the Conko-001 Trial Authors: A. C. Berger1,K. Winter2,J. P. Hoffman3,W. F. Regine4,R. A. Abrams5,H. Safran6,G. M. Freedman3,A. B. Benson7,J. MacDonald8,C. Willet9 Institution: 1 Thomas Jefferson University, Philadelphia, PA 2 Radiation Therapy Oncology Group, Philadelphia, PA 3 Fox Chase Cancer Center, Philadelphia, PA 4 University of Maryland School of
RTOG 0229: A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and Full Dose Radiotherapy (XRT) followed by Resection and Consolidative Therapy for LA-NSCLC Authors: M. Suntharalingam, R. Paulus, M. J. Edelman, M. Krasna, W. Burrows, E. Gore, S. S. Yom, H. Choy Institution: University of Maryland School of Medicine, Baltimore, MD; RTOG Statistical Center, Philadelphia, PA; University of Maryland Medical Center, Baltimore, MD; St Joseph's Medical Center, Baltimore, MD; Medical College of Wisconsin,
Risk Factors Predicting Failure and Prostate Cancer Mortality in High Risk Prostate Cancer Patients Treated with Definitive External Beam Radiation Therapy Authors: Q. Nguyen, L. B. Levy, A. K. Lee, S. Choi, S. J. Frank, K. Hoffman, S. McGuire, D. A. Kuban Institution: M.D. Anderson Cancer Center, Houston, TX Background Prostate cancer is the most common non-cutaneous malignancy in men and is the second most common cause of cancer deaths in the United States. High-risk prostate cancer is
Patterns of Radiotherapy Practice for Patients Treated for Intact Cervical Cancer in 2005-2007: A QRRO Study Authors: P. J. Eifel1, N. Khalid2, B. Erickson3, C. Crozier2, J. Owen2, J. F. Wilson3 Institution 1 M.D. Anderson Cancer Center, Houston, TX 2 ACR Clinical Research Center, Philadelphia, PA 3 Medical College of Wisconsin, Milwaukee, WI Background Cervical cancer represents a worldwide problem, and is the third most common
Focus on Head Neck Cancers Conference Dates: April 8, 2011, 8am - 3pm Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Web Page URL: http://www.penncancer.org/events.cfm?type=1=view%3Devent%26eventid%3D9264606 Topics Covered: The incidence of head and neck cancers and the impact of this disease on men and women, of all ages, have made head and neck cancers a priority
Twelfth Annual Wallace H. Clark Jr., MD Lectureship in Cutaneous Oncology & Melanoma Symposium Conference Date: April 7, 2011, 8:30 AM - 12:00 PM Conference Location: University of Pennsylvania, Biomedical Research Building II/III, Ground Floor Auditorium, Curie Blvd. Osler Circle, Philadelphia, PA Conference Brochure: PDF Sponsoring Group: Supported, in part, by educational grants from The Noreen O'Neill Foundation for Melanoma
The Liver Seminar Dates: April 29, 2011 Location: Harvey, Illinois Sponsoring Group: YES! Beat Liver Tumors Web Page URL: www.liverseminars.com Topics Covered: Cutting edge treatments for cancers of the liver. Objectives: To provide a multidisciplinary treatment algorithm for cancers of the liver. Who Should Attend: Oncologists, Radiation Oncologists,
Focus on Melanoma Conference Dates: May 13, 2011, 8am - 3pm Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center Web Page URL: http://www.penncancer.org/events.cfm?type=1=view%3Devent%26eventid%3D92646431 Topics Covered: HOLD THE DATE The 8th Annual Focus on Melanoma Conference is a full day symposium designed to address
Hands-On Course in Thyroid and Parathyroid Ultrasound Imaging: A Multidisciplinary Approach Dates: Saturday, May 7, 2011 \| 7:15AM - 5:00PM Location: Translational Research Center, First Floor Auditorium, 3400 Civic Center Boulevard, Philadelphia, PA Sponsoring Group: Abramson Cancer Center Web Page URL: www.oncolink.org/conference/thyroid/ Objectives: Upon completion of this course, the participant should be able to:
2011 Update in Breast Cancer: Coverage of the ASCO Annual Meeting Dates: Tuesday, June 28, 2011 Location: The Hub Cira Center, 2929 Arch Street, Mezzanine Level, Philadelphia, PA Sponsoring Group: Abramson Cancer Center Web Page URL: www.penncancer.org/eventdetail.cfm?id=310 Topics Covered: This symposium is designed to present cutting-edge data from the 2011 American Society of Clinical Oncology Annual
Food As Medicine Professional Training Dates: June 9-12, 2011 Location: Bethesda, MD Sponsoring Group: Center for Mind-Body Medicine Web Page: www.cmbm.org/holistic_medicine_PROFESSIONAL_TRAINING_EDUCATION/food_as_medicine_description.php Topics Covered: Sustainable Nutrition: Origins, Evolution & Agriculture Nutrition in Practice: Tools & Techniques of Care Understanding
Family Matters: What Every Family Needs to Know About Colon Cancer Dates: June 23-25 Location: Denver, Co Sponsoring Group: Colon Cancer Alliance Web Page URL: http://support.ccalliance.org/site/Calendar?id=100216=Detail Topics Covered: Hear from national experts on: - genetic risks - designing a treatment plan - advanced disease treatment options - tips for living with colon cancer Objectives: Educate
PENN Neuroendocrine Tumor Cme Symposium: A CME-Certified Course Friday, September 9, 2011 7:30 AM — 8:00 AM Registration and Continental Breakfast 8:00 AM — 5:00 PM Educational SessionDownload Conference PDF University of Pennsylvania Biomedical Research Building II/III 421 Curie Boulevard Philadelphia, PA Course Directors: Debbie L. Cohen, MD David C. Metz, MD This conference is designed for
Understanding Pancreatic Cancer: A Free Educational Lecture Dates: October 15, 2011 Location: Cancer Support Community of Philadelphia, The Suzanne Morgan Center at Ridgeland, 4100 Chamounix Dr., Phila. PA 19131 Sponsoring Group: Pancreatic Cancer Action Network and the Cancer Support Community of Philadelphia Web Page URL: http://www.pancan.org Topics Covered: Diet and nutrition issues,
Integrative Medicine: Wellness Throughout Treatment and Survivorship Webinar Dates: October 5, 2011 Location: Online Sponsoring Group: Colon Cancer Alliance Web Page URL: http://www.ccalliance.org Topics Covered: Integrative medicine has been getting a lot of attention lately. Why? Because integrative medicine doesn't just treat a disease, it treats the whole body - mind, body and spirit - and has some
The AICR Annual Research Conference 2011 on Food, Nutrition, Physical Activity Cancer Dates: November 3-4, 2011 Location: Capital Hilton Hotel, Washington, DC Sponsoring Group: American Institute for Cancer Research Web Page: www.aicr.org/conference Who Should Attend: Health Professionals, Public Continuing Education: No
PurpleStride Philadelphia 2011 5K Walk Timed Run Dates: November 5, 2011 Location: Memorial Hall (near Please Touch Museum), Fairmount Park, Philadelphia Sponsoring Group: Pancreatic Cancer Action Network-Philadelphia Affiliate Web Page URL: http://www.purplestride.org Objectives: Fight pancreatic cancer through fundraising to advance urgently needed research, support patients,
Cancer and Careers Educational Series for Healthcare Professionals Date: November 17, 2011, 3PM ET Location: Teleconference Sponsoring Group: Cancerandcareers.org Web Page URL: http://www.cancerandcareers.org/en/community/events/healthcare-professionals Topics Covered: Do your patients ask for guidance on working through treatment? Do you wish you had better answers? Learn how to advise your patients at
Respiratory Liver Motion Extraction for Proton Therapy with Active Scanning Beam Delivery by Deformable Registration Presenter: Ye Zhang1,2, Antje-Christin Knopf1,Dirk Boye1, Tony Lomax1 Presenter's Institution: Center for Proton Therapy, Paul Scherrer Institut, Switzerland and Computer Vision Laboratory, ETH Zurich, Switzerland Background/Introduction Although proton therapy with active scanning beam delivery has advantages to conventional radiation
External beam radiation therapy continues to maintain pediatric Retinoblastoma Presenter: Andrew L. Chang, David Andolino, Hiral Fontanilla, Anita Mahajan Presenter's Institution: Indiana University Proton Therapy Cancer Center and M.D. Anderson Proton Therapy Center Background/Introduction Retinoblastoma is a malignant tumor, which arises from the retina. The disease is particularly common in the pediatric
Use of robots to improve patients' treatment and throughput Presenter: Regis Ferrand Presenter's Affiliation: Institut Curie-Centre de Protontherapie d'Orsay Presentation/Overview The purpose of this presentation was to provide an overview of the 15-20 year history of the use of robotic couches at Institut Curie-Centre de Protontherapie d'Orsay (CPO). In the past 15 years, use of robotic
Proton beam therapy for retroperitoneal neuroblastoma Presenter: Hiroshi Fuji, M.D. Background/Introduction Neuroblastoma is the most common extracranial solid tumor malignancy in children and the most common malignancy in infants less than 1 year old. Neuroblastoma most commonly arises in the adrenal gland, followed by the abdominal cavity. Radiation therapy is associated with GI and
Spot-Scanning based proton radiation therapy for pediatric ependymoma: clinical outcome of 25 patients treated at Paul Scherrer Institute (PSI) Presenter: Ares, C. Presenter's Affiliation: Center for Proton Therapy, Paul Scherrer Institute (PSI), Switzerland Background Ependymomas are rare brain tumors that occur in young children. They arise from ependymal cells which form the lining of the ventricular system and the central spinal canal. United States: <150
Proton Therapy for Craniopharyngioma Presenter: Andrew Chang, MD Presenter's Affiliation: Indiana University, Bloomington Proton Center Background Cranipharyngiomas are benign intracranial tumors arising from Rathke’s pouch in the sellar region. They often have a solid and cystic component. Although these tumors do not have potential for malignant spread, they
Spot-Scanning based proton radiation therapy for complex benign, atypical, and anaplastic meningiomas: 5 year results from the Paul Scherrer Institute (PSI) Presenter/Author:Ralf Schneider, MD Presenter's Affiliation:Center for Proton Therapy, Paul Scherrer Institute (PSI), Switzerland Background Meningiomas are the most common non-glial brain tumors, which are slow growing and extra-axial. They arise from the arachnoid cap cells of the central nervous system. The WHO classification system
Treatment of NSCLC patients with proton beam-based stereotactic body radiation therapy: A dosimetric comparison with photon plans highlights the importance of range uncertainty Presenter/Author: Seco, J. Presenter's Affiliation:Massachusetts General Hospital Background Non-small cell lung cancer accounts for 80% of all lung cancers. Surgery is the gold standard and main curative modality for early-stage lung-cancers (T1-T2, N0) and results in favorable treatment outcomes. However, stereotactic body
A prospective trial of proton radiotherapy for retreatment of recurrent tumors Presenter: John P. Plastaras, MD PhD Presenter's Affiliation: The University of Pennsylvania Background Retreatment with radiation therapy presents a very challenging problem for both radiation oncologists and patients. Certain types of cancers, such as sarcoma, are more prone to local recurrence than others, and therefore more likely
Two-staged proton beam stereotactic radiosurgery (P-SRS) for high-risk cerebral arteriovenous malformations (AVMs) Presenter: Jona Hattangadi, MD Presenter's Affiliation: Harvard University Background Arteriovenous malformation (AVM) is a congenital abnormality of arterial and venous communication, caused by failure of the vascular plexus to develop into a mature capillary bed. The direct connection between the arterial and venous systems exposes the
Protons, photons and brachytherapy as the boost in locally advance prostate cancer Presenter/Author: I.N. Kanchelli Presenter's Affiliation: Russian Scientific Center for Roentgen-Radiology, Moscow, Russia Background Locally advanced prostate cancer is a serious health problem, and recurrence after treatment with conventional radiation therapy can leave patients and providers with few curative options. Previous
Paving the way towards clinical PET-based in-vivo treatment verification at HIT Presenter: Julia Bauer, PhD Presenter’s Affiliation: Heidelburg Ion-Beam Therapy Center Background Treatment planning generates a dose distribution that is approved by a physician and reviewed by a physicist. Unfortunately, in vivo activity may not reflect this ideal dose distribution due to multiple factors. Similarly, planned
Spot scanning proton therapy: single field simultaneous integrated boost Presenter: X Ronald Zhu, PhD Presenter's Affiliation: The University of Texas MD Anderson Cancer Center Background Spot scanning proton therapy (SSPT) is the fast, dynamic scanning of a proton pencil beam over a target volume to provide better conformal coverage. Many individualized static dose applications are superimposed, creating a total
Phase II clinical studies of high-dose proton therapy in stage I/II and III non-small cell lung cancer Presenter: Joe Y. Chang, MD PhD Presenter's Affiliation: MD Anderson Cancer Center Background NSCLC is a prevalent and deadly disease. Over 160,000 cases are diagnosed per year in the U.S., and over 157,000 deaths occur. For early stage disease, surgery is the mainstay of therapy; however, limited surgery (or wedge resection) is not
Proton therapy of esthesioneuroblastoma Presenter: Robert Malyapa MD, PhD Presenter's Affiliation: University of Florida Background Esthesioneuroblastoma, also know as olfactory neuroblastoma, is a rare malignancy originating from the olfactory epithelium in the roof of the nasal cavity. About 4 per 10 million cases are reported, only 1200 have been diagnosed since 1924,
Proton beam therapy for locally advanced Sinonasal squamous cell carcinoma Presenter: Marco Cianchetti, M.D., Annie W. Chan, M.D., Minh T. Truong, M.D., Judy G. Adams, C.M.D., Paul M. Busse, M.D., Norbert J. Liebsch, M.D., and Jing J. Wang, M.P.H. Presenter's Affiliation: Department of Radiation Oncology, Harvard Cancer Center Background Sinonasal carcinomas are tumors found within the nasal cavity and paranasal
Hypofractionated proton beam scanning radiotherapy for prostate cancer Presenter: Herbst M, Wilms M, Dohr D, Hillbrand M. Presenter's Affiliation: Renecker Proton Therapy Center, Munich, Germany Background Prostate cancer is the most common non-skin cancer found in men, with approximately 200,000 cases occurring per year in the United States. The optimal radiation dose fractionation schedule for localized
Scanning proton beam radiotherapy under functional apnea Presenter: Eckermann M, Hillbrand M, Herbst M, Rinecker H Presenter's Affiliation: Rinecker Proton Therapy Center, Munich, Germany Background Proton therapy potentially has numerous advantages to conventional radiation therapy when treating cancer in locations that remains relatively motionless; however, many tumors are found in the
Capecitabine versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial Presenter: Ralf Hofheinz, MD Presenter's Institution: Day Treatment Centre at the Interdisciplinary Tumour Centre Mannheim, Universitätsmedizin Mannheim, Mannheim, Germany Background 5-FU based chemoradiation prior to total mesorectal excision (TME) followed by additional 5-FU chemotherapy is the standard of care for locally advanced
Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and Oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial Presenter: Claus Roedel, MD Presenter's Institution: German Rectal Cancer Study Group; University of Frankfurt, Frankfurt, Germany Background The first German Rectal Cancer Study (CAO/ARO/AIO-04) established pre-operative chemoradiotherapy with infusional 5-FU given during the first and fifth weeks of RT (50.4 Gy), followed by TME and an
A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma Presenter: Amit M. Oza, MD Presenter's Institution: Princess Margaret Hospital, Toronto, ON, Canada Background/Introduction Endometrial cancer is the most common gynecologic malignancy, with an estimated 43,470 new cases and 7,950 deaths in 2010. Primary treatment consists of surgical resection including hysterectomy, bilateral
Predictors of early response and event-free survival in Hodgkin lymphoma (HL):PET versus CT imaging Presenter: C. L. Schwartz Presenter's Institution: Hasbro Children's Hospital/Brown University Introduction/Background Response directed therapy is an important concept in the management of Hodgkin Lymphoma (HL). In adult HL, risk stratification after early therapy response assessment with PET allows tailoring therapy for patients with
A population-based, case-control study of MC1R variants, ultraviolet light exposure, and melanoma Presenter: D. Polsky Presenter's Institution: New York University Background/Introduction It is well known that ultraviolet light (UV) exposure is associated with increased melanoma risk. In addition, several different genes have been identified as increasing the risk of developing melanoma. Melanocortin-1 receptor gene (MC1R), located
Melanoma as a subsequent neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Presenter: A. S. Pappo Presenter's Institution: St. Jude Children's Research Hospital, Memphis, TN Background Survivors of childhood cancer are at increased risk of developing secondary malignant neoplasms (SMN). Generally speaking, children treated for malignant disease are acknowledged to be at greatly increased risk for SMN following
Effect of screening on ovarian cancer mortality in the prostate, lung, colorectal, and ovarian (PLCO) cancer randomized screening trial Presenter: Saundra Buys, MD Presenter Affiliation: University of Utah Background Ovarian cancer is a deadly disease with high case fatality rate. Approximately 22,000 women are diagnosed yearly in the U.S, and 14,000 die from the disease. Women presenting with lower stage disease have better survival outcomes, but unfortunately
Results of a prospective clinical trial for VAMP alone without irradiation for pediatric favorable, early-stage Hodgkin lymphoma patients who achieve an early complete response Presenter: Monika Metzger, MD Presenter's Affiliation: St. Jude Children's Research Hospital Background Low-risk Hodgkin lymphoma typically refers to stage I-IIA, non-bulky disease in less than 3 sites, and without extranodal involvement. 10-year event free survival (EFS) and overall survival (OS) are 90-95%. Treatment paradigms have
Impact of traditional cardiovascular disease risk factors on long-term cardiovascular outcome in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Presenter: Gregory Armstrong, MD Presenter's Affiliation: St. Judes Children's Research Hospital Background As progress in the treatment of childhood cancers has improved survival, late effects of therapy have become more pronounced and widely recognized. The Childhood Cancer Survivor Study (CCSS) was established to monitor these late
Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study Presenter: Wolfgang Wick, MD Presenter's Institution: University Hospital Heidelberg, Heidelberg, Germany Background/Introduction The standard of care for patients diagnosed with Glioblastoma multiforme (GBM) includes maximal safe surgical resection followed by chemoradiation with the alkylating agent temozolomide (TMZ) followed by more
Outcome of infants and young children with newly diagnosed medulloblastoma treated on Head Start III protocol Presenter: Girish Dhall, MD Presenter's Affiliation: Children’s Hospital Los Angeles Background The standard of care for newly diagnosed medulloblastoma is tri-modality therapy with surgery, chemotherapy, and radiation all playing a role in both standard-risk and high-risk disease. Craniospinal radiation is indicated for all
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) Presenter: V. Guarneri Presenter's Institution: Modena University Hospital, Modena, Italy Background The treatment of patients with breast cancer continues to evolve, with cytotoxic chemotherapy, endocrine therapy, and molecular targeted therapies as the backbone of systemic therapy. As we continue to better our understanding of the
Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1) Presenter: K. Jahnke Presenter's Institution: Charité Hospital, Campus Benjamin Franklin, Berlin, Germany Background CNS lymphoma is rare but incidence is rising in both immunocompetent and imuunocompromised patients. For reference, the incidences in 1973 and 1992 were: 1973: 2.5/10,000,000 1992: 30/10,000,000 The
Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial Presenter: Ruth Ladenstein, MD Presenter's Affiliation: St. Anna's Children Hospital; SIOPE (The European Society for Clinical Oncology) Background Neuroblastoma is a cancer of the sympathetic nervous system and is comprised of a spectrum of tumors arising from the primitive ganglion cells. It is the most common extracranial solid
Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO) Presenter: Heikki Joensuu, MD Presenter's Institution: Helsinki University Central Hospital, Helsinki, Finland Background/Introduction Gastrointestinal stromal tumors (GISTs) are tumors of the bowel wall that originate in the interstitial cells of Cajal. They represent the most common mesenchymal tumors of the GI tract. They carry
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma Presenter: P. B. Chapman Presenter's Institution: Memorial Sloan Kettering Cancer Center Background Dacarbazine (DTIC) was approved for melanoma in 1975; the overall response rate has been reported at 7-12% and median OS after starting the drug is less than 8 months. High dose IL-2 was approved in 1998, with a durable CR of 5-7%. IL-2
Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232 Presenter: Eric C. Larsen, MD Presenter's Institution: Maine Children's Cancer Program, Scarborough, ME Background/Introduction There are approximately 5,300 new cases of acute lymphoblastic leukemia (ALL) diagnosed every year in the United States; 60% of these cases are in children and young adults (age < 20), while 40% of these cases
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma Presenter: Wolchok Presenter's Affiliation: Memorial Sloan Kettering Cancer Center, New York, NY Background Metastatic melanoma is an aggressive and deadly disease with limited treatment options. The incidence of metastatic melanoma, particularly in young adults, is rising world wide. Typically, the 1-year survival
NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer Presenter: Timothy Whelan, MD Presenter's Institution: Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada Background/Introduction The majority of women with early stage breast cancer are managed with breast conserving surgery (BCS) and surgical staging of the axilla, followed by adjuvant systemic therapy as
Effect of yoga on QOL, cortisol rhythm, and HRV for women with breast cancer undergoing radiotherapy Presenter: L. Cohen Presenter's Institution: University of Texas MD Anderson Cancer Center Background Yoga is an ancient practice that originated in India; this "old" practice has a new following, as complementary medicine utilization has increased in recent years within the general population and among cancer patients. Yoga is both a
Impact of out-of-pocket expenses on cancer care Presenter: Yousof Zafar Presenter Affiliation: Duke University Medical Center Background The cost of cancer treatment is high and growing rapidly. Although national media attention and public policy has focused on the cumulative costs of care at the macroeconomic level, the burden on individual patients is great, even among patients
A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013) Presenter: JM Crook Presenter's Institution: British Columbia Cancer Agency, Kelowna, BC, Canada Background Androgen-deprivation therapy (ADT) is the standard treatment for metastatic and recurrent prostate cancer, and is used frequently as adjuvant treatment for high-risk localized prostate cancer. Continuous hormonal therapy has been the
Toward a rationale strategy for prostate cancer screening based on long term risk of prostate cancer metastases and death: data from a large, unscreened, population-based cohort followed for up to 30 years Presenter: H. Lilja, MD Presenter's Institution: Memorial Sloan-Kettering Cancer Center, New York, NY Background/Introduction Routine screening for prostate cancer using prostate-specific antigen (PSA) testing remains controversial. A European study demonstrated that PSA screening reduced the rate of death from prostate cancer by
Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? Presenter: S. Domchek Presenter’s Institution: U. of Pennsylvania School of Medicine Background Research has shown that women who carry the BRCA mutations benefit from risk-reduction procedures to reduce their risk of developing breast and ovarian cancers. The best risk-reduction strategy appears to be surgical removal of the
A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC) Presenter: Kian K. Ang, MD, PhD Presenter’s Institution: University of Texas M. D. Anderson Cancer Center, Houston, TX Background/Introduction The concurrent use of cisplatin or cetuximab with radiation (RT) has been shown to improve survival of patients with locally advanced stage III-IV head and neck squamous cell carcinoma. A
The impact of socioeconomic status on cancer care and survival Presenter: Sandra L. Wong Presenter's

Cancer Types

View by Cancer Types

Cancer Treatment

Cancer Risk and Prevention

Cancer Drugs

Support

Healthcare Professionals

Clinical Trials

Oncolink Features

Find My Cancer Drug

Conferences